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ABSTRACT
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common
genetic disorders (Gabow, 1993), with an estimated prevalence of 1 in 400 to I in 1000
(Dalgaard, 1957; Gabow, 1993). The disease is the fourth leading cause ofrenal failure
with more than 10 million people affected worldwide (Grantham, 1997). Mutations in
at least two genes (PKDJ, PKD2) can lead to the disease (European PKO Consortium,
1994; Mochizuki, et al. 1996).

This project deals with autosomal dominant PKO,

caused by mutations in the PKDJ gene, which account for 85% ofreported cases.

Mutation detection in the PKDJ gene is difficult as the gene is relatively !arge (46 exons
over 52kb of genomic DNA), it has a high GC content, and is duplicated in numerous
homologues of unknown function. Mutations detected to date are usually private and
many neutral polymorphisms have also been detected.

Co-amplification of PKDJ

homologous genes, which correspond to at least 75% of its mRNA, poses the largest
obstacle fot PKDJ mutation detection studies.

In this study, novel strategies for mutation screening in the duplicated region ofPKDJ
have been developed. In the process of the work further characterisation ofthe PKDJ
homologous genes has been achieved, and the results suggest that at least two of the
homologues are non-functionmg (i.e. not translated) pseudogenes.

Subjects from three countries were screened for mutations in the PKDJ gene in order to
detect mutations and to attempt genotype-phenotype correlations in a disorder which

exhibits a high degree of inter· and intra·fumilial phenotypic heterogeneity. Seventy·
four sequence variations were detected, of which twenty·four are believed to be
pathogenic.

In the Australian cohort, DNA was screened over 95% of the coding region aT1d a
mutation detection rate of74% was achieved. This result is favourable wh�n compared
to other studies. Findings from the study and others in the literature suggest that PKDI
gennline mutations do not indicate a simple genotype·phenotype correlation, and future
studies will need to incorporate many other biological and environmental variables in
order to establish how the genotype influences the complex phenotype of the disease.
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DEFINITION OF ABBREVIATIONS AND TERMS

ADPKD

Autosomal dominant polycystic kidney disease

ARPKD

Autosomal recessive polycystic kidney disease

bp

Nucleotide base pairs

cDNA

Complementary deoxyribonucleic acid

CMC

Chemical mismatch cleavage

CRF

Chronic renal failure

CSGE

Conformational sensitive gel electrophoresis

DGGE

Denaturing gradient gel electrophoresis

DHPLC

Denaturing high perfonnance liquid chromatography

DNA

Deoxyribonucleic acid

EMC

Enzymatic mismatch cleavage

Endo VH

T4 endonuclease VII

ESRF

End stage renal failure

FN·III

Fibronectin type-3 repeat

HDA

Hetero Duplex Analysis

HG(s)

Homologous gene or genes

3'-HVR

Three prime hypervariable repeat region of the alpha-globin gene.

IVS

Intervening Sequence (intronic region)

kb

Kilobase (equivalent to 1000 bp)

LDL-A

Low density lipoprotein type-A

LRR

Leucine rich repeat

V

mRNA

Messenger ribonucleic acid

NIRCA

Non•isotopic RNase Cleavage assay

nt

Nucleotide

PAH

Phenylalanine hydroxylase gene

PBP

Polycystic breakpoint

PCR

Polymerase chain reaction

PKD

Polycystic kidney disease

PKDl/213

Polycystic kidney disease gene ( 1. 2 or 3 ).

PKDJPJ-6

Polycystic kidney disease gene l pseudogene ( l ·6)

PKU

Phenylketonuria

PIT

Protein truncation test

REJ

Receptor egg jelly domain/module

RT-PCR

Reverse transcription·Polymerase chain reaction

SSCP

Single·strand conformation polymorphism

TSC

Tuberous sclerosis

TSC2

Tuberous sclerosis 2 gene
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I.

Introduction

I. Introduction

I. 1. Introduction

1.1.i. Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common
genetic disorders (Gabow, 1993), with an estimated prevalence of 1 in 400 to I in 1000
(Dalgaard, 1957; Gabow, 1993). The disease is the fourth leading cause of renal failure
with more than 10 million people affected worldwide (Grantham, 1997).

Although most cases of the disease present in adulthood, hence the synonym adult
polycystic kidney disease, it is in fact a systemic hereditary disorder which can occur at any
time of life, including in utero (Zerres et al., 1985). The mode of inheritance in ADPKD
was defined over 40 years ago and the disease exhibits complete penetrance with respect to
the occurrence of renal cysts (Dalgaard, 1957), although it does not always progress to
chronic or end-stage renal failure (Churchill, et al., 1984). Mutations in at least two genes
(PKDJ, PKD2) can lead to the disease (European PKD Consortium, 1994; Mochizuki, et
al. 1996). This project deals with autosomal dominant PKD, caused by mutations in the
PKDJ gene.

1.1. ii. The PKD1 Gene

Tr.e first gene for polycystic kidney disease (PKDJ) is located on human chromosome
16pl3.3 (The European PKD Consortium, 1994). The gene produces a 14 kb transcript
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which has been detected in many tissue-specific cell lines (The European PKD Consortium,
1994). The highest PKDJ gene expression levels were found in kidney- and liver-derived
cell lines {The European PKD Consortium, 1994). The PKDJ gene spans 52 kb of
genomic DNA, and includes 46 exons. A 14 kb mRNA transcript is produced and encodes
a novel protein, polycystin-1, which is 4302 amino acids in length (The International PKD
Consortium, 1995). PKDJ is duplicated at least 3 times on human chromosome 16p13.l.
The PKDJ homologous genes (HGs) are up to 97% homologous with the PKDJ gene over
two-thirds of its length (The European PKD Consortium, 1994). It is not known if the HG
transcripts produce functional proteins (Hughes et al., 1995). Due to their co-amplification
with PKDJ, they represent a major obstacle for mutation detection studies in the PKDJ
gene (Peral et al., 1997).

I. I.iii. The ADPKD Phenotype
Both inter- and intra-familial phenotypic variation have been observed in autosomal
dominant polycystic kidney disease. Some affected individuals do not progress to end
stage renal failure (ESRF), and those that do exhibit a wide variation in age at onset of
ESRF (Milutinovic et al., 1984; Parfrey et al., 1990; Gabow, 1993; Gn1nfeld, 1998). In
addition to renal disease, ADPKD has been associated with a number of extra-renal
symptoms, these also vary both between and within affected families (Gabow, 1993).
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1.2 Strategy of the Study

I.2.i. Study Aims & Expected Outcomes
The aim of this study is to design and implement screening techniques for mutations in the
PKD 1 gene. Mutations identified will be assessed in order to detennine if significant
genotype/phenotype correlations exist in ADPKD.

To date, no common pathogenic

mutations have been detected in PKDJ (Krawczak & Cooper, 1997).

Since private

mutations in the PKDJ gene are usual, and the size of the population in the present study is
relatively small, it is not anticipated that a definitive answer to the genotype/phenotype
question will be achieved. However, novel sequence variations discovered here in both the
unique and duplicated regions ofthePKDJ gene will add to the growing numbers ofPKDI
mutations and polymorphisms.

As

greater numbers of mutations are discovered, it will be

possible to assess if there is a pre-disposition to particular types of mutation in the gene and
if clustering of mutations exist. If mutational clustering does exist, it will be of interest to
assess in which functional domains of polycystin-1 it occurs. In addition to improved data
on the PKDI gene, the detection of familial mutations will also allow diagnostic
laboratories to offer molecular diagnosis to pre-symptomatic family members.

III.2.ii. Study Plan
The investigation of mutations in the PKD1 gene in this study will be divided into three
parts. The first wiH involve screening of the unique region of the gene by single strand
confinnation polymorphism analysis (SSCP) in 48 PKDJ-linked unrelated individuals from
Australia, Bulgaria and Poland. When sequence variations are indicated by SSCP, manual

4

DNA sequencing will be perfonned. Manual sequencing was chosen because of its
availability. It also has the advantage that heterozygotes are easily detected without the
ambiguity often associated with other methods. This will be followed by an assessment of
mutation detection efficiency using SSCP compared to direct automated sequencing
analysis. The second part of the study will address one of the major problems associated
with mutation detection screening of the PKDJ gene. It will involve the determination of
appropriate methods to investigate the duplicated region of the gene without the co
amplification of PKDI homologous genes. It will also include investigation of the PKDI
HGs, to provide inf'orrnation on their functional significance. The final

part

of the study

will be the implementation of these mutation-screening techniques in the duplicated region
of the PKDI gene. This screening will be performed on the DNA of PKDI-linked ADPK.D
individuals from Australia
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II.

Review of Literature

II,

Literature Reyje»;:

II. I, General

Literature

11.1.i. Clinical Course and Heterogeneity of ADPKD
The first major study on AD PKD was based on 284 Danish patients and their families
(Dalgaard, 1957).

Apart from reporting the prevalence of ADPKD, this study and

others since (Churchill et al., 1984; Gabow et al., 1992; Ravine et al., 1992; Coto et al.,
1995) have shown marked phenotypic heterogeneity. Differences have also been noted
in the prevalence of ADPKD (Yersin et al.. 1997; Kirubakaran, 1998).
appears to

be

ADPKD

less common in people of African descent than in Caucasians (Yersin et

al., 1997). Approximately 65% of the population of the Seychelles are of African
descent and 30% are of Caucasian or mixed descent. Of 42 families with ADPKD
studied in the Seychelles over a three-year period, only three families were of African
descent (Yersin

er al., 1997). A low incidence (2/423 renal patients) of ADPKD has

also been noted amongst Central Australian Aborigines (Kirubakaran, 1998).

As stated, there is wide variation in age at onset of end-stage renal failure (ESRF)
(Milutinovic et al., 1984; Parfrey et al., 1990; Gabow, 1993; Grilnfeld, 1998). Most
affected individuals reach ESRF between the ages of 45-70 years, and approximately
30-50% never progress to ESRF (Parfrey et al., 1990). Mutations

in

the PKDJ gene

generally lead to an earlier age at onset and a faster rate of progression towards ESRF
than mutations at the PKD2 locus (Ravine et al., 1992; Hateboer et al.. 1999b). A small
proportion of affected individuals who show linkage to PKDJ exhibit very early onset
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(Zerres, er al., 1993). Such patients can present in utero and, if they survive the first 12
months, ESRF can occur as early as 3 years of age (MacDennot et al., 1998).

Hypertension is the most common complication associated with ADPKD, occurring in
approximately 30% of children and 60% of adults prior to the onset of chronic renal
failure (CRF) (Gabow, 1993). Hypertension in ADPKD appears to result in an earlier
age at onset and an increased rate of progression of renal disease (Milutinovic, et al.,
1984; Chapmen & Schrier, 1991; Gabow er al., 1992). A multi-centre study (Geberth et

al.. 1995b) has shown that ADPKD families with a concomitant genetic predisposition
to essential hypertension show earlier onset of terminal renal failure. Left ventricular
hypertrophy has been shown to occur at a relatively early age in ADPKD hypertensive
individuals by comparison with non·ADPKD patients with essential hypertension
(Chapman & Schrier. 1991).

Extra-renal manifestations of ADPKD include hepatic, ovarian, seminal vesicular,
pancreatic, pulmonary, oesophageal and splenic cysts (Danaci, et al., 1998). Hep atic
cysts a.e the most common and, although not usually pre'>ent in ADPKD patients at an
early age, they are detected in approximately 75-80% of affected individuals aged 60-70
years (Dalgaard, 1957; Milutinovic, et al., 1980; Grunfeld et al., 1985). Cysts in other
organs appear to be less common, with little information on their incidence (Gabow,
1993; Danaci, et al., 1998).

lntracranial aneurysms (ICAs) are another well-<iocumented symptom associated with
ADPKD, with an estimat�d incidence of 4-11% (Kaehny & Everson. 1991; Lozano &
8

Leblanc. 1992; Chapmen er al., 1992; Schievink, er al.. 1992; van Dijk et al., 1995; Fick

et al., 1995). These figures may be under-estimates, since a prospective Japanese study
on 41 ADPKD patients identified ICAs in 17 patients i.e. 41% (Wakabayashi et al.,
1983). ADPKD has been associated with a higher incidence of several other diseases
compared to the incidence found in the general population. These include heart disease,
particularly mitral and tricuspid valve prolapse (Hossack et al., 1988), and colonic
diverticuli (Starnes et al., 1985; Gabow 1990). ADPKD patients show increased rates
of colonic perforation compared to other renal patients (Scheff et al., 1980).

ADPKD co-occurs most commonly with tuberous sclerosis (TSC), an autosomal
dominant disorder that results in benign tumours (hamartoma), usually in the brain, skin
and kidney. The TSC2 gene, mutations in which account for approximately 50% of
cases of tuberous sclerosis, is located adjacent to PKDJ in a tail-to-tail orientation on
chromosome 16 (Harris, 1997). A gross deletion involving both TSC2 and PKDJ was
instnunental in mapping the PKDJ gene (Wunderle et al., 1994), (see section 11.2.i).

Other conditions reported to co-occur less commonly with ADPKD are summarised in
Table 11.1. No genetic cause of co-occurrence has been established between ADPKD
and any of these conditions.

The co-existence of cystic fibrosis (CF) and ADPKD may prove te> bt one of the most
interesting associations. Cystic fibrosis, the most common autosomal recessive disease
in Caucasians, has a reported incidence in Australia of l :3,000 births and is
characterised by intestinal and pulmonary obstruction (Massie et al., 2000).

The
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presence of both disorders seems to have an effect on the phenotype of ADPKD
(O'Sullivan

el

al., 1998). In a large family, adult members affected by both ADPKD

and CF (but not the CF carriers) displayed less severe polycystic kidney and liver
disease (O'Sullivan, et al., 1998).

In vitro experiments on monolayer cell cultures from ADPKD renal cystic epithelia,

suggest that the CF protein, cystic fibrosis transmembrane conductance regulator
(CFfR), is responsible for active chloride ion (Cl-) and fluid secretion in the cysts
(Brill et al., 1996; Davidow et al., 1996; Hanaoka et al., 1996). In pulmonary cells, the
CFfR controls the net movement of Cl- across the apical membrane (Bear et al., 1991)
and may also be involved in modulating vesicle transportation, organelle function and
P�eudomonas binding (Bradbwy 1999). Mutations in the CFTR gene lead to a decrease

in fluid secretion and an increase in fluid absorption (Grantham et al., 1995). It has
been proposed that in contrast to CF, where too little Cl- and fluid are secreted, in
ADPKD patients too much Cl- and fluid are secreted by cyst epithelia (O'Sullivan et
al., 1998). This finding has been supported by other studies (Devuyst et al., 1999;

Hanaoka & Guggino, 2000), although the change in expected phenotype may be
dependent on the specific CF mutations (Persu et al., 2000). A decline in ADPKD
phenotype severity, associated with co-occurring ADPKD and CF, suggests that the
modulation of epithelial Cl- secretion may have therapeutic benefit (Cotton & Avner,
1998), but this hypothesis has yet to be tested in vivo.
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Table 11.1. Diseases Reported to Co-occur with ADPKD
Disorder

Description

Number of
families
4

References

Caroli's disease

Cystic dilations of the intrahepatic biliary ducts

Adenoma of the
ampulla of vater

Causes biliary obstruction

2

Norton el al. (1995 ); Serafini &
Carey (1999)

General overlap
connective
tissue disorder

Aortic root dilation & aneurysm, aortic valve incompetence,
pectus abnonnalities. joint laxity, arachnodactyly. scoliosis,
dolichostenomella, and high arched palate

4

Somlo et al. (1993); Kaplan et al.
(1997)

Jordan et al. ( 1989): Mousson et al.
(1997); Torra et al. (1997)

Marfan syndrome

A connective tissue disorder affecting the skeletal and
cardiovascular systems and the eyes

At least 5

DiMatteo et al., (1965); Selgas et al.,
( 1981); Ortino et al., (1988);
Biermann et al., ( 1992); Hateboer el
al., (2000)

Oral-facialdigital syndrome
(type I)

Oral and digital anomalies with facial dysmorphism

Numerous

Harrod et al. ( 1976); Donnai et al.
(1987); Connacher er al. ( J 987);
Feather et al. (1997)

Skeletal
malformations

One case with polydactyly and PKD

I

Turco el al. (1993)

II. I .ii. The Pathogenesis of ADPKD
Altered growth in the kidney epithelial cells of ADPKD patients has been observed
under electron microscopy, with cyst wall epithelial cell hyperplasia and micropolyp
fonnation within the cyst observed (Evan et al., 1979). The formation of cysts is not
simply caused by an increase in the size of the renal tubules due to the stretching of
cells, but results from cell proliferation (Grantham et al., 1987). It has been suggested
that, by precipitating renal ischaemia and an increase in renin release, cyst expansion
can contribute to the early development of hypertension in ADPKD and thus further
accelerate progression to ESRF (Chapman et al 1990).

Apoptotic DNA fragmentation has been detected in the poJycystic kidneys of J 6
patients, 10 of whom had ADPKD and renal failure, 5 had ADPKD but no renal failure,
and one was from a one day-old infant with a terminal recessive form of PKD (Woo,
1995). Apoptosis was not observed in the kidneys of 12 normal controls or in the
kidneys of 25 renal patients who did not have polycystic disease (Woo, 1995}. The
results suggest that apoptotic loss of renal tissue may contribute to the progressive
deterioration of renal function in PKD (Woo, 1995). Since the gene products of PKDJ
and PKD2 are believed to be involved in cell-matrix and cell-cell interactions, their
deficiency or altered function may play a role in the development of apoptosis seen in
ADPKD kidneys (Zhou & Kukes, 1998).

There is evidence that fewer than I% of renal tubules become cystic and lead to loss of
renal function (Grantham, 1997).

As cyst numbers increase, kidney function

concomitantly deteriorates and serum creatinine levels rise, ultimately leading to ESRF
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in 50% of affected individuals by 59 years of age (Parfrey et al., 1990). Kidney cysts
have the following characteristic features:

(a) they all originate from renal tubular

epithelium; (b) as cysts expand, there is a differential increase in the number of
epithelial ceJls found in kidney tubules compared to the number of cells in nonnal
tubules; (c) fluid derived from the glomerular filtrate and net trans-epithelial secretion
of solute accumulates in the cyst cavity; and (d) cysts become enlarged in association
with matrix re-modelling (Grantham, 1997). Since there is substantial intra· and inter
familial variance in the rate of kidney enlargement, it has been postulated that
epigenetic factors play a role in the modulation of renal cyst growth (Grantham, 1997).
Evidence of a neutral lipid, which has the capacity to advance the progression of
ADPKD, has been reported (Grantham, 1997). This lipid, or family of lipids, acts as a
secretory agonist (secretagogue) and has been detected in the cyst fluids removed from
patients with advanced ADPKD and in the cyst fluid of mice with PKD (pcylpcy)
(Grantham, 1997). These cyst fluids have also been shown to stimulate the proliferation
of MOCK (Madin-Darby canine kidney) renal epithelial cells in culture (Yamaguchi et

al., 1995). The secretagogue, referred to as cyst-activating factor (CAF), may stimulate
progression of the disease in two ways; (a) by increasing cellular proliferation and fluid
secretion, and (b) by increasing interstitial inflammation and fibrosis (Grantham, 1997).

The glycoprotein laminin present in human serum and urine, is a.'lother factor that may
play a role in cyst proliferation (Slade et al., 1998).

Laminin is one of the major

intrinsic macromolecules of the tubular basement membrane. In a study by Slade et al.
( 1998), undiluted cyst fluid contained no intact laminin but laminin fragments were
present. Fragments of this type, isolated from human placenta, have previously been
13

shown to increase proliferation of cultured epithelial cells, both nonnal and ADPKD
(Slade et al., 1996). It is believed that contact between laminin fragments and the
epithelial cells lining renel tubular cysts could contribute to increased epithelial
proliferation in ADPKD (Slade et al., 1998).

The effect of transforming growth factor-alpha (TGF-a.) and epidennal growth factor
(EGF), have also been investigated in terms of their effect on ADPKD cell proliferation
(Lee et al., 1998). Both of these agents are known mitogens expressed in the kidney,
and bind to the same epidermal growth factor receptor (EGFR) (Lee et al., 1998). A
study employing immuno-staining showed that renal cystic epithelia exhibit increased
expression of both the growth factor TGF-a and its receptor (EGFR) mRNA (Lee et al.,
1998). Intense cytoplasmic staining of the tubular epithelia for TGF-a and EGFR
proteins has been shown at all stages of cyst development in ADPKD kidney tissues
compared to normal human controls (Lee et al., t 998). These elevated levels of TGF-cx.
and EGFR expression were not detected in the surrounding tissues, suggesting that
TGF-a and EGFR signalling may be a common mechanism in cystic epithelial
proliferation (Lee et al., 1998).

Cysts require a net influx of fluid to prevent collapse of the cell walls (Murcia et al.,
1999). Therefore the transition of nonnal absorptive epithelium into cystic secretory
epithelium is necessary for cyst pathophysiology (Murcia et al., 1999). This transition
is not irreversible, as cystic epithelia have been shown to revert to wild-type absorptive
behaviour in the absence of the stimulating endogenous secretagogues found in cyst
fluid. such as fOiSkolin, an adenylate cyclase activator (Grantham et al., 1995).
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Monolayer human ADPKD patient-derived cell cultures embedded in type- I collagen
have been shown to fonn cysts in the presence of forskolin or epidermal growth factor
(Woo et al., 1994). This cyst formation does not occur when nonnal kidney cells are
treated in the same manner, indicating that mutant ADPKD cells have an intrinsic
ability which differs from that of normal kidney epithelial cells (Woo et al., 1994). Cyst
formation has been reversibly inhibited in vitro by ouabain and amiloride (both are
diuretics used as anti-hypertensive drugs), plus colchicine, vinhlastine and taxol (these
compounds interrupt the cell cycle during mitosis and have been used as anti-cancer
drugs) (Woo et al., 1994). Experiments using colchicine, vinblastine and taxol have
been conducted in vivo on cpk mice, a murine model of autosomal recessive PKD (Woo
et al., 1994). Both colchicine and vinblastine proved lethal in the mice, however taxol

administered on a weekly basis decreased cyst enlargement, resulted in minimal loss of
renal function, and prolonged life from 25-28 postnatal days in untreated mice up to 200
days in taxol-treated mice (Woo et al., 1994). These findings imply that, when the key
processes of renal cyst formation and proliferation are understood, dietary and
pharmacological treatments may help to delay the proliferation of cysts and the onset of
ESRF in ADPKD (Grantham, 1997).
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Il.2. The Genetic Basis of ADPKD

11.2.i. Locus Heterogeneity in ADPKD
The first major breakthrough in the localisation of the ADPKD genes occurred when
close linkage to the a.-globin locus on the short arm of chromosome 16 was observed
(Reeders et al., 1985). This was achieved using a highly polymorphic DNAmarker (the
3' HVR-hypervariable region) approximately 8 kb beyond the 3' end of the a-globin
gene. The marker was analysed in four British and five Dutch families totalling 183
members, and gave a maximwn combined lod score of 25.85 at 8 = 0.05 (99%
confidence interval 2-11 cM) (Reeders et al., 1985). Each of the nine families displayed
linkage to this locus, now known to be the PKDI gene. The families presented with the
most typical clinical form of the disease, ESRF occWTed at a mean age of 48 years and,
in the effective absence of phenotypic variation, genetic heterogeneity was deemed
improbable (Reeders et al., 1985). A subsequent study in South Wales of 12 ADPKD
kindreds gave a maximum combined lod score of 24.187 (8 = 0.03) using the a.-globin
and 3' HVR probes (Lazarou et al., 1987).

Refined linkage mapping became possible shortly afterwards with the marker 24-1,
which flanks the PKDJ gene on the side opposite to the a.-globin gene (Breuning et al.,
1987). Ajoint study analysing 27 Northern European ADPKD families failed to detect
evidence of linkage heterogeneity (Reeders et al., 1987). A not: 1l)' Kimberling and
Gabow added to this paper in proof, suggested possible locus heterogeneity in families
with more diverse ethnic origins. The first example was an ADPKD family of Sicilian
origin which did not show linkage to the a.-globin gene on chromosome l 6p
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(Kimberling et al., 1988). An average of 85% of all Caucasian families with ADPKD
show linkage to PKDJ (Peters & Sandkuijl, 1992). For that reason this is the major
gene selected for investigation in this thesis.

The position and order of the many markers isolated around the PKDJ region was
initially determined using a panel of somatic cell hybrids and extensive linkage analysis
in normal and PKDJ families (Breuning et al.• 1990; Reeders et al., 1988; Germino et
al., 1990). Further work creating a long-range restriction map localised the PKDJ

region to an area spanning approximately 750-500 kb (Harris et al., 1990; Gennino et
al., 1993), flanked by the markers GGG I and SM7 (Hanis et al., 1991; Somlo et al.,
1992). The region has a high CpG content and could contain as many as 20 genes. This
large nwnber of candidate genes hindered the subsequent fine localisation of the PKD1
gene (Gennino et al., 1993).

Linkage disequilibrium studies were undertaken using additional markers: VK.5B in a
Scottish study (Pound et al., 1992), and BLu 24 with a Spanish population (Peral et al.,
1994). These studies showed evidence of a common ancestor in a proportion (approx.
40%) of each population, but the degree of linkage disequilibrium was too weak to
position the PKDJ locus with precision.

As previously noted, the first ADPKD family which did not display linkage to the
alpha-haemoglobin complex on chromosome 16p was of Sicilian origin (Kimberling et
al., 1988), and was clinically indistinguishable from families in which ADPKD was
linked to chromosome 16 (Kimberling et al., 1988).

Numerous families were
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subsequently reported in the literature to have a form of ADPKD that did not co
segregate with genetic markers on chromosome 16p (Elles et al., 1990; Bachner et al.,
1990; Coto et al., 1992; Bear et al., 1992). As more non-PKDJ-linked families were
identified it was noted that ADPKD in these families appeared to exhibit a milder
clinical phenotype (Bear et al., 1992; Ravine et al., 1992).

The second .-;;JPKD gene, PKD2, was mapped in the original Sicilian kindred to a 9cM segment flanked by the markers� D4S23 l and D4S4l 4 on the long arm of
chromosome 4 (Kimberling et al.. 1993). The highest lod scores in this two-point
lin�age analysis were obtained between ADPKD and D4$395 (Z = 9.83, 8 = 0.07) and
AOPKD and D4S4l4 (Z = 10.13, 8 = 0.06). Peters et al. (1993) independently mapped
the PKD2 gene to chromosome 4q, in a study of eight families where ADPKD did not
co-segregate with markers on chromosome 16p. This chromosome had previously been
studied for Huntington disease (Gusella et al., 1983) and facioscapulohumeral
dystrophy (Wijmenga et al., 1991), so markers closely linked to PKD2 were readily
available for predictive diagnostic purposes (Peters et al., 1993).

The

question of further locus heterogeneity in ADPKD remains open, since at least five

families show linkage to neither PKDJ nor PKD2 (Daoust et al., 1995; Bogdanova et
al., 1995; de Almeida et al., 1995; Turco et al., 1997; Ariz.a et al., 1997). A possible
positive lod-score to markers linked to chromosome 7 has been reported for "PKD3"
(de Almeida et lll.. 1999). Pbenotypic variation has been found between the five
families, which may result from modifying or environmental factors, as suggested in
PKD1 and PKD2 (Hateboer, et al., 1999a). Alternatively, there may be more than three
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genes responsible for the ADPKD phenotype, although the existence of even a iliird
locus for ADPKD has been questioned since mnny confounders can lead to false
exclusion of linkage (Paterson & Pei, 1998).

It was suggested that bilineal transmission of two independent PKD mutations within
the same family might lead to false exclusion of linkage when only one disease locus is
considered at a time (Paterson & Pei, 1998). This could arise either through mutations
involving both copies of PKDJ or

PKD2 segregating within the same family. In such

cases, individuals carrying two identical mutations are referred to as homozygotes,
whereas those with two different mutant alleles are tennec! compound heterozygotes.
Alternately, one PKDJ and one PKD2 mutation could segregate within the same family.
In such cases, some affected individuals would have digenic mutations (i.e. in both
ADPKD genes) and others would have only

PKDJ or PKD2 mutations. Predictably

these events would be rare. However, only five ADPKD families have failed to show
linkage to either the

PKDJ or PKD2 genes (Paterson & Pei, 1998). In 2001 the first

family with bilineal ADPKD was reported (Pei
either germline mutations in

et

al., 2001).

Family members had

PKDJ or PKD2, and a smaller, more severely affected

subset were shown to have both mutations.

A novel

PKD2-like gene (PKDL} has been reported (Nomura et

al., 1998) which

displays 50% amino acid (aa) sequence identity and 71% homology to

PKD2. The

structure of the gene is suggestive of a role as a sub-unit of an ion channel, but there is
no evidence of linkage to suggest that it could be associated with ADPKD in humans
(Nomura et al., 1998).

PKD2L2 is a third gene with significant homology to PKD2 and
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PKDL.

It has been recently mapped to human chromosome 5q31. and the gene product

(polycystin-L-2) h1ls 48% identity with polycystin-2 and 47% identity with polycystin- L
(Guo

et al., 2000).

11.2.ii. Ethnic Heterogeneity of ADPKD
Two Southern European groups have reported a lower incidence of linkage to th� PKDJ
gene than had previously been reported.

A Bulgarian study of 22
(Bogdanova

et al.,

1995). and a

smaller study of seven Greek-Cypriot families showed linkage to

PKDJ

in only four

approximately 68% of patients with linkage to

PKDJ

families showed

families, the others were linked to PKD2 (Constantinou-Deltas et al., 1995). Due to the
small numbers in each study, it is not possible to detennine if locus heterogeneity is
significantly different when compared to the larger study populations previously
conducted in Northern Europeans (Peters & Sandlruijl. 1992). A more recent study on
48 ADPKD families of Korean descent found that 79% of individuals had ADPKD
linked to PKDJ, and 21% were linked to PKD2 (Lee et al., 2001).

Il.2.iii, Molecular Cloning of the PKD Genes
Cloning of the

PKDJ

gene was facilitated by the identification of a family with two

genetic disorders, both due to mutations in genes located on chromosome 16 p l3.3
(Wunderle

et al., 1994).

Affected members in a Portuguese kindred had two distinct

phenotypes, either typical autosomal dominant polycystic kidney disease

(PKDJ)

or

type-2 tuberous sclerosis (TSC2). The mother and daughter in this family bad balanced
translocations, 46:XX t( l6;22)(p l3.3;q l 1 .21) and displayed ADPKD but not
contrast,

the

son

had

an

unbalanced

translocation

TSC2. In

45XY/-16-22+der(l6)
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(16qter�l6p13.3::22q l l .21� 22qter) and displayed the clinical features of 1SC2 but
not ADPKD.

It was therefore concluded that the unbalanced translocation most

probably resulted in a deletion at the 1SC2 locus, whereas the balanced translocation
was investigated to see if it disrupted the PKDJ locus (The European PKO Consortium,
1994). Investigation of the family using polymorphic markers refined the PKDJ locus
to 60 kb and enabled the construction of a cosmid contig covering the breakpoint
region.

Hence the polycystic breakpoint

(PBP) gene was listed as the most likely

candidate gene for PKD/ (The European PKO Consortium, 1994).

More recently in humans the polycystic kidney disease and receptor for egg jelly related
gene (PKDREJ) was localised close to the same region of chromosome

22 (Hughes et

al., 1999). The PK.DREG protein is expressed exclusively in the testis of humans
coincident with sperm maturation, suggesting a role in the fertilisation process (Hughes

et al., 1999).

The PKD2 gene was cloned by the construction of a cosmid- and Pl-based contig
extending over 680 kb on chromosome 4q. Northern blot hybridisation revealed a 5.4
kb transcript (cTM-4) expressed in most fetal and adult tissues, including kidney, ovary,
testis, small and large intestine and fetal lung (Mochizuki et al., 1996 ), which showed
homology at the amino acid level with the PKDI gene product. Mutation screening in
the cTM-4 transcript in three unrelated affected individuals revealed three nonsense
mutations that segregated with the disease phenotype in their families, and on that basis
cTM-4 was deemed to be the PKD2 gene (Mochizuki et al., 1996).
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ll.2.iv. Structure of the PKDJ Gene
As previously stated, the PKDJ gene comprises 46 exons spanning 52 kb, and produces
a 14.5 kb mRNA transcript which encodes a 4302 aa protein with novel domain
architecture (The International PKO Consortium 1995). The PKDJ gene contains 3
long polypyrimidine tracts in introns I , 21 and 22 (Van Raay et al., 1996) the longest
of which (depicted in Fig ll.l) is located in IVS 21 and spans 2.5 kb.
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e on 1. 33

Duplicated

e,on Jt · ..f6 Unique Pl([)J region

··h -, 1111111111111 . '1 ~111111

11111111111 1

3•

Polypyrimidine Repeat

Figure Ill. The PKDJ Gene. (Adapted from Hughes et al. , 1995).
U.2.v. The PKDl Protein
Polycystin-1 , the predicted PKDl protein, is a glycoprotein which consists of an
extracellular 5' N-terminus of over 2500 aa, multiple transmembrane domains, and a
cytoplasmic 3' C-terminus (Fig II.2) (The International PKD Consortiwn, 1995 ; Hughes

et al. , 1995).
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Figure 11.2. Polycystin-1.

The basic defect in ADPKD is believed to be tubular dysmorphogenesis. The principal
features include altered structure and function of the Golgi complex altered structure
and composition of the matrix, and abnormal cell differentiation, resulting in faulty
matrix-cell communication (Carone et al. , 1995). It has therefore been proposed that
polycystin-1 is either involved in the mediation of cell-cell or cell-matrix interactions,
or that it could be an intrinsic component of the extracellular matrix (The International
PKD Consortium, 1995).
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The domain architecture of polycystin-1 has been predicted by several groups, with only
slight suggested variations (The International PKD Consortium, 1995; Hughes et

al.,

1995). The presence of two leucine-rich repeat regions (LRRs) is probably one of the
most striking features (The International PKD Consortium, 1995; Hughes

et al., 1995).

Proteins which contain this domain are believed to be involved in protein-protein
interactions, such as cell recognition, binding to components of the extracellular matrix
or signal transduction (Hughes et al., 1995). The LRRs in PKDJ are very close to the 5'
terminus, in exons 2 and 3, and are flanked by two cysteine-rich domains (The
International PKD Consortium, 1995). This combination of 2 LRRs flanked by the
cysteine-rich domains is a feature of a number of proteins involved in protein-protein
interactions (Hughes el al., 1995). Examples of these LRR-containing proteins include
the von Willebrand factor receptor (Lopez et aL, 1987) and the

Drosophila proteins

chaoptin, involved in cell adhesion (Reinke, et al., 1988), toll, involved in dorsal-ventral
polarity (Hashimoto et al., 1988), and slit, involved in morphogenesis (Rothberg et al.,
1990). Homology has also been observed between the PKDI exon 4 encoded domain
and the

trk gene (Hughes et al., 1995), a proto-oncogene known to encode a membrane

spanning tyrosine kinase expressed in neural tissues (Martin-Zanca et al., 1986).

The next functional domain in

PKDJ is a C-type lectin domain. The usual function of

the domain, associated with cell adhesion and recognition, is to bitid specific
carbohydrates in the presence of calcium ions. In most proteins, this domain is encoded
by either one or three exons (Drickamer, 1989),

e.g. the human LOX-I gene (Aoyama et

al., 1999) and the C-type lectin superfamily cartilage derived gene, CLECSFI (Nearne
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et al., 1999), both of which have three exons for this domain. In PKDI the domain is

not typical, as it is encoded by a novel number of exons (exons 6 and 7), in association
with a previously unreported combination of protein domains (Hughes et al., 1995).

The most numerous of the PKDI domains is a novel lg-like repeat, dubbed the PKO
domain (The International Consortium, 1995). According to this source, the lg-like
domain is repeated 14 times, once in exon S, once in exon 13, once in exon 14 and 11
times in exon 15 (aa 1031-2142). The lg-like repeat was detected 16 times by Hughes
et al. ( 1995), who placed the first repeat in exon 5 and the remaining 15 repeats in exons

11-15. Both groups state that the repeat motif consists of about 80-90 aa and, although
the function of the lg-like repeats has not been established, they too are in an
extracellular position. The area covered by these repeats represents approximately 30%
of the PKDI gene. The current opinion is that there are 16 copies of the repeat (van
Adelsberg, 1999). The lg-like repeats have been shown to have a Greek key

13-

sandwich topology (Bycroft et al., 1999), also known as the immunoglobulin (lg)-like
fold (Bork et al., 1994). It is built from two (3-sheets, one with three strands (labelled A,
B, and E) and the other with four strands (labelled G, F, C, and C'), packed face to face.
The structure of the lg-like repeat found in PKDI is similar to the lg-like fold found in
other cell surface proteins, however it is not identical to any known protein· and
therefore represents a novel protein family (Bycroft et al.. 1999).

Repeat number ten is believed to be of particular functional significance, as all of its
surface residues are conserved on one (3-sheet in the Fugu genome (Bycroft et al.,
1999).

Comparative analysis of the human and Fugu genomes for PKDI has
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demonstrated PKDJ repeat number 10 to be in an evolutionarily conserved synteny
group, suggesting that it may play an important role in normal cellular physiology
(Sandford et al., 1997).

The 40% sequence identity between human and Fugu

polycystin-1 suggests that it is the tertiary structure of this protein, rather than sequence
identity, which is necessary for normal function (Sandford et al., 1997).

The next domain, FN-III, shows extensive homology to the sea urchin receptor for egg
jelly (REJ) protein (Moy et al., 1996). REJ, a 210-kD sperm membrane glycoprotein,
has been shown to function as an ion channel regulator and is believed to trigger the sea
urchin sperm acrosome 1 e :.ction (Moy et al., 1996 ). The REJ protein is modular in
design and consists of one EGF module (containing the 7 diagnostic Cys residues), two
C-type lectin carbohydrate recognition modules and a novel module, ·the REJ module',
which shares homology with the human PKDJ protein. The REJ module comprises
50% of the REJ protein (residues 480-1187) and 17%. of polycystin-1 (residues 21462882). The two modules (Altschul et al., 1990; Pearson & Lipman, 1988) are 20%
identical (Moy et al., 1996). The evolutionary homology between the REJ of sea urchin
and human PKDJ suggests that PKDJ may also be involved in ion channel regulation
(Vacquier & Moy, 1997).

There is some inconsistency in the literature concerning the other domains of the PKDJ
gene. The International PKO Consortium (1995) reported a low-density lipoprotein
type-A (LDL-A) domain in exon IO. Due to its hydrophobic nature, the domain was
predicted to have a receptor-related role as a ligand-binding region.

Hughes et al.

(1995) failed to mention such a domain but they did predict the presence of four
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fibronectin type Ill (FN-III) repeats, situated beyond the lg-like repeats toward the 3' C
tenninal region of polycystin-1.

These domains are found in extracellular matrix

proteins, and in extracellular locations of receptor and cell adhesion molecules (Hughes
et al.. 1995).

Each of the groups studying polycystin-1 also indicated the presence of several (most
probably 11) transmembrane domains (Hughes et al., 1995; The International PKD
Consortium. 1995). The region around the transmembrane (TM) domains (numbers
TMl-6 and TMI 1) has recently been subjected to further analysis (Bateman &
Sandford, 1999). This investigation was undertaken using the PSI-BLAST sequence
comparison program, on the premise that there is a high degree of sequence
conservation between human and Fugu polycystin-1. This sequence region was found
to have matches to 67 other sequences in SWISS-PROT version 37 and TrEMBL
version 9 (Bairoch & Apweiler, 1999), namely mammalian lipoxygenases,
triacyglycerol lipase and lipoprotein lipase. Following this work, a new protein domain,
the PLAT domain (after polycystin-1, lipoxygenase and alpha toxin) has been described
(Bateman & Sandford, 1999). The PLAT domain is found in the first intracellular
region of the PKDJ gene between TMI-TM2, corresponding to exons 26-29 (Bateman
& Sandford, 1999). The domain is associated with protein-protein and protein-lipid

interactions in other proteins, suggesting that the first cytoplasmic loop of polycystin-1
may be important in mediating interactions with other membrane protein{s) involved in
polycystin-l function- (Bateman & Sandford, 1999). All of the polycystin-1 domains
predicted to date indicate a role in protein:protein signalling (Harris, 1999).
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11,2.vi. PKDI Homologous Transcripts
In addition to the PKDJ gene, three other homologous genes (HGs) have been identified
by Northern blotting (The International PKD Consortium, 1995; Hughes et al., 1995;
The European PKD Consortiwn, 1994). These genes, named HG-A., HG-B, and HG-C,
produce transcripts of approximately 21 kb, 17 kb and 8.5 kb respectively (Hughes et
al., 1995). As noted previously, the HGs are up to 97% homologous with the PKDJ
gene over two-thirds of its length and it has not been detennined if the HG transcripts
produce functional proteins (Hughes et al., 1995). The origins of these HGs could be
explained in two ways: either they are alternatively spliced forms of the PBP (PKDJ)
gene or they are separate genes co-located in 16p l3.l. All three of the identified HGs
map to chromosome 16pl3. l proximal to the PKDJ region (The European Polycystic
Kidney Disease Consortiwn, 1994 ).

II.2.vii. Polycystic Kidney Disease in Animals
The ADPKD murine gene (Pied/) has been mapped to mouse chromosome 17 (Olsson
et al., 19%). Like its human counterpart, it lies tail to tail with the murine Tsc2 but is

not duplicated elsewhere on the murine genome, and does not include the
polypyrmidine tracts in intrans 21 and 22, suggesting that these changes are recent
evolutionary events (Piontek & Germino, 1999). The expression of Pkdl has been
observed from the morola embryonic stage up to adulthood (Guillaume et al., 1999).
High levels of pkdl protein expression in the embryo suggest a role in development
(Guillaume et al., 1999). Phenotypic variation had been observed between two reported
Pkdl murine models (Lu et al., 1997; Kim, et al., 2000a). The first Pkdl model (PKDJ
�34) involves a frameshift mutation {Lu et al., 1997), which produces a less severe
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phenotype than that observed in the L3946* mutant polycystin 1 model, where the
mouse polycystin-1 is expected to terminate after amino acid L3946 (equivalent to
polycystin-1 L3955 in humans) (Kim, et al., 2000a). Other animal models which may
be useful for the study of ADPKD are the Persian cat (Felclhahn, 1995; Biller et al.,
1996) and the bull terrier dog (O'Leary et al., 1999).

11.2.viii. The Structure of the PKD2 Gene
PKD2 has been shown to consist of at least 15 exons (Hayashi et al., 1997), and its
architecture includes six membrane-spanning domains and intracellular amino- and
carboxy- termini (Mochizuki et al., 1996).

There is approximately 25% identity

between the putative 968 aa PKD2 gene product, polycystin-2, and almost 450 aa of
polycystin-1 (Mochizuki et al., 1996). This homology corresponds to transmembrane
domains 1-6 of PKD2 and covers four transmembrane domains of PKDJ. The PKD2
gene is not duplicated on chromosome 4q as PKDJ is on chromosome 16. The domains
that are found in PKD2 share homology with a family of Ca2+ (and Na2) channels,
+

mostly with the L-type voltage-activated Ca2 channel etrn (VACC am) (Mochizuki et
al., 1996).

The murine Pkd2 gene has been reported by two independent groups (Wu et al., 1997;
Pennekamp et al.. 1998). Pkd2 is located on mouse chromosome 5 spanning at least 35
kb and, like its human homologue, consists of 15 exons (Pennekamp et al., 1998). The
peptide shows 95% homology to human polycystin-2, with well-conserved functional
domains (Pennekarnp et al., 1998).
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The most interesting aspect of the
interaction with

PKD2 gene structure relates to its apparent

PKDJ. A coiled-coii domain in the C-terminus of the PKDI gene has

been described which binds specifically to the C-tenninus of the

PKD2 gene product

(Qian et al., 1997}. This heterodimeric interaction suggests that PK.DJ and PKD2 may
interact in vivo in a signalling pathway for normal tubular morphogenesis. Mutations in
either gene could then lead to the identical pathology observed
1997).

The interaction of

expression, suggesting that

in ADPKD (Qian et al.,

PKDJ and PKD2 results in the up-regulation of PKDJ
PKDJ may require PKD2 for the maintenance of normal

expression levels (Tsiokas er al., 1997). Inactivation of the heterodimeric-signalling
pathway may impair terminal differentiation and lead to cysts (Arnould et al., 1999).
Given evidence of the five known polycystin-type prcteins, it is possible that more than
two polycysrin proteins interact in such signalling pathways (Nomura et al., 1998).

Il.2.ix. Expression Patterns of Polycystin-1 and Polycystin-2
Polycystin-1 is expressed in a number of tissues, including the thymus, thyroid, adrenal
glands, tonsils, duodenum, stomach, liver, spleen, heart, lungs, testes, brain and kidney
(Ward er al., 1996), and it is present from fetal to adult life (Peters et al., 1996).
Polycystin-1 has been detected at higher concentrations in cystic kidneys than in normal
controls (Ward et al., 1996).

In

both normal and cystic kidneys, polycystin-1

expression is localised to the epithelium of all tubular structures and the glomerular
parietal and visceral epithelium (podocytes) (Peters et al., 1996). Fetal expression of
polycystin-1 is higher than the normal adult level (Griffin et al., 1996; Wilson, 1997;
Huan & van Adelsberg, 1999; Weston et al., 1997). Some cultured kidney cyst-lining
epithelial cells have shown strong staining for polycystin-1 at the site of inter-cell
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interaction, adding evidence to the hypothesis that polycystin-1 is involved in cell:cell
interactions (Veldhuisen et al., 1999). More recent studies by the same group have
shown that polycystin-1 expression is not confined to epithelial cells but is also present
in endocrine cells involved

in the secretion or transport of molecules. Much stronger

staining for polycystin-1 was detected in cardiac muscle compared to skeletal muscle.
Cardiac muscle fibres communicate via gap junctions, and the high expression of
polycystin-l may correlate with the munber of interactions between these cells (Peters

et al., 1999).

With the exception of Ibraghimov-Beskrovnaya et al. (1997), all studies (Ward et al.,
1996; Griffin et al., 1996; Palsson et al., 1996; Peters el al., 19%; Geng et al., 1996;
Wilson, 1997; Huan & van Adelsberg, 1999; Weston et al., 1997; van Adelsberg et al.,
1997), have reported that polycystin-1 is expressed at higher levels in the cystic kidney
epithelia of adult ADPKD individuals than in normal adult kidneys (van Adelsberg et

al., 1999). This contrasts with what one would expect due to the haploinsufficiency
associated with an autosomal dominant disorder, or indeed with the two-hit model of
cystogenesis (see section II.3.i.). A higher level of expression in affected individuals
may be the result of an accumulation of non-functional protein caused by truncating or
rnissense mutations in the PKDJ gene. Such increased levels of protein exp1ession have
been associated with mutations

in the NEMJ and TPM3 genes linked to nemaline

myopathy (Tan et al., 1999).

Polycystin-2 presents with a similar pattern of expression to polycystin-1 in the distal
tubule and collecting duct kidney epithelia, but with more marked vascular endothelial
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cell staining (Foggensteiner et al., 2000). Co-localisation of the two polycystins was
demonstrated by dual colour immunofluorescence (Ong et al., 1999). A 34 aa region of
polycystin-2 (Glu

787

-Ser

820)

had been localised to the endoplasmic reticulwn of

endothelial cells (HEK.293) in culture, where it was the site of specific interaction with
an as yet unidentified protein (Cai et al., 1999).

The localisation of full-length

polycystin-2 to intracellular membranes suggested that this protein may be a sub-unit of
intracellular channel complexes (Cai et al., 1999).
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11.3. The Mutations and Polymmphisms Associated with ADPKD

11.3.i. Mutational Mechanisms of ADPKD
In ADPKD, it is important not only to understand how cystic proliferation occurs, but
also to appreciate the underlying genetic mechanisms and the factors causing their
initiation. A two-hit model has been proposed to explain cyst formation (Qian

el

al.,

1996), involving the hereditary germline mutation (first hit) and a somatic mutation of
the normal allele (second hit) which results in the loss of heterozygosity (LOH) of the
normal PKD gene product (Qian et al., 1996). The two-hit model was first proposed to
explain the genetic origin of retinoblastoma (Knudson, 1971 ), a form of cancer affecting
the light-sensitive retinal ce11s. Unilateral and segmentally localised forms of PKD give
credence to the two-hit hypothesis of ADPKD ( Gouldesbrough & Fleming, 1998).
Individuals with the disorder have segmental cystic abnormalities in one kidney that are
morphologically identical to ADPKD, however they have no family history of the
disease and simple surgical resection is curative (Gouldesbrough & Fleming, 1998). If
the two-hit model explains cyst formation in ADPKD, it could be postulated that two
somatic mutations could lead to the rare disease phenotype in unilateral and segmentally
localised PKD (Gouldesbrough & Fleming, 1998).

A number of additional studies have shown that LOH is associated with ADPKD in
individual renal cysts (Brasier & Henske, 1997; Koptides et al., 1998; Torra et al.,
1999 ). Three different somatic mutations, along with a missense germline mutation in
exon 31 of PKDJ, were detected in 3 of 17 renal cysts removed from an ADPKD
patient during transplantation surgery (Koptides et al., 1998). As previously stated,
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accwnulation of non-functional protein may occur in these cells and could account for
the over-expression of polycystin-1 often associated with ADPKD.

Renal cysts

associated with a germline mutation in the PKD2 gene (Koptides et al., 1999; Torra et
al., 1999), and hepatic cysts of ADPKD individuals (Watnick et al., 1998b) have also
been shown to involve somatic mutations, extending the two-hit hypothesis of cyst
formation to the PKD2 gene and to other organs apart from the kidney.

This

homozygous loss of normal PKDJ or PKD2 function preswnably alters the ability of
epithelial cells to retain tissue organisation, resulting in proliferation and cyst formation
(Wu & Somlo, 2000). In a murine model (WS25) carrying an unstable allele, which
introduced an in-frame stop codon nine codons downstream of the 5' cloning junction,
there was a cessation in Pkd2 protein expression in renal epithelial cells after cyst
formation (Wu et al., 1998).

A true null allele mouse model (WS183) was also

observed, and in this model Pkd2-I- mice were not viable (Wu et al., 1998).

A paper on polycystin-2 expression confinned the positive staining for polycystin-2 in
individual kidney cysts from PKD2-linked individuals, thus questioning the two-hit
hypothesis as the pathological factor in cyst formation (Ong et al., 1999). It was argued
that if the staining is positive for a mutant protein inactivated by a missense mutation,
then the two-hit hypothesis is plausible (Ong et al., 1999). Alternatively, the detection
of polycystin-2 in cystic epithelia may indicate that cyst initiation can occur without
loss of the normal protein or possibly through somatic mutations at other loci (such as
PKDI), affecting proteins which may be part of the polycystin complex (Ong t:t al.,
1999).
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A dominant negative effect of the mutated allele has been proposed (Roelfsema et al.,
1997). This occurs when the mutated protein interacts with the wild-type gene product
and adversely affects the normal function of that protein. It is suggested that the model
applies to a nwnber of autosomaI dominant diseases, including generalised resistance to
thyroid hormone (GRTH) (Yen et al., 1992), Marfan syndrome (Aoyama et al., 1993),
Diabetes-insulin receptor mutation (Levy-Toledano et al., 1994), and growth honnone
deficiency (Hayashi et al., 1999). This form of mutational mechanism has also been
shown to be associated with a variable phenotypic effect. Differing mutations in the c
erbA-beta-J-thyroid-hormone receptor have divergent effects on dimerization activity,
and appear to influence the level of dominant negative activity in humans (Hao et al.,
1994).

Gene conversion may be a mutational mechanism in ADPKD. One group proposed that
the HGs of PKDJ might represent reservoirs for mutation generation in ADPKD via
gene conversion (Watnick et al.. 1998a). Gene conversion was first studied ili yeast and
bas been defined as the non-reciprocal exchange of genetic information (Murti et al.,
1994). It has been postulated that gene conversion and recombination may be related
processes that involve pairing of homologous sequences, although in gene conversion
genetic information is transferred from the donor gene to the recipient without the donor
undergoing concomitant modification (Murti et al., 1994).

The role of gene conversion as a mutational mechanism has been linked to other human
genes and their pseudogenes, e.g., with congenital adrenal hyperplasia (CYP21 gene)
(Collier et al., 1993), neurofibromatosis (Hulsebos et al., 1996), and the von Willebrand
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factor gene (Eikenboom et al., 1994). CYP21 is somewhat similar to PKDJ: both genes
are duplicated on the same chromosome and share greater than ()5% sequence identity
across many thousands ofbase pairs with their respective homologue(s) (Collier et al.,
1994; Tusie-LWla & White, 1995). In the PKDJ gene, gene conversion is proposed as a
likely cause ofthe cluster ofmissense mutations in exon 23 (Watnick at al., 1998a). It
is yet to be detennined if this mutational mechanism is responsible for germline
mutations in other duplicated parts ofthe gene, or for somatic mutations. C-iven the fact
that the HGs extend over approximately 70% ofPKDJ, gene conversion could well be a
major mechanism ofmutation (Watnick et al.. 1998a).

Another possible source of mutation in the PKDJ gene is the polypyrimidine tract in
IVS 21 (Van Raay et al., 1996), because of its many triple helices (Watnick et al.,
1998a). The tract (-2.5 kb) contains a nwnber ofrepeat elements that are predicted to
form H-DNA structures. These structures form a triple helix and have been shown to
promote mutagenesis in cultured cells (Wang et al., 1996a). Triplex formation by a
poly(dG)-poly(dC) tract separating two homologous sequences in a bacterial system
was shown to promote recombination when transcription of the downstream gene was
activated (Wang et al., 1996a; Kohwi & Panchenko, 1993). Since recombination and
gene conversion are related processes, it might be expected that the polypyrimidine
tracts in PKDJ increase the rate of rnutagenesis (Watnick et al., 1998a). Preliminary
evidence supporting this theory comes from the potential clustering of missense
mutations in exons 23 and 25 of PKDJ (Watnick et al., 1997; Peral et al., 1997), around
the polypyrimidine tracts in introns 21 and 22.
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ll.3.ii. Mutations Found in PKDI
As of February 2002 there have been 185 mutations reported in the gene (Table ll.2}.

Table 11.2. PK/JI Mutations by Type and Region
Mutation Type

Total
Number

3' Unique
R�ion

5' Repeated
Re2ion

53
45
15

15
19
6

39
26
9

Nucleotide Substitutions
missense
nonsense
splicing
Deletions. Insertions and Duplications
Small deletions
Small insertions
Large deletions
Large duplication
TOTAL
(Krawcz.ak & Cooper. 1997; Afaal et al., 2000;

43
16
9

32
12
10
7
4
5
0
I
l
67
185
118
Aguiari et al., 2000; Kim. el al .. 2000b;

Koptides et al.. 2000; Perrichot et al., 2000 a & b; Phakdeekitcharoen el al., 2000 &
200 I: Rossetti et al., 200 I; Mizoguchi et al., 200 I: Bouba et al., 200 l; Tsuchiya et al..
200 I; Ding et al.. 2002).

1I.3.1ii. Tvpes of Mutations in PKDI
Approximately 80% of all mutations in the 3' region and 67% of mutations in the 5'
region are truncating. This figure is probably biased as PTI was used by two groups to
screen for mutations (Peral et al.. 1997; Roelfsema et al., 1997). Mutations have been
detected in cxons I to cxon 46. although few !,>Toups have screened the entire region
(Rossetti et al.. 200 I; Phakdeekitcharoen et al., 200 I), and a bias exists for mutation
screening in exons 15. 23 and 25 (Table 11.3 ). As more studies screen the entire 5'
region ( exons 1 to 33) for both truncating and non-truncating mutations, a true
indication of the specific types of mutation involved will be established for the l'KD 1
gene
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Il.3.iv. Location of PKDI Mutations
A comprehensive list of mutations published in the PKDI gene are given in Table 11.3,
and their locations are depicted in Figure 11.3. More than half of the studies (19/30)
show a bias for mutation detection in the non-duplicated 3' region of the gene. Thirty
six percent (67/185) of all reported mutations are clustered

in the unique region, which

accounts for only -2.Skb of the gene product (International PKD Consortium, 1995).
Only 6-7% of individuals with ADPKD Jinked to the PKDJ gene have detectable
mutations in the unique region of the gene (see Table II.3), this region represents
approximately 18% of polycystin-1.

Mutations have been detected in each exon of the 3' region of PKDJ. A non-disease
causing VNTR is located in IVS 42 (Peral et al., 1996b). The seven alleles detected at
this site range from 410 bp to 215 bp, representing an intron size variation of 325-130
bp. The intron is a complex structure and includes a 34 bp repeat that was present five
times in the analysed clone (Peral et al., 1996b). The variation may interfere with
amplification by changing the primer binding sites, or result in an amplicon too large for
the chosen mutation screening technique to be effective. Physical difficulties associated
with amplification could perhaps explain why so few variants have been detected in
exon 42 and IVS 42 of the gene.

Mutation screening results infer that the majority of gcrmline mutations are located in
the duplicated region (82%) of polycystin-1. As of February 2002, 118 mutations have
been reported in the duplicated region from approximately 600 individuals analysed
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(see Table 11.3). A true mutation detection rate cannot be estimated, as most studies
have failed to screen the entire gene, however a relative rate of detection can be
observed by comparing the number of patients screened with the percentage of the gene
covered (Table VII. I).
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Figure 11.3. Mutations of PKD 1
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11.3.v. Recurrent Mutations in PKDJ
There have been no reports on any common recurring pathogenic mutations in PKDJ
and no mutational hot-spots are apparent in the gene. As indicated in Table ll.5 the
nonsense mutation, Q4041X, in exon 44 has been reported in four families (Turco et al.,
1995; Daniells et al., 1998b; Torra et al., 1998).

Comparisons of polymorphic

haplotypes of the Q4041X-bearing chromosomes in families with this mutation revealed
no identity by descent (Torra et al., 1998).

A slipped-mispairing model has been

proposed to explain the recurrence of the mutation (Daniells et al., 1998b). Whatever
the mechanism of origin, the most common PKDI mutation known to date, Q4041X,
accounts for only 4 of approximately 950 disease alleles.

Other possible recurring mutations that have been found include: a small deletion in
exon 15 (5224del2) in three families (Watnick et al., 1999); a nonsense mutation in
exon 46, R4227X in two families (Peral et al.. 1996b &1997); and a missense mutation,
R4275W in exon 46 (Badenas et al., 1999) in a further two families. Most mutation
detection studies so far conducted for ADPKD have involved multi-generational
families. Spontaneous (de novo) mutations are estimated to account for 10% or less of
all reported ADPKD cases (Gabow, 1993 & 1996; Koptides et al., 2000).

11.3.vi. Mutational Effects on Protein
The majority of PKDI mutations detected result in a truncated protein that lacks a part
of or possibly the entire C-tenninus of polycystip-1, suggesting that this region has an
important function (Li et al., 1999). A nonsense mutation (R4227X) towards the 3' end
of the gene results in the loss of a phosphorylation site in the polycystin-1 C-terminal
41

domain at serine residue 4251.

It is proposed that this serine is the site of

phosphorylation by a cAMP-dependent protein kinase in normal human renal collecting
tubule cells and may be necessary for normal kidney function (Li et al., 1999).

Until more ADPKD genotypes (including both tnutcating and non-tnutcating mutations)
can be related to the function of PKDJ and

PKD2 gene products, and their interactions

or pathways, it will not be possible to predict the severity of particular mutations.
Hence the importance of gathering phenotypic information, and using it in the
correlation of mutations resulting from truncated proteins and missense changes in
particular protein domains. No significant clustering of mutations, either truncating or
in-frame, in any particular region of the gene have been reported

in PKDJ,

however,

trends such as the number of missense mutations in exons 23 and 25 (Watnick et

al., 1997) are emerging. The occurrence of missense mutations in these exons, and other
patterns, will

be discussed in Chapter VII together with the results of mutations detected

in this study.
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Table 11.3. Mutations Detected in PKDJ
Mutation
Tvoe
Large deletion
Total deletion of the
(entire gene)
PKDJ gene
c.224del l 3
Small deletion
Frameshift
exon 1
LI3Q
Missense
exon 1
Large deletion
g.18177del 3 kb
Frameshift
IVS 1-exon 5
S75F
Missense
exon 2
W139C
Missense
exon 4
Nonsense
S225X
exon 5
Q227X
Nonsense
exon 5
R324L
Missense
exon 5
IVS7+1G>A
Splicing mutation
Frameshift
IVS9+1G>T
Splicing mutation
Framesluft
Small deletion
c.2296delC
Frameshift
exon 10
Small insertion
c.2296insC
Frameshift
exon 10
Q705X
Nonsense
exon 11
S745
Nonsense
exon 11
Missense
L845S
exon 11
Missense
W967R
exon 12
c.3220del4
Small deletion
Frameshift
exon 13
Small deletion
c.3336delG
Frameshift
exon 13
Splicing mutation
IVS13-2A>T
Splicing mutation
IVS 14-1 G>A

Reference
European PKD Consortium, (1994).
Rossetti et al., (200 l )
Rossetti et al, (2001)
Thomas et al., (1999)
Rossetti et al., (20u 1)
Rossetti et al., (2001)
Rossetti et al., (2001)
Rossetti et al., (2001)
Thomas et al., (1999)
Rossetti et al.. (2001)
Rossetti et al., (200 I )
Rossetti et al., (2001)
Rossetti et al., (2001)
Rossetti et al., (2001)
Rossetti et al., (2001)
Thomas et al., (1999)
Phakdeekitcharoen et al., (2001)
Watnick et al., (1999)
Phakdeekitcharoen et al., (2000)
Thommoppakhun et al., (2000)
Thomas et al., (1999)
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Gl I66S
c.3804del7

c.3866delT
c.4036/4 2del2
c.4137delCT

c.429IdelG

c.4787delG

El537X
c.4898 insT

c.50I4de1A
Ql653X
c.5224del2

W l826X
c.5782dell

W l874X
c.5870dell4

Q1922X
c.6187delC

Vl956E

Missense
exon 15
Small deletion
Frameshift
exon 15
Small deletion
exon 15
Small deletion
exon 15
Small deletion
Frarneshift
exon 15
Small deletion
Frameshift
exon 15
Small deletion
Frarneshift
exon 15
Nonsense
exon 15
Small insertion
Frameshift
exon 15
Small deletion
exon 15
Nonsense
exon 15
Small deletion
Frameshift
exon 15
Nonsense
exon 15
Small deletion
Frameshift
exon 15
Nonsense
exon 15
Small deletion
Frameshift
exon 15
Nonsense
exon 15
Small deletion
In-frame
exon 15
Missense
exon 15

Phakdeek itcharoen et al.. (2000)
Watnick et al., (1999)
Roelfsema et al., (1997)
Roelfsema et al., ( 1997)
Rossetti et al., (200 l)
Rossetti et al., (2001)
Rossetti et al., (2001)
Rossetti et al., (200 I)
Thomas et al., (1999)
Roelfsema et al., (1997)
Phakdeekitcharoen et al., (2000)
Watnick et al., (1999)
Watnick et al., (1999)
(Fl826X in paper!)
Watnick et al., (1999b)
Roelfsema et al., (1997)
Rossetti et al., (2001)
Thomas et al., (1999)
Rossetti et al., (2001)
Phakdeek itcharoen et al., (2000})

Q1960X
Q2039X
c.6434del 28
c.6574del7
R2163X
c.6868del15
c.6937delAC
Q2243X
C2229X
T2250M
IVS15 +2 T>G
c. 7 I74/7 l 79del14
R2329W
c.7205del7
c.721 l ins7
Y2336D
Y2336X
7277-3 C>G
IVS 16/exon 17
C2370X
c. 7324delGT
c.7397insl l

Nonsense
exon 15
Nonsense
exon 15
Large deletion
exon 15
Small deletion
exon 15
Nonsense
exon 15
Small deletion
In-frame
exon 15
Small deletion
Frameshift
exon 15
Nonsense
exon 15
Nonsense
exon 15
Missense
exon 15
Splicin� mutation
Small deletion
Frameshift
exon 16
Missense
exon 16
Small deletion
Frameshift
exon 16
Small insertion
Frameshift
exon 16
Missense
exon 16
Nonsense
exon 16
Splicing mutation
Frameshift
Nonsense
exon 17
Small deleti:.m
Frameshift
exon 17
Small insertion
Frameshift exon 17

Phakdeekitcharoen el al., (2000)
Phakdeekitcharoen et al., (2000)
Thomas et al., (1999)
Roelfsema et al., ( 1997)
Rossetti et al., (2001)
Rossetti et al., (200 I)
Rossetti et al., (200 I)
Rossetti et al., (200 I)
Rossetti et al., (2001)
Penichot et al., (2000b)
Penichot et al., (2000b)
Bouba et al., (2001)
Perrichot et al., (2000b)
Phakdeekitcharoen et al., (2000)
Rossetti et al., (2001)
Rossetti et al., (20G l)
Penichot et al., (2000b)
Watnick et al., (1999)
Rossetti et al., (2001)
Rossetti et al., (200 I)
Watnick et al., (1999)
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R2402X
R2408C
R2430X
c.7535ins3
P247IL
Q2519L
Q2558X
c.7946del3
c.8030del5
c.8047del3
R2639X
c.8126ins20
T2649I
c.8159delCT
c.8I83del8
IVS2 l -2delAG
L2696R
A2752D
M2760T
R2761P
L2763V

Nonsense
exon 17
Missense
exon 18
Nonsense
exon 18
Small insertion
In-frame
exon 18
Missense
exon 18
Missense
exon 19
Nonsense
exon 19
Small deietion
In-frame
exon20
Small deletion
Frameshift
exon20
Small deletion
In-frame
exon20
Nonsense
exon21
Small insertion
Frameshift
exon21
Missense
exon21
Small deletion
Frameshift
exon21
Small deletion
Frameshift
exon21
Splicing mutation
Missense
exon22
Missense
exon23
Missense
exon23
Missense
exon23
Missense exon 23

Phakdeekitcharoen et al., (2000)
Phakdeekitcharoen et al., (2000)
Phakdeekitcharoen et al., (2000)
Phakdeekitcharoen et al., (2000)
Bouba et al., (2001)
Bouba et al., (2001)
Phakdeekitcharoen et al.. (2000)
Bouba et al., (200 l )
Perrichot et al., (2000b)
Bouba et al., (200I)
Perrichot et al., (2000b)
Rossetti et al., (2001)
Bouba et al., (2001)
Phakdeekitcharoen et al., (2000)
Bouba et al., (2001)
Rossetti et al., (2001)
Phakdeekitcharoen et al., (2001)
Rossetti et al., (200 l )
Watnick et al., ( 1997)
Watnick et al., ( 1997)
Watnick et al., (1997)
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M2764T
c.8507 ins l2
V2768M
E2771K
R2791Q
L2816P
12826T
c.8657delC
G2858S
Q2900X
H2921P
c.9I42/9I43del3
E2966D
R2985G
L2993P
W3001X
V3008L
c.9245dell8
Q30I6R
E3020X
R3039 C
F3064L

Missense
exon23
Small insertion
In-frame
exon23
Missense
exon23
Missense
exon23
Missense
exon 23
Missense
exon23
Missense
exon23
Smalldeletion
Frameshift
exon23
Missense
exon23
Nonsense
exon23
Missense
exon23
Smalldeletion
In-frame
exon24
Missense
exon25
Missense
exon25
Missense
exon25
Nonsense
exon25
Missense
exon25
s�_1al ldeletion
In-frame
exon25
Missense
exon25
Nonsense
exon25
Misscnse
exon25
Missense exon25

Watnick et al., {1997)
Rossetti et al., (2001)
Rossetti et al., (2001)
Rossetti et al., (2001)
Watnick et al., ( I997)
Rossetti et al., (2001)
Watnick et al., (1997)
Peral et al., (1997)
Rossetti et al., (2001)
Roelfsema et al., (1997)
Koptides et al., (2000)
Bouba et al., (2001)
Afzal et al., (2000)
Phakdeek itcharoen et al., (2001)
Peral et al., ( 1997)
Phakdeek itcharoen et al., (200 I)
Watnick et al., (1997)
Rossetti et al.. (2001)
Peral et al., (1997)
Peral et al., (1997)
Phakdeek itcharoen et al., (2001)
Watnick et al., (1997)
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c.9299delC
IVS25-16G>A
W3180X
c.9867delT
Q3206X
R3247H
V32851
c.10135-2A>T
V3375M
T3382M
Deletion of2 kb
exon 31-exon 34
c.10378 + 25del 19
IVS31
Q3394X
Deletion of5.5 kb of
genomic DNA
Q3474X
T3509M*
L3510V
Q3513X
G3559R
c. l 0946insT
E3631D
P3648L
M3677T

Small deletion
Frameshift
exon 25
Splicing mutation
Frameshift
Nonsense
exon 27
Small deletion
Frameshift
exon 28
Nonsense
exon 28
Missense
exon 29
Missense
exon 29
Splicing mutation
IVS29
Missense
exon 31
Missense
exon 31
Large deletion
Frameshift
Small deletion
Frameshift
Nonsense
exon 32
Large deletion
exon 34- 3 'UTR
Nonsense
exon 34
Missense
exon 35
Missense
exon 35
Nonsense
exon 35
Missense
exo n 36
Small insertion
exon 36
Missense
exon 37
Missense
exon 37
Missense exon 38

Peral et al., (1997)
Rossetti er al., (2001)
Rossetti et al., (2001)
Perrichot et al., (2000b)
Perrichot et al., (2000b)
Afzal et al., (2000)
Phakdeekitcharoen et al., (200 I)
Afzal et al., (2000)
Koptides et al., (1998)
Afzal et al., (2000)
European PKD Consortium, (1994)
Peral et al., (1997)
Rossetti et al., (2001)
European PKD Consortium, (1994)
Perrichot et al., (1999)
Mizoguchi et al., (2001)
Peral et al., (1997)
Peral et al., (1997)
Tsuchiya et al., (2001)
Peral eI al., (1996b)
Peral et al., ( 1996b)
Ding et al., (2002)
Turco et al., (1997)
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C3693X
R3718Q
c.l l284 insT

c.1 l285 insC

c.l1307del61
l1449del l5
( cDNA level)
c.l1453dell5
R3752W
I39E40-25 to139E40+47
72bp deletion
IVS39+1 G>C
c. l1549ins10
IO b pduplication
c. l l548del8

C. l l674 insG

Y3818X
Q3820X
Q3837X
D3814N
IVS41 +2 ins3 **
L3851P
c.12187ins9
c.12714ins23

Nonsense
exon38
Missense
exon38
Small insertion
Frameshift
exon38
Small insertion
Frameshift
exon38
Largedeletion
exon38
Smalldeletion
exon39
Smalldeletion
in-frame exon39
M issense
exon39
Largedeletion

M izogu chi et al., (2001)

Splicing mutation
Small insertion
Frameshift
exon 40
Small deletion
Frameshift
exon40
Small insertion
Frameshift
exon41
Nonsense
exon41
Nonsense
exon41
Nonsense
exon 41
Missense
exon41
Splicing mutation
M issense
exon42
Small insertion
exon43
Large insertion
duplication
exon43

Peral et al., (1997)
Turco et al.. (1997)

Aguiari et al.. (2000)
Perrichot et al., (1999)
Perrichot et al., (1999)
Tsuchiya et al., (200 I)
Afzal et al.• (1999)
Peral et al.. (1996b)
Kim et al., (2000b)
Peral eI al.. (1996b)

Kim et al., (2000b)
Kim et al., (2000b)
Peral et al., (1996 a)
Perrichot et al., (2000 a)
Peral et al., (1996b)
Kim et al., (2000b)
Perrichot et al., (2000 a)
Aguiari et al., (2000)
Perrichot et al., (1999)
Perrichot et al., (1999)
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18 bpdeletion
E43IVS43 +15/16
20 bpdeletion
E43IVS43 + 5-13
15 bpdel in75 bp intron
Paper statesIVS 47!
Q4010X
W4011X
R4020X
E4024X
G4031D
Y4039X
Q4041X
c.12252del2

c. l2262delAT

c. l2290 insG

IVS 44

+

I G>C

IVS44-l G>C
Q4059X
C4086X
Q4124X
Y4126X
R4135 G
W4139X
c.12412 ins20

SmallDeletion
Splicing
SmallDeletion
Splicing
Splicingmutation
Prob ab ly IVS 43?
Nonsense
exon44
Nonsense
exon44
Nonsense
exon44
Nonsense
exon44
Missense
exon44
Nonsense
exon44
Nonsense
exon44
Smalldeletion
Frameshift
exon44
Smalldeletion
Frameshift
exon44
Small insertion
Frameshift
exon44
Splicingmutation
In-frame
S plicingmutation
IVS 44
Nonsense
exon45
Nonsense
exon45
Nonsense
exon45
Nonsense
exon45
Missense
exon45
Nonsense
exon45
Small insertion
Frameshift exon45

Peral et al., (1995)
Peral et al., (1995)
Tighe et al., (1998)
Daniells et al., (1998b)
Roelfsema et al., (1997)
Rossetti et al., (1996)
Daniells et al., (1998b)
Daniells et al., (1998b)
Rossetti et al., (200 I)
Turco et al., (1995)
Afzal et al., (1999)
Daniells et al., (1998b)
Afzal et al., (1999)
E uropean PKO C onsortium, (1994)
Badenas et al., ( 1999)
Daniells et al., (1998a)
Neophytou et al., (1996)
Daniells et al., (1998a)
Turco et al., (1997)
Perrichot et al., (1999)
Perrichot et al., (1999)
Daniells et al., (1998a)
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Small insertion
Ding el al., (2002)
Frameshift
exon 45
c. l 2506insG
Small insertion
Daniells el al., ( 1998a)
Frameshift
exon 45
c. l 2593delA
Small deletion
Ding et al., (2002)
Frameshift
exon 45
c.12601 del3
Afzal et al., (1999)
Small deletion
In frame
exon 45
c.12617delC
Rossetti et al., (2001)
Small deletion
Frameshift
exon 45
Large deletion
1YS45+55del25
Aguiari er al.. (2000)
intron 45
IVS 45-1 G>A
Splicing mutation
Badenas et al.. (1999)
R4153C
Missense
Perrichot et al., (1999)
exon 46
Q4224P
Missense
Badenas et al., (1999)
exon 46
R4227X
Nonsense
Peral et al., (1996b)
exon 46
Y4236X
Nonsense
Perrichot et al., (2000a)
exon 46
12722delT
Small deletion
Kim et al., (2000b)
(cDNA level)
Frameshift
exon 46
c. l 2739delA
Small deletion
Peral er al., (1997)
Frameshift
exon 46
c.1280 I del28
Large deletion
Torra et al.. (1997)
exon 46
R4275W
Missense
Badenas er al.. (1999)
exon 46
•T3509M Mizoguchi er al.. (200 I) list this change as disease-causing, Peral er al.,
( 1997) and the present study propose that the same variation is neutral.
00
IVS41 +2ins3 Penichot er al., (2000a) list this change as disease-causing, Koptides
et al., (2000) cite the same variation as neutral although no RNA work was performed.
c. I 7 4 70insA
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11.3.vii. Neutral Polymorphisms in the Human Genome
Single nucleotide polymorphisms (SNPs) represent the most frequent type of variation
in the human genome. It was originally estimated that they occur at about I per I 000 bp
in a population (Wang et al.. 1998), but more recent estimates from the International
SNP Map Working Group are l SNP per 1.9kb, with a higher SNP occurrence within
genes (Sachidanandam et al .. 2001). The genetic diversity created by SNPs could
contribute to the basis of heritable variation in disease susceptibility and supply
information on human migrations (Wang et al.. 1998).

There has been increased

appreciation that large collections of SNPs could provide a useful tool for studies into
the genetic basis of complex human diseases (Risch & Merikangas, 1996 ). For whole
genome association studies, it has been calculated that useful levels of linkage
disequilibrium are unlikely to extend beyond a distance of 3 kb in the general
population, and so for screening to be informative approximately 500,000 appropriately
spaced SNPs are required (Kruglyak, 1999).

In practice, one SNP for a particular gene may be informative and associated with a
disease gene, whilst another in the same gene may well be informative as a genetic
marker, however, not be associated with disease susceptibility. For example, there are
tens of polymorphisms found in the beta-globin gene but only one single nucleotide
polymorphism in this gene is associated with sickle-cell disease (Roses, 1997). Two
particular SNPs within the sequence of apolipoprotein E are phenotype-associated; one
is responsible for the transition from APOE4 to APOE3, and the other from APOE3 to
APOE2.

APOE4 is associated with an increased risk and lower age al onset of

Alzheimer's disease, whereas APOE2 is associated with decreased risk and older age at
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onset of Alzheimer's disease (Roses, 1997).

When choosing SNPs for genome

screening, it wilJ be necessruy not only to monitor how they are spaced as infonnative
genetic markers, but also to consider their biological relevance to the disease (Roses,
1997).

Obviously it is not only work specific to SNP discovery which will record
polymorphisms in the genome. All mutation detection screening studies, including the
present investigation, have the potential to uncover disease-causing and neutral
polymorphisms. The HGBASE database, Human Genie Bi-Allelic Sequences database
(Uppsala University & lnteractiva Biotechnologie GmbH. http://hgbase.interactiva.de/)
has the capacity to list known polymorphisms within particular human genes (Brookes

et al., 2000). As of February 2002 only 11 SNPs have been listed in HGBASE for the
PKDJ gene, although many more are reported in the literature (Tables Il.4(a) & II.4(b)).

11.3.viii. Neutral Polymorphisms in PKDJ
Of the 132 neutral polymorphisms detected from exons 2 to the 3' UTR

in the PKDJ

gene, 126 are SNPs, the remaining six consist of three small deletions and three small
insertions (Table ll.4.b). A r,Jmber of studies have focused on exons 5 to 15� exons 17
to 21; and exon 23 to the 3' UTR, equivalent to an overall genomic area of 27,073 bp.
This indicates a frequency in that portion of PKDJ of l SNP per 237 bp (114 in all). a
figure that is in accordance with currently reported frequencies for the rest of the
genome (htt_p;/&gbase,cgr.ki.se/). If the proposed pathogenic SNPs of PKDJ are added
(92 in all, not nonnally defined as SNPs because they are disease-causing), this figure is
1 nucleotide variant per 131 bp in PKDI. confirming the high mntability of the gene.
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The non-disease-causing polymorphisms so far recorded in the PKDI gene are listed in
Tables ll.4.a & II.4.b. Mapping and understanding this high level of polymorphism in
the PKDI gene (and in the PKD2 gene), could lead to a better comprehension of the
mutation rates and mutational mechanisms associated with ADPKD. The presence or
absence of particular non-disease-causing polymorphisms may also correlate with
clinical heterogeneity in ADPKD (Watnick et al., 1999). Some neutral polymorphisms
may associate with particular disease-causing mutations displaying a similar phenotype,
or they may influence phenotypic heterogeneity between family members with identical
gennline mutations. Although for diagnostic purposes it is the detection of disease
causing mutations that is of primary concern, all neutral polymorphisms should be noted
for future consideration with regard to clinical heterogeneity and association with
particular disease-causing mutations.
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Table II.4(a). N on-diseaseC au singM issenseC hangesD etected in PKDJ
Neutral Missense Chanf!e
4406T/A- W/RI399
4406T/C- W/R1399
S568Cff- PILI786
6I95G/A- R/HI995
7347A/G- Y/C2379
7386G/C - R/P2392
7479C/T - S/F2423
7853G/C - E/02548
7956C/T- T/M2582
8021G/A-D/N2604
8124A/G- H/R2638
8231C/T- P/S2674
8334C/T-T/M2708
841 lC/A- P/T2734
8415A!T- Q/L2735
8S04C/T-R/C2765
85S6G/A- V/M2782
8651G/A- G/R2814
8873C/G-R/G2888
89240/A - V/12905
90190/C- E/D2966
912SG/A-D/N2972
9235G/A - V/M3008
9406GT/CC- F/L3066
9407T/C- F/L3066
9627G/T- G/V3139
9789C/T - P/L3 l93
10737C/T - T/M3S09
I0743C/T- A/V35 l l
10893G/A- S/N3S61
12168C/G - A/G398S
12341 A/G - I/V4044
I2384C/T- AIV4058
12777C/T- S/F4189

Location
ExonIS
ExonIS
Exon15
Exon 15
Exon17
Exon17
Exon 18
Exon19
Exon20
Exon20
Exon21
Exon22
Exon22
Exon23
Exon23
Exon23
Exon 23
Exon23
Exon23
Exon23
Exon24
Exon24
Exon25
Exon25
Exon25
Exon27
Exon28
Exon 35
Exon35
Exon36
Exon43
Exon44
Exon45
Exon46

Reference
Thomas et al., (1999)
Watnick et al., (1999)
T homas et al., (1999)
Phakdeekitcharoen et al., (2000)
Perrichot et al., (2000b)
Watnick et al., (1999) ##
Watnick et al., (1999) ##
Watnick et al., (1999)
Bouba et al., (2001)
Phakdeekitcharoen et al., (2000)
Watnick et al., (I999)
Rossetti et al., (2001)
Rossetti et al., {2001)
Rossetti et al., (200I)
Rossetti et al., {2001)
Rossetti et al., (2001)
Rossetti et al., (2001)
Rossetti et al., (200I)
Rossetti et al., (200I)
Rossetti et al., (200 l)
Rossetti et al., {2001)
Bouba et al., (200I)
M izosru chi et al., {200I}
Peral et al., (1997)
Perrichot et al., (2000b)
Perrichot et al., (2000b)
Perrichot et al., (2000b)
Peral et al., (1997).
Peral et al., (1997).
Perrichot et al., (1999)
Badenas et al., (1999)
Rossetti et al., (1996)
C onstantinides et al., (1997)
Peral et al., (1997)

## Watnick et al., (1999). Onl y found in affected members with aneurysm ( may be a
pol ymorphism associated with disease phenotype).
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Table H.4(b). Neutra l Po lymorph isms Detected inPKDJ

Polvmorohism

487G/A-A92
1023Cff ( l234Cff)- A34 l*
1330T/C - L373
1420C/T-H403
1921Cff- H570
2694A/C (2905A/C)- A898*
27000/A (2911G/A)- P900*
2730Cff (2941Cff)- D910*
291 lG/A - P900
2941Cff- D910
g.25134Cff
2972T/G (3 l83T/G)- V991*
3274T/C - 01021
3111A/G (3322A/G) - L l037*
3372Cff (3583Cff)- Al 124*
3375Cff (3586Cff) - SI125*
3864C/T (4075Cff) - H1288*
46350/A (48460/A)- Kl545*
4876A/C - AI555
4885G/A-Tl558
5383Cff - TI 724
5359C/T (5570Cff)- L1787*
5485Crr (5696Cff) - LI829*
57630/A (59740/A) - L l921*
6058Cff- S1949
7 l 38Cff - 02309
71470/A-A2312
IVS 16-9 GIA
73450/f - V2378
7376TIC- L2389
IVS 17 -27 CIA
IVS 17- 10 CIA
7652Cff- L2472 u
7652Cff- L248l
7696Cff - C2495
7919TIC - L2570
8002A/G - P2597
8446T/G - S2745
8650C/f-S2813
8890C/G - S2893
9124T/C- A.2971
9159 + 14A/G
IVS 24- 17 A/G

Location

Exon2
Exon5
Exon5
Exon6
Exon7
ExonI I
Exon 11
Exon 11
Exon11
Exon11
IVS 11
Exon 12
Exonl3
Exonl3
Exon 15
Exon15
Exon15
Exon 15
Exon15
Exon 15
Exon 15
Exon15
Exon 15
Exon15
Exon15
Exon16
Exon 16
IVS 16
Exon 17
Exonl7
IVS 17
IVS 17
Exon18
Exon18
Exon18
Exon 20
Exon 20
Exon 23
Exon 23
Exon 23
Exon24
IVS 24
IVS 24

Reference

Rossetti et al., (2001)
Thomas et al., (1999)
Rossetti et al., (2001)
Rossett i et al., (200I)
Rossetti et al., (200 I)
Thomas et al., (1999)
Thomas et al., (1999)
Thomas et al., (1999)
Watnicket al., (1999)
Watnicket al., (1999)
Thomas et al., (1999)
Thomas et al., (1999)
Watnicket al., (1999)
Thomas et al., (1999).
Thomas et al., (1999)
Thomas et al., (1999)
Thomas et al., (1999)
Thomas et al., (1999)
Watnicket al., (1999)
Watnicket al., (1999)
Watnicket al., (1999)
Thomas et al., (1999)
Thomas et al., (1999)
Thomas et al., (1999)
Phakdeekitcharoenet al., (2000)
Perrichot et al., (2000b)
Rossetti et al., (200 I)
Perrichot et al., {2000b)
Watnicket al., (1999) ##
Watnick et al., (1999)
Perr ichot et al., (2000b)
Perrichot et al., (2000b)
Watnick et al., (1999)
Perrichot et al., (2000b)
Phakdeekitcharoen et al., (2000)
Watnicket al., (1999)
Bouba et al., (2001)
Watnicket al., ( 1997)
Rossetti et al., (2001)
Rossetti et al., (2001)
Watnicket al., (1997)
Watnicket al., (1997)
Perr ichot er al., (2000b)
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91750/A - A2988
g.38997C/A-L2995
94060/e - V306S
9481
- v3090
9541T/e- P31 l0
98800/A - T3223
IVS 31 +7 NG
IVS 34 +20 GIA
948I
- v3090
1076Serr- L3589*
(10976err)
10976C/A - L3589 ***
is this L3589M
or I0976err L3589
�.47848err
g.47853dele
108690/A P3623*
(110800/A)
g.48085err
g.48205e/G
11364+ 13 G>A
11477 +17de114
115210/A-A337I
g.485090/ A-L3674
L3753
115840/e - S3791
g.496370/A
IVS41 +2ins3 ° 0
IVS4 l +8ins3
g.49833err
g.49942T/G
g.49942T/G
g,50075G/A-E3871
g.50493C/A-A3910
I2124Crr- R3971
I2184C/G - A399I
123070/C - L4032
12212 - 34C/A
12211 + 37ins5
12346 +19de1G
12485C/G - A4091 ***
(L4092 V)
or l2483C/G-A409IG
12271A>T/G/C-A4091 *
(12484A>T/G/C)
12617Crr - L4136

err

err

Exon 25
Exon 25
Exon 25
Exon 26
Exon 26
Exon 28
IVS 31
IVS 34
Exon 36
Exon 36

Perrichot et al., (2000b)
Mizoauchi et al., (2001)
Watnick er al .• (1997)
Perrichot et al.• (2000b)
Peral et al., (1997)
Peral et al., (1997)
Perrichot et al., (2000b)
Perrichot et al., (2000b)
Koptides et al., (2000)
Aguiari et al., (2000)

Exon 36

Perrichot et al., ( 1999)

IVS 36
IVS 36
Exon 37

Mizoauchi et al., (2001)
Mizoszuchi et al., (2001)
Aguiari et al., (2000)

IVS 37
IVS 37
IVS 38
IVS 39
Exon 40
Exon 38
Exon 39
Exon 40
IVS 40
IVS 41
IVS 41
IVS 41
IVS 41
IVS 41
Exon 42
Exon 43
Exon 43
Exon 43
Exon 43
IVS 43
IVS 43
IVS 44
Exon 45

Mizoszuchi et al., (2001)
Mizoauchi et al., (2001)
Perrichotetal, (1999)
Badenas et al., (1999)
Rossetti et al., (200 I)
Mizoauchi et al., (2001)
Tsuchiya et al., {200 l)
Peral et al., ( 1996b)
Mizoauchi et al., (200 I)
Koptides et al., (2000)
Aszuiari et al., (2000)
Mizoro.ichi et al., (2001)
Mizoszuchi et al., (2001)
Mizoauchietal, (2001)
Mizoauchi et al., (200 I)
Mizoauchi et al., (2001)
Perrichot et al., (1999)
Badenas et al., (1999)
Badenas et al., (1999)
Daniells et al., (1998b}
Badenas et al., ( 1999)
Daniells et al., (1998b)
Perrichot et al., (1999)

Exon 45

Aguiari et al., (2000)

Exon 45

Badenas et al., (1999)
57

Perrichot et al., (1999)
IVS 45
12652+ 34 G>T
Exon 46
Peral et al., (1997)
12838TiC - P4209
Exon 46
Mizoiruchi et al., (200 I)
g.51659C/T-D4234
Exon 46
Aguiari et al., (2000)
12444C/T- P4254*
(12655Cfr)
Exon 46
Peral el al., (1996b)
12973Cfr - P4254
Perrichot el al., (1999)
13133G>A
3'UTR
Badenas et al., (J 999).
131350/A
3'UTR
Badenas et al., (1999)
13233A/G
3'UTR
Badenas et al., (J 999)
13357T/C
3'UTR
Badenas el al., (1999)
13364Cfr
3'UTR
Badenas et al., (1999)
133700/A
3'UTR
*Both Thomas et al., ( 1999) and Aguiari et al., (2000) published nucleottde positions
(in bold) that do not correspond to the c.DNA sequence (Acc. L33243), the nucleotide
positions that do correspond toL33243 are given in brackets.
** Watnick et al., ( 1999). If 7652C/T is correct then amino acid sf,.,u)d read L248 I. If
not the c.DNA position maybe 7625C/T.
0• Perrichot et al., (1999) published 2 polymorphisms 10976C/A and 12485C/G where
the corresponding amino acid change is unclear.
uu Koptides el al., (2000) list IVS41 +2ins3 as neutral, Perrichot et al., (2000a), cite
the same variation as disease-causing, no RNA work was performed.
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Jl.4. Genotype-Phenotype Correlation in Single-Gene Disorders

11.4.i. Phenotypic Variation
A topic of particular interest is why some families, or individuals within families, are
severely affected by a monogenic inherited disease whilst others are not. It is important
to understand what is happening at the molecular level in order to ascertain if any
prediction of disease outcome is possible and, if so, how to establish a course of
treatment which may prevent, delay or minimise the onset of particular symptoms.
Understanding the mode of action of specific mutations will also contribute towards a
more coherent picture of gene structure and protein function (Waters el al., 1998). The
prevalence of ADPKD in the general Japanese population has been estimated at I in
4,000, approximately one quarter of that in Caucasians (Higashihara

el

al., 1998),

whereas the prevalence diagnosed at autopsy in Japan is about 1 in 400 (Higashihara el
al., 1998). This discrepancy suggests that a large proportion of ADPKD individuals do

not progress to ESRF during their lifetimes (Higashihara et al., 1998). The less severe
clinical phenotype does not correspond to fewer families Jinked to PKDJ (Wang et al.,
1995), so there must be other mechanisms, apart from locus heterogeneity, which
control phenotypic variation in this population. In addition to the genotype associated
with a disease gene, other modifying factors, both genetic and environmental, must be
considered when comparing disease phenotypes (Dipple & McCabe, 2000).
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11.4.ii. Genotype-Phenotype Correlation Studies
Genotype-phenotype correlations have been investigated in many Mendelian diseases.
Examples include phenylketonuria (PKU) (Ledley, 1991; Scriver et al., 1996; Waters et
al., 1998); cystic fibrosis (The Cystic Fibrosis Genotype-Phenotype Consortium, 1993;
Zielenski & Tsui, 1995; Ferrari & Cremonesi, 1996); adrenoleukodystrophy (Dodd et
al., 1997; Smith et al., 1999); spinal muscular atrophies (Brahe & Bertini, 1996);
inherited peripheral neuropathies (Nelis et al., 1999); breast cancers associated with
mutations in the BRCAJ and BRCA2 genes (Weber, 1998; Presneau et al., 1998), and
Marfan Syndrome (Ramirez et al., 1999). Genotype-phenotype correlations have not
yet been reported for PKDJ. Any significant trends in phenotype variation, associated
with particular types of mutations and located in regions of the gene corresponding to
various protein domains, will be discussed in Chapter VII. Possible genetic factors
contributing to phenotypic expression include locus heterogeneity, mutation
heterogeneity (including complexities such as compound heterozygosity, the presence
of double mutant alleles and neutral variants), and the genotypes of modifying genes.
Examples of how each of these factors may affect the disease phenotype are outlined
below.

II.4.ii.(a). Locus Heterogeneity
There are numerous conditions that are classified clinically as one disorder but which
are in fact caused by mutations in different genes. A few examples of such conditions
and their associated genes are tuberous sclerosis (TSC/ or TSC2), inherited breast
cancer (BRCAJ or BRCA2), and hereditary non-polyposis colorectal cancer (hMSH6,
PMS2, hMLHJ, hMSH2 or TGFBR2). One condition displaying a particularly high
60

level of locus heterogeneity is retinitis pigmentosa, with 14 loci so far associated with
the clinical phenotype (http://www.ncbi.nlm.nih.gov/Omiml).

As previously stated,
Ravine

PKD2 is generally associated with a milder phenotype than PKDJ.

er al. (1992), found that non-PKDJ patients lived longer than PKDJ patients,

had a lower risk of hypertension and progression to ESRF, and had fewer renal cysts at
the time of diagnosis.

A more recent multi-centre study reviewed the differences

between the two phenotypes by comparing 333 people with

ADPKD linked to the

PKDJ gene (33 families) and 291 people with the PKD2-linked disease (31 families)
with 398 matched controls (Hateboer et al., 1999b). It found that the median age at
death or at ESRF was 53 years

in

PKDJ-affected individuals, 69 years in

PKD2-

affected individuals and 78 years in normal controls (Hateboer et al., 1999b).

Il.4.ii.(b}. Mutation Heterogeneity
The position and type of mutation within a gene may

be used to predict its effect on

gene expression. A missense variation that is not predicted to alter protein structure
would not be expected to be associat�d with a severe phenotype, whereas a large
deletion or early truncation resulting in loss of function could have severe
consequences. For example, the first mutation detected in
most, if not all, of the

ADPKD was a deletion of

PKDJ gene (European PKD Consortium, 1994). This type of

deletiora is associated with very early onset ADPKD and a particularly severe phenotype
(Brook-Carter et al.,

1994; Longa et al., 1997; Harris, 1997).

The HPA

(hyperphenylalaninaemia) gene has a large number of mutations similar to
More than 300 mutations have been identified in

PKDJ.

HPA and the associated phenotype
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ranges from classical PKU, with impaired cognitive development, to non-PKU HPA,
with a low risk of mental retardation (Waters et al., l 998).

Complex genotype-phenotype correlations exist m cystic fibrosis, with over 900
mutations found in the CFFR gene (http://www.genet.sickkids.on.ca/cftr/). While there
is no obvious correlation between the genotype and the severity of most CF symptoms
(The CF Genotype-Phenotype Consortium, 1993), there is a general correlation with
respect to long-term pancreatic sufficiency involving a group of mutations (The CF
Genotype-Phenotype Consortium, 1993). The CFFR model was first proposed by
Riordan et al, ( 1989) and consists of two portions each with similar nucleotide binding
folds (NBD1 & 2) that connect via a regulatory domain, plus a membrane-spanning
domain which forms a channel pore. CF patients who display pancreatic sufficiency
generally have mutati, .s which are found outside the NBDl domain, whereas the most
severe phenotypes are often associated with a cluster of mutations in the NBD1 domain
(Nousia-Arvanitakis, 1999).

The emerging mutational pattern in ADPKD is that of a large number of private
mutations confined to individual families, thus complicating the identification of
molecular defects and the study of genotype-phenotype correlations. An additional
factor that will impact on the feasibility of genotype-phenotype correlations is the lack
of clinical detail in many published mutation studies (Daniells et al., 1998a & 1998b;
Roelfsema et al., 1997; Thomas et al., 1999; Afzal et al., 1999; Thongnoppakhun et al.,
1999 & 2000; Rossetti et al., 2001), and in the mutation database (Ki·awczak & Cooper,
1997).
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No specific mutation has been associated with a particular phenotype, however, large
deletions of the PKDJ gene with involvement of the TSC2 gene have shown a pattern of
severe early onset renal disease (Hanis, 1997). Another example of pbenotypic severity
associated with a particular mutation has been reported in three unrelated families with
the same deletion (c.5224del2) in exon 15 of PKDI (Watnick et al., 1999). The three
families formed part of a group of 35 families who were chosen for the study because
they each had some individuals with either very early onset of disease symptoms or
cerebral aneurysms. The biased selection of the study group does not allow the
conclusion that c.5224del2 in PKDI is invariably associated with a phenotype
associated with early disease onset or cerebral involvement.

The most frequently occurring mutation in the PKDI gene is a nonsense mutation in
exon 44 (Q4041X), which has been detected in four families to date (Turco et al., 1995;
Torra et al., 1998; Daniells et al., I998b). The number of affected people in the
families are, however, too small to permit a significant genotype-phenotype
comparison. The phenotype details associated with Q4041X are outlined in Table II.5.
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Table 11.5. Phenotype associated with Q4041X
Family
details

Reference

VR4001

Turco ct al.. ( 1995).

Ethnicity

Sex and
age

Italian

#I female
deceased

ESRF56
Death 68

Hepatic cysts

#2 male
39 years

CRF39

Hypertension

#3 female
72 years

ESRF70

Hcpallc cysts

#4 male
48 years

ESRF 42
Transplant 45

Hepatic cysts

#5 female
34 years

Normal renal
function

Hepatic cysts,
hypertension

#1 malr
39 years

CRF(n/a)

Hepatic cysts,
hypertension

#2 male
deceased

ESRF(n/a)
death age 42

(n/a)

#3 female
42 years

CRF (n/a)

(n/a)

5 affected

members

Torra et al.• ( 1998)
(This includes Ox 1433
detected by Peral ct al..
1997).

PR43
3 a1Tccred
members

Daniells ct al.. ( 1998b)
Rossetti et al.. (200 I)

Spanish

I

Age at
CRF/ESRF/
death

Other
symptoms

Ox 1433
(I member
adopted,
no
children)

British

Maie age
60 years

CRF(n/a)

Hypertension

Family69
No details
cnta)

Caucasian
(Welsh)
(n/a)

(n/a)

{n/a)

( n/a)

(n/a)

(n/a)

(n/a)

(n/a - no details available. age at death given is due to ESRF).
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11.4.ij,(c). Compound Heterozygotes and Double Mutant Alleles
Many individuals affected by single-gene disorders carry two different mutations, one
on each homologous chromosome.

Such individuals are tenned compound

heterozygotes. It has not been possible to make genotype-phenotype correlations for
PKU compound heterozygotes, as the phenotype variation is too complex (Scriver,
1995).

A further complication can occur when a double mutant allele is present, with two
mutations on the same chromosome. This can lead to three (or theoretically even four)
different mutations in the same gene in one individual contributing to the phenotype in
conjunction with other modifying factors. A number of examples have been shown,
including cystic fibrosis (Savov er al., 1995; Steffann et al., 1998; Fanen et al.. 1999),
homocystinuria ( de Franchis et al., 1999), and Marfan syndrome (Wang et al., 1996b).

As ADPKD is inherited in a dominant manner, it seems improbable that a large number
of compound heterozygotcs could exist. Mutation detection of cystic epithelial cells
has, however, revealed somatic as well as gennline mutations present in both the PKDJ
and PKD2 genes.

The mutational mechanism associated with this is the "two-hit

model" (Knudson, 1971) (see section Il.3.i). The phenotypic variability in ADPKD
could be partially attributable to the two-hit model of mutation, with a combination of a
germline muta:ion and variable somatic mutations. This is more complex than the
phenotypic variability associated with different compound heterozygotes for PKU
mutations (Scriver, 1995) as variable somatic mutations are found in the same
individual.
65

11.4.ii.Cd}. Neutral Variants
Neutral variants are non-disease-causing polymorphisms which occur in the disease
gene of interest. Whilst they alone do not appear to cause the disease, it is not yet
known how or if different combinations of variants could affect phenotypic severity. It
should be remembered that many genes harbour an array of polymorphisms. The PAH
(Phenylalanine hydroxylase) locus (100 kb) associated with PKU has at least 18 single
nucleotide polymorphisms (SNPs), eight bi-allelic restriction fragment length
polymorphisms (RFLPs), and two multi-allelic sites (Scriver & Waters, 1999). The
individual polymorphisms and their corresponding haplotype structures, along with
allelic variation in the 5' untranslated region of the gene, may influence gene
transcription and expression (Scriver & Waters, I 999).

No conclusion has been reached as to how neutral variation may (or may not) influence
the phenotype of ADPKD. However, a paper by Watnick et al. ( 1999) proposed that the
combined effect of a number of apparently "neutral" missense substitutions could result
in a pathogenic "hypennorphic" allele. For example, mutations in the SOD] gene are
usually associated with the autosomal dominant condition familial amyotrophic lateral
sclerosis (FALS).

There is a polymorphism in this gene (090A) which, in the

heterozygous state, produces no clinical effect, but homozygmes for the change display
the clinical phenotype (Andersen el al., 1995).

It will be important to record all

polymorphisms detected in the PKDJ gene in a designated database in order to test this
hypothesis in the future. Even if the hypermorphic allele is not disease-causing, the
polymorphic variation may act as a modifying factor. Thus it would be advantageous
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for future studies if such a database contained detailed phenotypic information along
with specific genotype, i.e. both the mutations and the non-disease causing
polymorphisms found in the PKDJ gene.

II.4.ii.(e). Modifying Genes
The specific genotype of a disease gene is not the only factor which influences gene
expression and phenotype severity.

Gene interactions can be expected to have a

functional effect. For example, phenotypic severity in CF has been difficult to correlate
with the CFfR genotype. In a CFfR murine model (cftr°1 1Hsc /cftr°11Hsc), little lwig
involvement is displayed but an intestinal obstruction similar to the meconium ileus
observed in human infants with CF is present (Rozmahel et al., 1996). A possible
modifying gene has been reported in these mice, localised close to the centromere on
mouse chromosome 7, where several genes are possible candidates for the modulation
of disease severity (Rozmahel et al., 1996). A region of synteny exists between this
region and human chromosome 19qI3 (Rozmahel et al., 1996), which was
demonstrated to harbour a similar hwnan CF modifier gene (Zielenski et al., 1999}.

Several possible modifying genes involved in ADPKD have been examined, including
the genes fowid in the renin-angiotensinogen-aldosterone system (RAS) proposed as the
widerlying caus e of hypertension in ADPKD (Chapman et al., 1990). A modifying
factor of particular interest is the insertion/deletion polymorphism at the locus for the
angiotensin I-converting enzyme (ACE) polymorphism, associated with cardiac
pathology such as myocardial infarction and angina (Behn et al., 1993; Caulfield et al.,
1994; Nakai et al., 1994), and left ventricular hypertrophy (Schunkert et al., 1994;
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Prasad el al., 1994 ). The deletion allele of this polymorphism has been implicated in an
earlier age at onset of ESRF for individuals with diabetic nephropathy (both IDDM and
NIDDM), lgA nephropathy (Doria et al., 1994; Yoshhida et al., 1995), and
nephroangiosclerosis (Mallamaci et al., 2000). Three independent studies on the ACE
polymorphism and ADPKD have suggested that individuals homozygous for the
deletion allele (0/0) are at increased risk of early onset of ESRF compared to their I/0
counterparts (Baboolal et al., 1997; Perez-Oller et al., I999;Van Dijk et al., 1999). The
poor prognosis was not invariably associated with a higher tendency towards the
development of hypertension, however, an association between the 0/0 genotype and
the occurrence of microalbuminuria has been reported (Van Dijk el al., 1999). A recent
study on ADPKD individuals from Australia, Bulgaria and Poland found no relationship
between ADPKD severity and ACE in terms of plasma enzyme activity and 1/0
genotypes (Schiavello et al., 2001}.

II.4.iii. Environmental Factors
Environmental factors need to be considered when assessing the genetic contribution to
the phenotype. For example, in the PiZZ form of a-1 antitrypsin deficiency some of the
phenotypic variation with respect to lung involvement reflects smoking behaviour
(Scriver & Waters, 1999).

Another major environmental modifying factor to be

considered is diet. In some diseases, such as PKU or hypergalactosemia, the exclusion
of certain foods (containing phenylalanine or galactose respectively) from the diet
prevents the onset of clinical symptoms. As illustrated in a-1 antitrypsin deficiency,
life style choices and exposure to toxins and carcinogens can also contribute to
phenotype. In the case of Gorlin's syndrome, a hereditary predisposition to nevoid
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basal cell carcinomas (Gorlin, 1995), levels of UV radiation due to sun exposure may
impact on the severity of the skin cancer phenotype.

The effect of dietruy intake of protein on the rate of decJine of glomerular filtration rate
was investigated in a study population of 200 participants with ADPKD (Klahr et al.,
1995). Specifically, protein was restricted in the diet and blood pressure was controlled
with the use of anti-hypertensive medication. Lower protein intake, but not prescription
of a keto acid-amino acid supplement, was marginally associated with a slower
progression of renal disease (Klahr et al., 1995). ADPKD patients often consider a low
protein diet to delay the onset of renal failure (Maroni, 1998; Zarazaga et al., 2001),
however, this is not mandatory and depends on advice from clinicians. A recent study
by Davis et al. (200 I), suggests that the use c,f tyrosine kinase inhibitors combined with
future gene therapy techniques may prove more effective than low protein diets and
traditional anti-hypertensive medication.

11.4.vii. The importance of Genotype-Phenotype Studies for ADPKD
Genotype-phenotype correlations for ADPKD will not be possible with any degree of
accuracy until many mutations have been detected. All new mutations, along with the
respective phenotypes, give further information as to how truncating mutations and
missense changes relate to protein function and subsequent pathogenesis. Where intra
familial variation is observed, the study of modifying factors will lead to a better
understanding of how the PKD genes interact with other genes in the same pathway in
the control of normal epithelial cell function, and how environmental factors can
influence cystic proliferation. If genotype-phenotype correlations are established, it will
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be possible to more reliably predict disease outcome and perhaps to establish if a certain
course of treatment could delay the onset of particular symptoms for some patients, i.e.
getting the right drugs to the right people.
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III.

Methodology

Ill. Methodology (Part I)

Ill. l Literature Review of Methodology

Many screening techniques are available for mutation detection and all rely on the basic
premise that they should be simple, accurate, time-efficient, economical and sensitive.
The choice of mutation detection method depends on a number of factors.

The

necessary equipment must be available and many techniques require a high degree of
laboratory skill to yield maximal detection rates. In addition, the nature of the gene
screened must also be considered.

If mutations in the gene of interest are

predominantly truncating, as seen in the dystrophin gene (Krawczak & Cooper, 1997), a
method such as the protein truncation test (PIT) would be suitable. In contrast, if a
significant proportion of the mutations are missense, as found in CFfR (Krawczak &
Cooper, 1997), the conventional PIT would then not be applicable. The size of the
template and its relative GC content must also be taken into account. Single-strand
conformation polymorphism (SSCP) analysis as a mutation screening method has been
shown to be cheap and efficient but only when PCR fragments are of optimal length
(200 to 400 bp) (Orita et al., 1989; Savov er al., 1992).

Mo�eover, the quality and specificity of template influences the efficiency of all
mutation detection screening techniques and sequencing methods. Jn the case of PKDJ
this is particularly important when trying to screen for mutations in the 5' duplicated
region of the gene.
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Ill, Li. Pre-Screening Methods
Prior to screening, most techniques require the amplification of gene products using the
polymerase chain reaction (PCR) (Saiki er al., 1986). The nature of the PKDI gene
makes it technically challenging to amplify because of a high G-C content and the co
amplification of homologous gene transcripts. Strategies employed to produce a PKDJ
specific template for mutation detection of the duplicated region are discussed here and
novel strategies are presented in section 111.5.

General techniques to improve the specificity of PCR include the addition '.'r' PCR
enhancers (Kramer & Donald, 1999). In addition to the basic PC..t<. mix, enzyme
stabilising proteins including BSA (bovine serum albwnin) or gelatine, and enzyme
stabilising solvents e.g. glycerol, are routinely included (Kramer & Donald, 1999).
Enzyme-stabilising solutes e.g. betaine, and solvents such as dimethyl sulphoxide
(DMSO) have been shown to dramatically reduce non-specific priming events by
decreasing inter- and intra-strand reannealing (Winship, I 989). Tetramethylammonium
chloride (TMAC) has also been used as a PCR enhancer (Hung et al., 1990).
Commercially available PCR additives such as Q-solution (QIAGEN) and the
Advantage-GC™ PCR Kit (Clontech) can increase reaction specificity.

III. I.ii. DNA Screening Techniques.
111.1.ii.{a). Single-Strand Conformation Polymorphism Analysis
Single-strand conformation polymorphism (SSCP) analysis detects single base
substitutions. It relies on the assumption that changes in nucleotide sequence affect the
confonnation of PCR product when it has been convened into its single-strand forms by
heating and then snap-chilling the PCR products in fonnamide- or DMSO- based
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loading buffers. The single-strand DNA is fractionated through a polyacrylamide gel
under non-denaturing conditions, hence its altered electrophoretic mobility (Orita et al.,
1989).

This is one of the techniques most commonly used for mutation screening since it is a
relatively simple procedure and gives rapid results. The length of PCR fragments that
can be analysed by SSCP does, however, restrict the usefulness of the method. It was
initially believed that SSCP was limited to testing PCR products of less than 200 bp
(Orita et al., 1989).

Subsequently, it has been reported that, by increasing the

percentage of the acrylamide gel, SSCP can screen PCR products greater than 400 bp in
length (Savov et al., 1992).

Even with this increased length, the technique can be

restrictive when large genes are involved, due to the numerous products that need to be
analysed. The sensitivity of the method in detecting mutations must also be considered;
in a blind trial on the CITR gene it has been estimated to be as high as 84% (Jordanova

et al., 1997). Methods to improve the sensitivity of SSCP include using a variety of
cross-linking ratios, by altering the acrylamide:bisacrylamide ratio of the gel.

In

addition to conventional polyacrylamide gel, a number of commercial gels (such as the
MOE gel solution, BMA, Rockland, ME) are also available. The use of 5-10% glycerol
in the running buffer has also helped to increase SSCP sensitivity. The theory behind
this modification was explained by Kukita et al. (1997), who found that TBE buffer
with glycerol maintained a relatively low pH (8.1 or less) with improved separation of
mutant fragments of up to 800 base pairs.
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In addition to the electrophoretic conditions of SSCP, the gel visualisation technique
can also influence the sensitivity of the method and detection rates. Radiolabelling of
DNA, by end-labelling one of the PCR primers, has traditionally been used to allow
visualisation by autoradiography (Nataraj et al., 1999).

For simplicity and ease of

handling silver-staining is often the method of choice, although it is not always as
sensitive as radiolabelling (Budowle et al.• 1991). When a high throughput of samples
is required, SSCP using fluorescently-labelled primers on automated capillary
sequencers can be used (Larsen et al., 1999). Running times on conventional gels can
be improved using fluorescent scanners with dyes/stains such as SYBR Gold
(Molecular Probes) (Tuma et al., 1999).

111.1.ii.{b). HDA, CSGE, DGGE and DHPLC.
Other electrophoretic gel-based screening techniques, akin to SSCP in their simplicity
and dependence upon confonnational change, include heteroduplex analysis (HOA)
(Nagamine, et al., 1989; White et al., 1992), conformation sensitive gel electrophoresis
(CSGE) (Ganguly et al., 1993), and denaturing gradient gel electrophoresis (DGGE)
(Fischer & Lennan, 1979).

HOA works on the principle that mismatched DNA

duplexes, i.e. heteroduplexes, have an altered electrophoretic mobility compared to
homoduplexes (White et al., 1992). Heteroduplexes form when PCR products from a
heterozygote template re-anneal and can be distinguished from homoduplexes by
electrophoresis.

The conformation changes which result from single base pair

alterations (a bubble-type) can be much more difficult to detect by this method than a
small deletion or insertion (bulge-type) (Battacharyyu & Lilley, 1989). HDA has been
used to detect mutations in the unique and duplicated regions of PKDJ (Table Vil. I,
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p252). Mutation detection rates can improve when a combination of HOA and SSCP
are used, e.g. with the neurofibromatosis type 1 gene (NFJ) (Abernathy, et al., 1997).
CSGE is a modification of HOA with 15% fonnamide and 10% ethylene glycol used to
emphasise confonnational differences (Gangtily et al., 1993).

DOGE works on the principle of partial melting of double-stranded DNA in
polyacrylamide gels (Fischer & Lennann, 1979).

In the presence of urea and

fonnamide gradient, DNA which is A:T-rich denatures more readily than G:C-rich
reg;(ms, thus altering the electrophoretic mobility of the DNA (Fischer & Lermann,
1979). If the sample is heterozygous, the four possible homoduplex and heteroduplex
species formed during PCR amplification melt at different rates to produce four bands
on the polyacxylamide gel, compared to the one band seen
(Cotton, 1997).

in

the wild-type control

If, however, the DNA is homozygous for a particular sequence

variation it produces only one band, which is different to that seen

in

the wild-type

homozygous specimen. Mutations in PKDJ have been detected using DOGE, although
the method generally requires significant optimisation and can be difficult to use
because of the high GC content of the gene (Perrichot et al., 1999).

Denaturing high performance liquid chromatography (DHPLC) involves the liquid
chromatography of PCR products through a column containing alkylated nonporous
particles (Hayward-Lester et al., 1996; Liu et al., 1998a). Due to a lower binding
capacity,

heteroduplexes display reduced

homoduplexes.

column retention time

relative

to

DHPLC is highly sensitive for fragments between 220 to 445 bp

(Arnold et al., 2000). A disadvantage of the technique is that relatively expensive
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equipment is required for DHPLC and mobile phase temperatures must be calculated
with regard to GC content for all PCR fragments screened (Liu et al., 1998a).

111. l .ii.(c}. Dideoxyfinget:printing
This method is a hybrid of SSCP and Sanger dideoxyfingerprinting (Sarkar et al.,
1992). Sanger sequencing reactions, performed in forward and reverse directions using
only one dideoxy terminator, are subjected to non-denaturing gel electrophoresis.
Mutations present in the sequencing reaction can be detected in the dideoxy component
of the reaction because of a gain or loss of a dideoxy tennination segment. Since this
gain or loss could be masked by the normal allele, the method is further enhanced by
the inclusion of a SSCP gel fractionation reaction, which can detect a shift in mobility
of at least one of the termination segments that follow the mutation (Blaszyk et al.,
1995). The strength of this assay is therefore in the ability to generate a spectrum of
fragments for modified SSCP analysis, thus increasing the sensitivity of SSCP.

Improvements to the technique have been made by increasing the length of fragment
screened from about 250 bp up to 500 bp, through Bi-directional dideoxy fingerprinting
(Bi-ddF). Two simultaneous cycle sequencing termination reactions are performed in
the down- and upstream.directions, using only one dideoxy tenninator and two labelled
primers (Haavik et al., 1996; Liu et al., 1996). The most recent update to the protocol,
denaturation fingerprinting (dnF2R), is suitable for screening regions with a high GC
content and utilises DOGE and Bi-ddF with two dideoxy tenninators (Liu, et al.,
1998b). During the course of the Human Genome Project, relative direct sequencing
costs have fallen. Sequencing is now the first choice of many researchers.
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III.1.ii.(d). Mismatch Cleavage Methods
Enzymatic mismatch cleavage (EMC) is another mutation detection screening test
which, as its name suggests, utilises the properties of specific enzymes to cleave
double-strand heteroduplex DNA at sites of mismatch (Kleff & Kemper, 1988). A T4
Endo VII-based mutation detection kit, the PASSPORT Mutation Scanning Kit
(Amersham, Pharmacia Biotech), is now commercially available ( lnganas et al., 2000).

In EMC, heteroduplex DNA is formed when an excess of mutant DNA is mixed in the
same tube with wild-type DNA, melted, and then allowed to re-anneal. The technique
has been shown to detect all 4 possible types of mismatched bases with up to 95%
efficiency (Youil

et al., 1995). As it can screen in excess of I kb (Forrest et al., 1995),

it may be preferable to SSCP in terms of the number of reactions required to screen
large genes.

A similar technique to EMC is referred to as chemical mismatch cleavage (CMC),which
was developed as a modification of the Maxam-Gilbert DNA sequencing method
(Cotton et al., 1988). Mismatched thiamines are susceptible to modification by osmium
tetroxide and mismatched cytosines by hydroxylamine. The modified bases are then
cleaved by piperidine treatment.

Unfortunately, osmium tetroxide is a noxious

chemical, and for this reason the use of CMC has been somewhat limited (Taylor &
Deeble, 1999).

Ill. 1.ii.(e). DNA Sequencing

In

addition to its capacity in characterising sequence variations indicated by other

screening techniques, DNA sequencing can also be used as a direct screening technique.
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Sequencing can be perfonned using traditional single-strand manucl dideoxy
sequencing and radio-labelling (Sanger et al., 1977 & 1980; Gyllensten & Erlich, 1988),
or thennal cycle sequencing (Murray, 1989).

The first approach can be undertaken in two ways. The traditional Sanger sequencing
method used the Kienow fragment (large subunit of DNA polymerase I} to synthesise a
short complementary copy from specifically primed DNA template (Sanger et al.,
1977). This was performed with radiolabelled dATP and then transferred into four
separate reaction tubes, each containing all four dNTPs and a specific ddNTP. This
approach failed to sequence the first 50 or so bases from the primer. Alternatively, a
labelling/tennination method could be perfonned (Tabor & Richardson, l 987), where
asymmetric PCR products are used as template for the sequencing reactions. Primers
are annealed to the template and radiolabelled dNTPs are incorporated into the
sequencing reactions using T7 polymerase. For both methods, sequencing reactions are
denahtred then loaded in adjacent lanes of denaturing polyacrylamide gels. Thermal
cycle sequencing is less cwnbersome to perform, as fluorescent primers can be used and
only one reaction tube per sample is necessary (Murray, I 989).

A dideoxy cycle sequencing reaction is performed when template, primer, dNTPs,
ddNTPs and a thermostable polymerase are subjected to repeated rounds of
denaturation, annealing and synthesis. Most commercially available sequencing kits for
automated sequencing now use fluorescently labelled dideoxynucleotide terminators,
relying on fluorescence imaging systems for detection.

For example, the Applied

Biosystems Incorporated (ABI) Prism Dye terminator chemistry provides a robust non79

isotopic method of sequencing on an automated sequencer (Kwok et al., 1994). DNA
sequencing technologies have improved rapidly during the course of the Genome
Projects. Advancements and modifications include the invention of high-throughput
sequencers, the use of dideoxy-terminators labelled with energy transfer dyes (BigDyes)
(AB1), and combination of the annealing and extension steps of sequencing reactions.
The new chemistry has increased peak heights and allowed greater sequencing accuracy
(Wen, 2001).

III. I .iii. RNA Screening Technigues.
Another cle.;vage-bascd method of mutation screening is non-isotopic RNAse cleavage
(NIRCA) (Goldrick et al., 1996 ), developed as a modification to ribonuclease cleavage
(Myers et al., 1985). NIRCA works on the principle that duplex RNA targets, up to I
kb in length, are cleaved by RNAse at their site of base pair mismatch (Goldrick et al.,
1996 ). The mismatched substrates are generated by ir. vitro transcription, and PCR or
RT-PCR (Reverse Transcription-Polymerase Chain Reaction) amplification is
performed using primers with bacteriophage RNA polymerase promoters ro
subsequently generate large quantities of RNA from both strands (Goldrick et al.,
1996 ). Complementary wild-type and mutant transcripts are hybridised and incubated
with RNAse. Cleavage products are subjected to electrophoresis and geis are visualised
by ethidium bromide staining (Goldrick e1 al., 1996). Mutations in PKDJ have been
detected using this method (Peral et al.. 1997).
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Ill, J .iv. Protein Screening Techniques.
TI1e protein truncation test (PTT) is usually based on a combination of RT-PCR coupled
to in vitro transcription and translation, and is used to selectively detect translation
terminating mutations (Roest et al., 1993), it can also be perfonned on DNA from
within large exons. PTT is an appropriate mutation screening method for disorders
where the majority of mutations result in premature translation termination. The PTT
comprises 4 main steps: (i). RNA is isolated from peripheral blood lymphocytes or
other tissue, with the assumption that it is processed in an identical manner to the target
tissue; (ii). it is then reverse transcribed tc c.DNA; (iii). c.DNA (or DNA if used) is
amplified by PCR; (iv). the PCR product is used as template in a 'nested PCR',
performed with an inner primer containing a T7-promoter and a eukaryotic translation
initiation sequence at the 5' end. This extra sequence allows a single tube in vitro
transcription and translation of the PCR products. The coupled T7 RNA polymerase
transcription and rabbit reticulocyte lysate system (Promega™) results in the
incorporation of [35S] methionine or other radio-labelled amino acids into the nascent
peptides.

The translation products are then fractionated by polyacrylamide gel

electrophoresis (SDS-PAGE), and visualised by autoradiography (Roest et al., 1993).

Truncated protein products resulting from premature termination are shorter than the
normal protein product and migrate more quickly through the gel. Size markers are
used to estimate the length of a truncated protein and automated sequencing can then be
performed in the region where a mutation is expected. Although this method can only
be used when the disease gene is prone to translation-terminating mutations, it is
particularly useful if the gene is large and has many exons. PTT has been successfully
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used to detect mutations in products varying in length from 971 to 5,131 bp (Roest et
al.• 1993), including PKDI (Roelfsema et al., 1997; Peral et al., 1997). There is a
limitation associated with this technique, as it can fail to detect mutations in the
presence of nonsense-mediated mRNA decay.

This limitation can be reduced by

combining the RT-PCR/PTT protocol with the preincubation of cells in cyclohexamide
to stabilise the mutant RNA (Bateman er al., 1999).

III. I. v. Comparison of Mutation Detection Methods.
A recent study by Yuan et al. (1999) using the Marfan syndrome FBNJ gene (encoding
a 2,871-aa protein) and the hepatocellular carcinoma P53 gene (encoding a 393-aa
protein) compared SSCP/HDA, EMC and direct sequencing in tenns of cost and
efficiency. When labour and reagents were taken into account SSCP/HDA was the
cheapest method with a cost of US$865.84 per patient, compared to US$1585.82 per
patient for EMC. and US$ l 74 l .02 per patient for direct sequence analysis.

The detection efficiency of the three methods varied. Although SSCP/HDA was the
cheapest method of mutation screening, four of the twenty control mutations tested
remained undetected (80% detection rate); three of these mutations were contained in
PCR fragments greater than 400 bp in size (Yuan et al., 1999). When the direct
sequencing method was performed with primers in only one direction two mutations in

FBNI were missed, this represents a 90% detection rate.

Missed mutations were

claimed to be due to fluorescent background interference (Yuan et al .• 1999). When the
samples were re-amplified and directly sequenced in both directions, the mutations were
duly detected, the sequencing chemistry used was not described (Yuan et al., 1999). All
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20 mutations were detected by EMC. A criticism made by the authors rc:garc!ing EMC
was that considerable time and effort were needed for initial optimisation.

Pre

diagnostic optimisation would increase the cost of the analysis when compared to other
more widely practised methods (Yuan et al., 1999).

Tnere is a lack of literature on cost and efficiency analyses of different screening
methods, although individual studies provide approximate rates of efficiency/detection
with various genes. A detection rate of almost I 00% has been reported using DGGE
after the design of specific primers and the addition of GC clamps (Lerman &
Silverstein, 1987; Theophilus et al., 1989; Fodde & Losekoot, 1994). NIRCA has beeu
estimated to have a detection rate of 80-90% (Taylor & Deeble, 1999). A 100%
detection rate was achieved using ddF to on the hwnan factor IX gene (Sarkar et al.,
1992) and the P53 gene (Blaszyk et al., 1995). It is difficult to estimate the overall
efficiency of mutation detection with PIT as it can only be used to detect truncating
errors. The PTT detection rate in NF/ (nueurofibromatosis gene) has been reported at
47.l % (40/85) (Fahsold et al., 2000). As 80% of mutations in the NFJ gene are
estimated to be truncating, if this is considered, the relative detection rate of PIT for
truncating mutations increases to 58.8% (40/68) (Fahsold et al., 2000).
It can be assumed that the choice of screening technique for any particular mutation
detection study must be the one that is expected to achieve a high detection rate and is
available within a given budget.

Since no screening technique can offer 100%

accuracy, and sequencing costs are becoming lower, many researchers are choosing
direct sequencing rather than preliminary screening techniques.
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III.1.vi. Amplification of PKDI without Homologous Gene (HG) contamination
Methods to prevent the co-amplification of the HGs when screening for mutations in the
duplicated region of PKDJ are swnmarised in Table lll.2.

They include: (l )

"anchored" primers in the unique region of the gene for long-range amplification into
the duplicated area (Watnick et al., 1997; Peral et al., 1997; Kopndes et al., 1998;
Thongnoppakhun et al., 1999); (2) the PIT method (Roelfsema et al., 1997); or (3)
design of PKDI specific primers (Watnick et al., 1999; Thomas et al., 1999).

Amplifications from primers anchored in the unique sequences of PKDJ into the
duplicated region of the gene have been successful from exon 34 to primers located
upstream of exon 23.

It was not considered possible to perform long-range

amplification of genomic DNA from exon 34 further 5' of ex.on 23 as IVS22 contains
the longest polypyrimidine tract (approx. 2.5 kb) found in any human gene (Van Raay
et al., 1996). Most researchers have fowtd it impossible to amplify across the tract to

include exons upstream of exon 23.

The design of PKD/-specific primers for use in the duplicated region has been difficult
due to a lack of sequence information on the HGs.

Although some sequence

information has been produced, the Human Genome Project has not completed
characterisation of the entire chromosome 16 region where the HGs lie. To solve this
problem, sequences in the 5' region of PKDJ unique to that gene were sought, so that
appropriate primers could be designed. It has been shown that the HG identity with
PKDJ does not span the entire 5' region (Watnick er al., 1997).

BAC (bacterial
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artificial chromosome) libraries can be screened by PCR to locate clones (or "pools" of
clones) containing DNA inserts that amplify with the primers of interest.

BACs can be used for cloning large inserts of DNA ranging from 100 to 300 kb
(Monaco & Larin, 1994 ). Clones consist of a bacterial vector with a stretch of foreign
insert DNA (Shizuya el al., 1992). There is little chimaerism associated with BACs, so
insert DNA is expected to originate from a single source of continuous DNA (Monaco
&

Larin, 1994). This implies that when the clones in a BAC library are screened for

PKDI sequences, some may correspond to the PKDI gene and others to one or more of

the HGs. No single BAC clone could contain both PKDJ and the HGs, as these
sequences are physically too far apart on chromosome 16.

BAC libraries are arranged in 96-well microtitre plates and correspond to particular
chromosomes. The super-pool plates have DNA from eight individual clones pooled
together per well. A detectable product indicates that one or more of the clones in the
super-pool plate contain the specific insert of interest, so corresponding pool plates can
then be screened to determine which clones are of interest. Clones are then obtained as
glycerol stocks, cultured, and the DNA is extracted. This DNA originating from PKDJ
or the HGs (but not both) is sequenced, and variations in DNA sequence can be used to
design PKDJ specific primers.

III. I .vii. Methodology specific to ADPKD
Most studies of mutations in the PKDJ gene have screened only the 3' unique region
(Table III.I). The groups that report mutations in the duplicated region (Table III.2)
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have used slightly different strategies to prevent co-amplification of the HGs and detect
mutations in PKDJ .

Table Ill.I. Mutation Screemng of DNA in Exons 34 to 46 of the PKDJ Gene.
Screening Method
Reference
Mutations detected/ ADPKD
Individuals tested
SSCP
Peral et al., (1996b)
2/45-6/ 150
Peral et al., (1996a)
l family only
Neophytou et al., (1996)
1/14
Torra et al., (1997)
1 family only
Daniells et al.. ( l 998b)
5/147
7/175
Badenas et al., (1999)
Afzal et al., (1999)
4/90
Kim et al. , (2000b)
6/91
Total = 31/669
HDA

Peral et al. , (1995)
Turco et al. , (1995)
Rossetti et al. , (1996)
Aguiari et al., (2000)

2/ 130
1/20
1/67
3/40
Total = 8/257

HDA&SSCP

Turco et al. , (1997)

3/60
Total= 3/60

DHPLC&SSCP

Mizoguchi et al. , (2001)

4/ 176
Total = 4/176

DGGE

Perrichot et al. , ( 1999)
Perrichot et al., (2000a)

8/146
additional 3/ 146
Total = 11/146

PTT & Direct Sequencing

Rossetti et al. , (2001)

6/ 131
Total = 6/131

RT-PCR&PTT

Roelfsema et al., (1997)

1/20
Total= 1/20

Grand Total

Grand Total== 64/1459
(4.4%)
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Table 111.2. Mutations Detected in the Duplicated Region of the PKDJ gene.
Screening
Method**
(& Template)
SSCP
(DNA)

Reference

Mutations
Detected/Tested
Individuals

Exons Screened
in Duplicated
PKDJ Region

Koptides et al., (1998)
Watnick et al., (1999)
Afzal et al., (2000)
Koptides et al., (2000)
Bouba et al., (2001)
Phakdeekitcharoen et al.,
(2000 & 200 I)

1 patient only
8/35
3/90
1 patient only
8/53
19/54

Ex23-34
Exll-21
Ex 23-34
Ex 23-34
Ex 16-34
Ex 1-34

Total= 40/234
HDA
(DNA)

Watnick et al., (1997)

8/80

Ex 23-34

Total= 8/80
DGGE
(DNA)

Perrichot et al., (2000b)

8/146

Ex 15-21 & 23-34

Total= 8/146
PTT

Roelfsema et al., (1997)

6/135

Ex 15 &23

(in vitro

translated)
PTT &NIRCA
(RT-PCR)

Total= 6/135
Peral et al., (1997)

6/95

Ex 22-46

Total= 6/95
PTT &Direct
Sequencing

Rossetti et al., (2001)

51/131

Ex 1-34

Total= 51/131
Direct Sequencing
DNA

Thomas et al., (1999)

7/24,

Ex2-15

RNA

Thongnoppakhun et al.,
(2000)

1 patient only

Full length RNA

Total= 8/25

Grand Total

Grand Total=
127/846 (15.0%)

**Screening was usually performed on dilute XL-PCR PKDJ-spec1fic template, from pnmers
anchored in the unique region of the gene or by using sequences in the duplicated region
specific to PKDJ.
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The European PKO Consortium ( I 994) first reported mutations in the duplicated region
of PKDJ, although they did not specifically screen for 5' mutations. Rather, they were
able to confirm that the PBP (Polycystic Break Point) gene was the PKDJ gene
following the discovery of a total deletion in a Portuguese family. Three additional
aberrant transcripts were then detected in PKDJ, namely a 2 kb deletion between exons
31-34, a 5.5 kb deletion from exon 32 to the 3'UTR, and a splicing mutation in IVS 44.

The first study to specifically screen for mutations in the 5' region used PTI' to detect
six truncating mutations in PKD I exons 15 and 23 (Roelfsema el al., 1997). On the
assumption that the HGs were transcribed but not translated (European PKD
Consortium, 1994), only the PKDJ protein product was screened by PTI and the HGs
were not translated (Roelfsema el al.. 1997). The approach was somewhat limited
because amplification required exonic primers, and only the larger exons of PKDJ, e.g.
15 and 23, could be screened using genomic DNA as template. In addition, missense
mutations, which may account for approximately 30% of mutations in the duplicated
region of PKD (see Chapter II). would not be detected by PIT (Roelfsema et al., 1997).
Peral et al. ( 1997) also used a combination of PIT and NIRCA to detect six mutations
in cDNA templates amplified by RT-PCR. The 2.4 kb template was amplified with a
PKDJ-specific primer in the unique region of the gene (exon 34) and a forward primer
in the duplicated region (exon 22).

Most groups have used genomic ON A as template for mutation screening. Anchored
PKDJ-specific primers in the unique 3' region were used with primers which extend
88

into the repeat region of the gene for Jong range amplification (XL-PCR), followed by
various screening methods (Watnick et al., 1997; Peral et al., 1997; Koptides et al.,
1998 & 2000� Perrichot ei al., 2000b; Afzal ei al., 2000; Phakdeekitcharoen et al., 2000
& 2001; Bouba et al., 2001).

The PKDJ-specific XL-PCR amplified product was

-4

diluted {> 1: 10 ) prior �u re-amplification, with nested primers to overcome the
problem of any residual genomic contamination by HGs from the initial PCR
amplification (Watnick et al., 1997).

The first two groups to detect PKDJ mutations between exons 2 to 5 and 11 to 21 of the

PKDI gene used XL-PCR from PKDJ-specific primer sites in IVSl and exon 15
(Thomas er al., 1999; Watnick et al., 1999).

Long-range PCR products were then

diluted and used as template for the amplification of individual exons. Specific PKDJ
primers were designed by comparing the known PKDJ sequence to a BAC clone
(GenBank AC002039) that contained 2 copies of the HGs (Loftus et al., 1999).

More recently two groups (Rossetti et al., 200 I; Phakdeekitcharoen et al., 2001),
reported screening the entire duplicated region of the PKDJ gene. In the Rossetti study,
51 mutations were detected between exons 1 to 34 from 13 i individuals tested with a
combination of the PTT and direct sequence analysis. Phakdeekitcharoen et al. (2001)
compared the PKDJ sequence to the published sequence of HGs 1 & 2 (Loftus et al.,
1999), in order to desi gn PKDJ-specific primers sites. From these results they were
able to amplify exons I to 34 as eight XL-PCR fragments. Exon 22 was amplified as a
separate exon to avoid amplification across its surrounding polypyrimidine tracts. XL-
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PCR fragments were then diluted (> I: IO"") and used as template in nested-PCR
followed by SSCP analysis.

One group has reported the first long-range RT-PCR of the entire coding sequence of
the PKDI gene (Thongnoppakhun et al., 1999), with the XL-PCR cDNA template
diluted I 000-fold prior to nested PCR to avoid HG contamination. This lead to the
discovery of a splice-acceptor site mutation, in IVS 13 of PKDI, by direct manual
sequencing (Thongnoppakhun et al., 2000).

Afzal & Jeffery (2001), recently reported the XL-PCR amplification ofa 13.S kb PKDI
fragment between exon 34 and IVS2 J. An amplification of this type from genomic
DNA was previously believed to be impossible, due to difficulties involved in
extending amplification over the 2.5 kb polypyrimidine tract in IVS 22 (Van Raay et
al., 1996). The present study was not able to replicate the results for this amplification.
If this XL-PCR amplification could be performed routinely, it would allow full
screening ofthe PKDI gene between exons 22 and 34 without HG i'.lterference.

PJtematively, other strategies could be developed which permit the amplification of

PK.DI without co-amplification of the homologous genes. Either way, it would mean
that more mutations could be detected throughout the gene and a significant genotype
phenotype correlation study would be possible.

Outcomes of this type of research

would lead to a greater understanding of the mechanisms of mutation in ADPKD, the
function of polycystin-1, its possible pathways and interactions, the disease
pathogenesis, and the wide-ranging phenotypic variability found in ADPKD.
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Ill. Methodology (Psrt II)

m.2-7,

111.2,

Subjects and Methods

Additional Protocols

Additional methods used in this project may be found in Appendix A.

Details of

protocols relevant to the thesis, accompanied by the various solutions used, are
presented in that section.

IIJ,3 Subjects
111.3.i, Sample Collection and Preparation Prior to Analysis
Researchers other than this candidate undertook the preliminary set-up of the �•,,dy,
phenotypic data and clinical samples were collected. genomic DNA from peripheral
blood was extracted, and linkage analysis studies were performed. Results of this work
were made available to this candidate. Except where specifically indicated, the author
conducted all further practical work and statistical analyses.

Genomic DNA or blood spots from patients tested as part of this project were obtained
from three collaborative studies.

Australian, Bulgarian and Polish families were

recruited for a multi-centre study investigating the genetic and environmental factors
involved in ADPKD.

Families were ascertained through the patient regisuy at the

Department of Nephrology, Royal Perth Hospital (RPH), Perth, Western Australia; the
haemodialysis centres at the Departments of Nephrology in Plovdiv and Pleven,
Bulgaria; and the Depdrtment ofNephrology, Jagiellonian University, Krakow, Poland.
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The diagnosis of ADPKD followed standard u!trasonographic criteria first describ.:d by
Bear er al. ( ! 984 ). then further refined by Ravine et al. ( J 994 ). The same diagnostic
protocol was used in all three countries.

When patients gave informed consent to

participate in the study. they were invited for interview at the various centres and
familial and clinicai histories were established. Infonnation on the nnture and pattern of
inheritance of the disease was provided to patients with prdimimuy genetic counselling,
additional counselling was available if requested. A pedigree was constructed for each
patient and questionnaires on genetic, clinical, dietary and lifestyle factors were
administered. The results of these questionnaires, in combination with clinical tests,
provided the basis of the phenotypic information made available to this candidate. All
index patients were requested to invil� family members to participate in the study, and
most families responded positively with affected and unaffected (or unknown status)
individuals agreeing to join the study. The information gathered from patients included
general questions, such as date and place of birth, ethnic origin, number and disease
status of family members. This was followed by specific clinical questions on diagnosis
and reason for examination, first symptom (and what that symptom was), onset of
hypertension, CRF, and ESRF, details of kidney transplantation, occurrence of extra
renal cysts and other extra-renal symptoms. The ages at which these events occurred
were a1so noted.

To ensure confidentiality, a numbering system, rather than family name was used to
identify all participant data and biological samples in the study. Clmical data y.,ere a1so
obtained from medical records with patients consent. These data included ultra:.ound
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findings, blood pressure values, and biochemical analyses including serum creatinine
levels, plus the type and severity of symptoms at diagnosis and at subsequent visits.

Linkage analysis was performed when possible by Ms Tina Schiavello (Centre for
Human Genetics, Edith Cowan University, Perth, Australia), Prof Joachim Hallmayer
(University of Western Australia, Perth, WA) and Dr Nadja Bogdanova (Institute of
Human Genetics, Westfiilische Wilhelms-Universitiit (WWU), Munster, Germany),
results of their work were made available to this candidate. Using this information, it
was possible to screen those families who had ADPKD most probably linked to the
PKDJ gene on chromosome 16, thus increasing the chance of mutation detection.

Observed minimum and maximum LOD scores in those "positively" PKDJ-linked
families ranged from 0.3-1.8 and all families had a probability of linkage to PKDI of
0.9 or greater using the methods described by Hateboer et al. ( 1999b).

The study populations consisted of 26 families from Bulgaria, 19 from Australia and 7
from Poland. In addition to the 19 Australian families, 31 Australian ADPKD index
patients of unknown linkage status were included for direct sequence analysis of exons
44-46 of the PKDJ gene.

Genomic DNA samples were either extracted from peripheral whole blood or blood
spots, or made available as a blood spot on filter paper. The DNA extractions of whole
blood were performed by Dr Bogdanova and Ms Schiavello using a salt precipitation
method (Miller et al., 1988), and DNA from blood spots was extracted using a
phenoVchloroform method (Sambrook et al., 1989).
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l11e extracted genomic DNA was measured by UV-light spectrophotometry at 260run to
detennine its concentration and to assess DNA purity. Stock solutions were stored at
-70°C, and working DNA solutions were prepared at concentrations of 50ng/µJ and
lOng/µI and stored at 4°C.

It was possibie to directly PCR amplify fragments of 200-400 hp in length of genomic
DNA from blood spot filter papers without prior extraction.

A blood spot

(approximately 3 mm in diameter) was cut from th1: filter paper and placed into the PCR
reaction tube. An extra 5µ1 of ddH20 was added to the 25µ1 total reaction volume to
replace the 5µ1 volume of DNA typically used. This type of PCR was only perfonned
on some family members who were unable to provide whole blood samples for analysis.
All index patients in the study donated whole blood for DNA extraction.

lil.4. Mutation Detection of PKDJ - 3' Unique Region
The region spanning exons 34 to the 3'- UTR of PKDJ is unique to the gene, therefore
co-amplification of homologous genes was not a problem. However, PKDJ is GC-rich
and some exons required a high degree of optimisation prior to successful amplification,
after which mutation screening was perfonned using SSCP analysis. Any variations
detected in SSCP banding patterns were further investigated by direct sequencing.
Where possible, suspected disease-causing sequence variants were tested for familial
segregation.

Mutations not resulting in premature truncation, i.e. missense variants and in-frame
deletions and insertions, were subjected to secondary protein structure programs such as
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the PHDsec algorithm (Rost et al., 1994) or nnPredict (BCM HTfP address) in order to
predict their likely effect on protein structure.

Evolutionary conservation of DNA

sequence variations was assessed with BLAST (http://www,ncbi.nlm.nih,gov/BLASTD
or Pfam (http://www.sanger.ac.uk/Software/Pfam/).

Phenotypic data for recurrent

mutations and mutations in identical protein domains were compared between and
within families.

III.4.i. Polymerase Chain Reaction
PCR was used to amplify genomic DNA for the individual exons in the unique region
of

the PKDI gene. The basic amplification reagents are detailed below (Table 111.3)

and specific primers and conditions to each amplification reaction arr .iisted

in Table

III.5.
Table 111.3 PCR Amplification Reagents.
PCR Reaction Mix (xl volume)
Reagent {cone.)

Volume

Final Cone.

Template genomic DNA ( lOnglµl)
IOX Buffer
MgCh(SOmM)
1.25mM each dNTPs
Forward Primer (60nglul)
Reverse Primer (60nglul)
Taq Polymerase (5.5U/µl)*
ddH20 up to 25 µI

5.0µ1
2.5µ1
0.8µ1
4.0µ1
0.5µ1
0.5µ1
0.2µ1
11.5µ1

2nglµl
xi

Total Volume

25µ1

l.6mM
200µ.M each/rxn
l.2ng/µI
l.2nglµl

0.044U/µl

(*Unless stated standard Taq DNA Polymerase and accompanying IOX Reaction Buffer
for PCR were purchased from Life Technologies-Gibco BRL or QIAGEN).
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Examples of the thermocycling conditions for PCR are given below (Table III.4), exon
specific conditions are listed in Table Ill.5. Unless othenvise stated, all PCR reactions
have three cycling steps (denaturation, annealing and extension).

A two-step PCR

indicates the same temperature for both the annealing and extension steps.

Table 111.4. PCR Cycling Steps
30 cycles at 65° C (3-step_)

35 cycles at 68°C (2-step}

95°C for 3 mins

xi

95°C for 3 mins

XI

65°C for l mins
72°C for 2 mins
95°C for 0.5 mins

}x30

68°C for 2 mins
95°C for 0.5 mins

}
}x35

65°C for I min
72°C for 7 mins

xl
xi

68°C for 7 mins

xl

}

Despite repeated attempts to PCR amplify exon 42, a specific product for this region
could not be generated. The various primers used are listed in Table III.6. In addition
to the routine PCR reaction mix, additives such as DMSO, BSA plus gelatine, betaine,
Q-solution (QIAGEN) and Perfect-Match PCR enhancer (Stratagene), and altered
cycling conditions with annealing temperatures ranging from 55°C to 68°C were also
evaluated. A series of buffer solutions (A-0 see Appendix A) with differing MgCh
concentrations were also unsuccessful in generating the expected amplification product.
Attempts to amplify a product of 82lbp across exon 42 (from exon 41 to exon 43) was
also unsuccessful, even after employing nested PCR
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..

Ta bl e III 5 PCR 0 f PKD 1 Umque
.
reg:10n
Exon

Primers

34

Size (bp)
of Product

Genomic
Position

F 5' gtgagctggggtgagaggag 3'
R 5 · acggctgcctggcctgagtc 3 ·

Annealing
Temperature &
Special Conditions
65°C (X 30)
(BSA & Gelatine)

240

44276-295
44496-515

35

F 5' ctgcaactgcctcctggagg 3 '
R 5' agctcacagggaggggctag 3 ·

68°C (X 35)
2-step

219

47330-349
47530-549

36

F 5 · ctgtgagctgcctctcacag 3 '
R 5' cccgtgatggaggcctgtag 3'

63°C (X 30)

286

47541-560
47807-826

37

F 5' ggtaggctacaggcctccat 3 ·
R 5' ggagacaagagacggaggtg 3 '

68°C (X 35)
2-step

299

47801-820
48080-099

38

F 5' caaagccctgctgtcactgt 3 '
R 5' cctagggtctggctggacta 3 ·

64°C (X 30)

272

48439-458
48691-710

39

F 5' gtctctggtggccgctcact 3 '
R 5' agagctccgctaaaggctgc 3 ·

68°C (X 35)
2-step

259

48929-948
49167-187

40

F 5' gagctggccagcaggaaaca 3 ·
R 5' ctcccttgtccttggcgtaga 3 ·

68°C (X 35)
2-step

264

49330-349
49573-593

41

F 5 · cgtctacgccaaggacaagg 3 '
R 5' tggctgaggggctgtggaag 3'

68°C (X 35)
2-step

355

49571-590
49906-925

42

Failed to amplify despite
repeated attempts

43

F 5 · cagcgtccctcccgccctcctga 3 ·
R 5'gcttgcagccctggggtgtgcgc 3 ·

60°C (X 40)
4%DMSO
& 10% SM Betaine

383

50381-403
50741-763

44

F 5 · caccccagggctgcaagcag 3 ·
R 5 · acgctccagagggagtccac 3 '
(3A3 C2 EPKDC, 1994)*

68°C (X 35)
2-step

292

50746-765
51018-037

45

F 5 · cgtcttagctcagctcagct 3 '
R 5' gtgtccctctcccccccact 3 '

65°C (X 30)

396

50946-965
51322-341

46

F 5 · gtgcagccggactgactgag 3 '
R 5 · gctgctccagctggtagacg 3 ·

68°C (X 35)
2-step with TMAC

318

51361-380
51659-678

F 5' gaccgactcaaccaggccac 3 '
R 5' cgtgcagccattctgcctg 3 '
(PTI4, Peral 1997)**

66°C (X 35)

336

51633-652
51950-968

(a)

46
(b)

(L39891)

• Previous reference for exon 44 primer (3A3 C2) European Polycyst1c Kidney Disease Consortium,
(1994).
•• Previous reference for exon 46 primer (PTI -4 reverse) Peral et al. (1997).
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Table IIL6. Exon 42 Amplification Primers
Primer Sequence
Primer Description
Initial Exon 42
Exon 41- Exon 43

Forward 5' cttccacagcccctgagcca 3'
Reverse 5' ctgcgaggggtgagacgctg 3'

Genomic
Position
49906-925
50244-263

Size of
Product
358 bp

Forward 5' agctgcacaactggctggac 3'

49789-808

821 bp

(Peral et al., I 996b)

Reverse 5' cgcacgaaacgggtccac 3'

50592-609

(Peral et al., l 996b)

Nested Exon 42

Forward 5' ctgagccacgcctgcactgc 3'
Reverse 5' ctgcgaggggtgagacgctg 3'

49918-937
50244-263

346 bp

III.4.ii. Agarose Gel Electrophoresis
To confirm successful PCR amplification and the absence of primer-dimer
contamination, 5µ1 aliquots of all PCR products in Ficoll loading buffer were loaded on
a 2% agarose gel containing Ethidium Bromide (0.5µg/ml).

Electrophoresis was

performed in wide Mini-Sub™ cells (BIO-RAD), with gels (15 x 10 x 0.7cm; 2 x 20
wells) run in 1 x TAE buffer at a constant 80V for 40 to 60 mins. A suitable size
marker (eg. lOObp DNA ladder, Gibco BRL) was also loaded on to the gel to ensure
that the amplified products were of the expected size. After electrophoresis, the gels
were

visualised

on

a

bench-top

UV -transilluminator

(Mighty

Bright

UV -

transilluminator, Hoefer Instruments), and a polaroid photograph or digital image was
taken as a permanent record.

fll.4.iii. Single Strand Confonnation Polymorphism Analysis
Single strand conformation polymorphism analysis (SSCP) was chosen as the method
for mutation screening of the unique region of PKDJ. After testing different crosslinking ratios, it was determined, that a 12% Polyacrylamide gel (acrylan1ide crosslinked with bis-acrylamide at a ratio of 29: 1) was the most suitable for SSCP as
previously reported (Savov et al., 1992). Gels were poured between vertical BIO-RAD
98

glass plates (using the BIO-RAD gel pouring stand) to produce a gel size of 16cm x
16cm x 0.5cm, with a 16-well comb. When polymerised, gels were assembled on the
PROTEANT"' II xi Vertical Electrophoresis Cell apparatus (BIO-RAD). The running
buffers were IXTAE or IXTBE (with 5% glycerol to prevent an increase in the pH of
TBE over 7. 7) (Kukita et al., 1997).

PCR products (2µ1 aliquots) were prepared for SSCP analysis by the addition of equal
volumes of fonnamide loading buffer and made up to a final volwne of 61,11 with
ddH20. Samples were denatured in a water bath at 95°C for two minutes and then
placed immediately on ice prior to loading.

Gels were electrophoresed at various

temperatures between 4°C and 25 °C. It was determined that gels run at 25°C gave the
best resolution. 1be gels were run in the Protean™ apparatus for varying lengths of
rime at different constant voltages (see Table Ill.5 for exon-specific conditions) using a
BIO-RAD power supply (PowerPac 1000). The voltage and time were considered to be
optimal when a clear gel image was obtained by silver staining, and a good separation
of bands had been achieved.

The use of positive PKDJ mutation/polymorphism controls for SSCP optimisation was
not possible, as prior to analysis we had no known sequence variants for any of the
fragments screened. All fragments were electrophoresed in both IXTAE and IXTBE
{+ 5% glycerol) as the sensitivity of these buffers occasionally seemed to vary between
PCR fragments. In most exons, both buffers were equally useful (as listed in Table
III.7), however screening results of the 263 bp fragment containing exon 40 indicated
that different conformational changes were detected when the two buffers were
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compared.

Thus choice of running buffer should be considered when establishing

SSCP running conditions for any fragment.

The efficiency of the initial SSCP optimisation was later tested by comparing SSCP
results with automated direct sequence analysis of the 3' unique region (see
methodology III.4.viii). It was found that all disease-segregating mutations in the rescreened sub-group detected by direct sequence analysis had been indicated in the initial
SSCP screen (See Chapter V). However, a neutral polymorphism in a relatively large
PCR fragment (396bp) was not detected by SSCP (See Chapter VI).

Table 111.7. Exon-Specific SSCP Conditions
Exon

12% PAG and Preferred Buffer

34
35

1 X TBE + 5% glycerol
1 X T AE or 1 X TBE +5% glycerol
1 X T AE or 1 X TBE +5% glycerol
36
37
1 X T AE or 1 X TBE +5% glycerol
1 X T AE or 1 X TBE +5% glycerol
38
1 X TBE + 5% glycerol
39
1 X T AE & 1 X TBE +5% glycerol
40
1 X TBE + 5% glycerol
41
I X T AE or 1 X TBE +5% glycerol
43
I X T AE or 1 X TBE +5% glycerol
44
45
1 X T AE or l X TBE +5% glycerol
l X TAE + 0.1% SDS
46 (a)"'
1 X TAE or I X TBE +5% glycerol
46 (b)"'
Exon 46 is relatively long (- 1.5 kb) and was only
start of the exon to the start of the 3'-UTR (a & b).

Running
Time
8 hours
8 hours
14 hours
8 hours
6 hours
8 hours
7 hours
14 hours
15 hours
7 hours
15 hours
7 hours
14 hours
amplified as 2 fragments that

Running
Volta2e
300V
300V
150V
300V
300V
300V
300V
150 V
200V
300V
200V
300V
200V
spanned the

III.4.iv. Silver Staining
After electrophoresis the SSCP pattern was visualised by a silver-staining procedure
(modified from Budowle

el

al. , 1991) as detailed below.
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Silver staining protocol
I. The gel was placed in 10% Ethanol (EtOH) and gently agitated for 5 minutes before
the EtOH was removed.
2. The gel was then covered in I% nii.ric acid oxidising solution and agitated for 3
minutes before rinsing in distilled water.
3. The gel was placed in 0.1 % silver nitrate and agitated for 20 minutes. AgN03(aq)
was then removed and the gel rinsed 3 times in distilled water for 2 minutes.
4. A small amount of developer was added (sodium carbonate anhydrous 0.56M and
0.04524% formaldehyde) until it just covered the gel. The gel was agitated and
when the developer began to turn brown it was replaced with fresh developer and
further agitated until an adequate signal appeared.
5. When the staining was sufficiently intense to see the marker and SSCP bands, the

gel was quickly rinsed in distilled water, drained and immediately covered in 10%
glacial acetic acid for at least 10 minutes to stop further development of the signal
and fix the silver stain.
6. Acetic acid was drained and the gel covered in distilled water.

Gels could be stored for one to two days in distilled water containing 5% glycerol, or
dried overnight in cellulose film using the Gel Drying Kit™ from Promega.

III.4.v. Single Strand DNA Ampiification
When conformation changes were observed by SSCP, sequencing was performed to
characterise the precise variation from the published sequence (GenBank Acc. L3989I).
Manual isotopic sequencing was chosen as the sequencing method in the frrst instance,
IOI

as heterozygotes are easily characterised for autosomal dominant diseases such as
ADPKD and, at the time of analysis, it was a readily available method.

In

later

experiments when SSCP efficiency was evaluated, automated sequencing was
performed.

Prior to manual isotopic sequencing, a single-stranded DNA (ssDNA) template was
prepared from double-stranded PCR product template by asymmetric amplification
(Gyllensten & Erlich, 1988). The remaining PCR product, initially amplified for SSCP
analysis, was purified to remove any excess primer or non-specific product prior to this
procedure.

QIAquick PCR purification kit (QIAGEN) was used as per the

manufacturer's reconunendations and the clean dsDNA was eluted in 30µ1 of pure
water (Appendix A).

The primers used for this ssDNA amplification were the same as those already listed in
Table III.5. The cycling conditions for each exon were retained for both the for.vard
and reverse reactions, however the nwnber of cycles was increased to 40. The detailed
protocol for ssDNA amplification (Table III.8) is an example of the forward reaction;
reverse product was obtained with an excess of reverse primer.

After amplification the product was concentrated and excess oligonucleotides were
removed using Centricon™ centrifugal filter columns (Millipore, Centricon-30) as per
manufacturer's recommendations (See Appendix A).
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Table 111.S. Asymmetric PCR Amplification Reagents.
Asymmetric PCR Reaction Mix (xi volume)

Reagent (cone.)

Volume

Final Cone.

Template DNA
10 x Buffer (with MgCh)
l.2 5mM dNTPs
Forward Primer (60ng/ul)
Reverse Primer (6ng/ul)
Taq Polymerase (5.SU/µl)•
ddH20 up to 100µ1

1.0µ1
10.0µ1
1 6.0µ l
10.0µ1
1.0µ1
0.5µ1
61.5µ1

xi (l.SmM)
200µ M each
600ng
6ng
2.75U

Total Volume
100µ]
(The IO X Buffer and Taq polymerase were from Gibco BRL).

Ill.4.vi. Isotopic Seguencing Reaction
When SSCP analysis indicated a confonnational variation, fragments were directly
sequenced in both forward and reverse directions using the oligonucleotide internal
primers listed in Table.III. IO.

5
Samples were rac:!iolabelled with [a-3 S]-d ATP (Amersbam) for sequencing.

This

32

isotope was chosen in preference to [a- P]-dATP, as its low energy .8 emissions result
in relatively sharper autoradiographic bands.
needed for autoracliography with
products labelled with

35

32

S than

32

P, its longer half-life means that sequencing

S can be stored for longer periods prior to electrophoresis,

compared to those labelled with
radiation than with

35

Although increased exposur� times are

32

35

P. Users of S also are exposed to a lower dose of

P (Ausubel & Albright, Current Protocols in Molecular Biology

Chp 7 suppl 26, 1994). The protocol for this method of sequencing is outlined in Table
III.9.
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Table 111.9. Isotopic Labelling Reaction.

In microcentrifuge tube mix the following:
ssDNA
Annealing buffer
Sequencing primer (6ng/µI)
Totai volume

10µ1
2µ1
2µ1
14µ1

[Incubate at 80°C for 5 minutes and
allow to cool to room temperature]

A "master-mix" was prepared in a designated radioisotope laboratory in compliance
with standard safety procedures.

Use of a "master-mix" reduces the handling of

radioisotope and minimises error from small volume pipetting. The volume of each
reagent in the master-mix was equal to the volume for one sample multiplied by (n + I )
where n was the number of samples.
Preparation Qf_an Isotope Master Mix for LabeJJing
(X l volume)
Labelling Mix• ( 1 :5)
3.0µ1
0.5µ1
ddH20
[a-35S]-dATP ( lOµCi/µI)
92.ul
Total volume
1.QiJl
Add 4.0µ1 of isotope mix to the template mix and then add T7 DNA polymerase
14µ1
Template mix
4.0µ1
Isotope mix
2.0ul
T7 Polymerase {l U/µ1)
Total volume
20.0µJ
Stand at room temperature for 5 minutes prior to sequencing reaction.
* Labelling Mix* ( I :5) (Epicentre Technologies, Madiosn, WI, USA)
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Table 111.10. Sequencing of PKD I Unique region
Primers (Forward and Reverse)
5 ' caggctgctgagcaggtccg 3 ' R (reverse)
(use with forward primed ssPCR product)
5 ' gctctgaagctcacccttgc 3 ' F (forward)
(use with reverse primed ssPCR product)

Genomic Position (l,39891)
44428-44447
44299-44318

35

5' gctacgcaagcacacctgtc 3 ' R
5 · cgggatgaattcacagccta 3 ' F

47498-47517
4 7351-47370

36

5' ccctggcagccccctcacct 3 ' R
5 · ctgtctctgcttccccagga 3 ' F

4 7563-4 7582
4 7782-4 7801

38

5' gtgcagctcctgcttgatgg 3 ' R
5 ' accagagcctcctggtgtac 3 ' F

48595-48614
48496-458] 5

39

5 · cacgccctgccagctca 3 ' R
5 · gtgtgactgatgctgtggca 3 ' F

49116-49132
48981-48990

40

5' cgtccccgagccattgtg 3' ** (FFR) R
5 ' gggctctgtgtgtttcagca 3 ' F

49501-49518
49388-49407

41

5 ' cctgttgtccagccagttgtg 3 · ** (NNR) R
5 · gagtagttctccaggagtgc 3 ' F
5 ' cacgccacccctctccggca 3 ' F

49794-49814
49591-49610
49667-49686

44

5' ccgcgcagtcacctacca 3 ' R
5 ' cagatttctcgtccgcaggct 3 ' F

50918-50935
50767-50787

45

5 ' gggccgtacccacctcctt 3 ' R or
5 'aggaacaactccaccatctcgtag 3 '** (HHR) R
5 'cagctcgtgtcttcctgtgt 3 ' F or
5' ggctgggggctgttattctc 3 '** (MMF) F or
5' tctaccctgtgtcctgccgag 3 '** (HHF) F

51303-51321
51242-51265
51000-51019
51163-51182
51078-51098

46 (a)

5 ' gggagggctcaggctcacac 3 '* * (JJR) R
5' gttccgccacaaagtccgct 3 ' F or
5 ' tccgctttgaagggatggag 3 '** (JJF) F

51575-51594
51398-51417
51412-51431

46 (b)

5 ' ggactaagtgctgctggggt 3 ' R or
5' caaggcggctgggcagtg 3 '** (KKR)

51850-51896
51760-51777

Exon

34

** Previous reference (with primer name) from Peral et al. (1996b).
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IHA,vii. Direct Seauence Analysis (Isotopi c)
111.4,vji.(a). Seguencins Reaction
After radiolabelling of the ssPCR product, sequencing reactiofis were performed with
termination mixes prepared as directed by the manufacturer (Boehringer Mannheim
GmbH) for each of the 4 nucleotide-mixes (Table Ill. I I).

Table IILl 1. Termination Mixes for Sequencing
Reaeent

dATP

dCTP
(7-deaza) dGTP
dTIP
ddATP
ddCTP
ddGTP

A mix
150umol/L
ISOµmol/L
150umol/L
I50µmol/L
lSumol/L

Cmix

Gmix

Tmix

lSOumol/L
I50µmol/L
150umol/L
150urnol/L

150umol/L
I50umol/L
I SOumol/L
lSOµmol/L

I501-1mol/L
150umol/L
I50umol/L
150wnol/L

15umol/L
ISumol/L

ddTIP

IOmmol/L
M�Ch
Tris-HCL pH 7.5 40mmol/L
50mmol/L
NaCl

IOmmol/L
40mmol/L
50mmol/L

ISumoVL
IOmrnol/L
40mmol/L
SOmmol/L

lOmmol/L
40mmol/L
SOmmo!/L

For each sample, four ( 1.5ml) microcentrifuge tubes were labelled (A, C, G or T) and
3.5 µI of e!\ch respective termination mix were pipetted into the tube. These tubes were
then placed in a heat block at 37 °C and allowed to equilibrate for several minutes and

4.Sµl of isotopically labelled sequencing mix was added. The reactions were allowed to
undergo annealing and extension for five minutes at 37°C.

The reaction was then

stopped by the addition of 5µ1 of 95% (vol/vol) formamide/20

mM

EDTA buffer.

When all reactions had been stopped, tubes were stored at 4°C prior to gel
electrophoresis (or at -20°C if electrophoresis did not occur within 24 hours). Reactions
were run on 6% denaturing (6M urea. 1 x TBE) polyacrylamide gels within 48 hours of
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sequencmg. Prior to electrophoresis, the sequencing reactions were heat denatured at
95°C for five minutes and immediately placed on ice before being loaded on to the gel.

III.4.vii.(b). Polyacrylamide Gel Electrophoresis for Manual Sequencing
Electrophoresis was perfonned using a vertical gel apparatus system {Hoefer™ Poker
Face II). Two clean glass plates, a 37x43cm back plate, and a Sigmacote™ treated
(chlorinated organo;,olysiloxane in heptane, Sigma) 33x4 l cm top plate were assembled
with a bottom spacer and side-spacers (0.4mm) and clamped together to prevent gel
leakage prior to polymerisation.

A denaturing 6M urea 6% polyacrylamide {19: l acrylamide:bis-acrylamide) gel
solution {80ml) was prepared with 80 µI of TEMED {Sigma) and 800µ1 of 10% APS
{ammonium persulphate, Sigma). The gel mix was poured between the plates, an
inverted sharks-tooth comb was inserted and secured with clamps. The gel was allowed
to polymerise for between forty minutes to two hours at room temperature. The clamps,
bottom spacer and comb were then removed and the excess gel solution was wiped from
the glass. The plates were assembled in the electrophoresis apparatus (Hoefer) with
IXTBE buffer and the gel was pre-wanned at 68W constant power for 30 minutes.
Prior to gel loading, excess urea was displaced from the well with buffer and the sharks
tooth comb {64-wells) was ir,serted to fonn the loading slots.

Denatured sequencing reactions (2.5µ1) were fractionated on 6% denaturing gels at
68W constant power (BIO-RAD PowerPac 3000) for 2-3 hours at 45°C. Bands were
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detected by autoradiography after the gel had been fixed and dried on Whatmann paper
(3MM).

III,4 .vii.(c). Autoradiography of Sequencing Gels,
Dry gels were placed in autoradiographic cassettes and a sheet of X-OMAT

autoradiographic paper (Kodak) was layed over the gel.

The gels were exposed

overnight at room temperature to X-OMAT films (or longer if the isotopic signal was
weak) and developed through an automatic X-ray developing machine (Kodak). When
developed, the films were examined over a standard white light box and a comparison
was made between the resultant and the published sequence (see Fig III.I).

Wild-type

AC

Mutant

GT

AC

GT

Arrow depicts a deletion of
base G in the mutant
sequence on the left.
The autoradiograph above
this position demonstrates
the sequence frameshift after
the deletion.

Fig 111.1. Autoradiograph showing wild-type and mutant sequences
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III.4.viii. Direct Automated DNA Sequencing.
To evaluate the relative efficiency of SSCP, the amplified genomic DNA for PKDJ
exons 44 and 45 from approximately 50 Australian ADPKD patients was screened by
direct automated sequencing. Fifteen of these patients had been screened previously by
SSCP and the sequence and SSCP results were directly compared. The same previously
listed oligonucleotide primers and conditions (Table

IIl.5) were used to prepare

templates for sequencing and SSCP analysis. These primers were then used in forward
and reverse dideoxy sequencing reactions. Sequencing was performed using the Big
Dye ready reaction terminator cycle sequencing kit (Applied Biosystems Inc. Prism) for
electrophoresis on the 377 Sequencer (Applied Biosystems Inc.). The recommended
protocol was modified to a total volume of 1Oµl. Approximately 20ng of clean double
stranded template were used per reaction (Table 111.12).

Table IIL12. Automated Sequencing Protocol.
Sequencing Protocol Using Big-Dye Kit (ABI Prism)
Terminator mix
Primer (20ng/µl)
Template (dsDNA)
dd.H20

4.5µ1
1.0µ1
20ng
to a final volume of 10µ1

The reaction was then cycle-sequenced using the following conditions:
5 sec
X1
1.
95°C
°
10 sec}
95 C
2.
50°C
5 sec }
X 25
°
60 C
4 min}
3.

4°C

Hold at this temperature W1ril purified.

109

The sequencing reactions were ethanol-salt precipitated as recommended by
manufacturer to remove fluorescently labelled dNTPs and cL-ied to :zero volume (see
Appendix A for details).

Sequencing reactions were mixed with 4 µI of formamide EDTA loading buffer,
denatured and electrophoresed in a denaturing (6M urea) 4% polyacrylamide gel (19:1
FMC) on an ABI 377 DNA Sequencer (as per manufacturers recommendation). The
sequencing results were analysed using Sequence-Navigator™, a software package by
ABI (Perkin-Elmer), or Sequencher 1995 (Gene Codes Inc).

III.4.ix. Characterisation of Sequence Variants.
It was necessary to establish whether detected variants were pathogenic or neutral.
When a sequence change was detected its genomic position was noted, and if exonic or
in the splice-site region, the effects on the mRNA and amino acid sequences were
determined. RNA was not available in this study and therefore it was not possible to
perform RT-PCR, which means that splice-site mutations could not be fully
characterised. Some intronic polymorphisms located in exon recognition sequences can
lead to exon skipping, and this type of mutation would remain undetected without RT
PCR.

All sequence variations were analysed using DNAsis (Hitachi Software) or
WEBCUTTER (http://bio.lundberg.gu.se/cutter2D.

These programs also indicate

restriction enzyme sites within a given sequence of DNA. When the variant sequence is
compared to the published "wild-type" sequence, differences in restriction sites may be
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found.

The results of these comparisons were used to locate suitable restriction

enzymes for family segregation analyses.

Restriction digest analyses were also

performed on individuals for some common polymorphic changes indicated by SSCP.
The use of such restriction digests not only confirms sequence variation results but also
negates the need for extra sequencing. The specific restriction enzymes suitable for
particular sequence variations are listed in Chapters V & VI. All restriction digests
were performed as recommended by the manufacturer.

Digested DNA fragments were run on 4% agarose gels or 10% non-denaturing
polyacrylamide gels ( 19: l) using the Multiphor II Electrophoresis unit (Phannacia
Biotech), which allows rapid separation of fragments. The gels were electrophoresed at
a constant temperature of 10°C.

When polymerised, the gels were placed cellophane-side down on the ceramic back
plate of the Multiphor apparatus. Agarose gel buffer strips were prepared (3% agarose
pre-soaked in I xTBE with a few drops of bromophenol blue added), and placed at the
upper and lower edges of the gel. The acrylamide gel was then loaded with 2-3 µI of
the restriction digest mix. The gels were run at a constant power output of 3 W for
between 40 to 60 nunutes at 10 °C, and then silver stained as previously described
(Section IIl.4.iv). The gels were dried under vacuum on Whatmann paper (3 MM).

If no change in the restriction site was detected, SSCP analysis or sequencing was used
for family studies. In addition to family segregation analysis, all missense changes
were compared to the wild-type sequence using the secondaiy structure protein
I II

prediction

algorithms

PHDsec

(Rost

et

al.,

1994)

and

nnPredict

(hm,:/ldot.imgen.bcm.tmc.edu
:9331/seq-search/struc-predict.html).

The wild type and variant sequences were

submitted separately and the predicted protein structures were obtained for comparison.

III.4.x. Characterisation of Insertions or Deletions.
When sequence analysis indicated an insertion or deletion, a second PCR was carried
out on the sample under investigation and the product was cloned using the TOPO TA
cloning kit (lnvitrogen). The vector with insert was then transformed into TOPIO one
shot competent cells. After heat shock at 42 ° C, the cells were cultured in SOC medium
at 37°C, spread on to 50µg/ml ampicillin plates with X-gal and IPTG and incubated
overnight at 37° C. On the next day, 8 to 10 white colonies were picked from each plate
and grown as separate cultures (4ml of LB medium, 50µg/ml ampicillin) at 37°C
overnight. Plasmid DNA was isolated using the QIAGEN Plasmid Mini Kit and then
sequenced with Ml3 Forward (-20) and MI3 Reverse primers using the Big-Dye
sequencing kit (Applied Biosystems) and a 377 DNA sequencer/genetic analyser.
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lll.5. Mutation Detection in the 5' Duplicated Region.

III.5.i, Amplification of PKDJ-specific template in the 5' Duplicated Regi..Q!!
The difficulty associated with amplification of a PKDJ-unique template in the
duplicated region of this gene poses a substantial problem to any mutation screening
study. The various methods that were attempted to achieve this specificity are reviewed
here.

They focus on the long-range a.-nplification of six PKDJ-specific templates

(Table 111.15) that in twn are used as template in nested amplification reactions (Tables
llI.16-21).

A reverse primer in exon 34 similar to those previously described (Watnick et al., 1997;
Peral et al., 1997) was designed to act as a PKDJ-specific anchor for the amplification
of exons 23 to 33. Known PKDJ-specific primer sites in exon 15 (Watnick et al.. 1999)
and IVS I (Thomas et al.. 1999) were used to amplify PKD 1 template for exons 15 to
21 and exons 2 to 5. Primer design was based on sequence variations between PKDJ
and a BAC clone (AC002039) containing HGI and HG2 (Loftus et al., 1999). A
comparison between AC002039 and PKDJ was performed to generate PKD-1 specific
primer sites around exon 1. Exon 22 of PKDJ was not screened. It lies between two
polypyrimidine tracts in introns 21 and 22, and as previously reported (Watnick et al.,
1997), it is exceedingly difficult to amplify across these tracts in either direction.

BAC and PAC libraries were screened and two clones found to contain HG inserts were
partially sequenced. The resulting sequence variations were used to generate specific
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oligonucleotide primer sites in IVS11, and XL-template was amplified from that PKD/
specific primer site in both forward and reverse directions to include �xons 6 to 14.

III.5.ii. Screening ofBAC and PAC DNA Pools for PKDI and the HGs
A PCR screen of two human DNA libraries was undertaken (Human BAC DNA pools,
Release II, Research Genetics and Human PAC DNA pools, Genome Systems). PAC
libraries are similar to BAC libraries and were developed from PI-derived artificial
chromosomes which have an average insert size of 130-150 kb (Ioannou et al., 1994).
PCR amplifications were performed with primers in both the duplicated and unique
regions of the PKDJ gene, as listed in Table III.13. This experiment aimed to identify
clones containing one or more of the homologous genes or the PKDI gene. When such
clones were detected, the duplicated region was sequenced and analysed to locate
differences that could be utilised for PKDI unique primer design.

III.5.ii(a). Screening BAC and PAC Pools
Both libraries were supplied as "super-pool" and "pool" plates (Research Genetics and
Genome Systems) in a 96-well microtitre format. The covering foil or plastic on each
plate was removed when frozen (and wiped with 100% ethanol) to prevent cross
contamination between wells, and the microtitre plate contents thawed at room
temperature.

The PCR screen was first performed on the superpool plate and the

addresses of any clones that were successfully PCR amplified using primers for PKDJ
were recorded. The corresponding pool plate and its row and column plates were then
amplified with the same primers to identify which individual clones in the superpool
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well were positive for the PKDJ primer sequence. Amplification reactions of 25µ1 total
volume used 1µl of superpool plate DNA as template and 2µ1 for all other plates.

Initial superpool screening was performed with primers for exons 2 to 3, exon 35 and
exon 45 . A more detailed screen of the clones was then undertaken using primers for
exons 5, 13, 15 and 31-33.

The primers, their genomic location, amplification

conditions and product size are listed in Table III.13. Cycling conditions include the
nwnber of cycles and annealing temperature (the times listed indicate the duration of
each repeated step, eg. l '/2 '12' represents 1 minute denaturation, 2 minutes annealing
and 2 minutes extension of primers).

Table III.13. Primers for DNA Pool Screening
Exons

Primer Sequence
1810 5' ggaaggcctctggcctacta 3'
1811 3 ' ggagggcagaagggatattg 3'

Cycling
Conditions
55°C (X30)
(l '/2'/2')

Genomic
Position
19848-864
20215-234

Product
size (hp)
387

2-3
5

5AF 5' tggagccaggaggagcagaac 3'
5BR 5' cagggcggcaggtgccgctt 3'

65°C (X25)
(0.5'/0.5'/1.5' )

20771-791
21347-366

595

13

13F 5' tcacctgccacctgggctcac 3'
13R 3' gacaagagcctggtgcccacc 3'

65°C (X25)
(0.5'/0.5'/l .5')

26279-299
26519-539

261

15

3134 5' gtgctggtcaccagcatcaa 3'
313 5 5' cagccagcaggatctgaaaat 5'

55°C (X30)
(1 '/2'/2')

28507-526
29826-847

1341

31-33

3853 5 ' ggactcgtccgtgctggac 3 '
2930 3 'ggatttggcaggcgagtaggggct 5'

68°C (X35)
2-step (0.5'/2 ' )

43672-690
44239-262

591

35

3651 5' ctgcaactgcctcctggagg 3'
3652 5' ggatttggcaggcgagtaggggct 3'

68°C (X35)
2-step (0 .5'/2' )

47330-349
47530-549

220

45

3686 5' cgtcttagctcagctcagct 3 '
3687 5' gtgtccctctcccccccact 3'

68°C (X35)
2-step (0.5'/2 ')

50946-965
51322-341

396
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111.5.ii.(b). Culture and Isolation of BAC and PAC DNA
When a BAC or PAC product was identified as positive for PKDI, or its HGs, a
glycerol stock solution for the specific clone was ordered from Research Genetics or
Genome Systems respectively. Stocks were streaked on LB (Luria Bertani) Agar-plates
(containing chloramphenicol 12.Sµg/ml) using aseptic technique and incubated at 37°C
overnight.

To obtain sufficient working volumes of the clonal DNA for PCR

optimisation and sequencing, a single colony from these plates was picked to inoculate
a bacterial culture. Purification of the culture was performed using a modification of
the QIAGEN Plasmid Mtdi Kit protocol (personal communication Dr. Arseni Markoff,
Munster) as detailed in Appendix A

IH.5.ii.{c). Amplification and Sequencing of BAC and PAC DNA.
The PKDI and HG isolated DNA was then amplified with the primers listed in Table
111.14.

. .

.

Tll bl e Ill 14 Pnmers ftor BAC and PAC DNA A mp l"fi
1 1cat1on.
Exons

Primer Sequence

2-5

1810 5 · ggaaggcctctggcctacta 3 •
1807 5 'tcagggaggcagg.cgacata 3 ·

7-9

4102 5 · cagctacgtctgcgagctgc 3 ·
4103 5 · ggtgnggaaggcttcacggc 5 ·

9-10

Cycling
Conditions

Genomic
Position

Product
size (bp)

I 68°C (X 5)
l 2-step (0 5'/2')

22420-439
23191-210

791

4104 5 · gcaggtgtaccggctcctca 3 ·
4105 5 · cagctgggtcctgttgtccg 3 ·

' 68°C (X 5)
2-step (0 5'/2')

23261-270
23695-714

454

11-12

4 I 06 5 • g<l<'gaccatgtccgagccgg 3 ·
4107 5 • gaagaccatgtccgagccgg 3 •

68°C (X 5)
2-step (05'/2')

25086-105
26011-030

945

12-14

4108 5 · cgcggcggtcltcaagctctg 3 •
4140 5 • gagggctgttggggaggaagg 3 ·

68°C (X 0)
2-step (0 5'/2')

26099-119
27023-043

945

J

68°C (X 5)
2-step (05'/2')

19848-864
20837-846

999
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After the PCR amplification of each clonal DNA with these primers, the products were
electrophoresed in a 1% agarose gel (a total PCR volume of 25µ1 was loaded into wells
formed with a wide tooth comb). Bands were excised from the gel and purified using
the QIAquick Gel Extraction Kit as recommended by the manufacturer (QIAGEN).
The concentration of DNA after cleaning was estimated against DNA of known
concentration on an agarose gel. Approximately 30ng of DNA were then sequenced in
both the forward and reverse directions for each amplicon using the individual primers
listed in Table IIl.14.

Sequencing was perfonned using the ready reaction tenninator cycle sequencing kit, as
recommended by the manufacturer (Applied Biosystems Inc. Prism). Clean pellets
were air-dried and then sent to the Inst'tute of Physiology, WWU, Munster, Germany
where samples were electrophoresed on an ABI 373 sequencer by the designated
operator (Appendix A).

III.5.ii.(d). PKD/·Specific Sequence in the Duplicated Region of the Gene.
Comparisons between the resultant BAC and PAC sequences and the published
sequence of PKDJ (GenBank Acc. L39891) were made by Dr. Arseni Markoff using
the GeneStream global alignment tool (http://www2.igh.cnrs.fr/home.eng.htrnl). PKDJ
introns 3, 4, 8, 9, 12, 13 and 14 were assessed for areas specific to PKDJ. On the basis
of these results {Chapter IV), PKDJ specific primers were designed in IVSI I to amplify

PKDJ exons 6 to 11 and 12 to 14. These are listed in Table III. IS with the other PKDJ
primers used for Xl,·PCR amplification.
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Ta ble 11115 Pnmers
.
f;or XL - Temp ate Amp.l'fi
t tcatton.
Cycling
Primer Sequence
Exons
Ex2-5

IVS I F5' cccagcgtctcatctgtctgg 3'
IVS5 R 5' ggtgggaacgagggtgtcaac 3'

Conditions

68 °C (X40)
2 -step
(0.5'/5')
Ex 6-11
2927 5' gccgcctacagcatcgtggccc 3 •
68 °C (X40)
I IR 5 • cagtgaggggaggcacctacact 3 •
2-step
(0.5'/4')
Ex12-14
I2F 5' cagtgtaggtgcctcccctcactg 3'
68 °C (X40)
3130 5' ccagcacggtcaggaggtact 3'
2-step
(0.5'/2 ')
Exl5
IVS I3F5' ctgtcccggttcactcactgc 3 •
68 °C (X40)
ExlSXLR 5' caacgtgggcctccaagtagttg 3' 2-step
(0.5'/4')
Ex15-21 Exl5XLF 5'gcaactacttggaggcccacg 3'
68 °C (X40)
IVS2 IR 5 'gcagggtgagcaggtggggccatc 3 • 2-step
(0.5'/4')
23-34
TWFI • 5' ctgcactgacctcacgcatgt 3'
68 °C (X40)
Ex34 R 5 • atgtgggtgtcttgggtag g 3'
2-step
(0.5'/6')
l11e amplification reactions were perfonned using long-range

Genomic
Position

Product

size (hp)

17049-69
21579-90

4.542

21447-470
25622-644

4,198

25621-644
27410-430

1810

26769-89
30607-29

3861

30606-26
33957-80

3375

37674-694
44403-422

6,749

amplification enzyme

with a hot-start (XL- rTth Applied Biosystems).

To ensure that diluted long-range PCR products were PKD/-specific, a senes of
5
3
dilutions (1:10·2, 1:10· and 1:10· ) were made prior to re- amplification and used to
-1

amplify exon 8 of PKDJ. A dilution factor of?:'.: I: I0 of PCR product had previously
been shown to produce PKD/-specific amplification when used as template (Watnick et
al., 1999). Diluted PCR products were then purified from an excised agarose gel slice
using the QIAquick PCR Purification Kit as per the manufacturer' s reconunendations
(QIAGEN). The purified products were sequenced using the SequiThenn EXCEL II
DNA

Cycle

Sequencing

Kit,

as described by

the

manufacturer (Epicentre

Technologies), and products were isotopically labelled with [ a-nP)-dA TP ( Hartmann
Analytics). l11e detailed protocol is listed in Appendix A.
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Prior to elec\rophoresis, the products of the sequencing reactions were denatured at
95 °C for 3 minutes and immediately placed .:,il ice. Denaturing PAG electrophoresis
and autoradiography was performed as previously described (Section III.S.vii).

The

sequencing results (Chapter IV) indicate that a dilution of 1: 10·5 produced specific
amplification of the

PKD J gene, whereas dilutions of l : 10-2 and I : 10·3 gave rise to the

co-amplification of homologous genes.

III.6, Mutation Detection Screen ofPKDI Exons 2 to 33

III.6,i.

PCR Amplification of individual PKD! Exons

Genomic DNA was amplified with XL primers (Table III.15), and the products were
5
diluted l: l 0· . The diluted products ( I µI in total reaction volwne of 25 µl) acted as
template for the nested PCR amplification of individual exons contained within the
respective XL-PCR products (IIl.6.i.a-g). Each PCR reaction included 200µM ofeach
dNTP, l .SmM MgCh, 30ng of forward and reverse primer, I X Buffer, I U of Taq
polymerase and Sµl ofQ-solution (QIAGEN).

Despite repeated attempts at the optimisation of reaction conditions we were unable to
produce a PCR product of suitable quality for mutational analysis of the PKDJ gene
surrounding exon l. The high GC content of the region surrounding exon 1 prevented
the specific amplification for screening purposes.

Other groups have reported the

difficulty of trying to screen for mutations in exon I of the

PK.DJ gene (Rossetti er al.,

2001; Phakdeekitcharoen et al., 2001). Both groups were only able to screen the region
after performing long-range amplifications, followed by nested amplifications u sing
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high

annealing temperatures and PCR enhancing additives

(DMSO

buffer

with

Taq

extender and Advantage-GC genomic polymerase and GC melt respectively).

Ill.6.i.(a) Amolification of exons 2 to 5

.

-

1 cation o fPKDIExons 2 5
f';or the PCR •A.mp l'fi
TablC 11116
.
. Pnmers
Exons

Primer Sequence

Cycling

Conditions

Genomic
Position

Product

size (bo)
230

Ex 2

Ex2F 5' ggaaggcctctggcctacta 3'
Ex2R 5' ggggattcggcaaagctgat 3'

64°C (X35)
(0.5'/0.S'/1')

19845-64
20064-74

l:.x 3

Ex3F 5' ctcagctgtgggggattcca 3 ·
Ex3R S' ggcagaagggatattggggg 3'

58°C (X35)
(0.5'/I '/I')

20045-64
20211-30

186

Ex4

Ex4F S' ggctggcatagacccttc�c J'
Ex4R 5' cctggctgggaaggacagag 3'

64°C (X35)
(0.5'/0.5'/I')

20378-97
20630-50

273

Ex 5(a)

Ex5aF 5· gtggagccaggagga gca 3'
ExSaR 5' gggaagacgtgctggagg 3'

58°C (X35)
(0.5'/1'/l ')

20770-87
21081-98

Ex S(b)

Ex5bF 5' cctccagcacgtcttccc 3'
Ex5bR 5' ccgcttccacctgcacg1 3'

64°C (X35)
(0.5'/0.5'/I')

21081-98
21335-52

272

Ex S(c)

ExScF 5' ctcagccctgctggggacaga 3'
IVSS R 5' ggtgggaacgagggtgtcaac 3'

64°C (X35)
(O.S'i0.5'/1')

21315-35
21579-89

275

329
. .
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IIl,6.i.{b) Amplification of exons 6 to 11

.

-

,able III I 7.

T

Exons
6

Pnm�rs
.
tior the PCR Am1p J"fi
I cation o f l'KDJ Exons 6 11
Primer Sequence
Genomic
Cycling
Conditions
Position
21491-508
4349 5' gtgagtgtctgctgccca 3'
58°C (X30)
21868-886
4350 5' cctccttcctcctgagact 3'
(I '/I'/I')

Product
size (bp)
396

1

4351 5' ggctctgagcctcagttt 3'
4352 5' taaccacagccagcgtct 3 •

58 °C (X30)
(I '/l '/1')

22104-121
22476-493

391

8

4353 5' gtctgttcgtcctggtgt 3'
4354 5 · ccatcttcactgggcaca 3 ·

58°C (XJO)
(I'/l'/1')

22575-592
22863-880

306

9

4345 5'gttcgggtagggggagtct 3'
4346 5'gtgaaagctcagagaggcca 3 •

60°C (X 35)
(0.8'/0.8'/0.8')

23090-108
23341-360

271

10

4347 5' gg tggcctgtgggcaaatca 3'
4348 5' gcctgaggagatgcaggga 3'

61 °C (X30)

23608-627
23929-947

340

()'/]'/}')

I I-I la

11AF 5' gggtccacgggccatgaccgt 3'
IIAR 5'cgcagtccagggttgggcctc 3'

66°C (X25)
(0.5'/1'/I')

24300-320
24610-630

331

11-1 lb

11 BF 5' acggaacagctcaccgtgct 3 '
11BR 5 • aaggtggccaccagggcaggg 3 •

66°C (X25)
(0.5' /I'/I')

24581-600
24880-900

320

II-I Jc

II CF 5' gcagtgtcagcgcccgctttg 3 ·
I ICR 5' agcaccctgtctgcaggcacc 3'

66°C (X25)
(0.5'/1'/I')

24849-869
25150-170

321

Exon 11 was amplified as three fragments (a, b & c) due to its size (756bp).

111.6.i.(c) Amplification of exons 12 to 14

.

.

-

Ta ble Ul 18 P.
nmers fior tI1e PCR Amp J"fi
1 1cat1on o fPKDJExons 1 2 14
Exons
Primer Sequence
Cycling
Genomic
Conditions
Position
25923-940
12
4355 5' ccaggaggcgacaggcta 3'
61 °C (X30)
26256-74
5135 5' cctggccctgattggcgtc 3'
(0 8'/0.8'/0.8')

size (bp)

l3

5228 5 · tcacctgccacctgggctcac 3'
5136 5' ccgaggctcagaa.aagca 3 •

68 °C (X35)
2-step (0.5'12')

26279•299
26581-598

320

14

5002 5 • ctgtcccggttcactcactgc 3'
4140 5' gagggctgttggggaggaagg 3'

68°C (X35)
2·step (0.5'/2')

26769-789
27023-043

275

Product
352
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m.6.i.(d) Amplification of exon 15
Pnmers fior the PCR Amo I'1 fi1cation o fPKD I Exon 15
Gi?nomic
Cycling
Primer Sequence
Position
Conditions

• 9.
Ta ble 1111

Exon 15
Fra2.
16

15
14
13
12
11
10
9
8
7
6
5
4
3

2

16F s· cgggtggggagcaggtgg 3'
I6R 5 · gctctgggtcaggacagggga 3'

68°C (X35)
2-step (0.5'/2')

14F 5' gcccccgtggtggtcagc 3'
I4R 5' caggctgcgtggggatgc 3 •

68°C (X35)
2-step (0.5'/2')

12F 5' cgtgaacagggcgcatta 3'
I 2R 5' gcagcagagatgttgttggac 3'

58°C (X30)
(0.5'/0.5'/I')

27569-86
27821-38

270

67°C (X30)
(0.5'/0.5'/I ')

27991-008
28229-46

259

I I F 5 · ccaggctcctatcttgtgaca 3'
II R 5 · tgaagtcacctgtgctgttgt 3'

62°C (X30)
{0.5'/0.5 '/I')

28433-53
28661-81

249

9F 5' gggctcgtcgtcaatgcaag 3 ·
9R 5' caccacctgcagcccctcta 5'

66°C (X30)
(05'/0.5'/I')

28758-77
29005-34

277

63 °C (X30)
(0.5'/0.5'/I')

29147-65
29414-33

287

66°C (XJO)

<os10.5·11·>

29598-616
29829-48

251

66°C (X30)
(0.5 '/0.5 '/I')

30065-85
30251-70

206

63 °C (X30)
(0.5'/0.5'/I ')

30388-407
30607-29

242

ISF 5' cgcctgggggtgttcttt 3'
15R 5' acgtgatgttgtcgcccg 3'

53°C (X30)
(0.5'/0.5'/I')

13F 5 • ctggaggtgctgcgcgtt 3 ·
13R 5 • ctggctccacgcagatgc 3'

IOF 5 • ctacctgtgggatctgggg 3'
IOR 5 · tgctgaagctcacgctcc 3'

65°C (X30)
(0.5'/0.5'/I')

SF 5' ccgcccaggacagcatcttc 3'
8R 5' cgctgcccagcatgttgg 3'

66 °C (X30)
(0.5'/0.5'/I ')

6F 5' cgagccatttaccacccatag 3'
6R 5' gcccagcaccagctcacat 3'

1 s8°C (X30)
(0.5'/0.5'/I')

7 F 5' cggcaaaggcttctcgctc 3'
7R 5' ccgggtgtggggaagctatg 3'

SF 5' ccacgggcaccaatgtgag 3'
5R 5' ggcagccagcaggatctgaa 3'

4 F 5' cagcagcaaggtggtggc 3'
4R 5 · gcgtaggcgacccgagag 3'

JF 5' acgggcactgagaggaacttc 3'
3R 5 · accagcgtgcggttctcact 3'
2F 5' gccgcgacgtcacctagac 3'
2R 5 · tcggccctgggctcatct 3 •

I F 5 • ctgggactttggggatgggt 3 •
XL I5R 5'ca<>cgtgggcctc�aagtagttg 3'
Primers first described by Watnick el al.. 1999.
t

27351-67
27610-30

Product

size (bn)
280

1

63°C (X30)
(0.5'/0 5'/1')

66°C (X30)
(0.5'/0.5'/I ')

27790-807
28022-39

250

28203-20
28452-72

270

28602-20
28801-18

217

28966-85
29208-25

260

29398-418
29610-28

231

29791-808
30106-23

333

30177-95
30424-41

265
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111.6.i,<e) Amplification of exons 15 to 21

. .

tior the PCR Am1p l'fi
1 1cat1on o fPKDJExons 15 -21
Ta ble 11120 Pnmers
.
Genomic
Cycling
Primer Sequence
Exons
Position
Conditions
15(a)

15{b)
16

Ex I 5XLF 5'gcaactacttggaggcccacg 3'
Ex15aR 5' ctcaatgatgggcaccaggcg 3'

Exl 5bF S' catccaggccaatgtgacggt 3'
Ex I 5bR 5' cctggtggcaagctgggtgtt 3'
Ex I 6F 5 • ctggalggggctctcagg 3'
Eid 6R 5' cctggtggcaagctgggtgtt 3'

17

Ex17F 5' gggtcccccagtccttccag 3'
Ex J 7R 5 · ccatccccagcccgcccaca 3'

18

Ex I 8F 5 · gccccctcaccaccccttct 3'
Ex18 R 5' gatcccgctgcctcccccca 3'

19

Ex I 9F 5 • gtgatgccgtggggaccgtc 3 •
Exl9R 5' gtgagcaggtggcagtctcg 3'

20

Ex20F 5' ctgctcaccaccccctctg 3'
Ex20R 5' ggtcccaagcacgcatgca 3'

21

Ex2lF 5 · cgctgctgacagcttgctgtgccc 3'
I VS2 I RS' gcagggtgagcaggtggggccatc 3'

66°C (X35)
(0.5'/0.5'/1')
64°C (X35)
(0.5'/0.5'/I '}

30606-26
30872-92
30841-61
31086-106

Product
size Ibo)

287
266

56°C (X30)
(0.5'/0.5'/l '}

31197-214
31468-85

289

32262-81
32489-508

247

66°C (X35)
(0.5'/0.5'/I')

32571-90
32895-914

64°C (X35)
(0.5'/0.5'/l')

33225-43
33445-63

66°C (X35)
(0.5'/0.5'/1')

I 66°C (X35)
(0.5'/0.5'/I')

66°C (X30)
(0.5'/0.5'/1')

32946-65
332! 3-32

33763-86
33957-80

344
287
239
218
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III.6.i.{f) Amplification of exons 23 to 33

. .

1 1catlon o fPKDJExons 23 .34
fior the PCR Am1prf
Ta ble III 21 Pnmers
.
Genomic
Cycling
Primer Sequence
Exons
Position
Conditions
i

Product
size lbol

23(a)

TWFl * 5' ctgcactgacctcacgcatgt 3'
23a-R 5' caccagaaagatgggctgcac 3'

58°C (X30)
(0.5'/0.5'/1')

37674-694
38006.026

23(b)

23bF 5' ggggccctggcc.aacctcag 3'
23bR 5' cgtgtgccccacccgctgca 3'

68°C (X35)
2-step (0.5'/2')

37979-998
38336-355

377

24F 5' tgtgacctgcgcgttc!g 3'
24R 5• ccaggctggcccgcagag 3•

68°C (X35)
2-step (0.5 '/2')

38600-617
38786-803

204

25

25F 5' ctgggctcacgtccgctacc 3'
25R 5' cctcgactctgcagaggctc 3 •

68°C (X35)
2-step (0.5'/2')

38927-946
39236-255

329

26

26F 5' cggctctatcctgagaaggc 3'
26R 5' cagcacagccagtgagagca 3'

68°C (X35)
2-step (OS/2')

39272-291
39567-586

315

27

2 7F 5' cctcccacccctccctcttg 3'
27R 5' cagagcttggcagggtccgc 3'

6fl °C (X35)
2-step (0.5'/2')

41000.019
41205-224

225

28

28F 5' cgagcctgacctccctcctg 3'
28R 5' cggagtgggaccatggaacg 3'

58°C (X30)
(0.5'/0.5'/I ')

41254-273
41438-457

204

29

29F 5 · cgtgg<.:ctcctgcagtgcgg 3'
29R 5' ggcaggaagaggctgccccg 3'

68°C (X35)
2-step (0.5'/2')

41486-505
41751-770

285

30

30F 5' cacctgtgtggcctcctctc 3'
30R 5' ggctccattcccagtactcc 3'

68°C (X35)
2-step (0.5'/2')

41794-813
41973-992

199

31

31F 5' gctgaccactgccctcgtc 3'
3I R 5' agtccaagctgcgccaagg 3'

68 °C (X35)
2-step (0.5'/2')

43585-603
43773-791

207

32

32F 5' ttggcgcagcttggactc 3'
32R 5' cagggctcgaggtttctc 3 •

43775-792
43879-896

123

33

33F 5' taccttgctgacccgcgc 3'
33R 5' ggtgagcttcagagcccc 3'

44064-081
44296-313

250

24

'

58°C (X30)
I (0.5'/0.5'/I')
68°C (X35)
2-step (0.5 • /2 ')

353

Exon 23 was ampltfied a'> two fragments (a & b) due to its size (630bp).
* Previous reference Watnick et al., I997.
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Ill.6.ii. Purification and Sequencing of Nested PCR Product§
5µ1 aliquots of the 25µ1 nested PCRs were electrophoresed on 1% agarose gels in IX
TBE at l 00 V for 40-60 minutes, stained with ethidium bromide and photographed
under UV-transillwnination as previously described (Section III.4.ii). When amplicons
resulted in a clearly detectable PCR product, the remaining 20µ1 were purified through
QIAquick PCR spin columns (QJAGEN ), and eluted in 20µ1 of ddH20. This is a lower
elution volume than recommended by the manufacturer, however, sufficient template
was recovered to proceed with direct automated sequencing reactions.

IIJ.7. Investigation of PKDJ Homologous Gene Seguences
In addition to specific mutation detection of PKDJ in the duplicated region sequence,
information on the BAC and PAC clones was also used to investigate the possible
functions of the homologous genes. This work was undertaken as a direct result of the
present study by Dr. Nadja Bogdanova and Dr. Arseni Markoff (Institute for Human
Genetics, Munster, Germany) using the following methodology.

III.7.i. Reverse Transcription and PCR (RT-PCR)
Total RNA was isolated from confluent astrocytoma T98G human ceil cultures using
the Trizol™ reagent (Gibco BRL) according to the manufacturer's protocol.

This

reagent is based on the single-step phenol/guanidine isothiocyanate isolation protocol
originally described by Chomczynski and Sacchi ( 1987). The RNA was subjected to
reverse transcription, primed with random hexamers and either PKDJ- or PKDJ
homologue- specific primer as detailed below.

125

Total RNA Isolation Protocol
1.

1ml of astrocytoma cell suspension was divided between two 1. 5ml microcentrifuge
tubes and centrifuged at 6,000 rpm for 5 minutes at 4°C.

2. The supernatant was discarded and the pellet was resuspended in 750µ1 of Trizol
6

reagent (2ml of reagent per I ;c 10 cells). The tubes were shaken to homogenise
cells.
3. RNA was isolated in an aqueous phase from DNA and organic compowtds by the
addition of 0.2 volumes of chloroform to the homogenate. The tubes were shaken
for 15 seconds and incubated at room temperature for 2-3 minutes.
4. The homogenate was then centrifuged at 12,000g for 15 minutes at 4°C.
5. The RNA-containing upper-phase was removed into clean tubes and equal volumes
of isopropanol used to precipitate the RNA
6. The tubes were then incubated at -20° C for IO minutes and centrifuged for a further
10 minutes at 4 °C to pellet the RNA
7. The supernatant was removed, the RNA pellets were washed with 500µ1 of 75%
ice-cold ethanol and the tubes centrifuged at 7,500 rpm for 5 minutes at 4 °C.
8. The ethanol was removed and the pellets air-dried for 15-20 minutes.

A paper

tissue was placed over tubes to prevent air-born contamination from entering the
tubes.
9. The pellets were resuspended in 30µ1 ofRNase-free ddH20 at 55°C for 10 minutes.
10. The quality of RNA and the possibility of DNA or RNase contamination was
assessed by the electrophoresis of a 5 µ1 aliquot sample on a 2% Agnrose gel stained,
with ethidium bromide.
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Translationally active RN A was prepared from the polysomal fraction (membrane
bound polysomes) as previously described (Mechler, 1987). The microsomal fraction
was obtained through sucrose gradient centrifugation of a T98G cytoplasmic extract and
mRNA was separated and purified from the bound polysomes. When the RNA was
considered to be of sufficient quality, cDNA was produced by reverse transcription
using Superscript II reverse trnnscriptase (Gibco BRL Life Technologies) as detailed
below.

Reverse TrnnscriP.tion
Total RNA and mRNA (0.5 - 3µg) were primed with random hexamer (IOOpM) and 3'
oligonucleotide primer ( lOpM) (5' GCCATCCCCGAAGGTCCAGTCGAA 3'), which
was common to PKDJ and the homologous genes. RNase-free water was then added to
a total volume of 12.5µ1.

The mix was incubated at 65°C for 10 minutes and

immediately placed on ice. An enzyme mix was prepared from l �t.l of Superscript II
reverse transcriptase (Gibco BRL Life Technologies), 5µ1 of 5 x RT 151 strand buffer,
2.5µ1 ofDIT (O.lM), 3µ1 of IOmM dNTPs (Gibco BRL Life Teclmologies), and lµl of
RNase in}tjbitor (Gibco BRL Life Technologies), in a final volume of 12.5µ1. The RNA
and enzyme preparations were mixed and incubated at the following temperatures, 25°C
for 10 minutes, 42 °C for 60 minutes, 50 °C fer 30 minutes and 70°C for 10 minutes.

The first round of PCR amplification was performed on 1µI aliquots of the reverse
transcribed products with primers listed in Table III.22. The PCR product of this first
reaction (lµl) was then used as template in a second amplification using PKDJ and HG
specific primers (see Table III.22). Agarose gel electrophoresis (Section III.4.ii) of
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cDNA was then performed to assess if the homologous genes produced iranslationally
active mRNA after specific amplification (see Chapter IV).

Table 111.22. Primers for Amplificat1on of PKDI and Homo ogous Genes
Cycling
Genomic
Exon Primer Sequence
Conditions
Position

Forward outer primer

5

5' gtgtgcccgtcctcm,rtgcaga 3 ·

15

Reverse outer primer
5' ccgaagtcccacgtgtaaagaa 3'

11

Forward PKDI nested p:-imer
5' cttgaggcccaaccctggact 3 •

13

Reverse PKDI nested primer
5' ccggcactgtggagacctgcaga 3 ·

11

Forward HG nested primer
5 • cstgaggcc:aaccctgg,gct 3 ·

13

Reverse HG nested primer
5· c!ggcactl-,rt!gagaccggcagg 3 ·

40 cycles of
94° C 45sec
55°C I min
72 °C 4 mins
40 cycles of
94° ( 45sec
68°C I min
72° C I min
40 cycles of
94° C 45sec
j 68° C I min
I 72°C I min

21373-94

cDNA
product
size

2,387 bp

27581-602
24607-27

7 I 5bp

26395-417
24607-27

(approx)
715bp

26395-417
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IV.

Results:

Specific Amplification of the Duplicated Region of PKDJ

IV. Results: Specific Amplification of the Duplicated Region of PKDI

IV. I . Introduction
The existence of ger1es highly homologous to

PKDI raises interesting biological

questions related to their physiological role, and at the same time presents a major
obstacle to the specific amplification of the PKDJ gene and hence to the study of the
molecular defects leading to ADPKD. During the course of this study, the genomic
sequence of two of the homologues, HGl and HG2, contained in a single BAC clone
(Accession# AC002039) became publicly available (Loftus et al., 1999). However,
earlier studies aimed at the cloning of PKDJ (The European PKO Consortium, 1994;
The International PKO Consortium, 1995; Hughes et al., 1995), had demonstrated the
existence of three homologous transcripts, suggesting that at least one additional
homologous gene remained to be characterised.

To address the questions of the

sequence characteristics of the homologues, their role, and the selection of PKO I
specific amplification primers, a collaboration as indicated below was conducted.
The genomic sequences of human genomic clones containing

PKD1 homologues, or

the PKDI gene itself, were compared and their expression was examined.

The work on the characterisation of the

PK.DJ homologous genes was undertaken in

collaboration with Dr. Nadja Bogdanova and

Dr.

Arseni Markoff at the Institute for

Human Genetics, Westfiilische-Wilhelm's University, Munster, Germany.

The

candidate acknowledges their contribution and presents the joint results with their full
knowledge and approval.
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IV.2. Identification of human genomic clones containing PKDJ and its homologous
genes
As described in Chapter III (Section III.5.ii), two human genomic libraries, Human
BAC DNA Pools (Release II, Research Genetics Inc.) and Human PAC DNA Pools
(Genome Systems), were screened by PCR analysis for clones containing inserts of
the duplicated and unique regions of PKDJ. Two initial PCR amplifications were
performed with primers for PKDJ. The first experiment amplified exons 2 and 3 in
the duplicated region of the gene.

This amplification aimed to detect clones

containing PKDI, and clones containing PKDJ homologous genes.

The second

amplification was performed "With primers for exon 45 in the unique region of the
PKDI gene; this experiment was performed to distinguish between PKDJ-containing
and HG-containing clones.

Screening of the BAC library super-pool identified two wells that contained clones
with inserts corresponding to the duplicated region of PK.DI. Subsequent pool plate
screening confirmed the presence of two clones wit'1 unique addresses (plate
addresses 204-o-15 and 267-d-9), that were PCR-pos1tive for exons 2-3, 5, 13, 15, and
31-33 of PKDI. Attempts to amplify the unique region (exons 35 or 45) of PKDI in
these clones were unsuccessful, indicating that the inserts corresponded to
homologous genes, rather than to PKDI. Partial sequence analysis of the homt'logous
genes contained in these clones revealed that they were not identical to other
identified PKDI homologues, HG I and HG2 (Loftus et al., 1999) see Chapter VII,
and they were named HG3 and HG4.
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Screening of the PAC library identified two clones (80-1-8 and 136-M-14), which
were PCR positive for exons 2 and 3 located in the duplicated region and exon 45 in
the unique region of PKD I.

These results indicated that the two PAC clones

contained the PKDI gene (see Figure IV.I).

1234567M

2 3 4 M

Key to Figure
A Lanes 1 & 2 HG 3&4 BACS with
primer for exon 45. Lanes 3 & 4 as
above with primers for exons 2-3.

B. Lanes 1-3 PKDJ PACS with
primer for exon 45. Lanes 4-7 as
above with primers for exons 2-3.

A
12

M

C. Lanes 1-2 HG 3&4 BACS with
primer for exon 5. Lane 3 genomic
control. Lanes 4-5 HG 3&4 BACS
with primer for exon 13.

B
345

12345M67891011
D. Lanes 1-5, genomic control,
PKDJ PAC, HG3 & 4 BAC and
negative control for exon 15. Lane 6
negative control, Lanes 7-9 genomic
controls, lane 10-11 HG 3&4 BACS
with primer for exons 31-33.

c

M - Size standard marker

D

Fig. IV.I. Amplification results ofBAC and PAC clones.

The glycerol stocks of the PKDI- and HG-containing clones were purchased from the
manufacturers, propagated and BAC and PAC DNA were extracted and purified for
sequence analysis.

IV.3. Sequence analysis of PKDI and the homologous genes

To identify PKD I-specific primers and amplify specific templates for mutation
detection analysis, the two clones containing the homologous genes and the PKD 1132

containing clone were sequenced and compared. This study attempted to characterise
a region of PKDJ that had not been screened previously. Early studies had screened

PKDJ-specific templates in the duplicated region by amplifying from exon 34 in the
unique region up to exon 23 (Peral et al., 1997; Watnick et al., 1997).

Two

subsequent studies reported screening for mutations in exons 15 to 21 (Watnick et al.,
1999b; Thomas et al., 1999).

For that reason, t.'ie present study focused on the

sequence 5' ofexon 15 of PKDJ.
The region from exon 2 to IVS14 (nucleotide positions 19,866 to 27,595 ofthe PKDJ
genomic sequence Accession# L3989l) was amplified, using as templates DNA from
the two BAC clones (204-o-15 anc� 2l7-d-9) that cont��n the HGs, and from one of
the PAC clones (136-M-14) representing PKDJ.

The region was covered by five

PCR fragments. These PCR products were analysed by automated direct sequencing
as described in chapter 111.

The resulting sequences have been deposited in GenBank under Accession numbers
AF320593 and AF320594 (Bogdanova et al., 200 l ).

Sequence alignment, performed by

Dr.

Markoff with the GENESTREAM alignment

tool (http://www.2.igh.cnrs.fr/bome.eng.html), showed that the two sequences derived
from BAC clones 204-o-15 and 267-d-9 differed from each other, as well as from the
previously published HG l and HG2 (Lo� et al. 1999). Compared to PKDJ, the
sequence of the newly identified homologous genes, HG3 and HG4, contained small
deletions or insertions (5 to 21 base pairs), and nucleotide substitutions.

The
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sequence identity for this 7.7kb region was found to be 96.4% between PKDJ and
HG3 and 96.5% between PKDJ and HG4.

Further analysis of GenBank, using the BLAST homo]ogy search tool at NCBI
(http://www.ncbi.nlm.nih.gov/BLAST/}, revealed two additional recent entries
(Accession numbers AC010488 and AC040I58) which are highly homologous to
PKD 1 and to its homologous genes. These findings point to the existence ofa greater

nwnber of homologous genes, at least six, than suggested in early publications (The
European PKD Consortium, 1994; The International PKO Consortium, 1995; Hughes
el al.,

1995).

IV.4. Functional characteristics of the homologous genes
The functional importance of the PKDI homologous genes was investigated in the
glioblastoma cell line T98G by RT-PCR. The presence of PKDJ, HG3, and HG4
transcripts was examined in total T98G RNA, and in translationally active RNA
prepared from a polysomal cell fraction. RT-PCR for exon 12, located in the
duplicated region and thus present in all three genes, was pertbnned with primers
specific to PKDJ or to HG3 and HG4. Total RNA yielded a product for exon i2 with
botll PKD 1 and the homologous gene primers. By contrast, in the trans1ntionally
active RNA, only a PKDJ-specific product was detected (see Appendix, Bogdanova
et al., 2001). This experiment indicates that whilst the HGs are transcribed. they are

not found in the translationally active polysomal fraction and therefore are unlikely to
be translated. These findings are supported by the sequence analysis of the coding
regions ofHG3 and HG4. The sequence was found to contain a number ofpremature
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stop codons, suggesting that even if the HGs were translated they would generate
short, and most probably non-functional, peptides (Bogdanova et al.. 2001).

On the basis of these results, it was concluded that the PKDJ homologous genes HG3
and HG4 are highly likely to be pseudogenes. We have proposed to refer to these
genes as PKDJ pseudogenes 3 and 4, PKDJP3 and PKDJP4 (Bogdanova et al. 2001).

IV.5. Design of PKD1-Specific Oligonucleotides
We have attempted to improve the specificity of PCR amplification and diagnostic
sequence analysis of PKDJ by selecting primers for long-range amplification (XL
PCR) that are specific to PKDJ in the duplicated region of the gene (exons 2 to 14),
when compared to all its known homologous genes.

All XL-PCR primers used (Fig IV.2), are specific to PKDJ relative to the PKDJPJ
(HG l) and PKDJP2 (HG2) sequences published in a previous study (Loftus e,
1999). We have also compared the PKDJ sequence between exons 2 to 14 to that of
PKDJPJ, PKD1P4 and PKDJP5 (Bogdanova et al., 2001).

PKDJP6 was not

included in this analysis, since its sequence homology to PKD 1 in this region extends
over only 2530 bp of the PKDI gene, corresponding to PKD l exon 2 to exon 7.
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PK.DJ XL·PCR Templates
IVSJ-JVSS contoins exons 2, 3, 4 & 5 (- 4.5 kb product)
IV:SS-IVSl I contains exons 6-11 (--4.2 kb)
TVS! 1-IVSl4 contains cxons 12-14 (-1 8kb)
IVS14 · E. on 15 (-3.8 kb product) ~qut.'IlCcd in 16 PCR fragments

1

l

I

s

I

-\\

11 11 1111 11 111 Duplicated reg:iou

Exon IS. IVS21 (-3.4 kb product) contains exons 15 to 21
sequenced m 8 fragments
IVS23 • TVSJ3 (-6.8 kb product) ren."fs.:
primer anchored in PKDl unique region exons
23 - 33 sequ1."Ilccd in 12 fragments

I IIIII 11111 11111 111

II 111111111 1

3'

PK.DJ unique region

Fig IV.2. XL-PCR primers used for the amplification of PKDJ (Exons 2-33)

To amplify a PKDJ-specific product we chose a novel primer site in IVS 11 that was
specific to PKDJ when compared to the sequence of the homologous gene. The site
was specific to PKDl compared with PKDJPJ, PKDJP2, PKDJPJ and PKDJP5.
The fourth homologue, however, was found to be identical to the PKDJ gene in this
primer site region. The primer site in intron 11 was utilised in the design of forward
(12F) and reverse (llR) primers as shown in Figure IV.3 . Primer 6F in IVS 5 was
used in an XL-PCR amplification reaction with primer l lR to amplify a region of 4.2
kb, containing exons 6 to 11 (Fig IV.2), using a long-range polymerase enzyme (XLrTth enzyme, Applied Biosystems). Forward primer 12F with a primer in IVS 14
(14R) (Fig IV.2) was used to produce a 1.8 kb PKDJ-specifc template, including
exons 12 to 14.
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The fourth homologue was found to be identical to the PKDI gene in the 6F and l IR
primer sites. therefore XL-PCR products (exons 6 to l I) sre not specific to PKDl
when compared v.-ith PKDJP4.

However, the nested primers used in subsequent

amplifications of exons 6, 9, IO and the first of three fragments of exon 11 (11 A) are
specific to PKDI when compared to PKDIP4. Only one sequence variation detected
in this study, Q563X

in exon 8 (Chapter V, Truncating Mutations), is possibly a HG

variation due to the co-amr' ification of PKD IP4. PKDIP4 was not identical to the

PKDJ sequence for the reverse primer for exons 12 to 14 (14R), and so this fragment
is PKDJ-spccific when compared to all of the known homologues in the region.

PK.DI sequence (L39891).
PK.Di Primer I2F
AC002039 PKD1P l
AC002039 PKO IP2
AF320593 PKD1P3
AF320594 PKDIP4
ACOI0488 PKD1P5
AC040158 PKDIP6

5' -CAGTGT AGGTGCCTCCCCTCACTG 3' (g.25621-44)
5' CAGTGTAGGTGCTGTCCCTGTGAG 3' (g.27954-78)
5' CAGTGTAGGTGCTGT(;CCTGTGAG 3' (g.67648-71)
5' CAGTGTAGGTGCTGTCCCTGT�AG 3' (g.5762-5787)
5' CAGTGTAGGTGCCTCCCCTCAC1 G 3' (g.5786-5809)
5' TGAGGCCCGTGCCTCCCCTCACTG 3' (g.59954-78)
5' Not present in this region

PKO I Primer 11R

5'CAGTGAGGGGAGGCACCTACACT 3' (g.25622-44)

Reverse Primer IIR is positioned at the same primer site as 12F, so it shares the same
homology as depicted above.
Fig IV.3. Alignment of PKDJ and HG Sequences in the IVS 11 Primer Region

Exons 2 to 5 were amplified using a previously published PKDJ-specific forward
primer site in JVSI (Thomas et al., 1999), and a reverse primer in exon 6.
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IV.6. Specificity of the PCR amplification
To confinn the specificity of the nested PCR technique with our newly designed
primers, the nested PCR products amplified from the XL-PCR template were
sequenced. The initial XL-PCR amplification of exons 6 to 11 was chosen as the test
fragment, this was followed by the nested amplification of exon 8, where the template
was used at various dilutions (1:10-4. 1:10-3 and 1:10-2). The resulting sequences were
compared for co-amplification of PKDJ and its homologous genes (Figure IV.5). The
experiments showed that a dilution factor greater than 1: 10-4 was necessary to produce
a PKDJ-specific template from long-range PCR amplified product.

~

Arrow indicates coamplified sequence.
PCR amplification
becomes more
specific to PKD 1 at a
dilution of 1: 10-4 or
greater.

Fig IV .4. Co-amplification of PKD 1 & HGs in nested PCR.

As indicated in Chapter Ill (Section III.6), we used a previously reported primer site
in exon 15 (Watnick et al. , 1999), specific to PKDJ when compared to HGl and HG2
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(Loftus et al., 1999), to amplify two long-range fragments.

The first fragment

included most of exon 15 (IVS14F & 15R), and the second amplified the rest of exon
15 to exon 21 {l5F & IVS2IR). The sequence of PKDP3, PKDP4 and PKDP5 has
yet to be determined for this region, and therefore a comparison between these
homologues and the PKDJ sequence was not possible. An anchored primer in the
unique region of PKDJ with a forward primer in the duplicated region was used to
amplify exons 23 to 33, as described previously (Watnick et al., 1997).

139

V.

Results - Mutations

Chapter V. Introduction

The mutation analysis of PKDJ spanned 94% of the coding sequence, namely exons 221 and 23-33 in the duplicated region, and exons 34-41 and 43-46 in the unique part of
the gene.

The duplicated region was investigated using PKDJ-specific primers,

previously published or designed in this study as a result of the findings described in
Chapter IV. These primers were used for the long-range PCR amplification of PKD 1
fragments ranging in size from 1,810 bp to 6,749 bp, followed by nested PCR
amplification and direct sequencing of the resulting products.

This analysis was

performed on 17 unrelated patients from Australian ADPKD families showing
"positive" linkage to the PKDJ region on chromosome 16 (see p.93).

IVSI-5 (4.5kb)
MNCP P

IVS5-11 (4.2kb)
P NCM

IVSI 1-14 (1.8kb)

p

M

M
p

NC

PM
IVSI4-Exl5 (3.8kb)

PPM
Exl5-IVS2l (3.4kb)

Marker
XL-PCR
product
Negative
Control

MPP
IVS23-33 (6.8kb)

Fig V.1 Results of XL-template amplification in the duplicated region of PKDJ
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The study of the unique 3' region of PKDJ was performed in two stages: a) screening
by SSCP analysis, which detects conformational changes and electrophoretic mobility
shifts resulting from sequence variation; b) specifying the nature of the sequence
variants by direct sequencing analysis.

The mutation analysis of the unique PKD 1

region was performed in 48 unrelated individuals from ADPKD families: 15 Australian,
26 Bulgarian and 7 Polish all showing "positive" linkage to the PKD 1 region on
chromosome 16 (as described p.93).

Initial PCR amplification and subsequent SSCP analysis were optimised for each of the
13 individual fragments used to screen the unique region of the gene.

The most

appropriate PCR amplification, SSCP gel composition, and electrophoretic conditions
are detailed in Chapter III (Section III.4 ). The gel conditions were optimised using PCR
templates for each fragment as can be seen below (Fig V.2). Variable SSCP conditions
markedly alter the efficiency of the technique.

2

1

4

Gel A:
Ex35 run in
TBE with
gly~erol

ilitlJt
Same
conditions
minus glycerol
Lane 1-3
Wild-type
Lane4
Mutant

Fig V.2. SSCP optimisation for mutation screening
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The efficiency of the SSCP screening was assessed in the 1: Australian ADPKD
patients by re-analysing part of the unique region, namely exons 44 and 45, and
fragment A of exon 46. These exons were selected on the basis of the different size of
the PCR fragments, which is a factor known to affect SSCP sensitivity (Orita, 1989), as
well as on the basis of the large number of disease-causing mutations detected by other
groups in this region of PKDJ (Turco et al., 1995 & 1997; Neophytou et al., 1996;
Rossetti et al., 1996 & 2001; Roelfsema et al., 1997;· Daniells et al., 1998a & b; Afzal et
al., 1999; Perrichot et al., 1999).

The direct sequencing approach was also applied to 4 additional Australian patients
from PKDJ-linked families that had joined the study at a later stage, as well as to 31
affected individuals where linkage analysis had not been possible due to small family
size.

The criteria for assigning a sequence variant to the group of pathogenic mutations
followed, as much as possible, the guidelines proposed by Cotton and Scriver ( 1998).
The following criteria were met: (I) the same sequence variant was detected upon
repeated analysis starting from PCR amplification; (2) the change caused a direct
truncation of the protein either through a nucleotide substitution generating a premature
stop codon or through a shift in the reading frame leading to a premature stop codon;
(3) if the nucleotide change(s) resulted in an amino acid substitution or in-frame
insertion or deletion, the altered residue was conserved in evolution and computer
analysis of secondary protein structure suggested conformation changes; (4) a family
study (performed whenever possible) indicated that the sequence variant segregated
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with the disease phenotype. In some cases, family members had provided fingerprick
blood samples r.ollected on to a filter paper card rather than whole blood. Due to the
amount of genomic template required for long-range PCR amplification, segregation
analysis in those few families could not be perfonned.

The analysis resulted in the detection of a total of 74 sequence variants, of which 24
were classified as probable disease-causing mutations (Table V.l). Twenty-one of the
proposed disease-causing mutations, including all 12 mutations in the duplicated region
of the gene, have been discovered as a result of this study.

The mutation analysis included a total of 19 Australian patients wiih evidence of
linkage to chromosome 16. The probable pathogenic mutation was identified in 14 out
of 19, giving a 74% overall mutation detection rate for this group.

Mutation detection in the PK.DJ gene is technically and financially demanding and is
therefore most efficient when preceded by linkage analysis. This pre-condition was met
for the core group of 19 Australian patients where PKDI was systematically screened.
Nonetheless, a Jess demanding analysis of part of the unique region of the gene was
conducted in 31 affected subjects with unknown linkage status. This part of the study
was productive, with three mutations identified in this additional group of patients.
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Table V.l. Summary of probable disease-causing mutations in the PKDJ gene.
Exon or
IVS

Affected
Family ID

Sequence
Variation

Predicted effect

Possible
Confirmatory Assay

Ex5

A9

c.l352G>T
g.2I430G>T

Missense

Ex8

A4

c.1898C>T
g.22716C>T

Nonsense Q563X none

IVS i4

A22

IVS14+1G>C
g.26942G>C

Splicing Variant

Alu I created

Ex15

A52

c.5105-5106del
(AT) g.29004de1AT

Frame-shift
deletion 2b p
II632fsX1656

Ode I created

Ex15

A36

c.5159del G
g.29058delG

Frame-shift
deletion Ib p
V 1650fsXl 721

Afl III created

Ex15

A61

c.6764T>G
g.30662T>G

Missense
Y2185D

Ava II created

Ex 15

AIS

c.7017C>G
g.30915C>G

Nonsense S2269X

Bsm AI created

IVS 16

AS

IVS16+1G>T
g.31394G>T

Splicing Variant

Mae II created

Ex18

A46

c.7472-74del (ACC)
g.32650-52del

In-frame deletion
2421del T

none

Ex23

A6

c.8565G>A
g.37893G>A

Missense
G2785D

none

Ex25

A42

C. 9289-93 27de!
g.39090del 39

In-Frame deletion
3027del 13 aa

Visible on 3%
agarose gel with
ethidium bromide

Ex28

AJO

c.9847del C
g.4 I352de1C

Frame-shift
deletion I b p
F 3213fsX3315

Bsl I created

Ex34

B 22

c. l 0635del 23
g.44374del 23

Frame-shift
P3475fsX36l 7

Ava II abolished

IVS 37

857

c.IVS37-10
C>Ag.48491C>A

Splicing mutation
fsX3684

Bsr I created

G381C Sac II abolished

.
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Ex40

B77

c.11587delG
g.4951SdelG

Frame-shift
deletion Ibp
R3793fsX3824

None

Ex40

PIOl

c.l1520C>A
g.49448C>A

Nonsense S3770X

Eag I abolished

Ex41

B25

c.l 1669-l I674de1
g.49737-49742del

In-frame deletion
3820-3821del QE

Alu I abolished

Ex44

Al8.l &
A41.l

c.12218C>T
g.5079IC>T

Nonsense
Q4003X

Mae I (or Bfa I)
created

Ex44*

A72

c.12239 C>T
g.50812C>T

Nonsense Q4010X

Mae I created

Ex44 °

A64.1

c.12269C>T
g.50842C>T

Nonsense
R4020X

Blp I created

Ex44***

A3

c.12332 C>T
g.50905C>T

Nonsense Q4041X

Mae I created

Ex45

A54

c.12347C>A
g.51003C>A

Missense
IA046F

Bbvl abolished

Ex46

A38

c.12891 G>C
g.5l637G>C

Missense R4227P

None

Ex46

B41

c. l 3069ins39
g.5l815ins39

In-frame insertion
aa4286ins13

None

*Previous reference Damells et al., I 998b. **Previous reference Rossetti et al., 1996.
*"'*Previous reference Turco et al., 1995.

Tne remainder of this chapter deals with the individual disease-causing mutations in

PKDI.

The results are classified according to the type of molecular change: protein

truncating, splice-site variation, missensc and non-truncating insertions and deletions.
As previously noted, some mutations may not be verified as pathogenic due to lack of
RNA for RT-PCR Mutations are named according to the recommendations of Cotton
& Scriver ( 1998), however we have used traditional numbering for the nucleotide
position in the gene (i.e. the first encoded nucleotide of the cDNA is at position 212
[L33243] and position 3648 [L39891] of the genomic DNA).
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TRUNCATING MUTATIONS
Mutation - QS63X
Novel

Yes

Patient

A4.l

Ethnic Origin

Australian, British descent

Nucleotide Change

C>T transition

Position

c.DNA

1898

g.DNA

22716

Gene Location

Exon 8, duplicated region

Method of detection

Direct sequencing
NB. This mutation was detected iu a PCR
fragment which may be co-amplified with
PKD1P4 (see Chapter IV).

Predicted Effect

Truncates polycystin-1 by 3,739 aa

Protein Domain

Extracellular region, downstream of C-type lectin
domain

Supporting Evidence:
Family Segregation Analysis

Segregates with disease in 2 affected (A4.1, A4.4)
and absent in 3 unaffected (A4.IO, 4.15 and 4.17)
family members

Confirmatory assay

Repeat sequencing {no restriction enzyme assay
possible)
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Pedigree:

A4 .10

A4.4

C>T

~

0
A4 .1

A4 .15

A4.17

Electrophoretogram:
A4 .15

A4.4

A4 .17

A4.1

A4 .10
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Mutation - S2269X
Novel

Yes

Patient

Al5. l

Ethnic Origin

South African, British descent

Nucleotide Change

C>G transversion

Position

c.DNA

7017

g.DNA

30915

Gene Locsrion

Exon 15, duplicated region

Method of detection

Direct sequencing

Predicted Effec!

Truncates polycystin-1 by 2,033 na

Protein Domain

PKD domun in extracellular region

Suppo!l"ting Evidenc;:e Family Segregation Analysis

Segregates with disease m 3 affected (Al 5.1,
Al5.3, Al5.5) and absent m 2 unaffected (Al5.2,
AlS.6) family members

Confirmatory assay

Sequencing (possible enzyme assay - Bsrn Al site
created)
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Pedigree:

Al5 . l

Al5 .3

Al5.5

Al5 .2

AJ5.4

Al5 .6

Electrophoretogram:
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Mutation S3770X
Novel

Yes

Patient

PIOI.l

Ethnic Origin

Polish

Nucleotide Change

C>A transversion

Position

c.DNA

11520

g.DNA

49448

Gene Location

Exon 40, unique region

Method of detection

SSCP and sequencing

Predicted Effect

Truncates polycystin-1 by 533 aa

Protein Domain

6 trans-membrane (TM) domain

1h

Sunporting Evidence Family Segregation Analysis

Segregates with disease in 4 affected ( t O1.1,
101.2, 101.3 and 101.6) and absent in 3 unaffected
(101.5, 101.4 and 101.7) family members

Confirmatory assay

Eag I restriction enzyme assay - restriction site
abolished (264 bp in mutant allele and 145bp +
1 l 9bp in wild-type)
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Pedigree:

101.4

101.2

101.6

101.7

SSCP 2el: Shows SSCP analysis of DNA from family PlOI Exon 40

IOI.I 101.2 101.3 101.4 101.5 101.6 101.7
. ;--- , ~ ~. ~· ~~-..:. ·-··-> ,,.:__ _ :-;i
t

.~~-1 l ·~

~
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Restriction digest of Exon 40 for Family Ptol with Eagl

.#
'· ~. ·

ff:
~

.>'"'

·

~

:::

264bp
145bp & l 19bp

Sequencing Gel S3770X

Normal PlOl.1
TGCA TGCA

Arrow indicates C>A
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Mutation 04003X

Novel

Yes

Patients

AI8.l & A41.l

Ethnic Origin

Both Australian of Macedonian descent

Nucleotide Change

C>T transition

Position-

c.DNA

12218

g.DNA

50791

Gene Location

Exon 44, unique region

Method of detection

Sequencing

Predicted Effect

Truncates polycystin-1 by 299 aa

Protein Domain

Extracellular loop

Supporting Evidence Family Segregation Analysis

Not possible

Confirmatory assay

Direct sequencing (Possible confirmatory assay Mae I restriction site created)
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Electrophoretogram:
Upper Row A41. l, middle row A64.l (wild-type), lower row Al8.1

C>T

l
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Mutation - 04010X
Novel

No: Daniells et al., 1998b & Kim et al., 2000b.

Patient

A72.1

Ethnic Origin

Australian, British descent

Nucleotide Change -

C>T transition

Position-

c.DNA

12239

g.DNA

50812

Gene Location

Exon 44, unique region

Method of detection

SSCP and direct sequencing

Predicted Effect

Truncates polycystin-1 by 293 aa

Protein Domain

Between gth and 9th TM domains

Supporting Evidence Family Segregation Analysis

Not possible

Confirmatory assay

Mae I restriction enzyme assay (restriction site
created - 226 hp + 66 bp in mutant allele and 292
hp in wild-type)
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Restriction Assay Mae I

Lane I A72.l
Lane 2 normal control

2

'-1..-

+-

292bp
226bp
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Sequencing Gel

Al8 .1 (wild-type)

A44.l (wild-type)

A72. l (C>T Q4010X)
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Mutation - R4020X
Novel

No: Rossetti et al.. 1996

Patient

A64.1

Ethnic Origin

Australian, British descent

Nucleotide Change -

C>T transition

Position-

c.DNA

12269

g.DNA

50842

Gene Location

Exon 44, unique region

Method of detection

SSCP and direct sequencing

Predicted E.:fect

Truncates polycystin-1 by 282 aa

Protein Location

Between 8th and 9th TM domains

Supporting Evidence Family Segregation Analysis

Not possible

Confirmatory assay

Direct sequencing (possible restriction enzyme
assay - Blp I site created)
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Electrophoretogram:
Upper row normal control; lower row A64 . l

C>T

i
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Mutation - 0404IX
Novel

No: Turco et al., 1995; Daniells et al.. 1998b
Torra et al., 1998; Rossetti et al., 2001.

Patient

A3.l

Ethnic Origin

Australian, British descent

Nucleotide Change -

C>T transition

Position-

c.DNA

12332

g.DNA

50905

Gene Location

Exon 44, unique region

Method of detection

SSCP and direct sequencing

Predicted Effect

Truncates polycystin-1 by 262 aa

Protein Domain

9"'lTM domain

Supporting Evidence Family Segregation Analysis

Segregates in S affected (A3.l, A3.l l, A3.13,
A3.l 8, A3.19), not found in 1 wiaffected (A3.12)
family members.

Confirmatory assay

Mae I restriction enzyme assay (restriction site
created - 159 bp + 133 bp in mutant allele and 292
bp in wild-type)
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Pedieree

3.11

?

3.13

3.12

3.18

~

3.1

3.19

Restriction Assay: Mae I

Lanes:
1
2
3
4
5
6
7.
8.

A3 .l
A3.ll
A3 .12
A3 .13
A3 .18
A3 .19
normal control
size standard I OObp ladder (Gibco BRL) - no well shown on gel.

12345678

+--- 292bp
+--- 159bp
+--- 133bp
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SSCP & Sequencing gels
1

2

3

4

Lanes 1, 3, 4 - Wild-type controls
Lane

CC

CC

T

T

A

C

A

C

G

G

2

- A3.l , C>T (Q4041X)

CCC

CCC

A

2
A

G

G

C

T

C

G

T

G

G

G
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Mutation - c.5105delAT
Novel

Yes

Patient

A52.l

Ethnic Origin

Australian, British descent

Nucleotide Change

deletion AT

Position-

c.DNA

5105

g.DNA

29004

Gene Location

Exon 15, duplicated region

Method of detection

Direct sequencing

Predicted Effect

Frameshift at codon T l632, addition of 24 novel
amino acids followed by a premature tennination
codon at position 1656 - truncation of polycystin1 by 2,646 aa

Protein Domain

PKD repeat domain nwnber 11

Supporting Evidence Family Segregation Analysis

Not possible

Confirmatory nasay

PCR repeated and products cloned into Topo-TA
PCR cloning vector and sequenced
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Electrophoretograrn

Upper row wild-type cloned product; lower row delAT cloned product
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165

Mutation - c.S159de1G

Novel

Yes

Patient

A36.I

Ethnic Origin

Australian, British descent

Nucleotide Change -

deletion G

Position-

c.DNA

5159

g.DNA

29058
15, duplicated region

Gene Location

Exon

Method of detection

Direct sequencing

Predicted Effect

Frameshift at codon Vl650, addition of 71 novel
amino acids, followed by a premature tennination
codon at position 172 I - truncation of polycystin-1
by 2, 581 aa

Protein Domain

PKD repeat domain number 11

Supporting Evidence Family Segregation Analysis

Segregates in 5 affected family members (A36. l,
A36.3, A36.6, A36. I 0, A36.20). No ur�'fected
members available for analysis

Confirmatory assay

PCR repeated and products cloned into Topo-TA
PCR cloning vector and sequenced
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Pedigree

---.--:D
36.1

36.3 36.6 36.10

36 .20

EJectropboretogram

Upper row delG cloned product and lower row wild-type cloned product.
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Mutation - c.9847delC
Novel

Yes

Patient

AlO.l

Ethnic Origin

Australian, British descent

Nucleotide Change -

deletion C

Position-

c.DNA

9847

g.DNA

41352

Gene Location

Exon 28, duplicated region

Method of detection

Direct sequencing

Predicted Effect

/rameshift at codon V3213, addition of 102 novel
amino acids, followed by a premature tennination
codon at position 331 S - truncation of polycystin-1
by 987 aa

Protein Domain

PLAT domein

Supporting Evidence Family Segregation Analysis

Not possible

Confirmatory assay

PCR repeated and products cloned into Topo-TA
PCR cloning vector and sequenced
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Electrophoretogram

Upper row delC cloned product; lower row wild-type cloned product
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Mutation- c.10635del23
Novel

Yes

Patient

B22.l

Ethnic Origin

Bulgarian

Nucleotide Change

deletion 23 hp

Position-

c.DNA

10635

g.DNA

44374

Gene Location

Exon 34, unique region

Method of detection

SSCP and sequencing

Predicted Effect

Frameshift at codon 3475, addition of 42 novel amino
acids, followed by a premature termination codon at
position 3517 - truncation of polycystin-1 by 785 aa

Protein Domain

th

th
Helix between 5 & 6 TM domains

Supporting Evidence Family Segregation Analysis

Segregates in 5 affec\'ed family members (B22. J,
B22.2, B22.3, B22.4, B22.5). No unaffected
members available for analysis

Confirmatory assay

Ava II r'!striction enzyme assEiy (Restriction site
abolished - 131 + 86 bp in mutant �Hele and 97,
57 + 86 hp in wild-type)
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Pedigree

B22.4 B22.5
Avall Restriction Digest Assay

B22.3

Family B22 (22.5-22.1), normal control (NC) Size standard (S) (JOObp ladder Gibco BRL)
22.5 22.4 22.3 22.2 22. l NC S

Only mutant allele produces band of 131 bp.

...
...
olll

13lbp
97bp
86bp

SSCP of B22. l in centre lane with normal controls in surrounding lanes
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Sequencing Gel c.10635del23

Normal

822.1

Deletion in sequence begins
above the arrow
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Mutation - c.1 IS87delG
Novel

Yes

Patient

B77.l

Ethnic Origin

Bulgarian

Nucleotide Change

deletion G

Position-

c.DNA

11587

g.DNA

49515

Gene Location

Exon 40, unique region

Method of detection

SSCP and sequencing

Predicted Effect

Frameshift at codon 3792, addition of 32 novel
amino acids, followed by premature tenninarion
codon at position 3824- truncation of polycystin-1
by 478 aa

Protein Domain

Loop between 6th and 71h TM domains

Supporting Evidence -

Family Segregation Analysis

Segregates in 6 affected family members (B77. l,
B77.2, B77.3, B77.4, B77.S, B77.6), not found in
the 2 unaffected spouses (B77.7, q77.8).

Confirmatory assay

SSCP and sequencing (no restriction enzyme
assay possible)
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Pedigree

77.5 77.6

77.3

77.4

SSCP
77. l 77.2 77.3 77.4 77.5 77.6 77.7 77.8

Sequencing change
N

M

N: nonnal M: Mutant

delG
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SPLICE-SITE VARIATION
M9tation-1vsu+1G>C
Novel

Yes

Patient

A22.l

Ethnic Origin

Australian, Spanish descent

Nucleotide Change -

G>C transversion

Position-

c.DNA

3506+1

g.DNA

26942

Gene Location

IVS 14, duplicated region

Method of detection

Direct sequencing

Predicted Effect

Canonical GT donor splice site abolished. Exact effect
has not been confinned, as RNA was not available.
However, the most likely effect is inactivation of the
splice site leading to translation into intton 14 for a
further 14 aa before truncation at g.26953. Another
possibility is the activation of a cryptic splice site 16
nucleotides beyond ihe canonical GT splice site at
position g.26957-8; this would lead to the addition of 5
novel aa to polycystin-1.

Protein Domain

PKD repeat domain

Supporting Exidmse Family Segregation Analysis

Segregates in 2 affected (A.22.1, A22.6), not
found in I unaffected (A22.S) family members

Confirmatory assay

Sequencing (possible enzyme assay Alu I,
restriction site created)
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Pedigree

D ,- .--22.s

22.6

22.1

Electrophoretogram

G>Cl
C
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C
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T
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A

G
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C

T

G
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C

A

G

G

T

G

A

G
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Mutation - IVS16+1G>T
Novel

Yes

Patient

AS.I

Ethnic Origin

Australian, British descent

Nucleotide Change

G>T transversion

Position-

c.DNA

7276+1

g.DNA

31394

Gene Location

IVS 16, duplicated region

Method of detection

Sequencing

Predicted Effect
(actual change of protein)

Canonical GT donor splice site aboiished. Exact effect
has not been confirmed, as R�· .\ was not available.
However, the most likely effect is inactivation of the
splice site leading to translation into intron 16 for a
further 25 aa before truncation at g.31468. Another
possibility is the activation of a cryptic splice site 70
nucleotides beyond the canonical GT splice site et
position g.314563-4; this would lead to the addition of23
novel aa to polycystin-1.

Protein Domain

RFJ domain

Supporting Evidence Family Segregation Amdysis

Segregates in 3 affected (A5. l, AS.3, A5.5} family
members. No sample of unaffected (AS.2)
available for analysis.

Confirmatory assay

Sequencing (possible enzyme assay Mae
restriction site created)

II,

Pedigree
Pedigree

~1

I ~2

A5.3

A5 .5

Electrophoretogram
Family A5 (from the top A5.l , A5 .3 and A5 .5)
Arrow indicates G>T transversion
CC A

CC AA CC A

G

A C

I

t
GG

T

GGG

T

G CC

C:

Nxm
I()

C

C A

C

C A

A C

C A

G

A C

G

TT

G

GG

T

G C

C

00

G CC A

C

C A

A C

C A

G

A C

3
G G T

G G

G T

G CC

~~
178

Mutation -

IVS37-10C>A

Novel

Yes

Patient

B57. l

Ethnic Origin

Bulgarian

Nucleotide Change

C>A transversion

Position-

c.DNA

11225-10

g.DNA

48491

Gene Location

IVS 37, unique region

Method of detectioa

SSCP and sequencing

Predicted Effect

Activation of cryptic acceptor splice site:
predicted addition of 8 nucleotides to coding
sequence resulting in frameshift and a premature
termination signal at codon 3685 - truncation of
polycystin-1 by 518 aa

Protein Domain

Loop between 5 th and 6th TM domains

Supporting Evidence Family Segregation Analysis

Segregates in 3 affected (B57. l, B57.2, B57.3), no
unaffected family members were available for
analysis.

Confirmatory assay

Bsr I restriction enzyme assay (restriction site
created - 52, 174 + 46 bp in mutant allele and 226
+ 46 bp in wild-type)
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Wild Type

48481 agggcccccc cgtccacc [ag] AGC CTC CTG ..... .
S
L
L

Mutant

48481 agggcccccc [ag] TCC ACC AGA GCC TCC TGG ..... .
S
T
R
A
S
W
Figure V.3 Proposed effect of splice site mutation g.48491 C> A

Pedigree

~

57.1

57.3

1

2

3

4

SSCP Gel: PCR fragment IVS37-IVS 38
Lanes 1-3
Lane 4

Normal controls

857.1
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Bsrl Restriction Digest
57 .1 57 .2 57 .3 NC

Family B57 with normal control (NC)

,.__ 372bp
·. . . - 226bp
..__ 174bp

Sequencing Gel
B57.l

Normal

ACGT

ACGT

Arrow indicates C> A mutation
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MISSENSE VARIATION
Mutation-G381C
Novel

Yes

Patient

A9.l

Ethnic Origin

Australian, British descent

Nucleotide Change

G>T transversion

Position-

c.DNA

1352

g.DNA

21430

Gene Location

Exon 5, duplicated region

Method of detection

Sequencing

Predicted Effect

Non-polar glycine { conserved between mouse and
human) is replaced by uncharged polar cysteine
with a sulphydryl group. Loop & helix changes in
protein topology predicted by PHDsec {Fig V.4 ).

Protein Domain

Between 1 st PKO domain and C-type lectin
domain

Supporting Evidence Family Segregation Analysis

Segregates in 3 affected (A9.l, A9.3, A9.5), not
found in I unaffected (A9.4) family members.

Confirmatory assay

Sequencing (possible Sac II restriction site
abolished)
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~ 9.3

9.4

9.5

9.1
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G38!C
Mouse
LVCPSFVHSNESLELGIRHRGGSALEVTYSILALDKEPAQVVHPLCPLDT
Human
LVCPSSVQSDESLDLSIQNRGGSGLEAAYSIVALGEEPARAVHPLCPSDT
G381
AA

ILVCPSSVQSDESLDLSIQNRGGSGLEAA YSIVALGEEPARAVHPLCPSDTI
I
EE HHHHHHHHHH HHH
I
PHDsec
IL.LLLLLLLL...L....LLLL. ..HHHH.. HH...LL....LLLLLLLLI
subset: SUB sec
lebbeeebebeebbcbbbeeeeeeebebbbbbbbbbee bebbbebbeeeel
P 3 ace
I................b.........bb.bbbbb.e.....b.....e.el
subset: SUB ace
C381
AA

ILVCPSSVQSDESLDLSIQNRCGSGLEAAYSIVALGEEP.'\R.A VHPLCPSDTI
PHDsec
I
EE
HHHHHHHHH HHH
I
subset: SUB sec
IL.LLLLLLLL........ LLLL..... HH.....L.LL....LLLLLLLLI
lebbeeebebeebbebbbt.eeeeeebebbbbbbbbbee bebbbebbeeeel
P_3 ace
subset: SUB ace
j..........................bb.bbbbb.e.....b.....e.el
Figure V.4 Evolutionruy conservation and topology prediction for mutation G381C.
Amino acids at position 381 are shown in bold and underlined. The human and mouse
protein sequences are aligned.

Predicted protein topologies for the wild-type and

variant alleles are shown. The abbreviations of E (extended sheet), H (helix)and L
(loop), are in accordance with PHDsec. PHD predicted relative solvent accessibility
(ace) in 3 states are represented by: b = 0-9%, i = 9-36%, e ::;: 36-100%. (Rost & Sander
1994).
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Mutation- Y2185D
Novel

Yes

Patient

A61.l

Ethnic Origin

Australian, British descent

Nucleotide Change

T>G transversion

Position-

c.DNA

6764

g.DNA

30662

Gene Location

Exon 15, duplicated region

Method or detection

Sequencing

Predicted Effect

Non-polar ttyptophan (conserved between
pufferfish, mouse and human) is replaced by
acidic aspartic acid. Loop lost in protein topology
predicted by PHDsec (fig V.5).

Protein Domain

PKDdomain

Supporting Evidence Family Segregation Annlysis

Not possible

Confirmatory assay

Sequencing (possible Ava II restriction site
created)
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Electrophoretogram

G

T

C

A

CC

T

J\

CC

A

N

A

CC

G

C

T

GGG

•

A61 .1

Normal
control

Y2185D
Mouse QRNYLEAHVDLRNCVSYQTEYRWEIYRT ASCQRPGRMAQMVLPGVD
HumanQRNYLEAHVDLRDCVTYQTEYRWEVYRTASCQRPGRPARVALPGVD
Fugu
LVEASVDLKGCLRYGAQYL WQILSAPSCDNDPHF ASGRVNGAT
Y2185

AA
JQRNYLEAHVDLRDCVTYQTEYRWEVYRT ASCQRPGRP ARVALPGVDJ
PHD sec
I EE
EE
EE I
subset: SUB sec
JLLLE .....LL. .... LLLL. .. ... LLL.LLLLLLLLL. ... LLLI
P 3 ace
le ebbebbbebbebbeeeeeeebee eeee e ee ebebbbebhel
Jsubset: SUB ace
Je ...b .b.b.b ... b .... e ... e .. ........... b.b ..... eJ
02185
AA

JQRNYLEAHVDLRDCVTYQTEDR WEVYRT ASCQRPGRP ARV ALPGVDI
PHO sec
I EEEE EEE EE HHHHEEEEEE E
EEEE I
subset: SUB sec
ILL. ....................... ...... LLLLL .. E. .LLLLI
P 3 ace
Jeee beb bebeebbb ee bebb ebebe ee ebebbbeeeeJ
Figure V.5 Evolutionary conservation and topology prediction for mutation Y2185D.
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Mutation - G2785D
Novel

Yes

Patient

A6. l

Ethnic Origin

Australian, British descent

Nucleotide Change

G>A transition

Position-

c.DNA

8565

g.DNA

37893

Gene Location

Exon 23, duplicated region

Method of detection

Sequencing

Predicted Effect

Non-polar glycine (conserved between pufferfish,
mouse and human) is replaced by acidic aspartic
acid. Slight change, loop shortened, in protein
topology predicted by PHDsec (fig V.6).

Protein Domain

Upstream of REJ domain in extracdlular region
prior to TM domains

Supporting Evidence Family Segregation Analysis

Segregates in 4 affected (A6. l, A6.3, A6.8, A6. 7),
not found in 2 unaffected (A6.4, A6.6) family
members.

Confirmatory assay

Sequencing (restriction assay not possible)

187

Pedigree
Jf6. l

6.4

6.6

6.7

6.8

Electrophoretogram
• 1 O•PKD1-EX23Af-6_ I •191 of ~04 •
T C G T G G C C C A G G II C A A G C G C T C G

T C GT 6 GC

CRG

NC R R G C GC T C G

A6. l

A6 .3

A6.6

A6.8

A6 .7

A6.4
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G2785D
Mouse
Human

Fugu

MRSRVLNEEPLTLAGEEIVALGKRSDPLSLLCY
MRSRVLN EEPLTLAGEEIVAQ!i.KRSDPRSLLCY
MHARVLNEEPLVLKGAEIAATGKLADPQSLLCY

G2785
!MRSRVLNEEPLTLAGEEIVAQ!iKRSDPRSLLCYI
AA
1 EE
HHHHHHHHHHHH EEEE I
PHDsec
ILL.. .. LLLL... HHHHHHHHH.LLLLL. EEELI
subset: SUB sec
P 3 ace
leebebbeeebbebbbeebbbebeeeeeebbbbel
1.......e.........b.... e......b.. I
subset: SUB ace

1)2785
AA
PHD sec

!MRSR VLNEEPLTLAGEEIVAQJ!KRSDPRSLLCYI
I EE
HHHHHHHHHHH EEEE I
subset: SUB sec
ILLL... LLLL... HHHHHHHHH.LLLLL.EEELI
P 3 ace
leebebbeeebbebbbeebbbeeeeeeeebbbbel
subset: SUB ace

1.......e .........b....e...... b... 1

Figure V.6. Evolutionary conservation and topology prediction for mutation G2785D.
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l\1utation - L4046F
Novel

Yes

Patient

A54.l

Ethnic Origin

Australian, British descent

Nucleotide Change

C>A transversion

Position-

c.DNA

l2347

g.DNA

51003

Gene Location

Exon 45, unique region

Method of detection

Sequencing

PrMlicted EfT�t

Non-polar leucine (conserved between mouse and
human) is replaced by aromatic hydrocarbon containing phenylalanine. Changes in protein
topology predicted by PHDsec

Protein Domain

91Ji TM domain

SupnortintLEvidens;e
Family Segregation Analysis

Not possible

Confirmatory assay

Sequencing (po�sible Bbv I restriction site
abolished).
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4046F

C>A
C G

C

A

G

A

T

C

G

A54.1

C G

C

A

G

C

T

C

G

Normal
control

U046F
Mouse
Human

AYAQMAIL11SSGAD
AYAQL AIL1VSSCVD

4046L
AA
ILGLVVLGV AYAQLAIL1VSSCVDSL WSV AQALL VLCPGTG!
PHD sec
I EE HHHHHHHHHHHHHH HHHHHHHHHHHHHHH I
subset: SUB sec
ILL. .... HHHHHHHHHHHH. ..HHHHHHHHHHHHH. .LLLI
4046F
AA
!LGL VVLGV AY AQLAIL.[VSSCVDSL WSV AQALLVLCPGTG!
PHD sec
I EEEEHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHI
subset: SUB sec
!L.EEE .. HHHHHHHHHH.HH.HHHHHHHHHHHHHH.LLLLI
Figure V. 7. Evolutionary conservation and topology prediction for mutation L4046F.
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Mutation - R4227P

Novel

Yes

Patient

A38.l

Ethnic Origin

Australian, British descent

Nucleotide Change

G>C transversion

Position -

c.DNA

12891

g.DNA

51637

Gene Location

Exon 46, unique region

Method of detection

Sequencing

Predicted Effect

Non-polar argmme (conserved between mouse
and human) is replaced by charged basic proline.
Changes in protein topology predicted by PHDsec

Protein Domain

Coiled-coil domain

ruspporting Evidence
Family Segregation Analysis

Segregates in 3 affected (A38.l, A38.3, A38.6),
not found in 2 unaffected (A38.2, A38.4) family
members.

Confirmatory assay

Sequencing (restriction assay not possible)
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Pedigree:

2t~~
38.4

38.3

6

38.6

Electrophoretogram:

2913.

4

CC

C

A

G

TTT

G

A

C

C

G

A

C

T

C

A

A

C

C

A

G

G

C

C

A

C

A

-~ ~'0~JS/Y~

From the top of the page these are A38.1, A38 .2, A38.3, A38.4 and A38.6.

193

R4227P
Mouse
Human

LHAVFESLLVQFDRLNQATEDVYQLEQQLQSLRG
LQAVFEALLTQFDRLNQATEDVYQLEQQLHSLQG

4227R
AA: LGRLGTRCEPEPSRLQA VFEALLTQFDRLNQATEDVYQLEQQLHSLQGRRI
Sec. structure I
HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH I
Prediction Subsets
ILLLLLLLLLLLL..HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH.LLLLI
SUB ace 1 ................bbb.bbb........ b...b.. b...........1
4227P
AA:LGRLGTRCEPEPSRLQAVFEALLTQFDfLNQATEDVYQLEQQLHSLQGRRI
Sec. structure I
HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH I
Prediction Subsets
ILLLLLLLLLL.HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH.LLLLI
SUB ace 1 ............ e.b..bb..bb..b.....b......b...b... e...l
Figure V.8 Evolutionary conservation and topology prediction for mutation R4227P.
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NON-TRUNCATING INSERTIONS & DELETIONS
Mutation - c.7472d-el3
Novel

Yes

Patient

A46.l

Ethnic Origin

Australian, British descent

Nucleotide Change

deletion ACC

Position-

c.DNA

7472

g.DNA

32650

Gene Location

Exon 18, duplicated region

Method of detection

Sequencing

Predicted Effect

Deletion of threonine residue at codon 2421
(conserved between pufferfish, mouse and
hwnan). Changes in protein topology predicted by
PHDsec

Protein Location

REJ domain

Supporting Evidence Family Segregation Analysis

Segregates in 2 affected (A46.1, A46.3), not found
in 2 unaffected (A46.4, A46.8) family members.

Confirmatory assay

Sequencing (restriction assay not possible)
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Pedigree

46.8

46.4

46.3
Electrophoretogram

A

T

G

del3

A

C

C A

C

i
C A

NN

T

C

A46.l

G

A

G

A

C

C A

C

A

N

C

NN

C

A46.3

f

f

G

G

A

A

G

G

A

A

C

C

C A

C

C A

C

A

T

C A

4
C

C A

C

A

T

C

C

A46.4

A46.8
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c.7472de13
Mouse
Human
Fugu

AARTFSNKTLVLNE TTTSTGSTGMNLVVR
AARTFSNKTL VLDE TTTSTGSAGMRLVLR
SAVTLQNDTL VLDSSSTif GSGGMNLVLR

Wild-type
IKRGRW AARTFSNKTLVLDETI'fSTGSAGMRLVLRRGVLRDI
AA
HHHEEEEE EEE I
PHD sec
I EEEEEE EEEE
ILL.. EEEE.. LL..EEE.LLLL.LL.............. LI
subset: SUB sec
P_3 ace
leeeeebb ebeeebbbbeeeeeeeb bbb bbbeebbbeel
subset: SUB ace
le....bb........b.e..........b.bbb......el
delT2421
IKRGRW AARTFSNKTLVLDET-TSTGSAGMRL VLRRGVLRDI
AA
I EEEEEE EEEEE
E EEEEE EEE I
PHD sec
ILL.EEEEE..LL.EEEE.. LLLLL.............. LI
subset: SUB sec
jeeeeebb ebeeebbbbeeeeeeb bbb bbbeebbbeel
P_3 ace
subset: SUB ace
je....bb........b........... b.bbb......el
Figure V.9. Evolutionary conservation and topology prediction for c.7472dell3.

197

Mutation - c.9289del39
Novel

Yes

Patient

A42.l

Ethnic Origin

Australian, British descent

Change

39 bp deletion
gac aga ggg get get gee ect gga gga gac etc gee ccg

Position-

c.DNA

9289

g.DNA

39090

Gene Location

Exon 25, duplicated region

Method of detection

Sequencing

Predicted Effect

Deletion of aa 3027-3039: delTEGLLPLEETSPR
(domain conserved between mouse and human).
Changes in protein topology predicted by PHDsec

Protein Location

Extracellular region prior to the 1st TM domain

Supporting Evidence Family Segregation Analysis

Detected in 1 affected (A42.1), absent in 1
unaffected (A42.3) family member. Linkage
analysis in this family was perfonned on DNA
from blood-spots. The yield was not sufficient for

XL-PCR
Confirmatory assays

PCR repeated and products cloned into Topo-TA
PCR cloning vector then sequenced. Agarose gel
electrophoresis also showed both alleles.
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Pedigree

42.3

Electrophoretogram
AGGAGGACAT GGTGTGGCGG ACAGAGGGGC 'l'GCTGCCCCT GGAGGAGACC TCGCCCCGCC AGGCCGTCTG C(
AGGAGGACAT GGTGTGGCG- --- -- -- - -- ---- - ----- - - -------- -------·}-C AGGCCGTI'TG C<

t

Start of 39bp deletion
A

G

C

G

A

GG

A

GG

A

C

A

T

C

A

T

G

G

T

G

T

G

T

G

G

2
A

G

C

G

c.9289del39
Human
Mouse

A

G

G

A

G

G

A

G

G

T

G

G

C

G

cl

G

G

C

A

C

C

A

GLYTSLCQYFSEEDMVWRTEGLLPLEETSPRQAVCLTRHLTA
GL YTSLCQYFSEEMMMWRTEGIVPLEETSPSQA VCLTRHLT A

Wild-type c.9289
AA
IGL YTSLCQYFSEEDMVWR-TEGLLPLEETSPR-QAVCLTRHLT Al
PHD sec
I EE
HHHH
EEEEE I
subset: SUB sec
IL.EE ...... LL.LL.H. .. LLLLLLLLLLLLL.L. .. .. .Lj
P 3 ace
lebbebbb bbbee eeeeeeebbebeeebeeebeebeeebeel
subset: SUB ace
le.b.bbb .. bb ...... ..e ...... e .. ee .......... ej
c.9289del39
AA
jGL YTSLCQYFSEEDMVWR--QA VCL TRHLT Al
PHD sec
I EEEHHHH HHHHHHHHHHHHHHH I
subset: SUB sec
jL.EE.HH ... .. HHHHHHHHHHHHHHHLLI
P 3 ace
jebbbbbbe bbee bbb bbbbbbeebeel
subset: SUB ace
je ...bbb ....... ... .. bbbbb .. .. ej
Figure V.10. Evolutionary conservation and topology prediction for c.9289del39.
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Mutation - c.l 1669del6
Novel

Yes

Patient

B25.l

Ethnic Origin

Bulgarian

Nucleotide Change

6 hp deletion CAGGAG

Position-

c.DNA

11669-11674

g.DNA

49737-49742

Gene Location

Exon 41, unique region

Method of detection

Agarose gel and sequencing

Predicted Effect

Deletion of glu and gin at codons 3820-21
(conserved between mouse and human). Changes
in protein topology predicted by PHDsec

Protein Domain

Extracellular region between 6 1h-J1h TM domains

SupportingEvidence Family Segregation Analysis

Not possible

Confirmatory assay

Alu I restriction enzyme assay (restriction site
abolished in mutant allele (resulting fragments are
214 and 135bp. Fragments are l 72, 48,and 135bp
in wild-type.
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S

N

N

825.1 N N

Agarose gel of Exon 41
SSize Standard
NNormal Control
825.1- c.11669del6 (Agarose gel appeared to have normal and larger allele;
when sequenced this proved to in fact be a 6 bp deletion).

Sequencing Gel c.11669del6

825.1
ACGT

Normal
ACGT

Arrow indicates start of 6bp deletion
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B25.1 Alul restriction assay

B25.1 NC

Only mutant allele has 214bp band
NC normal control does not

. - 349 bp (Incomplete digest -ID)
. _ 301 bp (ID 349 bp - 48 bp fragment)
~

214 bp (Mutant only)
172 bp (Mutant and wild-type)
. _ 135bp (Mutant and wild-type)
48bp Fragment not shown (ran off gel)

c.11669del6
Human
Mouse

DSGGYV.QE.LGLSLEESRDRLRFLQLHNWL
DSGGY I .QE.LGLSLEESRARLGFLQLHNWL

Wild-type c.11669
AA
I AWS WGSCA VYDSGGYV.QE.LGLSLEESRDRLRFLQLHNWLDN I
sec. structure I EEE EEEEEE HHHHHHHHHHHHHHHH I
prediction
subset
ILLLLL E LLL E
HHHHHHHHH LLI
c.11669del6
AA
IAWS WGSCAVYDSGGYVLGLSLEESRDRLRFLQLHNWLDNI
sec. structure I EEEE EEEE HHHHHHHHHHHHHHH I
prediction
subset
ILL L EEE LLL EEE HHHHHHHHHHHH LLI

Figure V.11. Evolutionary conservation and topology prediction for c.11669del6.
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Mutation - c.13069ins39
Novel

Yes

Patient

841.1

Ethnic Origin

Bulgarian

Nucleotide Change

ins 39bp
�cg cag gga cca ctt egg gee aag aac aag gtc cac ccc"'

Position-

c.DNA

13069

g.DNA

51815

Gene Location

Exon 46, unique region

Method of detection

SSCP and sequencing

Predicted Effect

Insertion of 13 aa (TQGPLRAKNKVHP) between
codons 4286-7 Changes in protein topology
predicted by PHDsec

Protein

Domain

Cytoplasmic terminal region

Supporting Evidence -

Family Segregation Analysis

Segregates in 2 affected (B41.l, B41.5) and 2 pre
symptomatic (B41.4, B4l.7), shown to be carriers
by linkage analysis, absent in 3 unaffected (B4 I .2,
B4 l .3, B4 I .6) family members.

Confirmatory assay

Size-separation by agarose gel electrophoresis
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Nucleotide Insertion
(4286) CCC "acg cag gga cca ctt egg gee aag aac aag gtc cac ccc " AGC(4287)
Additional Amino Acids
(4286) Pro "Thr Gin Gly Pro Leu Arg Ala Lys Asn Lys Val His Pro" Ser(4287).

Fig V.12. Nucleotide insertion and corresponding amino acids (c.13069ins39)
Pedigree

41.6

41.4

41.2

41.7

Individuals B41.4 and B41.7 both display the insertion; both children are asymptomatic
at this time.
Family B41
S

41.1

41.2

41.3

41.4

41.5

41.6

41.7
Agarose Gel
Lane 1:
Marker(S)
Lanes 2-8:
Family B41

(S) size standard- lOObp ladder
NB. Although 3 bands were seen on agarose gel in the affected individuals when this
PCR product was sequenced only 2 alleles were detected, namely the normal wild type
allele and the allele containing the 39 bp insertion as described. Future studies could
include sequence analysis of individual bands to solve this anomaly.
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Polycystin-1, pos. 4268- 4302
ex. 46, normal sequence
AA

IALPSRLARASRGVDLATGPSRTPLRAKNKVHPSSTI

sec. structure

I HHHHHHH

I

prediction
subset

ILL HHHHH LL LLLLLLL

LLLLLLLLJ

ex. 46, c.13069-13070ins39
AA

JALPSRLARASRGVDLATGPTORPLRAKNKVHPSRTPLRAKNKVHPSSTJ

sec. structure

I HHHHHHH

prediction
subset

ILL H HH LL LLLLLLL

LLLLLLLL

LLLLLLLLI

Figure V.13. Evolutionary conservation and topology prediction for c.13069ins39.
The 13 inserted aa residues are underlined. Repeated amino acids are shown in bold
case.
B41.1 Normal
TGCA TGCA

Arrow indicates position of insertion.
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VI.

Results - Polymorphisms

VI.1. Introduction

Alterations in the DNA sequence that have no apparent pathological significance and do
not segregate with the disease phenotype in the affected families were classified as
polymorphisms. Since the primary aim of this study was to identify the probable disease
causing mutations in PKDJ, polymorphisms were detected as a "side product", using the
same analytical methodology as that used for the detection of pathogenic mutations
(outlined in Chapter III.4).

When SSCP was used as a method for mutation screening, and several unrelated affected
individuals produced identical aberrant banding patterns, they were assumed to share a
common polymorphism. In such cases, sequencing analysis was performed on a small
number of representative samples.

After the sequencing identification of the variant

causing the SSCP mobility shift, a confirmatory restriction assay was designed and
performed on all DNA samples.

A total of 50 sequence variants in PKD 1 that did not segregate with the disease phenotype
were detected in the families investigated (Tables VI.I & VI.2). Nineteen of these variants
have not been described previously.

Eight polymorphisms were intronic and the remaining 42 occurred in the coding sequences.
This ratio is not likely to represent the true proportion of intronic to exonic polymorphisms
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in PKDI, as it reflects the biased design of the study. where only 50-100 bp of flanking
intronic sequence were included in the analysis of each exon.

All exonic polymorphisms were single nucleotide substitutions (SNPs). The overall length
of the coding PKDJ sequence analysed in this study was 12,163 bp, with a total of 42 SNPs
detected. This allows an approximate estimate of I SNP occurring per 290 nt in this part of
the genome.

Of the 42 exonic SNPs detected, 29 were silent, i.e. they did not result in an amino acid
subsutution. These variants, together with the intronic polymorphisms, are shown in Table
Vll.

VI.2. Missense Polymorphisms
A particularly interesting group of polymorphisms comprised 13 SNPs that resulted in
missense variations in polycystin-1, yet did not segregate with the disease. These sequence
variations are shown in Table VI.2. In general, missense changes present a challenge in
mutation analysis. Their causative role in relation to the disease phenotype is difficult to
establish, especialJy in cases such as ADPKD. where the role of the protein involved is
complex and poorly understood, and in vitro functional assays are not available. In
addition, even if unrelated to the disease phenotype, these variants may exert subtle
functional effects and thus modify phenotypic severity - a hypothesis that is to be tested in
future research.
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Table VI.I. Silent mutations in the PKDI gene.

Location

Patients
with
cbane:e

Sequence
Variation

Amino
Acid
Posn.

Type of
Change

Previous Reference

Exon 2

A7.I

c.487G>A
g.19963G>A

A92

Silent exonic

Rossetti et al .• (200I)

Exon5

A36.l

c.1234C>T
g.21312C>T

A341

Silent exonic

l110mas tit al.. ( 1999)

Exon 5

AS.I
A9.I
Al3.3
Al5.l*
A36.I
A42.I

c.1330T>C
g.21408T>C

L373

Silent exonic

Ross etti et al.. (200 I)

IVS 6

A7.I

g.22160G>A

-

lntronic

Novel

IVS 9

A9.I
A13.3
A36.I

g.23307del7

-

lntronic

Novel

(VNTR)

Exon 11

AS.I

c.290SA.C
g.249S2A>C g.

A898

Silent exonic

Thomas et al.. ( 1999)

Exon 11

A9.I
AJ3.3
A36.l

c.291 IG>A
g.249S8G>A

P900

Silent exonic

Thomas et al .• (1999}

Exon 11

A9.1
Al3.3
A36.I

c.2941C>T
g.24988C>T

D910

Silent exonic

l110mas et al.• ( 1999)

Exon 13

A6.l

c.3274T>C
g.26395T>C

01021

Silent exonic

Thomas et al., (1999)

c.3319G>T
g.26440G>T

TI036

Silent exonic

Novel

A29.I

A46.I
Exon 13

AS.I
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Exon 13

A7.l
AlO.l
A52.l
A61.1

c.3322A>G
g.26443A>G

Ll037

Silent exonic

Thomas et al., (1999)

Exon 15

A9.l
A46.l

c.3583C>T
g.27483C>T

All24

Silent exonic

Thomas et al., (1999)

Exon 15

A9.l
A46.l

c.3586C>T
g.27486C>T

Sll25

Silent exonic

Thomas et al., (1999)

Exon 15

A9.l
Al3.3
A29.l
A36.l
A46.l

c.4876A>C
g.28775A>C

AI555

Silent exonic

Watnick et al., (1999)

Exon 15

A7.1
AIO.l

c.4885G>A
g.28784G>A

T1558

Silent exonic

Watnick et al., (1999)

Exon 15

A9.l
Al3.3
A29.l
A36.1
A46.l

c.5383C>T
g.29280C>T

T1724

Silent exonic

Watnick et al., (1999)

Exon 15

A9.l
A13.3
A36.1

c.5974G>A
g.29872G>A

Ll921

Silent exonic

Thomas et al., (1999)

Exon 16

A13.3

c.7I38C>T
g.31255C>T

02309

Silent exonic

Perrichot et al., (2000b)

IVS 16

A42.1

g.31414 G>A

Intronic

Novel

Exon 17

A9.1
A13.3
A36.1
A46.l

c.7376T>C
g.32427T>C

L2389

Silent exonic

Watnick et al., ( 1999)

Exon 18

Al3.3
A29.l
A36.1
A46.l

c.7652C>T
g.32830C>T

L248I

Silent exonic

Perrichot et al., (2000b}

Exon 21

A61.1

c.8098G>A
g.33824G>A

A2629

Silent exonic

Novel

-
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Silent exonic

Peral et al., (1997)

lntronic

Novel

A351l

Silent exonic

Novel

c.1095IC>T
g.47705C>T

P3580

Silent exonic

Novel

c.10976C>T
g.47705C>T

L3589

Silent exonic

Aguiari et al., (2000)

Intronic

Perricho t et al., (1999)

Exon 26

A6.I
A9.1
A29.l
A36.l
A46.l

c.9541T>C
g.39466T>C

IVS 31

A61.l

g.4 3740T>C

Ex35

B71.1

c.10743C>A
g.47419C>A

11/48
Ex36

B62.4
8/48

Ex36

A29.I.
Pl 13.1

P3110

-

2/48
IVS 38

A25.l,
A34.1

c.IVS38+13G>A
g.48653G>A

-

3/48
Ex40

B23.l
1/48

Ex40

A4.1,
A22.l

c.11554C>T
g.49482C>T

D3781

Silent exonic

Novel

c.l 1584G>C
g.49512G>C

S3i9I

Silent exonic

Peral et al., (1996a)

-

lntronic

Perricho t et al.•
(2000a )

-

lntronic

Novel

-

Intronic

Novel

2/48
IVS 41

B23.1

"*

1/48
IVS 44

PI07.l
1/50

IVS 44

Pl 13.l,
A29.1

c.IVS4 I +5ins3
g.4981 SinsGGG
c.IVS44+12C>T
g.5093IC>T
c.lVS44+ 23insA
g.50942insA

2/50
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Ex45

A4.1,
Bl.I,
B78.l *

c.12484A>G
g.51140A>G

A4091

Silent exonic

Aguiari et al., (2000)

c.12838T>C
g.SI584T>C

4209P

Silent exonic

Peral et al., (1997)

c.12871C>T
g.516I7C>T

4220A

Silent exonic

Novel

c.12872C>T
g.516I8C>T

422IL

Silent e:rnnic

Novel

21/48
Ex 46(a)

B4.l
B78.1 *
17/48

Ex 46(a)

B3.l
1/48

Ex 46(a)

A3.1
1/48

*AI5.l homozygous for c.I330T>C. & *B78.l homozygous for c.12484A>G and
c.12838T>C. All other individuals are heterozygotes for the polymorphisms listed.
** IVS41 +5ins3 previously reported as disease-causing by Perrichot et al., (2000a) then as
a rare neutral polymorphism by Koptides et al., (2000).
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Table VI.2. Missense variations in PKDI that did not segregate with the disease
Sequence
Variation

Amino
Acid
cbanee

Frequency
(%) *

Previous
Reference

Exon

Patients with
change

Ex 11

A42.l

c.2427A **
g.24474G>A

Q739R

1/34 (2.9%)

Novel

Exl4

A6. I, A29. I,
A46.l

c.3486T>C
g.26921T>C

M1092T

3/34 (8.8%)

Novel

Ex15

A29.l, A46.l

c.4406T>C
g.28306T>C

W 1399R

2/34 (5.8%)

Watnick et al.,
(1999)

Ex 15

A52.1

c.5157C>T
g.29056C>T

T1649M

2/34 (5.8%)

Novel

Ex21

A29.I, A46.I

c.8124A>G
g.33849A>G

H2638R

2/34 (5.8%)

Watnick et al.,
(1999)

Ex23

A42.1, A46. l

c.8504C>T
g.37844C>T

R2765C

2/34 (5.8%)

Novel

Ex25

A6. l, A9.l,
A29.l, A36.l,
A46.l

c.9406GT>CC
g.39207GT>CC

F3066L

5/34 (14.7%)

Peral et al., (1997)

Ex35

B80.l PI08.I

c.10737C>T
g.47413C>T

TM3509

2/96 (2.1%)

P eral et al., (l997).

Ex36

BI.I A29.1

c.10986G>T
g.47737G>T

S/13592

2/96 (2.1%)

Novel

Ex38

Pl09.I

c.l 1295G>A
g.4857IG>A

G/Q3695

l/96 (1.0%)

Novel

Ex40

PI01.1

c.ll582T>A
g.49510T>A

S/T3791

1/96 (1.0%)

Novel

Ex44

22 p e ople
B78.l***

c.1234lA>G
g.50914A>G

l/Y4044

23/100
(23.0%)

Ross etti et al.,
(i996)

Ex45

B2.I

A/V4058

1/96 (1.0%)

Constantinides
et al., (1997)

c.12384C>T
I g.5I040C>T

* Frequency calculated as affected alleles divided by number of chromosomes tested.
**Genomic sequence lists G at nucleotide 24474, however cDNA has A at the
corresponding position 2427
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*** B78.1 was homozygous for I/\/4044 producing a different SSCP pattern compared to

heterozygotes for this change.

In this study, the non-pathogenic missense variations were investigated in greater detail in
terms of their predicted effect on protein topology. The analysis was conducted using
nnPredict, a secondary protein prediction tool (http://dot.imgen.bcm.tmc.c::du: 9331/seq
search/struc-predict.html). To assess evolutionary conservation, the amino acid involved
was compared between human and mouse and, when possible, the Japanese Pufferfish
(http://www.sanger.ac.uJrJSoftware/Pfam/index.html). The type of amino acid change was
also determined. The results are presented below.

Q/R 739

Glutamine, a polar amino acid with an amide side chain, is replaced by arginine, a basic
amino acid. The glutamine residue is conserved betweer. human (Accession# L33242) and
mouse (008852). however another published human polycystin-1 sequence (Accession#
P98161) lists this residue as arginine. One can presume therefore that the variation
between published sequences represents a non-disease causing polymorphism. The change
occurs between the LDL-A domain and the second PKD repeat The Q/R 739 mutation
causes a marked change in the predicted secondary protein structure. however it is in a
region of the protein which does not correspond to any known functional domain. Q/R 739
was detected in one Australian patient (A42.1) and subsequently in an ADPKD family from
Bulgaria (personal communication, Dr. Nadja Bogdanova).
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0739R
Human (L33243)
Human (P98161)
Mouse (008852)

AGPGALLHCSP APGHPGPQAPYLSANASSW
AGPGALLHCSP APGHPGPRAPYLSANASSW
LLQCPLASSC PG QAL YLSTNASDW

0739
JAGPGALLHCSP APGHPGPQAPYLSANASSWJ
AA
PHD sec
I EEEE
I
JLLL.EEEE.LLLLLLLLLLLL. .. LLLLLLJ
subset: SUB sec
Jeeeebbbbbbebee eeeebe bbbebeeeJ
P 3 ace
subset: SUB ace
Je ... bbb.b .... e ................ J
R739
AA
JAGPGALLHCSP APGHPGPRAPYLSANASSWJ
PHD sec
I
HRH
I
subset: SUB sec
JLLL..LLLLLLLLLLLLL. ..... LLLLLLJ
P 3 ace
Je beebbee eeeeee eebbebeeeeeeel
subset: SUB ace
Je .... b ....... e ..... b .... ee .... J
Fig VI.1. Evolutionary conservation and topology prediction for variation Q739R.

Sequencing gel

A42.1

AJG

Nonna!
Control
A
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M/1'1092
Methionine, a non-polar amino acid with a sulphur-containing side chain, is repiaced by
threonine, a polar amino acid with an aliphatic hydroxyl side chain. This residue is not
conserved between human and mouse, in fact the mouse has threonine at this homologous
position. The change occurs in the fourth PKD repeat domain of polycystin-1 and results in
predicted changes in secondary protein structure. The novel change was detected in the
DNA of three from 17 screened Australian patients (A6. l, A29 .1, A46.1 ). In two of these
families (A6. l and A46. l ), other sequence variants segregating with the disease phenotype
have been detected (Chapter V).
M1092T

Human
Mouse

PDPSVAQVLVEHNVMHTYAA
PDPTVAQVLVEHNTfHIYTT

Ml092
AA
IPDPSVAQVLVEHNVMHTYAAI
I HHHEEEEE EEEEEE I
PHl) sec
ILLL..H..EE.......E.LI
subset: SUB sec
jeeeebbebbbebbbebb bel
P_3 ace
lee...b.bbb...b......l
subset: SUB ace
Tl092
IPDPSVAQVLVEHNVIHTYAAI
AA
PHD sec
I EEEEEEEE EEEEE I
subset: SUB sec
ILLL...EEEEEE.....E.LI
P 3 ace
leeeebbebbbebbbebb bel
subset: SUB ace
lee...b.bbb...b...... I
Fig VI.2. Evolutionary conservation and topology prediction for variation MI092T.
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Sequencing Gel Mff1092

Normal
Control

A6.l

A29.1

A46.l
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W/R 1399

Tryptophan, a non-polar amino acid with an aromatic side chain, is replaced by arginine, a
polar basic amino acid. This residue is not conserved between human and mouse, the
mouse has arginine at this position. The substitution occurs in the PKD-repeat domain of
polycystin-1. No effect is predict�d on secondary protein structure. The change was
detected in two Australian patients (A29. l and A46. l) and has been detected previously in
a family living in the USA (ethnicity not given) (Watnick et al., 1999).

W1399R

Human
Mouse

PEVGNVTLQPERQFVQLGDEA\VL VACA
PEIRNITLQPERQFVKLGDEA,RLVAYS

W1399
AA

IPEVGNVTLQPERQFVQLGDEA WLV ACAi
I
HHHHHHH EEEEEE I
PHDsec
subset: SUB sec
ILLLL..LLL.H.I-Il-Il-LL. ...EEE.LI
P 3 ace
leebbeb b eeeebbebeeebbbbbbel
subset: SUB ace
lee...........b......bbbbb..I
R1399
IPEVGNVTLQPERQFVQLGDEARLVACAI
AA
I
HHHHHE EEEEEE I
PHDsec
subset: SUB sec
IL.LLLLLLL. ...H ...L. ...EEEELI
leebbeb b eeeebbebeeebbbbbbel
P_3 ace
subset: SUB ace
lee...........b......b.bbb..j
Fig VI.3. Evolutionary conservation and topology prediction for variation W1399R.
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Sequencing Gel W/R1399

Normal
Control

A46.1

A29.1
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TIM 1649

Threonine, a polar amino acid with an aliphatic hydroxyl side chain, is replaced by
methionine, a non-polar amino acid with a sulphur-containing side chain. This residue is
conserved between human and mouse. The change occurs in the PKO-repeat domain of the
protein. A slight change is predicted in protein secondary structure. The novel change was
detected in one Australian patient (A52. l ), with no other family members available for
segregation analysis.

In the same patient, a deletion resulting in a frame-shift

(c.5I05de1AT) was found in the same PCR fragment as the polymorphism (see Chapter V).
This deletion was investigated in detail after cloning of the PCR fragments with the TA10 cloning kit (Invitrogen). Subsequent sequence analysis of the cloned fragments
demonstrated that the TIM 1649 variation and the deletion occurred on different
chromosomes.
T1649M
Hwnan
Mouse
T1649
AA

P1NHTVQLQAVVRDGTNVSYSWTAWR
PTNYTLQLQAAVRDGTNISYSWTAQQ
IPTNHTVQLQAVVRDGTNVSYSWTAWR!

PHD sec
subset: SUB sec
P 3 ace
subset: SUB ace
M1649

AA

I EEEEEEEE EEEEEEEEE I
ILLLL.EEEEEE..LLL.E.EE..EELI
leeeebbebbbbeeebeebbebbbbbel
je ....b.b.. b...... b.. b..... j

IPTNHMVQLQAVVRDGTNVSYSWTAWRI

I EEEEEEEEE E EEEEEE I
PHD sec
subset: SUB sec
ILL. ...E.EEEE.LLL. ..EEE...LI
P_3 ace
leee ebbbebbb ebeebbbbbbbbel
lee... b.b.bb...............l
subset: SUB ace
Fig VI.4. Evolutionary conservation and topology prediction for variation Tl649M.
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Electrophoretogram T/M1649
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C

T
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C

A

G

Ml649

T1649

tI

C nt tr:mslMes to threonine

221

H/R2638
Histidine, a basic amino acid which can be polar or non-polar. is replaced by arginine, a
polar amino acid of the same group. This residue is not conserved between human and
mouse. The mutation is located in the REJ domain of polycystin-1. It has no predicted
effect on secondary protein structure. H/R2638 was detected in two Australian individuals
(A29.l and A46.1) and has been described previously in a family living in the USA
(ethnicity not given) (Watnick er al., 1999).

H2638R
Human
Mouse

EPKHERQHRAQIR.K.NITETLVSLRVHTVDDIQQIAAAL
EPNVEQ�RAQiviRKNITETLISLR VNTVDDIQQITAAL

H2638
AA
IEPKHERQ!!RAQIRKNITETLVSLRVHTVDDIQQIAAALI
PHD sec
HHE HHHHHHHH I
I
subset: SUB sec
ILLL..HHHHHHHHHHH.HH.H........HHHHHHH.LI
P 3 ace
leeeeeeebebebeeebeebbbbb bbbbeebebbbbbbl
subset: SUB ace
le.e........b.e.b...bb.b.......b..bb... l
R2638
IEPKHERQRRAQIRKNITETLVSLRVHTVDDIQQIAAALI
AA
IHEE HHHHHHHH I
PHD sec
I
subset: SUB sec
ILLL.HHHHHHHHHHHH.HH..........HHHHHHH.LI
P 3 ace
leeeeeeeeebebeeebeebbbbb bbbbeebebbbbbbl
subset: SUB ace
le.e........b.e.b...bb.b.... b..b..bb... l
Fig VI.5. Evolutionary conservation and topology prediction for variation H2638R.
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Sequencing GeJ H/R2638

A29.1

A46.l

C

A

C

G

A

G

C

GG

C

A

G

C

A

C

C

G

A

G

C

CC

A

G

A

T

Normal
Control
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R/C2765
Arginine, a polar basic amino acid, is replaced by cysteine, a polar amino acid with a
sulphydryl side chain. This ·residue is conserved in human and mouse but not in pufferfish.
The change occurs in the extracellular region of the protein, between the REJ and the first
transmembrane domain. No effect is predicted on secondary protein structure. The novel
RIC 2765 variant was detected in two Australian patients (A42. l and A46. l ). In both
families, probable disease-causing mutations in PKDJ have been detected ( see Chapter V).

R276SC
Human
Mouse
Fugu

VASQAYNLTSALNIRILMRSRVLNEEPLTL
VASKAYNLSSALMRILMRSRVLNEEPLTL
VAAKAYSLSSVLMLILMHARVLNEEPLVL

R2765
jVASQAYNLTSALMRIL.MRSRVLNEEPLTLI
AA
I HHHHHHHHHHHHHHHHHHH
PHDsec
I
IL.L..IIBHHHHHHHHHHHHHHH.LLLLLLI
subset: SUB sec
lebbeb ebbbbbb bbbeb bbeeeebeel
P 3 ace
subset: SUB ace
1.... b..b.. bbb.bbb.b....e.....1
C2765
IVASQAYNLTSALMCIL:MRSRVLNEEPLTLI
AA
PHDsec
I HHHHHHHHHHHHHHHHHHH I
IL.... Hffi-IHHHHHHHHHHHHHH.LLLLLLj
subset: SUB sec
P 3 ace
lebbeb ebbbbbbebbb b bbeeeebeel
subset: SUB ace
1 ....b..b..bbb.bbb.b....e.....1
Fig VI.6. Evolutionary conservation and topology prediction for variation R276 l C.
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Sequencing Gel R/C2765
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F/L3066
Phenylalanine, a non-polar amino acid with an amm�tic side chain, is replaced by leucine,
a non-polar amino acid with an aliphatic side chain. This residue is conserved between
human and mouse. A slight change is predicted in secondary protein structJre. The
variation occurs in the extracellular region of the protein, between the REJ and the first
transmembrane domain, and was detected in the DNA of five individuals (A6.1, A9.1,
A29. l, A36.l and A46. l). It had been detected previously in a British population at a
frequency of 23.5% (Peral et al.. 1997).
F3066L
Human
Mouse

HVRFVFPEPTADVNYIVMLTCAVCLVTYMVMAAILHKLDQLD
HVQFI FPEPSA S I NYIV LLTCV ICLVTY VVMAMILRKLDQLD

F3066
IHVRFVIPEPTADVNYIVMLTCAVCLVTYMVMAAILHKLDQLDI
AA
I EEEEE
EEEEEE EEEEHHHHI-IlIHHH I
PHDsec
ILEEEE.LLLLLL..EEEEEE.LLL.EE...HHHHHHHH.LLLI
subset: SUB sec
P 3 ace
leb bbbeebeeebebbbbbbbbeeebbbbbbbbbbeebeebel
subset: SUB ace
1 ... bb.......... b.bbbbb....b ..bbbbbb..b.... 1
l.3066
IHVRFVLPEPTADVNYIVMLTCAVCL VTYMVMAAILHKLDQLDI
AA
I EEEE
EEEEEE EEEHHHHHHHHHIIB I
PHO sec
subset: SUB sec
IL.EEE.LLLLLL. .EEEEEE.LL..E...HHHHHHHHH.LLLI
P 3 ace
jeb bbbeebeeebebbbbbbbbeebbbbbbbbbbbeebeebel
subset: SUB ace
l.b.bbb.....e...bbbb.bb....b..bbbbbb.......j
Fig VI.7. Evolutionary conservation and topology prediction for variation F3066L.
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Sequencing Gel F/L3066
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T/M3509
Threonine, a polar amino acid with an aliphatic hydroxy] side chain, is replaced by

methionine. a non-po]ar amino acid with a sulphur-containing side chain. This iesidue is
conserved in human and mouse but not in pufferfish. The mutation is located in a
cytoplasmic loop between the 3 rd and 4th transmembrane domains of polycystin-1. No
change is predicted in secondary protein structure. The mutation was detected in 2 families
(B80 and PI 08) out of 48 families screened for this part of the gene.

T3509M

Mouse
Human
Puffer fish

SSVPGEKTETLILQTVGEE
SSTPGEKTETLALQRLGEL
SSIFEDQTEVILLQKHHEP

T3509
HMETDLLSSLSSTPGEKTETLALQRLGELGPPSPGLNWEQPQAARLSRTG
Secondary structure prediction (H = helix, E = strand, - = no prediction):
----I-II-II-I-----------1-If-IIIfIJillrl----------------lilflifiif---M 3509

HMETDLLSSLSSTPGEKTEMLALQRLGELGPPSPGLNWEQPQAARLSRTG
Secondary structure prediction (H = he1ix, E = strand, - = no prediction):
----I-II-II-I----------liJ-I1Il-ll1l-Il-ItI----------------tifil-IlII-l---Fig VI.8. Evolutionary conservation and topology prediction for variation T3509M.
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Exon 35

SSCP gels arrows indicate B80. l & P 108

SfNal Restriction digest

1, 2, 3, 4, 5, 6, 7, 8, 9 ,10, 11, 12, 13

~

1 2

3

4

1

2

3

,)?"·

~·::\H.; ·.

Lanes 1-11 Families P108 & B80
Normal Control (NC)
Lane 12
Lane 13 Size Marker

Pedigree B80

Lanes 1-3 NC
Lane 4 B80.1

Lane 1 P108.1
Lane2NC
Lane 3 Size Marker

B8T05
880.p0.2
B80.3

229

S/13592

Serine, a polar amino acid with an aliphatic hydroxyl side chain, is replaced by isole1;1cine,
a non-polar amino acid with an aliphatic side chain. This residue is conserved in hwnan
and mouse but not in pufferfish. The mutation occurs in the 4th transmembrane domain of
the protein. A slight change is predicted in secondary protein structure. Two families (B 1,
A29). from 48 were detected to have this change.

S3592!

Mouse
Human
Pufferfish

WLLSS§SSFLASFLGWEP
WLLSS§ASFLASFLGWEP
WLLSCFASFLCSCLLLEP

S3592

PPGVSVAWLLSS§ASFLASFLGWEPLKVLLEALYFSLVAKRLHPDEDDTL
Secondary structure prediction (H = helix. E = strand, - = no prediction):
---EEEEEEH--HHHEEE------HHHHHHHHHHHHHH-------13592
PPGVSVAWLLSS}ASFLASFLGWEPLKVLLEALYFSL VAKRLHPDEDDTL

Secondary structure prediction (H = helix, E = strand, - = no prediction):
---EEEEEHHHHHHHHH-------HHHHHHHHHHHHHH---Fig VL9. Evolutionary conservation and topology prediction for variation S3592I.
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Restriction Digests of Exon 36 (Hhal);Gel A, arrows indicate A29 .1 and B 1.1
Gel B Family B 1 with normal control (far right)

SSCP Family B 1
Exon36
B 1.1 - B 1.10 ran in
lanes left to right.
Aberrant SSCP does
not co-segregate with
disease as seen in
pedigree below

Pedigree Bl

0
Bl. I

Bl.6

Bl.9 Bl.2 BI.3
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GiQ 36�5
Glycine, a polar amino acid, with an aliphatic side chain consisting of a hydrogen atom, is
replaced by glutamine, a polar amino acid with an amide group side chain. This residue i.:.
conserved between human and mouse but not in pufferfish. The variation occurs in an
extracellular loop of the protein, between the 6th and 7th transmembrane domains. A slight
change is predicted in secondary protein structure. One family (Pl09) out of 48 was found
to have this change.

G36950
Mouse
Human
Puffer fish

DASCHGHAYRLQSAIKQEL
DASCHGHAYRLQSAIKQEL
DSDKDAHSLRLRTQLQRAL

G 3695
LLVTLLASYGDASCHGHA YRLQSAIKQELHSRAFLAITRS
Secondary structure prediction (H = helix, E = strand, - = no prediction):
--EEEI-II-I----------B3695

LLVTLLASYGDASCHQJ!AYRLQSAIKQELHSRAFLAITRS
Secondary structure prediction (H = helix, E = strand, - = no prediction):
--EEEHH----HHHHHHHHHHHHHHHHHHHHHHHH--Fig VI.10. Evolutionary conservation and topology prediction for variation G3695Q.
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Lane 18

Restriction Digest
Family segregation
PlOl
Lanes 1-16
FamilyPlOl
Lane 17
Normal Control
Lane 18
1OOObp Marker

Pedigree

P109.8

P109.51

.13

P109.11

.10

.12

P109.16

.14

.15

P109 .. 2 P109.4
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srr 3791
Serine, a polar amino acid with an aliphatic hydroxyl side chain, is replaced by threonine,
an amino acid of the same group. This residue is conserved between human and mouse and
no infonnation is available on pufferfish.

The sequence variation corresponds to an

extracellular loop in the protein between the 6th and 7'11 transmembrane domains. No
change is predicted in secondary protein structure. One family (Ptol) from 48 was
detected to have this change. A disease-causing mutation (S3 770X) had been detected in
this family in the same amplicon.

S3791T
Mouse
Hu.man

WQSVVQNG§ET
WESP---HNG§GT

S 3791

YDVGWESPHNG§GTWAYSAPDLLGAWSWGSCAVYDSGGYV

Secondary structure prediction (H = helix, E = strand, - = no prediction):
-------------EE----H--------E.E:E------

D791
YDVGWESPHNGTGTWAYSAPDLLGA WSWGSCAVYDSGGYV

Secondary structure prediction (H = helix, E = strand, - = no prediction):
--------EE---H--------EEE--Fig VI.11. Evolutionary conservation and topology prediction for variation S3791T.
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1

2

3

Ava I restriction digest Exon 40
Lane 1
Lane 2
Lane3

PlOl. l
Normal Control
Size Standard (lOObp ladder)

264bp
182bp

82bp

Pedigree:

,Jf

101.4

101. l

101.2

101.6

101.7
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I/V 4044
Isoleucine, a non-polar amino acid with an aliphatic side chain, is repiaced by valine, an
amino acid of the same group. This residue is conserved between human and mouse and
no infonnation is available on pufferfish. The variation is located in the 9th transmembrane
region of the protein. No change is predicted in secondary protein structure. Of 48
families screened, 21 were detected with this polymorphism. Family analysis was not
undertaken for this common change. 1/V 4044 has been described previously (Rossetti et
al., 1996) as a non-pathogenic polymorphism in an Italian family. The 14044 variant was

detected at a frequency of26% in the Spanish population (Badenas et al., 1999).

14044V
Mouse
Human

LGVAYAQMA!l,LISSGAD
LGVAYAQLA!LLVSSCVD

14044

LGLVVLGVAYAQLA!LLVSSCVDSLWSVAQALLVLCPGTGLSTLCPAESW
Secondary structure prediction (H = helix, E = strand, - = no prediction):
--EEEEHHHHHHHHHEEE----HHHHHHHHEEE-------E-----V 4044

LGLVVLGVAYAQLAVLLVSSCVDSLWSVAQALLVLCPGTGLSTLCPAESW
Secondary structure prediction (H = helix, E = strand, - = no prediction):

-EEEEHHHHHHHHHHEE-HIDiHHIDilfEEE--E--

Fig VL12. Evolutionary conservation and topology prediction for variation I4044V.
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Sequencing Gel 1/V4044
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SSCP Exon 44
This common polymorphism can be seen across the gel with its two distinct SSCP patterns.
Lane marked 57.1 (far right) represents a sample that was homozygous for the less
common allele.
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A/V 4058

Alanine, a non-polar amino acid with an aliphatic side chain, is replaced by valine, an
amino acid of the same group. This residue is conserved between hwnan and mouse and
no information is available on pufferfish. The variable residue is located in the 10th
transmembrane region of the protein.

No change is predicted in secondary protein

structure. NV 4058 was detected in one family (B2) from 48 ADPKD families studied.

A4058V

Mouse
Human

TLYNMARAFLVLCPGARVPTL
SLWSVAQALLVLCPGTGLSTL

A4058

LGLVVLGVAYAQLAVLLVSSCVDSLWSVAQALLVLCPGTGLSTLCPABSW
Secondary structure prediction (H = helix, E = strand, - = no prediction):
--EEEEHHl-IHHHI-Il-Il-il-IEE------�EE------E -----V 4058

LGLVVLGVAYAQLAVLLVSSCVDSLWSVVQALLVLCPGTGLSTLCPAESW
Secondary structure prediction (H = helix, E = strand, - = no prediction):
--EEEEHHHHHHHHHHEE-----EHHHHHHEEEE-----E----Fig VL13. Evolutionary conservation and topology prediction for variation A4058V.
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Restriction Digest for family B2 (Avail) Exon 45
Lanes 1-8:
Family 82
Lane 9:
Normal Control
Size standard (cut off picture)
Lane 10:

l .\~~
.. ..kl ,..
\
\

:'-

..

SSCPExon 45
1. Normal control
2. 82.1

,.

PedigreeB2

0
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VI.3. A variant in the 3' Unique Region segregating with the disease phenotype
An intronic insertion was found to segregate with the ADPKD phenotype in Bulgarian
family B23, and was characterised using the TOPO-TA cloning kit (Invitrogen). Clones
containing the PCR inserts from patient B23. l were subject to sequence analysis. The
resulting electrophoretogram below (Fig VI.14) displays the sequence variation between
the cloned PCR insert of the wild-type allele and the IVS4 l + 5 ins3 variant allele.

insGGG
C

T

GG

A

C

T

G

f..

G

C
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GG
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GGG
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G

T

G

G
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G

C

T

CCC

G

C

T

T

C

CCC

CCC

T

T

CC

10229

Fig VI.14. B23.1 Clones showing Wild-type allele and below the IVS4 l +5insggg

The change was initially suspected to be pathogenic as it segregated with the disease in this
family.

The insertion of three nucleotides so close to the donor splice site could

hypothetically interfere with normal splicing and thus represent a disease-causing mutation.
This sequence change had been suggested previously to be the disease-causing mutation in
a French family (Perrichot et al., 2000a). However, shortly after the publication of the
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French report, Koptides et al. (2000) showed that the same DNA variation was detected in
a Greek-Cypriot kindred, where it did not segregate with the disease. In this study, the
mutatior1 occurred in all four affected subjects in family B23 and was not found in one
unaffected family member. No disease-causing mutation has been identified in this family.
The change was not detected in the other 47 families screened. RNA from this family was
not available for analysis. It was therefore not possible to determine the sequence of the
transcribed RNA to assess if the translated protein is affected by the sequence variation.

VI.4. Linkage Disequilibrium in the PKDJ gene

VI.4.i. Linkage Disequilibrium in the 5' Duplicated Region of PKDJ
A number of polymorphisms in the duplicated region of PKDJ (shown in Table VI.3)
appear to be in linkage disequilibrium. The physical distance between the polymorphisms
is approximately 18 kb of genomic DNA, corresponding to a region in PKD 1 between exon
5 and exon 26. Only a small number of families, mostly of the same ethnic background,

have been studied. It will be interesting to ascertain if linkage disequilibrium occurs in all
ethnic groups and whether this SNP haplotype can be used for investigating affinities
between populations.

241

Table VI.3. Shared polymorphisms of the 5' Duplicated region of PKDI
Patient

2<:)

1\46

A9

A13

A36

+

+

+

IVS9del7

+

+

+

P900

+

+

+

P910

+

+

+

A6

A7

AlO

+

+

+

+

Seq. Change
1373

1021

na

+-

+

+

Ll037
1 n-'1092

+

A1124

na

+-

+

Sl 125

na

+

+

W/Rl399

na

;-

4-

A1555

na

+

+

Tl558

na

T1724

na

Ll921

na

12389

na

L2481

na

+

+

I 'R2638

na

+

+

F/L3066

t-

+

+

+

+

+-

+

+

+

P3110

4-

+

+

....

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

*na Patient A6 was not screened in the region from exon 1 to 5 and 15 to 21.
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VI.4.ii. Linkage Disequilibrium in the 3' Unique Region ofPKDJ
An interesting observation on the inheritance of ancestral chromosomes was related to the
co-existence of three common polymorphisms in the final three exons of PKD1, over a
physical distance of670 hp. These are I/V4044 in exon 44; c.12484A>G (A4091) in exon
45 and c.12838T>C (in exon 46). Of 85 PKDJ-linked individuals from three ethnic groups

screened in this study, 29 (34%) shared all three polymorphisms and one (B78.l) was
homozygous for each. Patients who had the polymorphisms included 19 of 57 Australians
(33%}, 2 of 7 Poles (29%), and 8 of 21 Bulgarians (29%), suggesting that this haplotype is
common across Europe.

Greater vruiation in linkage disequilibrium was observed in Bulgarian individuals, where
five had a combination of one or two of the polymorphisms but not all three (see Table
VI.4). Two additional polymorphisms in exon 45, namely (AN4058 and c.12617C>T
4220A}, were noted to occur in addition to the other three polymorphisms. The sub-group
of individuals with all five polymorphisms represents nine of the total of 55 patients (16%).
This linkage disequilibrium had previously been noted in a Spanish population (Badenas et
al., 1999): 26% of the Spanish population had all three common polymorphisms, and 8%

of individuals also had the additional A/V4058 polymorphism. The ease of investigating
the I/V4044/c.12484A>G/c.12838T>C haplotype located in the unique region of PKDJ, its
high frequency in diverse ethnic groups, and the observed differences, suggest that these
polymorphisms may be useful in population genetics research.
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Table VI.4. The shared common polymorphisms of PKDI exons 44-46
Individuals with
Exon 44 IN4044

-

B2.l

-

BIS.I
B23.l
B41.l
BS3.I
BS7.l
B73.l
B74.1
B7S.3
B77.l
B78.l*
A3.1
A6.I
A9.J
AII.I
Al4.l
A2S.l
A27.l
A29.l
A34.l
A36.l
A37.l
A38.l
A44.l
A46.l
A49.2
ASS.I
AS7.l
AS9.l
A72.I
Pl09.l
Pill.I

Individuals with
Exon 45 c. l 2484A>G
4091A
B2.l

-

B4.l
BIS.I
B2:J.l
B4l.1
BS3.I
B57.I
B73.l
B74.1
B7S.3
B77.1
B78.1*
A3.l
A6.l
A9.l
Al1.1
Al4.l
A2S.l
A27.l
A29.l
A34.I
A36.l
A37.l
A38.J
A44.I
A46.l
A49.2
ASS.I
AS7.l
AS9.l
A72.I
Pi09.l
Pill.I

*B78. l was homozygous for each polymorphism

Individuals with
Exon 46 c.12838T>C
4209P
B2.l
B3.l
B4.l
BIS.I
B23.l
B41.1
B53.I

-

B73.I
B74.I

-

B78.1 *
A3.l
A6.l
A9.I
AlI.I
AI4.l
A2S.l
A27.l
A29.l
A34.I
A36.I
A37.l
A38.I
A44.l
A46.l
A49.2
ASS.I
AS7.l
AS9.l
A72.l
Pl09.l
Pill.I
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VII. Disct�aion

VIL Discussion

During the eight years since the cloning of the PKDJ gene (The European PKD
Consortiwn, 1994) there has been limited progress in understanding the mutational
basis of ADPKD. The detection of mutations in PKDJ has been hindered by the
existence of homologous genes interfering with PKDJ-specific PCR amplification, as
well as by the nature of the PK.DJ gene. Its very high GC content, 62% overall (The
European PKO Consortium, 1994), poses significant technical problems with
requirements for high annealing temperatures and careful optimisation of PCR
amplification conditions. By far the most significant obstacle, however, has been the
co-amplification of PKDJ homologous genes (HGs), leading to a heavy bias of
mutation detection studies toward the unique 3' region of PKDJ.

During the cloning of PKDJ, three HG transcripts were identified (International PKD
Consortiwn, 1995) whose sequences were not characterised.

Since the sequence

infonnation on this part of the genome is still incomplete, the structure of these genes
and even their exact number have remained unknown.

Loftus et al. (1999)

characterised a BAC clone (GenBank AC002039) containing two PK.DJ homologues,
referred to as HG1 and HG2. This publication opened the way to mutation analysis of
the entire PKDJ gene, with subsequent studies using the sequence of BAC clone
AC002039 for their PCR primer design (Watnick er al., 1999; Thomas et al., 1999;
Rossetti et al., 2001; Phakdeekitcharoen et al., 2000 & 2001). The high degree of
homology (about 95%) between PKDJ and the HGs, has added the requirement for
long-range PCR amplification of large DNA fragments to the existing problems of
PKDJ analysis. The number of mutation detection studies in ADPKD has remained
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small, therefore both the understanding of the molecular defects, and the possibilities
for molecular diagnosis in affected families are still limited.

The present study has added important new data on the PKDJ homologous genes.
Using different experimental approaches, we have identified two new homologues (HG
3 and 4 ), and detailed database searches have led to the detection of two more (HGs 5
and 6). At this stage, the total number of human duplications remains unclear and will
probably only be established after completion of the Human Genome Project when alJ
of the presently existing ''gaps" are filled. This uncertainty has to be taken into account
in the molecular diagnosis and counselling of ADPKD families.

The known number of PKDJ homologous genes is large enough to raise questions
about their role, and the molecular mechanisms leading to their appearance.

Our

analysis of the model glioblastoma cell line T98G showed that, although HG3 and HG4
transcripts are produced, they are not present in the translationally active poJysomal
fraction, i.e. they are most probably not translated (Bogdanova et al., 2001). However,
suppression of ribosome binding to the HGs cannot be discounted under certain cell
conditions, and additional work is required into the expression of the PKDJ HGs to
investigate this possibility. Further support is added to the hypothesis that the HGs are
transcribed, but not translated, by the abundance of premature termination signals in HG
coding sequences. Thus, even if the HGs were translated they would generate short,
most probably non-functional, polypeptides.

We have therefore proposed that the

PKDI homologous genes (HGs l to 6) are pseudogenes and should be referred to as
PKD/PI to PKDIP6 (Bogdanova et al., 2001 ).
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A pseudogene can be defined as "A DNA sequence which shows a high degree of
sequence homology to a nonallelic functional gene but which is itself non-functional"
(Strachan & Read, 1999, 2 nd Ed. p553).

There are several types of pseudogene,

including those with introns and exons that are probably the result of tandem gene
duplication events, and pseudogenes with exonic sequence only that originate from the
integration of reverse transcribed cDNA into a new chromosomal location. These types
of pseudogenes are conventionally non-processed, ie. they are non-functional copies of
the functional gene.

However, an intermediate class of expressed non-processed

pseudogenes also exist which undergo transcription (Strachan & Read, 1999).
Immediately after a gene duplication event, it is thought that both the original gene and
its homologue have the capacity to be expressed and function if the correct regulatory
elements are intact. Through time, the HG may undergo deleterious mutations which
prevent translation but stilJ allow transcription of the pseudogenc (Strachan & Read,
1999).

The PKDJ pseudogenes are homologous to the genomic DNA of PKDJ (Loftus et al.,
1999, and this study), and therefore probably result from tandem gene duplication
events. Given the fact that the mouse p/rdl gene is not �uplicated (Piontek & Oermino,
1999), these events have to be recent in mammalian evolution. It would be interesting
to discover what sequence changes have made this part of the hwnan genome
particularly unstable.

Some pseudogenes, such as the 8·globin gene (HBQ-1), are known to express a
polypeptide product whose role is unknown, and the gene sequence suggests that it is
non-functional (Clegg, 1987). One of the recent theories of gene duplication is the
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duplication-degeneration-complementation (DOC) model (Force et al., 1999).

Gene

duplication events can lead to three outcomes. The first is non-functionalisation, where
the duplicate becomes a true non-functioning pseudogene; the second outcome is neo
funcrionalisation, where the duplicate produces a novel protein product; and the third is
sub-functionalisation where the duplicate continues to be expressed at lower levels than
normal. The DOC model suggests that the sub-functional copy may become essential
for gene function and could account for a significant proportion of preserved duplicate
genes (Force et al., 1999).

If the PKDJ HGs are expressed in vivo they may interact with PKDJ or its protein
partners to alter the function of polycystin-1. Even if the HGs are not translated, their
transcripts may modi{)• PKDJ expression in various tissues at different stages of
development and pathogenesis. These intriguing possibilities remain to be addressed in
future studies.

By using sequence information on all six identified PKDJ pseudogenes, the design of
PCR primers for the specific amplification of the PKDJ gene has been improved.
Screening for ADPKD mutations was performed on over 94% of the PKDJ coding
sequence, spanning exons 2 to 2 1, 23 to 41 and 43 to 46. This represents 12 , 163 bp of
the overall 12909 bp PKDJ message (Hughes et al., 1995). So far, only two published
studies have reported screening a greater proportion of the entire PKDJ gene: Rossetti

et al.. (2001) screened the gene between exons I to 8, l5 to 17 and 22 to 26 by direct
sequence analysis and exons 8 to 46 using PTT. Phakdeekitcharoen et al. (2000 &
200 l) analysed the complete duplicated coding region ( exons l to 34) by SSCP 1U1alysis
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of genomic DNA Both studies relied on the sequence of HG l and HG2 (GenBank
AC002039) to design PKDJ-specific primers in the duplicated region of the gene.

A total of 74 sequence variants in the PKDJ gene were detected during the course of
this study. Fifty of these variants are probably non-pathogenic in nature. It is proposed
that 24 sequence changes are likely to be disease-causing mutations, of which twenty
one are novel and three have been previously reported.

Of the 50 neutral

polymorphisms, 31 have been published previously and 19 are described here for the
first time.

A two-stage strategy was employed for the detection of mutations in the unique region
of PKDJ, including SSCP screening and the subsequent sequencing of samples with
aberrant electrophoretic banding patterns. The efficiency of SSCP as a mutation
screening technique was compared with direct sequence analysis, using DNA samples
from 15 Australian patients who bad been screened previously for exons 44 and 45 in
the unique region. As described previously, (Chapter V), exons 44 and 45 were chosen
for this comparison because of their different sized PCR amplified fragments and the
relatively high number of sequence variations, both neutral and pathogenic, reported in
this area of the PKDJ gene. The failure of SSCP to distinguish between individuals
with the A4091 polymorphism in exon 45, and those with A4091 plus the A/V4058 and
L4136 polymorphisms, reflects the limitations of the technique, whose sensitivity is
lower for PCR fragment lengths over 300-400bp (Hayashi & Yandell, 1993). Therefore
the 396 bp exon 45 fragment was probably too long for efficient mutation detection by
SSCP. ln contrast, no additional variation was detected in the shorter 292bp fragment
that included exon 44 when it was re-screened by direct sequencing.
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Sequence analysis of exons 2-21 and 23-33 in 17 Australian PKD }-linked patients
identified 12 possible disease-causing mutations. This represents a mutation detection
rate of approximately 71% over 71 % of the coding region of the gene. In the unique
region of the gene (exons 34-41 & 43-46), nine disease-causing mutations were
observed in 48 PKDJ-linked individuals using SSCP analysis (detection rate 19% over
approx. 24% of the coding region). As the area screened did not include the entire
gene, and since different nwnbers of patients were analysed in the unique and the
duplicated regions, it was difficult to estimate the overall mutation detection rate.
However,

as illustrated in Table Vll.l, the approximate figures provided here compare

favourably to those reported in similar studies.
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Table VII.I Efficiency of PKDJ screening
-- -

Reference
Screening
method
(Template)
Koptides et al., (1998)
SSCP
Watnick
et al., (1999)
(DNA)

Mutations
detected/tested
individuals

Region covered
(% ofcDNA)

Present study

I patient only
8/35 (23%)
I patient only
2/45-6/150 (4%)
1 family only
1/14 (7%)
1 family only
9/147 (6%)
7/175 (4%)
4/90 (4%)
6/91 (7%)
8/53 (15%)
13/47 (28%)
6/41 (14%)

9/48(19%)

ex 23-34
(27%)
(42%)
ex 11-21
ex 23-34
(16%)
(25%)
ex 34-46
(25%)
ex 34-46
(2%)
ex 45
(16%)
ex 43-46
(3%)
ex 44-45
(16%)
ex 43-46
ex 37-39,44-45 (6%)
ex 34-46
(25%)
(23%)
ex 16- 34
(36%)
ex 13-21
ex 1-12, 22-34 (40%)

SSCP&
DHPLC

Mizoguchi et al. (200 I)

4/176 (2%)

ex 23-46

HDA
{DNA)

Watmck et al., ( 1997)
Peral el al., (1995)
T·Jrco et al, ( 1995)
Rossetti et al., ( 1996)
Aguiari et al.. (2000)

8/80 (10%)
2/130 (I%)
1/20 (5%)
1/67 (I%)
3/40 (7%)

ex 23-34
e,.; 43-46
ex44
ex 44-45
ex 36-46

(16%)
(16%)
(1%)
(3%)
(23%)

HDA&
SSCP

Turco et al.. ( 1997)

3/60 (5%)

ex 38,40,45

(4%}

DGGE
(DNA)

Perrichot et al. (2000b)
Perrichot el al.. (1999)
Perrichot et al., (2000a)

8/146 (5%)
8/146 (7%)
3/146 (2%)
(total "" 13%)

ex l 5-21, 23-34 (50%)
ex 34-46
(25%)
ex 34-46
(25%)

PTT
(ill i•itro
translated)

Roelfsema et al., ( 1997)

6/135 (4%)

ex 15 & 23

(30%)

Rossetti et al.. (2001 )

27/33 (82%)
(511131 (43%)

ex 8-46

(87%)

Peral et al.. ( 1997)

6/95 (6%)

ex 22-46

(42%)

Thomas et al.. ( 1999)
Rossetti et al.. (200I )

7/24, (29%)
30/98 (31%)
(57/131)" (43%)

ex 2-15
ex I-8,15-17.
22-26

(47%)
(51%)

I patient only

Full-length RNA
(100%)

Koptides et al, (2000)
Peral et al., (1996b)
Peral et al., ( 1996a)
Neophytou et al., (1996)
Torra et al., (1997)
Daniells et al., ( 1998a & b)
Badenas et al.. ( 1999)
Afzal et al., (1999)
Kim el al., (2000b)
Bouba et al.. (2001)
Phakdeekitcharoen (2000)
Phakdeekitcharoean (2001)

PTT&
NIRCA
Direct
Sequence
Analysis

Present study
Present study
Thongnoppakhun et al.,
(2000)

r

12/17(71%)
4/42 (10%)

ex 34-41, 43-46(24%)
(41%)

ex 2-21, 23-34 (71%)
44-45
(3%)

* Rossetti et al (200 I) detected 57 novel mutations in 13 l patients (exons 1-46 ). Of
these, 27 were detected by the PIT, and 30 by direct sequence analysis.
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Obviously a I 00% detection rate is to be ultimately desired, however, this is often
impractical and it can be technically and financially challenging. In other studies of
genes where a large number of private mutations occur. such as the NF/ gene
associated with neurofibromatosis, detection rates over 50% are considered average
across a number of screening methods (Fahsold er al., 2000).

We were unable to detect the probabie disease-causing mutations m five of the
Australian PKD/-linked families screened (A7, Al2. Al3. A29, ASS). The mutation
detection study in these families was preceded by linkage analysis, however it should be
noted that four of the five families had only a minimum number of four members. A
positive lod score was obtained for the chromosoml.! 16 locus and. given the fact that
approximately 85% of Caucasian ADPKD cases are due to mutations in PKDI (Hughes
et al., 1995). it seems highly probable that they are linked to PK/JI (See Table Vll.2).

However, with so few related individuals investigated. one cannot rule out the
possibility that the low positive lod score was a chance tinding.

Table Vll.2. Observed Lod Score Values for PK!JI families with undetec!·•d mutation
Family (Number of Observed Lod Score Observed Lod Score Probability of
PKD / linkage"'
Minimum
Maximum
Individuals tested)
0.2993
91%
A7 (4)
0.2984
0.3005
91%
0.3009
Al2 (4)
0.27 79
91%
Al3 (4)
0.2780
0.5568
0.5566
95%
A29 (5)
95%
A55 (4)
0.5809
0.5809
"' Probability of linkage to PKD1 was calculated as previously described (Hateboer et
al., 1999a). If probability was between 86-100% linkage to PKDI was inferred.

Assuming linkage to PKDJ, our failure to detect the mutation may be technical in
oribrin, in other words due to low sensitivity of the detection system. A more likely
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possibility is that these families may have mutations in regions of the PKD J gene that
were not scr�ned. As stated previously, exons l , 22 and 42 were not analysed, and
large areas of the untranslated region, including the promoter region, were also omitted.
The presence of gross deletions in the ADPKD allele is another possible reason why
disease-causing mutations were not detected.

In this case, only the wild-type allele

would be amplified for mutation screening. For example, cryptic splice-sites may be
activated in an intronic region that had not been screened. This form of variation could
lead to the truncation of polycystin-1 but the genomic variation in the screened
fragments would remain undetected. To test for this possibility it would be necessary to
amplify the full length RNA and exanune the size of the resulting transcriptional
products.

Analysis of the mutations that were detected

in the present study showed that 15 of the

24 possible pathogenic variants (62.5%) resulted from a single base; substitution and 9
resulted from small deletions or insertions. The nucleotide substitutions comprised 9
transversions and 6 transitions. Of the 50 neutral polymorphisms detected, 4 were the
result of a small insertion or deletion and 46 were single base substitutions. This group
sub-divided into 38 transitions and 8 transversions.

Although a greater number of transversions throughout the genome would be
anticipated to occur by chance (4 possible transversions compared with 2 possible
tmnsitions),

in reality this has not been reported.

Wheil 337 pairs of human and rodent

orthologues were compared, it was found that the transition rate exceeded the
transversion rate by a ratio of 1.4 to I for missense mutations and greater than 2.0 to 1
for silent polymorphisms (Collins & Jukes, 1994). Mor� recently work on the Huruan
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Genome Project has determined a transition to transversion ratio of 1.89: l (Venter et al.,
200 I). A total of 31 transversions and 63 transitions have been reported in the literature
as

PKDJ mutations which result from a single base substitution. This represents a

transition to transversion ratio of approximately 2.1: l for pathogenic variants, when
neutral variants are considered this ratio changes to of 3.25:l (see Tables II.3, ll.4.a &
11.4.b).

When the single base substitutions detected in the present study (both pathogenic and
silent) are combined with those reported in the literature, 72% were transitions and 28%
transversions. This represents a transition to transversion ratio of 2.6 to l, more in
accordance with that reported by Venter et al. (2001).

In classifying DNA variants as possibly pathogenic or non-pathogenic the guidelines
proposed by Cotton & Scriver ( 1998) generally were followed.

Mutations were

classified as disease-causing when they could be predicted to result in a truncated
protein or, in the case of missense mutations, segregated with the disease phenotype and
caused a change in the predicted secondary structure of the protein (Rost & Sander,
i 994 ). For the non-truncating mutations, the evolutionary conservation of the affected
protein sequence was also examined as another indication of the possible functional
importance of the particular codon(s).

One hundred nonnal chromosomes for

all

mutations in the duplicated region of the gene were not tested as recommended (C'"tton
& Scriver, 1998), because the demanding nature of very long range amplification of

PKDJ fragments made an extended analysis of this type impractical.
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Twenty-four of the DNA variants deter.ted in the sn1dy were classified as probable
disease-causing mutations. Twenty-one of these variants were novel and three had been
published previously (Turco et al., 1995; Ros�tti et al., 1996; and Daniells et al.,
1998b). Subdivision on the basis of the effect of the mutation on gene expression
showed that between 50% to 62.5% were truncating, these included seven nonsense
mutations, four small deletions and one large deletion {12/24}. A further three splice
site mutations may also result in a truncation (3/24). The remaining 9/24 variants
(37.5%) were missense or in-frame deletions or insertions.

The frequency of tnmcating mutations in the unique region of PKDJ was 66%, and in
the duplicated region of the gene it was 58%. Other studies (listed in Table II.3) have
reported that around 70% of mutations in PKDJ were truncating. These reported values
may be slightly biased towards an over-representation of truncating mutations, as a
number of studies (Roelfsema et al., 1997; Peral et al., 1997; Rossetti et al.. 2001)
favoured screening methods such as PTT and NIRCA which are specifically design ed to
detect truncating mutations. Taken together, the results of PKDJ mutation detection
studies suggest that the exclusive use of techniques aimed at the identification of
truncating mutations would miss a sign ificant proportion (around 30%) of the
pathogenic variants causing ADPKD.

Nine of the probable disease-causing mutations detected in this study were predicted to
result in an intact protein with an altered amino acid sequence. These include five
missense mutations, three in-frame deletions and one in-frame insertion.

These

mutations were examined {Chapter V) in terms of evolutionmy conservation and
predicted effect on the secondmy structure of the protein (Rost & Sander, 1994 ). If en
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amino acid (or group of amino acids) within a protein is conserved between species
during evolution, the conserved residue is more likely to be functionally important than
a non-conserved amino acid. In addition to conservation during evolution, the predicted
effect on protein topology was also analysed using the PHDsec program (Rost &
Sander, 1994). This program is based on the combination of evolutionary information
and neural networks and has a reported accuracy of over 72% (Rost & Sander, 1994).
When the disease•segregating non-truncating variants detected in the PKDJ gene in this
study were analysed using these two measurements, it was inferred that they were more
likely to be pathogenic if they altered a conserved residue and significantly shanged the
predicted topology of tl1e protein.

A further three probable pathogenic mutations were the product of nucleotide
substitutions in the canonical splice signals or near the splice site. The effect of these
pos�ible splice site mutations has to be determined by RNA studies. Unfortunately,
RNA samples were not available at the time of the project. Initial blood samples from
Australian index patients were divided equally, DNA was extracted from one half of the
sample, and immortalised lymphoblastoid cell lines were created from the other half
Due to equipment malfunction these cell lines were accidentally thawed during the
course of the study. Patients will therefore need to be re-bled in the future in order to
allow RNA experiments to be performed.

Two of the mutations, IVS14+1 G>C and IVS16+1 G>T, resulted in the replacement of
guanine at the GT donor site.

Tnis form of sequence alteration infers a loss of the

donor site that is likely to result in th� activation of a cryptic donor splice-site in the
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following intron, or in· the continuation of translation up to the beginning of the next
exon.

In the simplest prediction, the IVS 14+1 G>C mutation could cause the addition of five
novel amino acids prior to the utilisation of a cryptic GT splice donor site at genomic
position 26957-5814. Alternatively, if this cryptic splice site is not activated. 14 novel
amino acids may be translated before the introduction of a novel stop codon at genomic
position 26984-86.

Likewjse, the IVS 16+ I G>T alteration may result in the addition of 23 novel amino
acids prior to the introduction of a cryptic GT splice donor site at genomic position
31463-64.

Alternatively, 25 novel amino acids may be translated prior to the

introduction of a novel stop codon at genomic position 31469-71.

The third possible splicing mutation, IVS37-IO C>A, is more complex. The change is
sited 1Obp before the start of exon 38 in IVS37 and could constitute an acceptor site
alteration, which in tum may lead to the activation of a cryptic AG splice acceptor site
(see Fig V.3 for the proposed model).

If this cryptic splice-site is activated, the

resultant frame-shift could cause the addition of 13 residues to the protein prior to the
introduction of a novel stop codon. As shown in Chapter V, of the six family members
tested three were affected and had this mutation, and the three members who were
phenotypically unaffe;ted did not. The change was not detected in 47 other unrelated
PKDJ-linked jndividuals.

On the basis of the family segregation and the possible

acceptor site change, we presume that this could be the disease-causing mutation in this
family, although only RN A studies could confirm/refute this speculation.
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The early mutation detection studies were biased towards the unique region of the
PKDJ gene (Turco et al., 1995; Peral et al., 1995; Rossetti et al., 1996; Neophytou et
al.. 1996). Screening techniques in the duplicated region that favoured the detection of

truncating mutations followed these studies (Roelfsema et al., 1997; Peral et al., 1997).
Reports on analyses of the entire PKDI gene for all types of mutation have begun to
appear in the scientific literature only recently (Thomas et al., 1999; Perrichot et al.,
1999, 2000a & b; Rossetti er al., 2001; Phakdeekitcharoen et al., 2000 & 2001).
Truncating and in-frame pathogenic mutations have been detected across the PKDJ
gene from exon I. which corresponds to the flanking region arowid the leucine-rich
repeat domain, to exon 46 which translates into the coiled-coil domain in the
cytoplasmic region prior to the carboxy-tenninus.

When the type of mutation is considered in the context of its position, trends begin to
emerge in the published data that point to the possible existence of mutation hot spots in
PKDI which deserve special attention in mutation detection studies. It should be noted,

however, that as the number of PKDJ mutations identified increases these trends may
prove to be illusions. The location of the novel mutations detected in this study, and of
previously reported mutations (see Table 11.3), indicate that in the populations tested a
high proportion of pathogenic vHriants cluster in exons 15 to 18, 23 and 25, and in
exons 44 to 46. At the protein level, these areas correspond to the PKO repeat motifs,
the REJ domain, the final three transmembrane regions, the coiled-coil domain and the
cytopJasmic carboxy terminus.
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A clustering of truncating mutations appears to exist in two areas of the gene, one
within the unique region and anothef one within the duplicated region. Within the
unique region, most truncating mutations are located in the final three exons of the
gene, corresponding to the loops in the extracellular and cytoplasmic domains, the final
transmernbrane domains, the coiled-coil domain and the carboxyl-terminus of
polycystin-!. With the exception of exon 42, the entire unique region was analysed in
this study. Clustering was observed, with 29% (7/24) of mutations located in exons 44
to 46, which accom1t for only 5.6% of the coding region. The majority (4/24) were
nonsen� mutations in exon 44. Tnese four mutations constitute 9% of all truncating
mutations observed in our study population and are clustered in just 1.1% of the gene.

In the duplicated region, truncating mutations clustered in exon 15, with 24 of the 29
mutations identified so far in this exon resulting in premature truncation of the protein.
Only one study (Roelfsema et al., 1997) used PIT to detect five mutations in this exon.
The remaining 19 mutations have been identified using a variety of techniques (Watnick
et

al., 1999; Thomas el al., 1999; Perrichot et al., 2000b; Phakdeekitcharoen et al.,

2000; Rossetti et al.• 2001;), suggesting that the observed clustering may be real. Thus
it appears that exons 15, 44. 45 and 46 of may be suitable candidates for PTI screening.

Missense mutations predominate in exons 23 and 25 in the duplicated region of the
gene. These two exons harbour 15% (26/168) of all mutations reported to-date (Peral et
al., 1997; Watnick et al., 1997; Rossetti et al., 2001; Phakdeekitcharoen et al., 2001),

and the majority of these mutations (76%) are missense changes. Exons 23 and 25 are
adjacent to the polypyrimidine tracts in introns 21 and 22 (Van Raay et al., 1996). The
high GC content of the tracts makes them particularly susceptible to SNP vanation,
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since methylated cytosines in CpG dinucleotides are susceptible to forming thymine and
account for a 10-fold increase in mutation rate when compared to other dinucleotides
(Venter et al., 200 I).

These tracts have been implicated in gene conversion events

(Watnick et al.. I998a), with the homologous genes acting as reservoirs for inter-locus
gene conversion.

The second area where mutations seem to cluster in the duplicated region corresponds
to exons 16, 17 and 18 (Watnick et al.• 1999; Perrichot et al., 2000b; Phakdeekitcharoen

et al.. 2000; Rossetti et al., 200 I; Bouba er al., 200 I). These exons, encoding the REJ
domain of polycystin-1, nccow1t for 4.5% of the

PKDJ coding sequence but harbour

7.6% of all reported mutations. No particular type of mutation has been observed to
predominate in this region.

Like others to date (Krawczak & Cooper, 1997; AfLal et al., 2000; Aguiari et al., 2000:
Kim et al., 2000b;

Koptides et al.,

2000; Perrichot et al., 2000 a & b;

Phakdeekitcharoen et al., 2000 & 200 I; Rossetti et al., 200 I; Bouba er al., 200 i ), this
study failed to identify pathogenic variants in exons

3, 6, 7, 9, 14, 26, 29, 30 and 33.

This may be due to severa! reasons. Firstly, it could be that these regions of the gene
are not essential for protein function, and so m•.Jtations would remain w1detected due to
as�crtainment bias towards

ADPKD-affected individuals.

Only two neutral

polymorphisms have been detected in these exons; a novel missense variation in exon
14 (Mffl 092) and a previously described silent exonic change (P3110) in exon 26
(Peral et al., 1997).

Conversely, pathogenic mutations in these regions may be so

detrimental that they are not conducive to post-natal survival and so they would not be
found in the adult population. As greater numbers of individuals are screened for PKDJ
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mutations, it will become apparent if these regions are indeed devoid of disease-causing
mutations in the adult population.

Most mutation detection studies of the PKDI gene have been performed on the DNA of
Caucasian individuals, primarily those of northern European descent. Two studies have
focussed on the DNA of Asian individuals from Thailand and Korea respectively
(Phakdeekitcharoen et al., 2000; Kirn, et al., 2000b). The first mutations in exons 18
and 19 of the gene (R2408C, R2430X. c.7535ins3, Q2558X) were reported exclusively
in the Thai population (Phakdeekitcharoen et al., 2000). As yet, there are insufficient
published data on ethnic background to establish whether ethnic differences do exist in
the location and type of path,.;t{enic sequence variation present.

For example, three

recurrent mutations in exon 44 (Q40IOX, R4020X and Q404JX) have been recorded in
Anglo-Irish, southern European and Asian families (Daniells et al., I998b; Kim et al.,
2000b; Rossetti et al., 1996; Torra et al., 1998), providing further evidence that exon 44
is a hot spot for truncating mutations. A slipped-mispairing mode! has been suggested
as the mutational mechanism for Q404 l X (Daniells et al., 1998b).

An interesting observation on disease-causing mutations

in

the

PKDI gene is their

private nature, i.e. their restriction to single affected families, which account for the
large number of novel mutations discovered in mutation detection studies.

In this

project. 21/24 or 87. 5% of the probable pathogenic variants were novel, which is
comparable to the 85.2% (69/81 mutations) published recently by Rossetti et al. (2001).
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The high rate of private mutations in PKDJ seems to contradict the familial nature of
ADPKD, where only 10% of all patients are reported to have de novo mutations
(Gabow, 1993). One might expect a proportion of the remaining 90% of individuals
with ADPKD of familial origin to perhaps share a few common founder mutations. For
example, in this study we detected the same mutation (Q4003X) in two Australian
patients (A18. l & A4 l.l) of Macedonian origin.

Although they did not �lieve

themselves to be closely related, they shared common haplotypes and a founder
mutation can be presumed. Peral et al., (1995} also reported a similar situation where
two families shared the same mutation (E43IVS43 + 5-I 3del20) and haplotype analysis
suggested identity by descent.

The scarcity of founder mutations in the PKDJ gene may be related to the reduced
reproductive fitness of afiected individuals.

A phenomenon that could theoretically

contribute to this effect is that ofclinical anticipation in ADPKD (Geberth et al., 1995a;
Peral el al., 1996a; Torra el al., l 997; Penichot et al., 200 I), where the age of onset of
the disease, arid particularly the age at end-stage renal failure, tends to be earlier with
each successive generation. If anticipation in ADPKD exists, it may result in declining
reproductive fitness in the younger generations of affected families, and thus ultimately
lead to the elimination of the familial mutation.

The high mutation rate

in PKDJ could be attributed, at least partly, to the high nwnber

of potential gene conversion reservoirs. In addition to the homologous genes located on
chromosome l 6p13. l, four functional genes have been identified in the paralogous
polycystin family, PKD2, PKD2l, PKD2L2 and PKDREJ (Veldhuisen et al., 1999).
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All four paralogues share homology with the PKDJ gene between exons 38 to 45 in the
transmembrane regions and the cytoplasmic tail prior to the coiled-coil domain
{Veldhuisen et al., 1999). The high incidence of reported mutations in exons 44 and 45
might therefore be directly correlated with the nwnber of paralogous genes available for
gene conversion in this region.

Other mutational mechanisms in the PKDJ gene have been proposed.

As stated

previously, a slipped-mispairing model for the Q4041 X mutation has been postulated
(Daniells et al., 1998b). In that model a directly adjacent imperfect 5 nucleotide repeat
exists. If there is slipped mispairing between the nucleotide repeats then T replaces Cat
nucleotide 12332 and Q4041 X results {Daniells et al., 1998b). Other regions of the
gene may also be susceptible to such mutational events and give rise to novel variations
in the gene. By combining the mutational mechanism theories it is possible that gene
conversion, the high GC content of the gene, and the slipped mispairing model may all
contribute to the high level of private mutation.

We have detected 50 polymorphic variants, including 31 that have been published
previously and 19 novel changes. They represent 42 exonic (13 missense and 29 silent)
and eight intronic variations. This should not be interpreted as suggesting the erustence
of fewer polymorphic variants in the non-coding regions of the gene, but rather reflects
an analytical bias since only 50 to lOObp of the intronic sequences surrowiding exons
were screened in the study.

As of February 2002 the total nwnber of reported non-disease causing polymorphisms
in the PKDJ gene was 132 (Krawczak & Cooper, 1997; Afzal et al., 2000; Aguiari et
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al., 2000; Bogdanova et al., 2000; Kim et al., 2000b; Koptides et al., 2000; Perrichot et
al., 2000 a & b; Phakdeekitcharoen et al., 2000 & 2001; Rossetti et al., 2001;

Mizoguchi et al., 200 J; Bouba et al., 200 I; Tsuchiya

el

al., 200 I). Of these, 96 are

silent variations and 36 are missense variations. The localisation of polymorphisms
replicates that of pathogenic mutations in some parts of the gene. For example, 16%
(21/131) of polymorphisms occur in exons 23 to 25, around the polypyrimidine tracts
where a clustering of pathogenic missense mutations has also been observed, thus
providing further support to the gene conversion theory (Watnick er al., 1998a).
However, there did not appear to be a clustering of polymorphisms in exons 15 or 44 to
46 which, as discussed earlier in this chapter, harbour a large number of disease-causing
truncating mutations.

Particular attention in this study was given to polymorphisms that did not segregate
with the disease phenotype, yet cause an amino acid substitution in polycystin-1.
Missense changes present a serious interpretational problem in any mutation detection
study where a functional assay is unavailable as direct proof of the pathogenic effect.
As demonstrated in the study, computer modelling of secondary protein structures
predicts changes in a sign ificant proportion of the missense polymorphisms detected. In
the case of ADPKD the substantial number of novel mutations compounds the problem,
where possible functional effects need to be invoked in every new case. One of the
conventional approaches used to detemrine whether a missense mutation is indeed
associated with a given disease phenotype, is to screen 50-100 nonnal unrelated
controls for the mutation and, if present in the controls, the mutation is classified as a
non-pathogenic polymorphism. However, besides the prohibitive costs involved in
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screening PKDJ in 50-100 normal controls, the rarity of individual variants in this gene
would mean that lack of a mutation in the control subjects could still be inconclusive.

Family segregation may also be insufficient evidence in favour of a pathogenic role.
For example, an intronic variation in PKDJ (IVS41+S ins 3) was originally reported to
be a likely disease-causing change (Perrichot et al., 2000a). It was presumed that the
change was involved in aberrant splicing even though RNA analysis was not perfonned.
This insertion mutation segregated with the disease in a French family and was not
detected in l 00 normal chromosomes, nor had it been reported previously in the
literature. Soon after the initial report, the same variant was described as a non-disease
causing polymorphism in a large Greek-Cypriot kindred, where the mutation failed to
segregate with the ADPKD phenotype (Koptides et al., 2000). Again, however, no
RNA analysis was performed in this family. The same insertion mutation was d.:tected
by this candidate in Bulgarian patient, B23. l . Subsequent investigation revealed that it
segregated with the disease in family B23 (personal communication Dr. Nadja
Bogdanova, Munster, Germany). RNA was not available to further investigate if the
change had any effect on transcription in family B23. Its role therefore remains to be
assessed in future studies.

The so-called "neutral" polymorphisms, especially missense mutations, may have subtle
effects on protein function and thus act as modifiers of disease severity in cases where a
drastic mutation is the obvious major cause of the disorder.

Moreover, the

accwnulation of such "neutral" polymorphisms may lead to a cooperative effect on
protein function, through nwnerous changes in topology, even in the absence of an
obvious pathogenic mutation. The existence of such ..hypermorphic" alleles has been
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proposed by Watnick et al. (1998a). The polymorphisms detected in the present study
of five families where no pathogenic mutation was found are summarised in Table
VII.3. Four polymorphisms located between exons 2 and 15 of PKDJ were detected in
Australian patient A7 .1. Three of the variants were silent in the coding region and one
was intronic.

No variation was detected in patient Al2.3, which was unusual as

variation was detected in almost all of the other patient DNA samples analysed in this
study. Five common polymorphisms in linkage disequilibriwn were detected in patient
ASS.I between exons 44 and 46. Ten polymorphisms were detected in patient AB.I
between exons 5 and 18, nine of which were silent variants in the cocling region and one
was intronic. One patient (A29. 1) is a likely canclidate for a hypermorphic a11ele, if
such an allele exists. This patient had 15 polymorphisms from exons 13 to 46; of which
6 were missense, 8 were silent changes in the cocliog region, and 1 was intronic.
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Table Vll.3. Polymorphisms in PKD/-linked patients with an undetected mutation
Patient

A7. l

Al2.3
AIJ.I

A29.i

ASS. I

Polymorphisms

c.48"/G>A, A92 ( l/15)
IVS6-68G>A (1/17)
c.3322G>A, LI037 (4/17)
c.4885G>A, i 558T (2/15)

Silent exonic
Silent intronic
Silent exonic
Silent exonic

c.1330T>C. L373 (Sil 5)
g.23307de17 (3/17)
c.291 IG>A, P900(3/17)
c.2941C>T, D9!0(3/17}
c.4876A>C', Al 555(5/15)
c.5383C>T, Tl 724(S/15)
1
c.5974G>A, L l92l (3/15)
I
c. 7 I38C>T, 02309 { I /15)
c.7376T>C. L2389 (4/15)
c.7652C>T, L2481(4/15)

Silent exonic
Silent intronic
Silent exomc
Silent exonic
Silent exonic
Silent exonic
Silent exonic
Silent exonic
Silent exonic
Silent e:<onic

none dete.cted

, Silent exonic
c.3274T>C, 01021(3/17)
! Missense
c.3486T>C, Ml092T (3/17)
Missense
c.4406T>C, Wl399R (2/15)
Silent exomc
c.4876A>C, A I555 (5/15)
Silent exonic
c 5183C>T. Tl 724 (5/15)
Silent exonic
c.7652C>T, L2481(4/15)
Missense
c.8124A>G , H2638R(2/15)
c 9406GT>CC, F3066L (5/15) Missense
Silent exonic
c.Cl541T>C, P3110(5/15)
Silent exonic
c.l 0976C>T. L3589 (2/48)
M1ssense
c. I0986G>T. S3592I (2/48)
Silent intronic
!VS44+2JinsA (2/48)
Missense
c.12341 A>G 14044V(32/88)
Silent exonic
c.12484A>G, A4091 (31!85)
I s;,en, .,o.. ,
c. I2838T>C', P4209 01/89)
c I2341A>G, 14044V(32/88)
c.12384C>T, A4058V t9/5 I)
c 12484A>G. A4091 {Jl/85)
c 12617C>T. L4136(9/51)
c.12838T>C, P4209 t3 l /89)

Comments

Type of
Clume:e

?vtissense
Mis!>ense
Silent cxonic
Silent exonic
Silent exonic

I
I

(1/131) Rossetti et al., (2001)

--

g23307rlel7, P900 and 0910
occur in LD in (3/1?) patients.

i

l

j

L3589 & lVS44+23 in LD

I 14044V, A4091, P4209, in LD

I

Again 14044V, A4091, P4209,
LD with the subset of
i\4058\l and L4136

tn

Table 1:.:xpl!!ini:d;.

Please note that numbers listed in brackets after described polymorphi:m1s represent the

number of indi\'iduals with the polymorphism from the total number screened. e.g.
c.487G>A. A92 ( I/15) represents I individual with the c.487G>A from the. 15 tested.
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ADPKD is a well known example of phenotype variability (Milutinovic et al.• 1992�
Torra el

al., 1995; Hateboer et al., 1999a), with marked differences in disease severity

observed both between and within families. By analogy to other single gene disorders
(eg. neurofibromatosis (NF! gene) Fahsold et al., 2000), mutation heterogeneity should
be expected to accowit. at least partly, for the interfamilial variation. Again by analogy
with other single gene disorders, such as those described in chapter II cg.
phenylketonuria and cystic fibrosis, mutation detection studies should provide
information on genotype-phenotype correlations. This will allow conclusions to be
d.'1lwn on the functional importance of different protein domains, as well as predictions
on disease severity

in the preclinical testing of at-risk individuais.

In the case of ADPKD, the study of genotype-phenotype correlations is rendered
particularly difficult by different factors, some of which are biological in nature, while
others are the product of incomplete research or publication design. Biological factors
include the p1,vate nature of PK.DJ mutations, meaning that the number of individuals
ca.-rying the same mutation will never be sufficient for statistically significant
conclusions to be made. Another very important factor is related to the proposed two
hit model of cystogenesis (Knudson, 1971; Qian et al., 1996), where the random nature
of the second hit could have a major confounding effect on attempts to study the
phenotypic consequences of any germline mutation. In addition, the pathogenesis of
ADPKD is extremely complicated, with multifactorial traits such as hypertension,
known to play a major role in disease severity. This would suggest that a large number
of genetic and environmental variables need to be taken into account which, in
combination with rhe rarity of individual mutations and the two-hit model of
cystogenesis, makes genotype-phenotype correlations in ADPKD an impossible task.
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While the above factors are biological in nature and may thus present insurmountable
obstacles, the study of genotype-phenotype correlations in ADPKD is hampered further
by the failure of most research groups to provide adequate clinical information in the
mutation reports. To date only 16 of the 31 published articles on PKDJ mutations have
accompanying phenotype information, and this is usually limited to the age at onset of
end-stage renal failure (ESRF). The general paucity of detail on age at renal failure and
associated symptoms could be resolved by increased communication between clinicians
and diagnostic laboratories, and the introduction of a comprehensive ADPKD
phenotype database. Such a project was commenced by the PKO Foundation and
administered at Johns Hopkins University, USA. Unfortunately, due to lack of funding
the database was not maintained and a comparable substitute project has yet to be
initiated (personal communication Dr. Gregory Germino, Johns Hopkins University,
USA).

Even less information exists on phenotype severity as it relates to the occurrence of
supposed neutral sequence variations in the PKDJ gene. In future, as greater emphasis
is placed not only on the search for disease-causing mutations, but also on the variable
phenotypes that accompany them, it will be of vital importance to collate these data
from the expanding number of private mutations in the gene.

This PhD project was part of a larger collaborative study, resulting in an extensive
clinical database containing various measures of phenotype severity, which should
allow future analysis of the effect of both pathogenic mutations and polymorphisms on
the clinical manifestations of ADPKD.
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Here phenotype trends as related to the type of mutation (tnmcating versus missense) i."l
the patients included in the present study. and in other publications have been examined
in detail.

Age at onset of ESRF was used as a measure of phenotype severity. In the

study, 12 individuals with truncating mutations and 4 with in-frame mutations had
reached ESRF. Obviously the number of individuals was too small to attempt to test for
significance. Those with a rruucating mutation developed ESRF at a mean age of 51.1
years (range

=

42-74 years) and those with an in-frame variation developed ESRF at

65.7 years {range = '.19-73 years}. When truncating versus non-truncating mutations
reported in the literature were compared with respect to age at onset of ESRF. 42
individuals with truncating mutations had a mean age at onset of 50.1 years (range =

29-70 years), while 15 inrlividuals with in-frame mutations had a mean age at onset of
ESRF of 53.3 years (range = 43-68 years).

The difference was not statistically

significant in any of the comparisons.

A similar comparison has been conducted by Watnick et al. (1999), who found 10
fawilies out of 35 screened to have a clustering of truncating mutations between exons
13 and 17 in the duplicated region of the PKDJ gene. They proposed that these
mutations co-occured with a specific phenotype. including very early onset of the
diseru.. · and/or the presence of intracranial aneurysms (Watnick et al., 1999).

In a similar manner the clinical effects of gennline mutations in PKDJ that have been
found to occur in more than one family were tested in the present study. The numbers
of such mutations are very small and even fewer have been published with phenotype
infonnation, see Table VII.4.
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Table Vll.4. Shared pathogenic mutations in PKDJ
Mutation
c.5224del2

Q4010X
R4020X
Q404IX

R4227X

Number of families (reference)
3
(\Vatnick et al., 1999)
(Watnick et al., 1999)
(Watnick et al., 1999)
3
(Daniells et al., I998b)
(Kim et al., 2000b)
Present study

2
(Rossetti et al., 1996}
Present study

6
(Turco et al.. 1995)
( Peral et al., 1997)
(Torra et al., 1998)
(Daniells et al.. 1998b)
(Rossetti et al., 200 I)
I Present study
tPeral et al., 1996b)

II (Peral et al.. 1997)

(Rossetti et al., 200 I)

NIA - no infon11at1on available.

Other symptoms

Age at ESRF

YEO& ICA

NIA
NIA
NIA

ICA

NIA
NIA

NIA
NIA

58,51,49

ICA

YEO

49

Inguinal hernia

NIA

VEO

68,70,42

Anticipation

42
N/A

NIA

NIA
NIA
NIA
NIA

NIA

42,57

42.42
57,54,53

NiA

VEO - Very early onset of the disease (in utero to <30 years).

ICA

NIA
NIA
I NIA

I

ICA - Intra-cranial aneurysm.

Given the modest amount of mformation available at this point in time, it is not possible

to ascertain if a direct correlation between the age at onset of ESRF and the same

gennline mutation exists in different families. However, there may be certain mutations

which are associated with the occurrence of intracranial aneurysms and an unusually

early age at onset (in u1ero to before 30 years) of cyst development leading to severe

renal disease. An ADPKD phenotype with ICA or early onset of the disease with

clinical anticipation has been associated with two mutations (R4020X, and Q4041X) in
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more than one family, as outlined in Table VIl.5. Three unrelated families in the
Watnick et al. study (1999) shared the same frame-shift mutation in exon 15 of PKDJ,

c.5224del2.

Table VIII.5. Private mutations with a severe ADPKD phenotype

Mutation
IVS14+1G>
IVS16+1G>

Q3206X

c. l I 284insT
S3770X
Y3818X

c. ! 280 I del28

Phenotype
i ICA
ICA

Reference
Present study

Present study

Anticipation. ESRF in generation I age 37, Perrichot et al., 2000b
38 & 39. Generation II ESRF age 26.

Anticipation. ESRF in generation I age 40, Perrichot et al., 1999
generation II nonnal renal function age 25,
generation III palpable cysts at birth.
Aniicipation. ESRF in generation I age 70, Present study
and in generation II age 42.

I Anticipation. ESRF not reached in affected Peral et al., 1996a
father age 28 with de novo mutation. Renal
cysts detected m one dizygotic twin
daughter in 11/ero.
Anticipation. ESRF in generation I age 50, Torra et al., 1997
generation II age 58, generation III ages 60,
58, 53, generation IV chronic renal failure at
age 23.
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Conclusions and Future Studies

Much work remains to be undertaken on the mutational mechanisms and pathogenic
pathways of ADPKD. It is now possible to screen the major disease gene (PKDJ) for
mutations and polymorphisms. Each successive variant detected will contribute to a
greater understanding of the PKDJ gene and its protein products.
information is also published (or made publicly available

in

If phenotypic

designated databases), it

may be possible in the future to attempt genotype-phenotype correlation studies.

The discovery and further characterisation of additional PKDJ ·ps·eudogenes in this
study has lead to the amplification of a PKDJ-specific product for mutation detection
screening.

This will facilitate future studies that undertake molecular diagnosis of

ADPKD linked to thePKDJ gene.

The differences and similarities between the pseudogene and the PKDJ sequences will
provide a basis for further research at a nwnber of levels.

As sequence information

increases, the accuracy of PKDJ-specific primers will improve.

By comparing the

pseudogene sequences to PKDJ and each other, the order of evolution of the
pseudogenes may also be modelled. PKDJ pseudogene sequences and paralogous gene
sequences from genes in the PKD family will provide evidence to strengthen or dispute
the gene conversion theory.

As

genomic information on other species improves,

searches for PKDJ homologous sequences could be applied to primate genomic
libraries in order to assess the stage of molecular evolution at which PK.DJ duplications
first occurred.
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ln addition to providing molecular diagnostic strategies for the PKDJ gene, this study
may benefit other groups investigating genes where co-amplification of homologous
sequences presents an obstacle in mutation detection.

Similar approaches to those

outlined in this study, using BAC libraries, could be used for the unique amplification
of other genes, and the study of the function of homologous genes.

For ADPKD families pre-symptomatic diagnosis, preceded by informed consent, can be
extremely beneficial for various reasons. For example, individuals who are at-risk can
ascertain whether they are likely to develop renal cysts and thus be more likely to
develop renal failure with advancing age. Individuals who are pre-symptomaticaHy
diagnosed as affected can be monitored, and if necessary treated, for hypertension prior
to the onset of renal deterioration. These people then have tb opportunity to make
informed life-style and reproductive choices. At-risk individuals who are diagnosed as
unaffected can be spared mmecessary anxiety about developing the disease and, if they
wish, can volunteer as possible kidney donors for affected family members.

As suggested by Prof. Arno Motulsky in his address to the American Society of Human
Genetics (2000), in future it will be necessary to understand the pathways that lead from
an altered gene sequence to the disease phenotype.

A new discipline termed

"phenogenetics" is e:nerging that deals with the study of genotypic expression and how
it is influenced by modifying genes, somatic mutations and epigenetic factors
(Motulsky, 2000). Given the strong possibility that somatic mutations and modifying
factors greatly influence the variable phenotype associated with ADPKD, it will be
necessaiy to understand what influence all of these factors exert on the overall clinical
outcome of the disease.
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Microarray analysis may provide information of how gene expression levels of other,
possible modifying genes. are altered in varying PKDJ phenotypes both between and
within families. Although this analysis would not assist in determining the influence of
somatic mutations, it may reduce the number of variables in the overall question. It has
been predicted that there are as few as 26,000 to 40,000 protein-coding genes in the
hwnan genome (McPherson et al., 2001; Venter et al., 2001). Given the levels of
species complexity, this relatively low number of genes highlights the underlyfog gene
in�eractions as well as the pre- and post-natal environmental conditions which must
exist in order to account for phenotypic diversity in humans.
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Appendix A

Al. PCR Optimisation with Differing buffers
Table A.I. Enzvme Buffers for Optimisation of Mg 2+ Concentrations
Series
Buffer Mix
Final fl\i2Cl1llll�

II

m

SOmMKCL
10mMTris-HCI pH 8.4
0.01 gelatin
0.1%Triton X-1000

A=0.75
B = 1.50
C=2.25
D=3.00
E =3.75

40mMNaCI
lOmMKCI
0.01 gelatin
0.1%Triton X-1000

F=0.75
G = I.SO
H=2.25
I=3.00
J =3.75

lO mM (Nl-1.hSO..
lOmMKCI
10 mMTris-HCI pH 8.4
0.01 gelatin
0.1%Triton X-1000

K=0.75
L = I.SO
M=2.25
N =3.00
0=3.75

Al. OIAguick Spin Column Protocol
1. Initial PCR product was run on an agarose gel and the band excised and placed in a
microcentrifuge tube ( 1.5ml).
2. 3 volumes of QXl (QG) buffer were added to I volume of gel and it was melted at
50 °C until dissolved.
3. Mixtlll"e was briefly vortexd, if pH indicator was yellow, 1 gel volume of
Isopropanol was added and mixed.
4. Spin column was placed in 2ml collection tube and sample applied to column.
5. Sample was bound to the column by spinning at 13,000 rpm for l minute at room
temp.
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6. Flow through was discarded and 500µ1 of QXI buffer applied to column, this was
centrifuged again and flow through discarded.
7. 750µ1 of PE buffer was applied and column stood at nn. temp. for 2-5 minutes.
8. Column was centrifuged at 13,000 rpm for 1 minute, flow through discarded and
centrifugation repeated.
9. Column was placed in a clean 1.5ml microcentrifuge tube.
10. DNA was eluted by the addition of 30µ1 of pure water to centre of membrane, this
was allowed to stand for 1 minute and then centrifuged at 13,000rpm for I minute.

A3. Centricon Filter Protocol
1. The remaining 90µ1 of ssDNA PCR product was applied to a Centricon YM30
column (cut off size approx 60 bo s�DNA )
2. 2.5ml of ddH20 was added to the column and centrifuged at S,OOOg for 15 mins at
room temp.
3. Flow through was discarded and column rinsed with 2.5ml of ddH20, then
centrifuged at 5,000g for 10 mins at room temp.
4. Step 3 was repeated twice and column was remove.d from lower discard tube
5. Column was inverted into a clean collecting tube and centrifuged at 3,S00g for 5

minutes to collect concentrated ssDNA.

A4, Cleaning of AB I Seqµepcing Reaction Prior to Electrophoresis
1. 2.5 volumes (25µ1) of ice-cold 95% ethanol (EtOH) and 0.1 volumes (lµl) of 3M
sodium acetate (pH 4.6) were added to the 10µ1 sequencing reaction.
2. The microcentrifuge tube was vortexed and left on ice or at -20°C for 30 minutes.
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3. Tubes were then centrifuged at 13,000 rpm for 15-30 minutes at 4°C.
4. Supernatant was removed and care was taken not to disturb the pellet.

5. The pellet was rinsed in 250µ1 of 75% EtOH and then centrifuged at 13,000 rpm for
5 minutes at 4°C.
6. Supernatant was carefully removed and pellet dried to z.ero volume (either air-dried
or dried in a rotary vacuum at room temperature).
7. Sequencing reactions were stored at -20°C prior to pellet being redissolved for
electrophoresis.

AS. Plasmid Purification Post BAC/PAC clone identification
Purification of the culture was then performed using a modification of the Qiagen
Plasmid Midi Kit protocol (personal communication Dr. Arseni Markoff, Muenster).

Maxi Prep from BAC/PAC DNA
1. Two days prior to isolation a single clone was picked from those grown on the LB
Agar plate and used to inoculate 3-5ml of LB Media (containing chloramphenicol
12.Sµg/ml) (LB/Cm) in a 15ml glass centrifuge tube.

The culture was grown

overnight at 37°C with vigorous shaking (-300rpm).
2. After 24 hours the starter culture was used to inoculate one litre of LB/Cm in n five
litre flask and again shaken vigorously at 37°C overnight.
3. The following morning 500ml of the culture was transferred into 2 X IL Beckmann
centrifuge tubes and spun at 3,500 rpm for 10 mins at 4°C (JS horizontal rotor).
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4. Supernatant was discarded and cells were resuspended in I 0ml of Pl resuspension
buffer (5C:mM Tris-Cl (pH 8.0), 10 mM EDTA, lOOµg/ml RNase A, stored at 4 °C)
and vortexed.
5. 20ml of P2 lysis buffer (200mM NaOH, 1 % SOS) was immediately added and the
suspension was gently shaken then incubated at room temperature for 5 minutes.
6. 20ml of ice-cold P3 neutralisation buffer (3M potassium acetate pH 5.5) was added
and tubes were mixed by inverting several times.
7. A Qiagen-tip 100 was equilibrated with 10ml of QBT equilibration buffer (750mM
NaCl, 50 mM MOPS pH 7.0, 15% isopropanol, 0.15% Triton X-100).
8. The DNA precipitate was filtered through a funnel overlayed with cheese-cloth.
The clear filtrate was then passed through the Qiagen tip in 2-3 shots by the
application of vacuwn.
9. The tip was then washed with 3 X 20ml of QC washing buffer (I.OM NaCl, SO mM
MOPS pH 7.0, 15% isopropanol) by applying vacuum.
10. The DNA was then eluted from the tip by the application of 5 X 1ml of pre-heated
(65 °C) QF elution buffer (1.25M NaCl, SOmM Tris, Tris-Cl pH 8.5, 15%
isopropanol) into a 30ml Corex tube.
11. 0.7 X volumes (3.5ml) of isopropanol was then added and mixed well.
12. The tube was centrifuged at 10,000 rpm for 30 minutes at 4°C (JA 12 Sorvall rotor).
13. The supernatant was decanted and the pellet was washed with 10ml of 70% ethanol
for S minutes at 10,000 rpm at 4°C.
14. The ethanol was then carefully decanted and the pellet air-dried. The pellet was
resuspended in 500µ1 of TE buffer pH 8.0.
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A6. ABI 373 ON A Sequencer (Perkin Elmer). Sample Preparation
1. A mixture of 5: 1 deionised formamide (pH >7.0) to 25mM EDTA (pH 8.0), with

50mg/ml blue dextran was prepared.
2. 4µ1 of this mixture was added to each sequencing reaction.

3. Tubes were briefly vortexed, then centrifuged for 10 seconds.
4. Samples were denatured at 94°C for 3 minutes and placed immediately on ice.

Preoaration of Sequencing Gel
These quantities make 60ml of 4% (19:1 acrylamide:bisacrylamide) gel with 8.3M urea
in 1 X TBE, for a 48cm gel.
1. In a glass flask 30g urea, 22ml of ddH20, 6ml of 40% acrylamide stock and
approximately l g of mixed bed resin were mixed.
2. The solution was stirred on a magnetic stirrer over a slight heat until the urea
crystals began to dissolve and the flask was warm to touch. Stirring continued for
5-10 minutes without heating until all crystals were dissolved.
3. The acrylamide solution was filtered through a 0.2µm filter and the solution was
degassed under vacuum for 5 minutes.
4. The gel mix was transferred to a iOOml cylinder and 6ml of 10 X TBE was added
5. The mix was made up to a finai volume of 60ml with ddH20.
6. Clean plates were clamped together ready for gel pouring.
7. The gel solution was mixed in a beaker with 300µ1 of 10% ammonium persulphate
and 30µ1 of TEMED.

This was swirled gently to avoid air-bubbles being

incorporated into the mix.
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8. Plates were held at an angle, and gel was poured, when plates were full they were
lowered to a horizontal position and an inverted sharks-tooth comb (48-well) was
inserted to form the well trough.
9. The gel was allowed to polymerise at room temperature for 1-2 hours.

The comb was removed and the sequencing gel was assembled in the 373 DNA
sequencer, the plate was scanned to ensure it was clean in the read-region with no
fluorescent contamination. The sharks-tooth comb was re-inserted to form the wells.
The upper and lower buffer chambers were then filled with 1 X TBE and pre
electrophoresed for five minutes at 40W to ensure that al) connections were working
prior to loading. Power was interrupted and the wells were rinsed with buffer using a
syringe, 2µ1 of each denatured sample was loaded and the gel was electrophoresed at
40W constant power for 12-15 hours. Sequencing data were then saved to disk for
analysis by requestor.

A7. Seguitherm Excel II Cycle Sequencing
Cycle Sequencing Protocol
Premix
Primer 5pmol

lµl

[a33P ]-dATP

0.5µ1 (lOµCi)

5X SequiThenn EXCEL Buffer

5µ1

DNA Template (200 finales)

'.-µl

ddH20 (to 16µ1)

4.5µ1

SU of SequiTherm EXCEL II enzyme

1.0µ1
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For each template four 600µ1 microcentrifuge tubes were labelled A, G, T and C and
2µ1 of the appropriate SequiTherm EXCEL II Termination mix was placed into each
tube on ice. 4µ1 of the premix solution was then pipetted into each tube and mixed
thoroughly. The tubes were denattrred at 95°C for five minutes and the reactions were
cycled 30 times at 95°C for 15 seconds, 65°C for 1 minute and 70°C for l minute.
After 30 cycles 5µ1 of stop buffer (95% vol/vo! formamide, 20 mM EDTA, 1%
xylenecyanol FF, l % bromophenol blue) was added to each reaction tube.

Appendix B

Journal articles resulting directly from this thesis.
1. Bogdanova & McCluskey et al. (2000). Screening the 3' region of the
polycystic kidney disease 1 (PKO l ) gene in 41 Bulgarian and Australian
kindreds reveals a prevalence of protein truncation mutations. Hum Mu tat.
16(2): 166-174.
2. Bogdanova et al. (2001). Homologues to the first gene for polycystic kidney
disease are pseudogenes. Genomics. 74(3): 333-341.
3. McCluskey et al. (2002). Mutation detection in the duplicated region of the
polycystic kidney disease 1 (PKO I) gene in PKO I-linked Australian families.
Hum Murat. 19(3): 240-250.
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Screening the 1 Region of the Polycystic Kidney
Disease 1 (PKDl) Gene in 41 Bulgarian an.d
Australian. ·Kindreds Reveals a Prevalence ·of Protein
Truncating Mutations
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Screening for disease�causing mutations in the unique region of the polycystic kidney diac:ase l
(PKDl) gene was performed in 41 unrelated individuals with autosomal dominant polycyst:ic
kidney disease. Exons 34-41 and 43-46 were illlsayed using PCR amplification and SSCP analysis
followed by &rect sequencing of amplicons presenting variant SSCP patterns. We have identified
seven discase,causing mutations ofwhich pve are novel {c.1063+10656del; c.11587delG; IVS3710C>A; c.11669,11674del; c.13069,13070ins39] and two have �en reported p1-eviously
{Q4010X; Q4041X]. Defects in this part of the gene thus account for 17% of cur group of pa,
tient.s. Five of the seven sequence alterations detected are protein-truncating which is agree,
ment with mutation screening data for diis part of the gene by other group&. The two other mutatiom
are in-� deletions or insertions which could destroy important functional properties ofpolycyatin
I. These findings suggest that the first step toward cyst formation in PKO! patients is the lcoa of
one functional copy of pocycy5tin 1, which indirectly support& the "two-hit" model of cystogenesis
where a second somatic mutation inactivating the normal allele is necessary to occur for develop,
ment of the disease condition. Hum Mutat 16:166-174, 2000. C zooo Wllc:y.Uu, ln.c.
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INTRODUCTION

Autosomal dominant polycystic kidney disease
(ADPKD) is one of the most common Mendelian
inherited disorders (MIM# 173900) with an inci
dence of approximately one in 1,000 [Dalgard,
1957). The main clinical manifestation of the dis
ease is the develcpment offluid-filled cysts in both
kidneys which, in most affected individuals, results
in kidn ey failure. Eight to 10% of all patients re
quiring haemodialysis or renal transplantation have
ADPKD fGabow, 1993). Additional symptoms
may include hypertension, urinary tract infections,
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proximately 14 kb in length), located at the 3' end
haematuria, proteinuria, extra-renal cysts, cerebral
of the gene (exons 34 to 46), is unique to PKDl.
aneurysms, hemiae, cardiac valve defects, renal
The PKDl gene product, polycystin 1, consists of
caliculi, gastrointestinal diverticuli [Roscoe et al.,
4,30 2 amino acids and is predicted to contain a
1993], and spinal meningeal diverticula [Schie
vink and Torres, 1997}. The clinical course of
large N,terminal extracellular domain of -2,500
residues, several transmembrane domains, and a
ADPKD varies in tenns of presenting symptoms
short cytoplasmic C-terminal region [The Inter
and the rate of progression towards kidney fail
national Polycystic Kidney Disease Consortium,
ure. In some patients end-stage renal failure
(ESRF) occurs in adolescence while in others
1995; Hughes et al., 1995; Sandford et al., 1997].
ESRF does not occur at all [Choukroun et al.,
It has been demonstrated recently that polycystin
1995; Parfrey et al., 1990]. Among those who de
1 and the gene product of PKD2, polycystin 2, as,
velop ESRF the mean age at onset is approximately
sociatc in vivo in a heterodimeric interaction [Qian
50 years [Milutinovic et al., 1984]. The wide range
et al., 1997] involving the carboxy-tennini of the
two proteins. In polycystin 1, the proposed region
of clinical manifestations and the variation in se
verity are most probably a compound product of
of interaction is positioned in exon 46, the final
the genetic heterogeneity, locus as well as allelic,
exon of the gene (nucleotide positions 1 2854within ADPKD itself and of the effects of modif,r1 2955 ef the cDNA, acc. L33243). To date, a to,
ing genes and environment
tal of 40 mutations in the 3' end of PKDI have
At least three different genes are currently im
been reported, mostly detected in patients from
plicated in autosomal dominant polycystic kidney
western European countries.
disease: PKDl (MIM# 601313), located on chro
Here we present the results of a collaborative
mosome 16p l3.3 {The European Polycystic Kid
study of mutations in the unique region of PKDl
ney Disease 'Consortium, 1994], PKD2 (MIM#
in 41 Bulgaru:.n and Australian ADPKD individu,
173910) on chromosome 4q21-23 [Mochizuki et
als, which indicate predominant appearance of
al., 1996], and at least one more gene which is yet
protein-truncating sequence alterations in this part
to be identified [Bogdanova et al., 1995; de
1the gene.
Almeida et al., 1995; Daoust et al., 1995].
MATERIALS AND ME1H0DS
T he participation of additional environmental
Patients
and genetic factors in the course of the disease is
supported by the demonstration of a "two-hit"
Twenty-six of the affected subjects are from
mechanism in renal- and hepatic-cyst formation.
Bulgaria and represent a mixed southeastern Eu
ropean population. The Australian group consists
Germline and somatic inactivating mutations of
of 15 affected individuals predominantly of Brit
the two characterized genes for ADPKD, PKDl,
and PKD 2 have been identified in cyst-lining
ish descent with one far-.ily of Spanish origin. In
epithelial cells [Qian et al., 1996; Watnick et al .,
all patients, the diagnosis of ADPKD war; based
on standard ultrasound criteria [Bear et al., 1992].
1998; Koptides et al., 1999]. To study the geno
linkage studies have been conducted in 39 of the
type-phenotype correlation and address the func
families. Two affected individuals, one from Aus
tional importance of predicted protein domains
further efforts have been made to screen PKDl
tralia (A7 2.1) and one Bulgarian (B2S.l), were
included in rhe study without prior linkage analy
and PKD2 for disease-causing alterations of the
sis, based on the assumption that PKDI accounts
nucleotide and amino acid sequence.
for most cases of ADPKD.
In affected individuals ofEuropean descent, mu
tations in P.KD1 are the most common cause for
DNA Isolation and PCR Amplification
the disease and account for up to 85% of cases
[Peters and Sandkuijl, 199 2]. The PKDl gene con,.
DNA was extracted from peripheral whole
blood using standard procedures [Miller et al.,
sists of 46 exons sp8!U}ing-5 2 kb ofgenomic DNA
[The lntemational!f'olycystic Kidney Disease Con
1988]. Polymerase chain reaction (PCR) was per
sortium, 1995; The American PKDl Consortium,
formed on 50 ng of genomic DNA in a final vol
ume of 25 µI using 1.5 units of Taq polymerase
1995; Hughes et al., 1995]. A large part ol"'the gene
is duplicated in at least three homologous genes,
(Gibco BRL Life Technologies) and 1.5 mlvt MgClz.
HG-A, HG-B, and HG-C, which are located on
The optimised conditions for the PCR amplifica
chromosome 16p13.1 and share approximately 95tion of individual exons are shown in Table 1. Prior
97% homology with the PKDI .gene [Hughes et
to SSCP, the PCR products were electrophoresed
in 1% agarose gels and visualized with ethidium
al., 1995]. Only 3.5 kb of the PKDl transcript (ap-
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'mBl£ 1. AmeUBc::itfon CondltJon.s for SSCP AnnJysb of the Unique � Region of PKI>l
Annealing and
AmpUi:on
Additives
Ampllailion e!!mets
n:! (bp)
cydl!!!l cond.!tions
240
30 cyae:s m 65"C
BSA (0.5%)
Emn34
Fotward 5' gtgagctggggtgagngpg 3'
gelatine
(2'£)
Reve:me 5'acggct�3'
2-step PCR of SO cycle..
220
NonExcn35
flt 68":
Fonwrd 5' a� S'
... ......... .
.. Reveme.- 5' c:mgct:Cdcc.ctstgugd 3'
286
50
q,dea
at
63°C
Non
&on36
Fotward 5' ctgtgagctgcddalcag S'
Revcn.e 5' cf.lu.'aggcdca:ta,.cggg 3'
2-step PCR of35 cycles
299
Non
&onS7
at 68°C
fonwrd 5' ggtaggctacaggcdccat S'
Reverse 5' c:acc:tccgtctcttgtdcc 3'
272
Non
30 cycles at 64"C
Exon38
forwru-d 5' C!ll!Dga:ctgctgtcactg 3 '
Reverse 5' tagtccagccZlgaccctagg 3'
2-step PCR cf35 cycles
Non
259
Exon 39
at WC
fol"WZ!ro 5' gtctctggtggccgctcad S'
Reverse 5' gcagcctttagcggagctct 3'
2-step PCR of35 cyda
Non
264
Exon40
lit 68°C
forward S'ga�S'
Reverse 5' tdacgccaaggaC81'.lgggag 3'
Non
2-step PCR of 35 cycles
355
Exon41
at 68°C
Forward 5' cgtdacgccaaggaca&gg 3'
Rewra2 5' cttc:cac:agca:ctc:agcca 3'
DMS0(2%)
40 cycles st 60°C
883
Exon43
forward 5' cagcgtccctca:gccctcctga 3'
R.everae 5' gcgcacaca.:a,gggdgcangc 3'
Non
292
2-aep PCR of 35 cycles
Elton 44
at 6S°C
Forwnrd 5' au:a:cagggctgcaegczg 3'
Reverse 5' gtggactccctctggagc:gt 3'
Non
30 cycles at 68"C
396
Exon45
Forward 5' cgtcttagctc:agctcagct 3'
Reverse 5' agtggggggagagggacac 3'
Non
318
2-ctep PCR of 35 cydes
Exon 46 (fragment a)
at6WC
Forward 5' gtgcagccggadgndgag 3'
Reuense 5' cgtctaccagdggagcagc 3'
336
DMS0(2%)
35 cycles at 66°C
Exon 46 (fragment b)
Forward S' gaccgnctcaaccaggcau: 3'

,.

Reveme 5' caggcagaatggctga!Cg 3'

Nu=:leotide
position•

44276-295

44496-515
473S0-349

47630-549

47541..s60
47807-826
47801-820

48080-099

48489-458
48691-710

48929-948
49167-187

49330-349
49573-593
4957Ui90

49906-925

SOS81-403
50741-763
50746-765
51018-037

50946-965
51322-341

51361-380
51659-678
51688-652
51950-968

•Aa:ordlng to Genbank accesslon number 1.39891. ·

bromide staining in order to confirm amplification

and rule out large deletions or insertions.

SSCP Analysis
Single#strand conformation polymorphism
(SSCP) .-nalysis was performed using 2µ1 of PCR
product and an equal volume offonnamide loading
buffer (98% fonnamide, 0.025% xylene cyanol,
0.025% bromophenol blue). The mix was heat-de
natured and kept on ice prior to loading. We found
that the optimal gel composition for electrophore
sis was a 12% polyacrylamide gel with a cross-link
ing ratio (%C) equal to 2.5 [Savov et al., 1992].
The gels (160 x 200 x 0.75 mm) were run at 25°C
for varying lengths of time at different constant volt
ages using a vertical gel apparatus, D Gene .u Sys-

tern (Biorad), in 1 x TAE buffer without glycerol

and in 1 x TBE with 5% glycerol [Kuldta et al.,
1997]. The single strand separation was visualized
by a silver-staining procedure [Budowle et al., 1991].

The gels were dried and stored for documentation.
DNA Sequencing and Restriction Analyafa

All samples where an aberrant banding pattern
had been detected by SSCP analysis were subjected

t!) manual sequencing using internal labelling with
[a)3 P]-dATP {Hartmann Analytics). Products fur
the sequencing reactions were obtained by PCR on
genomic DNA with the amplification primers listed
in Table 1. Cycle sequencing in fmward and reverse
directions using the same or internal primers was
performed with the SeqmTherm.,,. Cycle Sequenc-

PROTEIN nmNCATING MlJI'ATIONS IN PKDl GENE
Protein Truncating Mutations

ing Kit according to the manufacturer's protorol
{Epicentre Technologies). The products of these

� Two nonsense mutations were detected in this
study, both of which have been reported previously.

quencing reactions were electrophoresed in 6% de

naturing polyacrylamide gels (C'%=5; 6M urea; 350

x 400 x 0.4mm), at 68W constant power for 2-3
lu: Gels were dried under vacuum prior to autorad
iographic exposure on Biomaxni films (Kodak).
Restriction digestion of gel purified PCR prod
ucts was performed in a total volume of 20 µI with
10 units of the appropriate enzyme (Gibco BRL;
New England Biolabs), in conditions specified by
the manufacturer. Reaction products were sepa
rated on a 2.5% agarose gel and visualized by
ethidium bromide staining.
All sequence changes were subject to family seg
regation analysis using SSCP or, where possible,
restriction fragment length polymorphism anal�.
RESULTS

Using the techniques outlined above, we have
identified disease-causing mutations in the unique
3' region of the PKDl gene in seven of the 41
ADPKD patients screened (summarized in Tables
2 and 3). Five novel and two previously reported
mutations were detected. The results are presented
according to the type of molecular change.
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Q4041X.

1bis is a C to T substitution at nucleotide c.12332

(Genbank acc. 133243) which changes a Glutamine

to a Stop codon and is predicted to truncate
polycystin 1 b-1 262 amino acids. It was first identi
fied by Turco et al. [1995} in an Italian patient and
subsequently reported in one Spanish and two Brit
ish families [Torra et al., 1998; Daniells et al., 1998}.
In our study, Q4041X was found in individual
A3.1, the index patient from a large Australian fam
ily of British origin, and was also detected in all six
affected family members participating in the study.
Hepatic cysts have been detected in 3/6 affected
individuals. Apart from that, the clinical course of
ADPKD, including rate of progression towards re
nal failure, appears variable, as shown in Table 2.
Q4010X.

T his is a C co T substitution at nucleotide
c.12239 which changes a Glutamine to a Stop
codon and is predicted to truncate polycystln 1 by
293 amino acids. It has been reported previously in

.,

TABl.E z. Clln!cal Data of Patients From 5 Bulgarian and 2 Australlan PK01 Families With Disease-Causing
Mutations In the Unique Part of the PKDl Gen2 ldenttfled In the Present Study

Mutation

(exon'lntron)

Fam.lJv&

patient ID

Sex

B22.1
B22.2

M

c.10634-10656del
(&on34)

B22.S

B22.4

822.5

B57.1
B57.2
B57.3
877.1
B77.2
877.3
877.4
B77.5
B77.6

IVS 37-lOC>A
(lntron S7)
c.11S87de1G
(Exon40)

F

F
F
F

CRF"
Current
age (ye.ms) �)
6S
42
61
54
No
26
S8

34
64

F
F

64

F
F

55
55

M

42

ESRP'

(years)
49
57
No

No
No

No
No

55
89
45
49

No
No
No

54

55

No

M

No
No
No
No
44

No
No
No
No
No

M
M

81

29

c.11669-U674del

B25.1

M -·

28
25
45

Q4010X
(Exo.. 44)
Q4041X

A72.1

M

58

45

49

AS.1
AS.11
AS.13
AS.18
A3.19

M

60
66
45·
41

?
50

42
57

(Exon41)

(Exon44)

c.51815-5181ins39
(Exon46)

"CRF. c:hronk: renal £anare.

A8.38

B41.1
B41.2

�RF. ei>d stage renal fa!Jum.

M

F

M

M

F

M
F

M

39

51
35

39

No

No
No
No

No
No

No
No
No
No
No
No

Hypertensron
Yes
Yes
No
No
No

Yes
No

Yes
)es

Yes

Yes
Yes

lJver lntraa.mlaJ

ststs
No
No
No

No
No

Yea
Yeo
No
Ye.a

Yea

Yes

No

anewy:ms

No
No
No
No
No
No
No
No
No
No
No

No

No
No

No

No

Yes

No
No
No

No

No

?

?
Yes

Yes

Yes
Yes
Yes
No
No
No

Yes

No

No

Yes

Yes

No
No
No

Yes

No

No

No

No

M:,

No
No
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TABJ.£ s. Disease-Causing Mutations In the Unique Part of the PKDJ Gn>e ldentffled In the Present Sh$'
Restrk:tton
.A.mino add
Site of nucleotkie
Exon/
stte dw1ge
change
lntron
changeO
-Awll
c.10634-10656de.1
Present study
P3457rsx3617
F.xon34
+Bsrl
Splice site
Present study
IVS37-10C>A
IVS37
c.l 1587delG
Preseit study
R3793fsX3824
Exon 40
c.11669-11674dd
QE3820-3821de!
Present study
Exon41
c.12239C>T
Q4010X
Exoo44
... Turco et al., 1995
c.12382C>T
Dnnlells et al.. 1998
Q4M1X
c:.l3069�13070in'°�9. - . . ...4286-42871nsl3a&
Preseid study . ..F.xon 4fj ..
•Accordlng to Gatlwlh ecce£Slon num� 1.33243.

an ADPKD patient of British descent [DanieUs et
al., 1998] and in a Korean patient [Kim et al., 2000].
In our study, the mutation was found in Aus
tralian patient A72.l. No other family members
were available for this study. The family has lived
in Australia for the past three generations and
originates from Britain. Patient A72.l was diag
nosed at 15 years of age due to positive family his
tory. He deveioped hypertension at age 27 and
reached ESRF at 49 years (fable 2). His other
symptoms include umbilical hernia and gout
Three of the novel mutations identified in this
study are predicted to result in a frameshift and
subsequent introduction of a preliminary stop
codon. Two ofthese changes are deletions and one
is a possible splice mutation likely to have a frame-,
shift effect
c.11587delG.

A single base pair deletion in exon 40 was found
in Bulgarian patient B77.l. The mutation is pre
dicted to result in termination of translation at
codon 3824 and to truncate polycystin 1 by 478
amino acids.
The presence of this mutation was tested by the
use of SSCP analysis in eight other family mem
bers, of whom six are known to have ADPKD.
Analysis of the other family members showed that
the c.11587delG mutation segregated with the dis
ease. The clinical features of ADPKD in this fam.
ily are shown in Table 2.
c.10634-10656dul.

This novel 23 hp deletion in exon 34 results in
a stop codon at position 3617 thus truncating the
protein by 685 amino acids. The mutation was
found in Bulgarian patient B22.l and in all five
affected members of the family.Their phenotypic
features are shown in Table 2.
Splice-Site Mmatlon (IVS37-10C>A)

A transVersion of C to A at position g.48491
(Genbank accession number Ll9891) in intron 37

of PKDl was detected in Bulgarian patient B57. l.
This change could create a new acceptor splice
site eight nucleotides upstream of the end ofIVS37
as shown below.
Wild Type 48481 agggcccccc cgtccac [cag]
AGCCTCCTG ...•
Mutant
48481 agggccccc [cag] TCC ACC
AGA GCC TCC TOG . . ..
The new acceptor site produces a fram.eshift with
a transiation stop at codon 3684 thus resulting in
truncation of polycystin 1 by 618 amino acids.
The nucleotide substitution creates a Bsr I re
striction site and restriction fragment length poly
morphism analysis was used to screen additional
family members and 50 unrelated normal subjects
for the presence of the mutation. It was found that
the mutation co-segregates with the disease in this
family and it is not present in the nonnal controls
(data not shown). Thus, we presume that this could
indeed be a disease-causing mutation, although no
RNA from this patient was available to verify that.
The disease manifestation in the affected family
members is summarized in Table 2.
In-frame Deletions and ln&erilons
c.11669-11674del.

This 6 bp deletion in exon 41, resulting in the
loss ofglutamine and glutamic acid at ccdons 38�
3821, was observed in Bulgarian index patient
B25. l. Overview of rhe disease phenotype in the
affected patient is shown in Table 2.
There were no other familv members available
so no segregation analysis has been performed.
However, 50 unrelated norm.al individuals were
tested for the presence of this deletion. using ge
nomic amplification and subsequent separation of
the PCR products on a 3% agarose gel. No earner
of the mutation was detected in the control group
(data not shown), thus sugge3ting that this could
be a disease-causing mutation.
In order to relate this mutation to an eventual

PROTEIN TRUNCA11NG MUTATIONS IN PKDI GENE
function distortion ofpolycystin 1, the protein seg
ment encoded by exon 41 was subjected to a sec
ondary structure prediction analysis, PHDsec [Rost
and Sandei; 1994], with and without the deletion
change. Figure 1 shows the comparison between
both variants; the deletion of glutamine and
glutamic acid at positions 3820 and 3821 modifies
the topology of this portion of the protein, which
is a predicted part of a loop exposed on the exter
nal cell surface [Hughes et al., 1�95).
An in-frame insertion in exon 46 of 39 hp was
detected in patient B41.1. T he insertion begins at
nucleotide 13069, between codons 4286 (Pro) and
4287 (Ser) as detailed below.
(c.13067)CCC "acg cag gga cca ctt egg gee
aag aac aag gtc cac ccc "' AGC(c.13072).
These 39 nucleotides encode the following ad
ditional amino acids:
(4286) Pro "Tur Gin Gly Pro Leu Arg Ala Lys
Asn Lys Val His Pro "' Ser(4287).
Ten of the 13 insened amino acids represent 2
repeated segment further downstream in the se
quence (positions 4290-4299). Titls insertion cre
ates a third additional loop at the very C-terminus
of the protein, as shown by using the PHDsec al
gorithm (Fig. 2).
The insertion was detected L"l the two mem
bers of the family who are known to be affected
and in two young individuals (born in 1987 and
1986) who are predicted to be carriers of a PKDl
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FIGURE L Alignment of polycystfn I, exon 41. and excn
41, c.11669-11674dcl mnlno add sequences and uecond
ary structure prediction using the PHDsec algorithm. The
deleted amino adds are underlined m the wild type se
quence. E means extended sheet, H means helix l!IJY.I L
means loop."The prediction subset fn both figures ls mean
tngfu) for all residues with an expected awmge correla
tion gn!lSler th.ml 0.69.

AGURE.2.. Alignment of the C-tennbml 35 amino adds of
polyc:ystln 1, ex. 46 and the CtennlnaJ 48 amino adds of
ex. 46, c.13069-13070lns39 and secondary Gtruc:ture pre
diction using the PHDsec algorithm. The 13 Inserted resi
dues are underlined. Repeated llilllno adds are shown fn
ttaUc cuse. The symbols for secondary s:lructme are the
same as· In Figure I.
mut&tion on the basis of the linkage analysis with
polymorphic markers flanking the PKDl gene. An
outline of die clinical findings in this family is pro
vided in Table 2.
DISCUSSION

Mutation detection in the PKDl gene is com
pticated by the high GC content of the gene
(around 62%) and, most of all, by the interference
of the homologous genes. Predictably, most mu
tation detection srudies have therefore focused on
the unique 3' region of PKDl. Of the 82 muta
tions reponed to date [Human Genome Mutation
Dai:abase], 45 (55% ofall mutations detected) are
in the 3' unique region which, howevet; accounts
for only 19% of the coding sequence. When these
data are viewed as a true proportion of all indi
viduals te.sted (approx 970 to date) [500 (British,
Italian and Spanish) Daniells et al., 1998; 175
(Spanish) Badenas et al., 1999; 15 (Cypriots}
Neophytou et al., 1996; 146 (French) Perrichot
et al., 1999; 90 (British) A&al et al., 1999; 41 (Aus
tralian and Bulgarian) present paper], only 5-6%
of individuals have mutations in this region. In
the present srudy, we have detected mutations in
16% of the ADPKD individuals investigated
(125% Australian and 18.5% Bulgarian) overthe
same region. Both sets of data suggest that there
is no clustering of mutations in the unique part of
the PKDI gene. Expressed as a percentage of pa
tients investigated, the number of disease,caus
ing mutations in the 3' end of the gene is roughly
proportional to its length, therefore die majority
of PKDl mutations should remain located in the
duplicated region.
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Given the sequence characteristics ofPKDl and
its complex genomic structure, designing a muta·
tion screening strategy is not easy. Our experimen
tal protocol, using SSCP as the screening technique,
has been successful in identifying seven disease
causing mutations in 41 individuals tested. Thus,
the proportion of identified mutations in our study
is at least asJJigh as iliat i.µ Qth.� s_tµ.d,ie.s Qfthis part
· of the gene. Five out of the seven sequence alter
ations detected would lead to a premature termi
nation of cranslation. They were all identified
through SSCP analysis, which is clearly not a
method biased towards this type of mutation.
The exons analyzed here in the 3' region did
not include exon 42 of the gene. Despite repeated
attempts at amplification, using two different sets
of oligonucleotide primers, we failed to obtain a
specific product. No mutations have been reported
to date in this exon, suggesting that other groups
may also experience similar difficulties with spe
cific amplification. This could be due to the pres•
ence of a non-disease-causing polymorphism in
IVS 42. It includes a 34 hp repeat region and pro,
duces an intron size variation of - 325 hp to -130
hp [Peral et al., 1996a]. This variation may explain
the problems we encountered in the amplification
of this part of the gene.
,.
Out of the total of 50 mutations identified in
the unique part of P:KD1 so far (including the
present study), only five, namely Q4041X [Turco
et al., 1995;Daniellset al., 1998:Torra et al., 1998;
Badenas et al., 1999], Q40IOX [Daniells et al.,
1998; Kim et al., 2000), R4020X [Rossetti et al.,
1996; Neophytou et al., 1998], R4227X [Peral et
al., 1996a; Peral et al., 1997], and R4275W
[Badenas et al., 1999] have been reported to oc
cur in more than one family. Two of these, ·namely
Q4041X and Q4010X, were also detected in �lie
present study. Comparison of polymorphic
haplotypes of the Q4041X-bearing chromosomes
in the Italian, British, and Spanish families with
this mutation [Torra et al., 1998], revealed no iden
tity by descent A slipped-mispairing model ex
plaining the recurrence of this mutation was
subsequently proposed by Daniells et al. [1998].
We cannot rule out identity by descent for either
Q4041X or Q4010X. The two mutations have
been identified previously in British patients
[Daniells et al., 1998] and in our study were de
tected in Australian individuals of British ances
try. Whatever the mechanism of origin, the most
common PKDl mutation known to date, Q4041X,
accounts for less than 1% (five out of 877) of dis
ease alleles.The emerging pattern is that of a large

multitude of private mutations confined to indi
vidual families, thus complicating further the study
of molecular d�fects and of genotype-phenotype
correlations in ADPKD.
Regardless of the variety of mutations detected,
preliminary conclusions are already possible on the
predominating type of defects. Of the reported
mutations in the 3' end ofPICT) 1 {Human C'-renome
Mutation Database, Cardiff], approximately 80%
are protein truncating. 1bis is.in contrast with the
findings in the 5' part of the gene, where 37% (13/
35) of the defects so far reported are missense
mutations resulting in amino acid substitutions
[Human Genome Mutation Database, Cardiff].
The same trend was observed in our study, where
five of the seven disease-causing mutations de
tected in the unique part of the PKDl gene would
lead to a truncated protein. Moreovei; missense
mutations were identified in our studies but failed
to segregate with the disease and were thus con
sidered to be polymorphic variations (manuscript
in preparation}. It should be noted, howevei; that
our study was performed on multiplex families
where the disease penetrance is high and linkage
analysis indicating PKDl as the gene involved in
ADPKD was possible. The spectrum of mutations
could be different in the whole disease population
which contains many isolated families with too few
cases to make linkage analysis possible and where
the disease penctrance may be low. Nevertheless,
the protein-truncating mutations identified in our
study cause C-terminal disruption of polycystin 1
prior to the last 113 amino acids, which would ren
der the protein incapable of interaction with
polycystin 2 [Tsiokas et al., 1997; Qian et al., 1997].
These findings suggest that the fust step toward
cyst formation in PKD1 patients is the loss of one
functional copy of polycystin l, which indirectly
supports the "two-hit" model ofcystogenesis where
a second somatic mutation inactivating the nor
mal allele is necessary to occur for development of
the disease condition.
The novel in-frame deletion and insertion we
found in this study seem to be pathological muta
tions, not only as judged by their non-occurrence
in healthy subjects. Tne secondary structure pre
diction data for the relevant segments of the pro
tein do show a potential functional interference
caused by these changes. c.11669-11674del is per
haps distorting a possible interaction of polycystin
1 with an extracellular ligand by changing the to
pology of the second large extracellular loop, ac
co"rding to the protein model proposed by Hughes
et al. [ 1995]. c.13069-13070ins39 is clearly chang-

PROTEIN TRUNCATING MUl'ATIONS IN PKDl GENE

ing the spatial organization of the very C-termi
nus of the protein by introducing an additional
loop. This mutation causes an early onset of
ADPKD in the assayed family. The last 115 amino
acids of the cytoplasmic C-tenninus of polycystin
1 seem to be essential for modulation of Wnt sig,
naling during renal development [Kim et al., 1999]
but the proposed potential ligand(s) for cytoplas,
mic-signalling cascades have not yet been identi
fied. A conformation change as gross as the one
induced by this insertion could definitely influence
the interacting properties of this portion of the
protein. The inserted repeated stretch of 10 amino
acids, on the other hand, could be a consequence
ofa more general slipped,mispai.ring mutation gen
erating mechanism.
An assessment of the phenotypic effects of mu
tations in PKDl is rendered difficult by the lim..
ited clinical data provided in mutation reports. We
have been able to find information on the age.at
onset of ESRF for 21 families with 19 different
mutations in the unique region of PKDl, includ
ing this study [Peral et al., 1996a, .1.!196b, 1997;
Turco et al., 1995; Neophytou et al., 1996; Torra
et al., 1998; The European Polycystic Kidney Dis
ease Consortium, 1994]. The total number of af,
fected individuals in these families was 39. The
mean age at onset ofESRF in patients with muta
tions in the rransmem.brane domain (N=28) was
53.8 years and for patients with mutations in the
cytoplasmic region (N= 11) it was 52.7 years. No
significant differences ce,uld be detected when
mean age at onset ofESRF was compared between
groups of patients with different typeS of muta
tion. It was 53.2 years for patients with truncating
mutations (N=30) and 54.5 years for non-tnm
cating mutations (N=9). A meaningful assess
ment of the clinical effect ofmutations in different
exons is not possible because of the very small
numbers of patients with mutations in the same
exon. Al;, already suggested by the comparison be
tween individuals with mutations in the traru
membrane domain and those with mutations in
the cytoplasmic part of polycystin 1, most reach
ESRF about age 55 regardless of the specific exon
- - ··- . ·affected.
Since the causes of clinical variation in ADPKD
are of great interest :and since allelic variation may
be one such cause, it is of interest to compare the
phenotype characteristics of individuals with the
same molecular defect. We have therefore exam
ined the information on ADPKD patienu; with
Q4041X. Hepatic cysts appear �o be commonly
associated with this mutation and have been re-
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ported to occur in eight of 12 individuals on whom
clinical information is available (including this
study). The rate of deterioration of kidney funr.
tion is variable, with 2/5 individuals developing
ESRF before age 45 a.11d 3/5 after 55 years. The
presence of hypertension has been reported in
seven of 10 individuals over the age of 30. This
variation points further to the complexity of the
disorder and supports again the "two hit" model
suggesting that gennline mutations in the PKO
genes are only one of many determinants in the
development and clinical spectrum of ADPKD.
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Germ-line and somatic inactivating mutations of the
two characterized genes for ADPKD, PKDl and PKD2,
have been identified in cyst-lining epithelial cells (Qian
et al., 1996; Watnick et al., 1998; Koptides et al., 1999),
providing evidence for a "two hit" mechanism causing
cyst formation.
In affected individuals of European descent, muta
tions in PKDl are the most common cause for the
disease and account for up to 85.6% of cases (Peters
and Sandkuijl, 1992). The PKDl gene extends over
-52 kb of genomic DNA and contains 46 exons encoded
by a 14-kb transcript (The International Polycystic
Kidney Disease Consortium, 1995; The American
PKDl Consortium, 1995; Hughes et al., 1995). The
PKDl gene product, polycystin 1, consists of 4302
amino acids and is predicted to contain a large N
terminal extracellular domain of -2500 residues, sev
eral transmembrane d1>mains, and a short cytoplasmfr
C-terminal region (The International Polycystic Kid·
ney Disease Consortium, 1995; Hughes et al., 1995;
Sandford et al., 1997). It has been demonstrated that
polycystin 1 and the gene product of PKD2, polycysti.n
2, associate in vivo in a heterodimeric interaction (Qian
et al., 1997; Tsiokas et al., 1997) involving the carboxy·
termini of the two proteins. This interaction of both
po!ycystines results in the formation of a new calcium
permeable nonselective cation channel recently de
scribed (Hanaoka et al., 2000). The complexly orga
nized extracellular N-terminus of polycystin 1 is
thought to be involved in cell-cell or cell-matrix inter
actions.
A large part of the PKDl gene is duplicated in an
unknown number of homologous genes (HG), which an?
located on chromosome 16p13.l and share approxi
mately 95-97% homology with the PKDl gene (Hughes
et al., 1995). Only 3.5 kb of the PKDl transcript, lo
cated at the 3' end of the gene, is unique to PKDl. The
exact number of the HG as well as their structure is yet
unknown. More important, although published data
indicate that these genes produce large transcripts
(The European Polycystic Kidney Disease Consortium,
1994), it is still unknown whether they would code for
functional polypeptides. An answer to this question is

PKDI is the first gene identified to be causative for
the condition of autosomal dominant polycystic kid
ney djsease. There are sev.aral genes homologous to
PKDl that are located proximal to the master gene on
the same chromosome, Two of these genes have been
recently covered in a Jorge sequencing work on chro
mosome 16, and their structure has been broad.Jy ans•
lyzed. However, the major question whether homolo
gous genes (HG) code for functionally active
polypeptides has not been resolved so far. The current
study identifies and partially characterizes four more
homologues of PKDl, different from the previously
published sequence, two of which were found by
screening of a BAC library and the other two con•
tained in available databases. Analysis of HG tran•
scripts shows that they are not tranolated in the model
cell line T98G. Taken together, these findings suggest
that homologues to PKDl form 2 family of
pseudogenes. o scot kcd=>!c p...,..

INTR0DUCI10N
PKDl is the first gene found to be impaired in auto
somal dominant polycystic kidney disease (ADPKD).
This condition is one of the most common monogenic
inherited disorders with an incidence of approximately
1 in 1000 (Dalgaard, 1957). Genetic linkage studies in
affected families show that at least three different
genes are implicated in ADPKD: PKDl, located on
chromosome 16p13.3 (The European Polycystic Kidney
Disease Consortium, 1994); PKD2 on chromosome
4q21-q23 (Mochizuki et al., 1996); and at least one
more gene, which is yet to be identified (Bogdanova et
al., 1995; De Almeida et al., 1995; Daowit et al., 1995).
Sequence data from tJtls article have been deposited with the
GenBank Data Library under Accession Nos. AF320593 and
AF320594.
1 Both first authors contributed equally to this work.
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TABLE 1
Primers and Annealing Temperatures for Second Round Amplification of Exons 6-14 of the PKDl Gene
Exon
6
7
8
9
10
11-lla
11-llb
11-llc
12
13
14

Primer sequence
6F 5' gtgagtgtctgr:tgccc 3'
6R 6' ccu:cttcctcctgaact 3'
7F 5' ggctctgagcctcagttt 3'
7R 6' taaccacagccngcgtct 8'
SF 5' gtctgttcgtc:ctg 3'
8R 5' ccatcttcactgggcaca 3'
9F 6' gttcgggtaggggga 3'
9R 5' gtgaaagctcagagaggcca 3'
lOF 5' ggtggi.-ctgtgggcaat1� 3'
lOR 6' gcctgaggAgBtgcaggga 3'
llaF 6' gggtccacgggccatgaccgt 3'
llaR 6' cgcagt.ccagggttgggc 3'
llbF 5' ncggaac:agctet.11:cgtgct 3'
llbR 6' aeggtggccaccagggcaggg 8'
llbF 5' gcagtgtcagcgc:ccgcttig 3'
llbR 5' agcaccctgtctgcnggcacc 3'
12F 5' ccaggaggcgacaggcta 3'
12R 5' ggcagnggtgaaggtggn 3'
13F 5' tcacctgccacctgggc:tcac 3'
13R 6' gecaagagcctggtgc:ccacc 3'
14F 6' ctgtcccggttcac:tcac:tgc 3'
14R 5' cagcttgactggggagctggg 3'

Genomic position
21491-21508
21868-21886
22104-22121
22476-22493
22676-22592
22863-22880
28090-23108
23341-23860
23608-23627
23929-23947
24300-24320
24610-24680
24581-24600
24880-24900
24849-24869
25150-25170
25923-25940
26178-26196
26279-26299
26519-26589
26769--26789
26998-27018

Annealing temperature c·c>

Product. size (bp)

58

896

65

391

68

306

so

271

61

340

66

331

66

320

66

821

61

273

68

261

68

250

of substantial int.cirest regarding the gene function and parison is that these genes are pseudogenes, dupli
the gene evolution in particular, because it has been cated in the course of molecular evolution.
shown that there are no Pkdl homologues in mouse
(Olsson et al., 1996).
MATERIALS AND METHODS
Up to now mutation screens of PKDl have been
heavily obstructed by the presence of these highly ho
BAC anc. PAC library screening and characterization. Primer
mologous copies of the gene extending from exon 1 to pain! from the PKDl unique and duplicated regions were used for
the first 87 hp of exon 33. Although different selective identification of PKDl or PKDl-homolcgoua genes contwning BAC
and PAC clones. The BAC (Human BAC DNA Pools, Release ll;
straregies for analysis of the duplicated part of the Research
Genetics, Inc., Huntsville, AL) and PAC (Genome Syatema)
PKDl gene have been employed successfully by several librarie!I were acreened through PCR according to the manufactur
groups, methods used, such as the long-range amplifi ers' instructions. Positive BAC and PAC clones were grown o.nd DNA
cation-based approacht:a, present a serious challenge was isolated as previously described (Pennekamp ct al., 1998).
Clones were sequenced for genomic regions covering e::on 3 through
for routine mutation detection. Therefore, the accumu to
intron 14 in direct or amplicon sequencing reactions using PKDl
lation of precise sequence information on the HG is exon-apecific primers in both direct.i01l8. Sequencing reactions were
desperately required to design PKDl-specific reagents performed with the Applied Biosystems CABD Bigl)ye Terminator
that would serve more conventional scanning tech Cycle Sequencing Ready Reaction Kit according to the manufactur•
cr'a guidelines and annlyzed on an ABI 310 automated GOqUencer.
niques.
Obtained sequences were compared with each other and w¥..b the
By screening a bacterial artificial chromosome (BAC) PKDl genomic sequence.
DNA library, we have identified clones that contain
PCR amplification on genomic DNk PKDl-specific templates
exclusively PKDl-homologous genes. Further analysis were generated for exons 6 -11 and 12-14 by amplification from
of these clones allowed us to characterize the near 6' genomic DN, with the following primers: for exons 6 -11, Fl primer
region of homo1ogues and to design primers for specific 6' GGCCGCCTACAGCATCGTGGCCC S', position 21447-21470
amplification of exons 6-14 of the PKDl gene. Differ CPKDl genomic sequence, GenBo.nk Accession No. I..39891), end Rl
primer 5' CAGTGAGGGGAGGCACCTACACTG S', position 25622ences identified by comparing the sequences of these 25€44, end for <?Xons 12-14, F2 primer 5' CAGTGTAGGTGCCTC
HG with the PKDl master gene allowed us also to CCCl'CACTGCT S', position 25621-25644, and R2 primer 5'
amplify specifically segments of PKDl and of the CCAGCGGTCAGGAGGTACACTC S', position 27410 -27430. PCR
PKDl-like genes from total and translated cDNA was 36 cycles of deneturation at 94•c for 1 min, annealing et 62"C
l min, end extension at 12•c for 4 min. Reactions were performed
pools. Results obtained clearly indicated that PKD! for
in a total volume of25 µ) end the reaction mix contained the follow
homologues are transcribed but not translated in the ing: 50 mM Tris-Cl, pH 9.5, 20 mM CNH,>.SO•• l mM DTT, 0.005'1>
glioblastoma cell line T98G. In addition, detailed anal NP-40, 1.6 mM MgCI,, 0.5 M betaine, 5% DMSO, 20 pM each primer,
ysis of the HG coding sequences demonstrates the pres 600 µM dNTP, 100-21}(} ng DNA, and 1.25 U Taq polymcn111e pro
end purified as previoualy described (Pluthcro, 1993). PCR
ence of premature stop codons and thus, if translated, duced
products of 4.2 and 1.8 kb accordingly were obtained and after
they would generate only short, most probably non dilution of 10-• they were used in second rounds of amplificatiODD
functional polypeptides. Our conclusion from this com- with primers specific for each exon to be nnalyzed (Table 1). Reaction
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conditions were 30 cycles of denaturotion at 94'C for l min, anneal
ing (see Table l) for 1 min, and extension at 72'C for l min.
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showed that both BAC clones contain different PKDl
homologous gene sequences. These clones were com
Reverse ,ranscription and PCR {RT-PCR). Total RNA was iso pletely sequenced for the region corresponding to posi
lated from confluent glioblnstoms. T98G cell cultures by using the tion 19866 through position 27596 (exon 2 to IVS 14) of
Triiol CGibw BRI.. Life Teclmologiea) reagent. Translationii1ly active the PKDl gene. The sequences obtained (7.7 kb) were
RNA was prepared from a polyaomal fraction (membrane-bound
polyaomes) as previoW1ly described (Mechler, 1987). Briefly, the mi queried against the GenBank and EMBL databases
crosomal fraction was obtained through sucrose gradient centrifuga and four more BAC clones showing high degrees of
tion of a T98G cytoplasmic extract and mRNA was separated and homology to the queried segment were identified. Fur
purified from the bound polyaomes. Total RNA and mRNA (0.3- ther analysis showed that two of those clones (Gen
0.5p.g) were subjected to reverse tr8.Dl!cription 1.111ing the SuperScript
II reverse tran.scriptase and reaction conditions specified by the Bank Accession Nos. AC009066 and AC012171) con
manufactww (Gibco BRL Life Teclmologies). Reactions were primed tain the PKDl gene or a part thereof Coverall sequence
with 100 pM random hexamer and 10 pM 3' oligonucleot.ide primer identity 99.6 and 99.8%) and two other clones contain
common for PKDl and homologous genes, 6' GCCATCCCCGAAAG PKDl-homologous genes.
GTCCAGTCGAA 3', position 4187- 4230 <PKDl cDNA sequence,
To answer the question whether the PKDl homolo
GenBank Accession No. L33243), located in exon 16 of the PKDl
gous
genes we identified are the same genes found in
gene. First round of PCR amplification was performed on 1-µ1 ali
quots ofUie RT reaction, with oligonucleotides RT-Fl, 6' GTGTGC the BAC clone A-13F4 described by Loftus et al. (1999),
CCGTCCTCGGTGCAGA 3', poeition 1294-1316 (exon 6), and RT we performed a eequence alignment of those genes
Rl, 5' CCGAAGTCCCACGTGTAAAGAA 3', position 3681-3702 with the genes contained in our BAC clones, as well as
(eion 16). Cycling conditions were denaturation at 941C for 46 2,
with the homologous gene sequences identified
nnne.aling at 661C for 1 min, and extension at 12·c for 4 min in 40
cycles. Aliquots (l µI) of the finrt PCR were used in a second ampli through our BLAST search, on regions correaponcling
fication round with "nested- oligonucleotide primei-s specific for to position 19866 -27595 of the PKDl genomic se
PKDl and for HG. PKDl reactions were primed with oligonucleo quence (Fig. 1). Overall sequence identity for each of
tides RT-F2-PKD1, 6' CTI'GAGGC,'CCAACCCTGGAC'l' 3', position the homologous gen�ntaining BACs with the PKDl
2660-2780 Cexon 11), and RT-R2-PKD1, 6' CCGGCACTGTG
GAGACCTGCAGA 3', position 3274-3296 (emn 13). HG reactions genomic sequence was 95.4-96.7% for the Sequenced
were performed with primers RT-R2-HG, 6' C.Q'l'GAGGCC_AAC regions. There were, however, several bigger deletions/
CCTGGQCT 3', end 6' CTGCACTGTAGAGACC�AGQ 3' (differ insertions (5-21 hp) identified in intrans 9, 11, 12, and
ences with the PKDl sequence are underlined). PCR waa 40 cyc]es of 13.
denaturation nt 94"C for 46 s, annealing at 681C for l min, and
The result of this sequence comparison of every pos
extension at 72'C for l min. React.ion products were resolved on
sible homologous gene couple, including the PKDl se
EtBr-stained 1% agaroae gel.a.
quence, is summarized in Table 2. The comparison
Sequencing ofPCR procwcts. The sequence of RT-PCR ampliCODS
clearly
indicates that we have identified in our BAC
from PKDl and bomologou.o genes was determined with the ampli
clones two more different homologous genes, which we
fication primers lillted above.
First- and �d-round amplicons from human genomic DNA term PKD1P3 and PKDIP4 (PKDl pseudogenes 8 and
were sequenced and compared with the PKDl genomic sequence. All 4), and another two homologous genes contained in
sequencing reaction.II were performed by using amplification primers publicly available BAC clone sequences (GenBank Ac
and the Sequitberm Exeel ll DNA Sequencing Kit as described by
the manufacturer (Epicent.re Technologies), and labeling was with cession Nos. AC010488 and AC040168). The latter
[cr-"P)dATP (Hart.mann Analytics). The products of the sequencing genes we term PKD1P6 and PKD1P6 accordingly.
reactions were electrophore,ed in 6% denaturing polyacrylamide PKD1P3 (CknBank Accession No. AF320593) is con
gels (0% "' 6; 6 M urea; 360 x 400 x 0.4 mm}, at 70 W constant tained in BAC clone 204_o_15, and clone 267_d_9 har
power for 2-3 h. Gels were dried under vacuum prior to autorndio bors the PKD1P4 gene (GenBank Accession No.
graphic e%Jl()8ure on Biomax films (Kodak).
AF320594). Preliminary data on those clones show
Computer analysi.8. Additional BAC clones containing other that PKD1P3 and PKD1P4 begin to share homology
PKDl homologous genes were found by using BLAST eearch on the with the PKDl genomic sequence in the first third of
GenBank and EMBL databaaes. The 7.7-kb region sequenced from
our HG-cont.'lining BAC clones was used for the query. Sequence intron 1, in the PKD1P5 sequence this is position 4150,
alignments and degree of homology estimates were accomplished by and in PKD1P6, position 6566. Both genomic positions
wiing the GENESTREAM global alignment tool. Sequenced regions land at potential splice acceptor sites. PKD1P8 and
were anal� for repeats and low-complexity DNA at the Repeat PKD1P4 seem to end their PKDl-homologous region
Masker Web Server.
with exon 31, PKDl homology in PKD1P5 ends at
position 34285, in the beginning of the polypyrimidine
RESULTS
tract found in intron 21. The PKD1P6 homology with
PKDl
ext.ends over only 2530 bp after position 19866,
Structural Analysis of Homologous Genes
before it ends with position .l2893 in exon 7 at a poten
Two positive BAC clones (204_o_15 and 267_d_9) tial splice acceptor site. That is why we exclude this
containing PKDl-homologous genes and a third clone, _gene from quantitative comparisons in the above de.
containing a part of PKDl as shown later by sequenc fined 7.7-kb region.
ing, amplified with primers from the repeated region
The sequence homology levels with PKO! show that
and did not amplify with the primers located in the PKD1P2 (p:reviously HG2, Loftus et al., 1999) is next to
PKDl unique region. The sequence comparison with identical with PKDl, whereas PKD!Pl (previously
the PKDl genomic sequence and with each other for HG!) and PKD1P5 are farthest distant and PKD1P3
intron regions in introrts 3, 4, 7, 8, 11, 12, 13, and 14 and PKD1P4 are in the middle, but closer to PKDIP2.
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TABLE 2

1

Degi-ees of Homology between PKDI and HG in the

2 3

4

M

Implicated Region of PKDl •

Ident

PKDlPl

PKD1P2

PKDlPS

PKD1P4

PKD1P5

PKDl
PKDlPl
PKD1P2
PKDlPS
PKD1P4
PKD1P5

95.4%

96.7%
97.4%

96.4%
97.6%
98.2%

96.5%
96.5%
98.0%
97.6%

95.5%
99.9%
97.5%
97.6%
96.5'ii,

97.49&
9,'.6%
96.5%
99.9%

98.2%
98.0%
97.5%

97.6%
97.6%

96.69&

• Genomic position 19866-27595.

HGl and HG5 possess the highest degree of identity
(99.9%), followed by PKD1P2 and PKD1P3 (98.2%),
whereas PKDlPl and PKD1P4 (or PKD1P5 and
PKD1P4) share only 96.5% identical sequence over the
examined region. On a first glance one might remain
with the impression that PKDlPl and PKD1P5 are the
same gene; however, when looking closer into sequence
details (Fig. 1) it is visible that these are two different
genes. PKDlPl for example should have a different
splicing at the exon 11 to exon 12 junction, and
PKD1P5 has other than the PKDlPl-specific deletions/
insertions in intron 12, by wh,ch PKD1P5 looks more
like the other HG. Overall for the region examined,
PIIDl exons 2 through 14, the splicing pattern seems
to be conserved for the homologous genes, with small
exceptions: exon 8 for PIID1P3 and PKD1P4, theafore
mentioned exon 11 in PKDlPl, and exon 15 in
PKDlP3. PKDlPl and PKD1P5 share another pecu
liarity, 91 bp from the beginning of exon 15, there is a
4.3-kb deletion first described by Loftus et al. (1999),
which contains most of PKDl exon 15 and exon 16.
PKD1P2, PKD1P3, and PKD1P4 do not have this fea
ture, the PKDl homologous sequence in PKD1P6 ex
tends until the last 55 bp of exon 7. Most of the se
quence variations are common for the HG; there are,
however, many specific differences in the coding and
noncoding sequences. Interestingly, exons 2, 3, and 4
and the adjacent intronic regions contain a very few
variations from the PKDl sequence. This is true for
exon 9, for example, whereas exon 8 is a hot spot for
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FIG. 8, RT-PCR on total RNA and tnmslationally active mRNA
(polysomal fraction) from the T9BG glioblaatoma cell line. Lanes 1
and 2, t.otal RNA; lanes 3 and 4, mRNA. Lanes l and 8, PKDI
specific amplification; lanes 2 3Dd 4, HG-apecific amplification. M, I
kb ladder.
such differences, six on a homologous gene on average,
in a segment of 116 bp. Almost all HG, with the
exception of PKD1P2, have a stop codon in exon 8
(CAGPJCDJ -TAGHo) with C -Tat position 22690 of
the PKDl genomic sequence.
In the 7.7-kb sequenced region, two mammalian
wide interspersed repeats were identified in all homol
ogous genes and in PKDl in matching locations (PKDl
positions 22068-22176 and 26717-25816) and
PKD1P2 and PKDl contain an additional simple re
peat of a slightly different length in a matching posi
tion (PKDl position 26133-26172). The level of re
peated sequence for all genes but PKDl and PKD1P2 is
2.7% over the analyzed segment; for PKD1P2 it is 3.7%
and PKDl has 3.2% due to a shorter simple repeat.
We used some of the identified clustered basepair
differences with HG (Fig. 1) to design PKDl-specific
primers for amplification of the genomic region con
taining exons 6 to 14 in two overlapping PCR for.:nat.s
and for differential amplification of exon 12 from PKDl
or HG from cDNA (eee Materials and Methods). First
and second-round amplicons from human genomic
DNA and T98G cDNA were also sequenced and com
pared with the PKDl and HG sequences for the ampli
fied segments. We showed that an input of a 10-& mini
mal dilution of the first-round PCR product into the
second (nested) PCR yields a PKDl-specific product,
whereas a dilution of 10-3 or lower gives rise to a
coamplification of the homologous genes (Fig. 2).

1 :102
1:103
1:105
Analysis of HG Transcripts
FJG. 2. Coamplification of the homologous genes, by lower dilu
tions of the first-round PCR. Intron 8 of PKDI is specifically ampli
To analyze HG transcripts further, we used RT-PCR
fied in the 1:10 1 panel. The observed differences with HG are in on total RNA and translationally active mRNA from
position 22770 of the PKDI genomic sequence. Note that only
PKD1P2 has an ·An at this position (sequence is of the opposite the cell line T98G with primers specific for PKDl or for
strand), which disappears in the 10-s dilution, whereas the 'T" (A in homologous genes (see Materials and Methods). We
the opposite strl!-]ld) present in four of the HG at matching location were able to amplify exon 12 of PKDl and HG from

is still visible.
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total RNA, as is shown on Fig. 3, lanes 1 and 2, and of
PKDl only from translationally active mRNA Oane 3).
The expected PCR product of 739 bp is detected in the
first three lanes, indicating that there is no genomic
DNA contamination in the cDNA preparations that
would result in coamplification of the abridging introns
and hence in an additional band of larger size (1.8 kb).
The EtBr staining of the HG amplification product is at
least twice as intensive as the staining of the PJ�l
amplification product by equal aliquots of the PCR
reactions loaded on the gel. This could be indicative of
at least two homologous genes, provided their trrn
scription rates do not differ significantly. PKDl and
HG amplicons were confirmed by direct sequencing
and it was demonstrated that HG amplicons contain
all specific sequence changes characteristic for both
PKD1P3 and PKD1P4 in the amplified region (results
not shown).
In contrast, there is no amplification of HG from
translationally active mRNA (see Materials and Meth
ods), whereas PKDl is amplified (Fig. 3, lanes 3 and 4).
In lane 4 (HG amplification) the primers not. utilized in
the course of the PCR can be seen as a "primer cloud,"
a diffuse band of a very low size, and there is no 739-bp
specific product. This failure to amplify HG from trans
lationally active mRNA shows that HG transcripts are
not bound on polysomes but rather segregated by pro
teins comprising the translation machinery. In addi
tion, translation of the HG sequences we obtained in
the three open reading frames (ORF) shows the pres
ence of multiple early stop codons; in the reading frame
matching the PKDl ORF they occur already in exon 8.
DISCUSSION

Since the discovery of genes homologous to PKDl in
1994, many ADPKD researchers have raised the ques
tion about the possible number of HG and their even
tual functional importance. The possibility that HG
might code for polycystin I-related proteins has been a
major concern in localization studies on cells and tis
sues for the past years. Since the availability of se
quence information on at least two of the homologues
(Loftus et al., 1999) it became evident that if trans
lated, those genes should produce much shorter
polypeptide chains of unknown functional importance
compared to intact polycyatin 1. The structural fea
tures of the two new HG we identified in the current
study conform to this rule, indicating that premature
stop codons can occur already in exon 8.
Our work confirms transcription of the homologous
genes shown by others (The European Polycystic Kid
ney Disease Consortium, 1994). However, the new
finding that HG are not translated in the model cell
line T98G, in which polycystines are well expressed,
guides us to the conclusion that this is the case in other
cells and tissues as well, since translation of functional
mRNA is a universal biological process. The polysomal
fraction that we used as a source for mRNA in our
RT-PCR experiments contains membrane-bound poly-
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somes, some SOS ribosomes and 608 subunits, as well
as mitochondrial ribosomes. The mRNA species ob
tained from this fraction are only those which are
bound on polysomes, i.e., this is the translationally
active mRNA. Homologues to PKDl seem to produce
nontranslatable mRNA species t'bat are segregated by
polysome complexes. The finding that certain mRNAs
are not used as protein templates is not unusual. For
example, genes in the Prader-Willi Angelman locus,
PAR-SN, PAR-5, PAR-7, IPW, PAR-1, and PAR-4, pro
duce processed but not translated mRNA species. It
could as well be that the only function of those non
protein--coding transcripts is to host multiple snoRNA
copies (Cavaille et al., 2000). For the PKDlP locus
there are no snoRNAs identified in introns. Neverthe
less, translation seems not to be favored for PKDl
pseudogenes. From our analysis, almost all of them
may lack the PKDl exon 1 carrying the firstATG codon
(in PKDlPl there is a sequence gap in this region).
According to the proposed scanning mechanism of
translation initiation, the 40S ribosome subunit scans
the transcript for an AUG codon that is in the optimal
sequence context (Kozak, 1999). Downstream ATG
codons in exons 6 and 9 could perhaps also make good
initiation sites, since they conform to the -3 A, +4 G
rule. It is, however, being demonstrated that highly
structured sequences preceding a downstream AUG in
the mRNA can block the advance of 40S ribosomal
subunits and prevent them from reaching the start
codon (Kozak, 1998). The 5' end of PKDl and PKDlP
transcripts is very rich in highly structured sequences,
and it should be expected that initiation of translation
cannot occur downstream of the first AUG codon in
exon 1. The absence of an optimal start codon in PKDl
homologues supports the conclusion that HG are pseu
dogenes.
In the course of molec1.. la.,. evolution these sequences
seem to have arisen at d• ,,,,t the same time, judging
from repeats distribution l'his should be a com
paratively recent event, sin, transcription is a very
energy-demanding process, which if not bound on func
tional entities might not be tolerated just for pseudo
gene divers: y. On the other hand, HG transcription
could additionally regulate the level of PKDl mRNA
through recruitment and titration of transcription fac
tors. It could : ie speculated that PKDlPl and PKD1P5
are the oldest and PKD1P2 the youngest member of
this pseudogene family, but additional sequencing
work is necessary to support such conclusion. The ex
act HG number is still unknown; these genes should
have arisen in a divergent fashion as paralogues to
PKDl. Their repeat abundance and high GC content
suggest that these pseudogenes might have emerged as
a consequence of retroposition and/or nonhomologous
recombination (Jurka, 1998). It is more likely that HG
have resulted from recombination/duplication events,
however, since they carry their intrans, and the splice
pattern in the PKDl homologous regions seems to be
overall conserved for these genes. Most of Llie retro
posed sequences found in eukaryote genomes are al-
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egy could be applied to primate genomic libraries to Jurka, J. (1998). Repeats in genomic DNA: Mining and meaning.
Curr. Opin. Struct. Biol. 8: 838-837.
find at which stage of evolution HG appeared.
The sequencing data on HG should allow for con Koptides, M., Hsdjimichael, C., Koupepidou, P., Pierides, A., and
Constantinou Deltas, C. (1999). Germinal and somntic mutations
struction of better reagents for mutation analysis of
in the PKD2 geue ofrenal cysts in autosomal dominant polycystic
PKDl using more conventional approaches, which in
kidney disease. Hum. Mol. GeneL 8: 609-518.
turn can be applied to routine diagnosis. This informa KD:tak, M. (1998). Primer-extension analysis ofeulcaryotic riboeome
tion should be instructive for development of a com
mRNA complexes. Nucleic Acids Ru. 26: 4863-4869.
plete PKDl analytic system, and it can be used for a KD:tak, M. (1999). Initiation of translation in prokmyote!I and eu
critical review of the mutation data on the duplicated
karyotes. Gene 284: 187-208.
part of the gene obtained by other groups.
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Screening for disease-causing mutations in the duplicated region of thePKDI gene wa5 perfonntd
in 17 unrelated Australian individuals with PKDl-linked autosomal dominant polycyi;tic kidney
disease. Exons 2-21 and 23-34 were assayed using PKDI-apecific PCR amplification and direct
sequencing. We have identified 12 novel probably pathogenic DNA variants, including five trun•
eating mutations (Q563X, c.S lOSdelA'I; c.5159delG, S2269X, c.9847delC}, two in,frame dele
tions (c.7472del3, c.9292del39), and two splice-site mutations (IVS14+ 1G>C, 1VS16+ lG>T).
Three ofthe mutations (G3S1C, Y2I85D, G278SD) were predicted to lead to the replncement of
conserved amino acid residues, with en.suing changes in protein c:cnformation. Defects in the
duplicnted region of PKDl thus account for 63% of our patients. Together with the previously
detected mutations tQ4041X, R4227P) in the 3' region of the gene, the study bas achieved an
overall mutition detection rate of74%.1n addition, we have detected 31 variants (nine novel and
22 previously published) that did not segregate with the disease and were considered to be neutral
polymorphisms. Three of the nine novel polymorphisms were misscnse mutations with a pre•
dieted effect on protein conformation, emphasizing the problems ofinterpretation in PKDl muta
tion screening. Hum Mutat 19:240-250, 2002. c 2002 Wiley,Liss, Inc.
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INIRODUCTION

Autosomal dominant polycystic kidney dis•

ease (ADPI<D; MIM# 173900) is a common

monogenic disorder with an incidence of ap
proximately one in 1,000 [Dalgaard, 1957]. The
disease manifests with the development ofbilat·
eral kidney cysts followed by renal failure in most
affected individuajs. Eight to 10% of all patients
requiring hemodialysis or renal transplantation
haveADPKD [Gabow, 1993].Additional symp
toms, such as hypertension, urinary tract infec
tions, hematuria, proteinuria, extra•renal cysts,
C2002 Wlley-l.lsa. Inc.

cerebral aneurysms, hemiae, cardiac valve de
fects, renal calculi, and gastrointestinal diver·
ticula, vary both between and within famtlies
[Roscoe et al., 1993; Schievink and Torres,
1997]. The rate of progression toward kidney
failure is also variable: end-stage renal failure
Received 1 June 2001; OCQ?Pted revlst?d !Mllusaipt 19 No
vember 2001.
•Co� to: Luba Kz!laydjleva, Centre for Human
Genetics, Edith Cowan Uniwmty, Joondalup, WAOO'l:l, Austra
lia. E-mail: LkalaydJleva@ecu.edu.au

PKDl DETEC110N IN AUS1RAUAN FAMILIES

(ESRF} occurs most commonly in the fifth de
cade [Milutinovic et al., 1984]. However, it can
present as early as in utero, while some individu
als may never progress to renal failure [Chou
kroun et al., 1995; Parfrey et al., 1990; Perrichot
et al., 2001]� T he wide range of clinical mani
festations and severity is probably a compound
product of heterogeneous germline mutations,
and of the random nature of the "second hit,"
namely soma.tic mutations in die two character
ize.cl genes for ADPKD, PKDl (MIM# 601313),
and PI<D2 (MIM# 173910) [Qian et al., 1996;
Wamick et al., 1998; Koptides et al., 1999].
Up to..85% of germline mutations in Cauca•
sian ADPKD individuals affect the PKD1 gene
[Peters and Sandkuijl, 1992], located on chro
mosome 16p13.3 [T he European Polycystic Kid
ney Disease Consortium, 1994]. The PKD1 gene
consists of46 e.,cons spanning-52 kb ofgenomic
DNA [The International Polycystic Kidney Dis
ease Consortium, 1995; The American PKDI
Consortium, 1995; Hughes et al., 1995]. A large
part of the gene is duplicated in at least six ho
mologous genes (HGs), which show > 95% ho
mology with the PKD 1 gene [Hughes et al.,
1995; Bogdanova et al., 2001). The homologous
genes cause problems of co-amplification, thus
creating major obstacles to the mutation analy,
sis of patients and families with the most com
mon form ofADPKD.
Here we present the results of a screening for
mutations in the duplicated region of PKDI in
17 Western Australian ADPKD families. Using
PKDl-specifit oligonucleotide primers and di
rect automated DNA sequencing, we have iden
tified 12 putative pathogenic mutations and
achieved a.., overall PKDl mutation detection
rate of74%.
Subjects

SUBJECTS AND METHODS

Nineteen ADPKD families, 18 of British and
one ofSpanish descent, were recruited through
index patients at the Department of Nephrol
ogy, Royal Perth Hospital, Western Australia, as
part of a large collaborative study of ADPKD.
The diagnosis was based on standard ultrasound
criteria [Bear et al., 1992]. Preliminary analysis
ofthese families had shown linkage to thcPKD 1
gene. Two families had mutations in the unique
part ofthe PKD1 gene [Bogdanova et al., 2000].
The scree1ting for mutations in the duplicated
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region of PKDI included the remaining 17 af
fected individuals.
DNA Isolation and PCH Amplification

DNA was extracted from whole blood using
standard procedures [Miller et al., 1988] . Prim
ers for long-range amplification were chosen to
be specific to PKD1 when compared with its
homologous genes. All long�range polymerase
chain reaction (XL-PCR) primers are specific to
PKDl when compared to HGl and HG2 [Loftus
et al., 1999]. The PKDl sequence between ex
ans 2 to 14 was compared also to HG3, HG4,
and HGS [Bogdanova et al., 2001]. All primers
in this region are specific to PKDl when com
pared to HG3 and HGS. Our XL-PCR products
are not specific to PKDl when compared with
HG4 between exons 6 arid 11, due to the iden
tity between the two sequences. However, the
nested primers used for amplification of exons
6, 9, 10, and i 1 (fragment A) are specific to PKD1
when compared to HG4.
XL-PCR was performed on 400 ng cfgenomic
DNA in a final volume of100 µl using 4 units of
Applied Biosystems XL-r T th Taq polym erase
with 200 µM of each dNTP, 120ng each of for
ward and reverse primer, 1.5 mM Mg()Ac, and
1 x buffer (Applied Biosystems, Foster City, CA).
The optimized conditions for XL-PCR are listed
in Table 1.
XL-PCR products (5µ1 aliquots) were elec
trophoresed in 1 % agarose gels :md visualized
with erhidium bromide staining in order to
confirm an amplification product of the ex
pected length and to rule out large deletions
or insertions.
Nested PCR reactions utilized lµl ofXL-PCR
template diluted by a factor ofat least 1 x lo-4 to
prevent co-amplification of the PKDl homolo
gous genes [Watnick et aL, 1997; Bogdanova et
al., 2001]. Nested PCR was performed in a fin2l
volume of 25 µI with 0.2 units of QIAGENe Taq
DNA polymerase with 200µM of each dNTP,
60ng each offorward and teverse prime� 20% Q
solution (QIAGEN, Hilden, Germany), 1.5 mM
MgCh, and 1 x buffer (QIAGEN).The optimized
conditions and specific oligonucleotide primers
for nested PCR amplification ofindividual frag,
ments are listed in Table 2.
DNA Sequencing

All samples were subjected to-cycle �equenc
ing in both directions with the BigDye ,.. Termi-
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Exons
Ex2.S
XIA
Ex6-ll
Xl..2
Ex 12-14
XL-3

Ex 15
XL4
Ex 15-21
XL,.5
Ex23-24

XL,.6

T.11.!lLE I. Primers for Xl,Temelate Am2llfladlon
Cycling
condttlons
Primer S!:!juence
JVSlF 5' cccagcgtdcatdgtctgg 3,.
IVS5R 5' ggtgggaacgagggtgtcaac 3'
2927 5' gccgcctacagcatcgtggca: 3'
1 lR 5' cagtgaggggaggcacdacact 3'
12F 5' cagtgtaggtgcdcccctcactg 3'
31SO 5' ccagcacggtccgg11ggmct 3'
IVS13F 5' ctgtcccggttcadcactgc 3'
ExlSXLR 5' caacgtgggcdccangtagttg 3'
Ex15XI.F 5' gcaactacttggagga:cacg 3'
IVS2IR 5' gcasggtgagcaggtg�c 3'
&23F 5' ctgcactgacdcacgcatgt
Ex34R 5' atgtgggtgtcttgggtagg 3'

68°C(X40)
2-step (0.5'/5')
68°C(X40)
2-step (0.5'/4')
68°C (X40)
2-step (O.S'tl')
68°C (X40)
2-step (0.5'/4')
68°C (X40)
2-step (0.5'/4')
6f>OC (X40)
2-step (0.5'/6')

Genomic
�lilon
17049-69
21579-90
21447-470

25622-644

2562i-644
27410-430
26769-89
30607-29
30606-26
33957-80
37674-694

44403-422

Product

me Cb2>
4,542
4,198

1,810
3,861
3,375
6,749

a(VS1F used by Thomiw et al. [1999] designated l7EXT.
bEx23F U$ed by Watnldc et Ill. (1997] designated lWFl.

RESULlS

nator Cycle Sequencing Ready Reaction Kit
(Applied Biosystems), using the nested PCR
primers listed in Table 2. The products were elec
trophoresed on an automated 377 DNA Ana•
lyzer (Applied Biosystems).
Deletions and· insertions were characterized
by oerforming a fresh PCR reaction, cloning the
products using the TOPO "' TA Cloning� Kits
with the pCR2.1-TOPO "' vector (lnvitrogen,
San Diego, CA);and subsequent sequencing.

Using the techniques outlined above, we have
identified a total of43 DNA sequence variations
in the duplicated region of the PKD1 gene in
the 17 unrelated affected individuals. The de
'tected variants include 12 probable pathogenic
mutations, all of which are reported for the first
time (Table 3 and Fig. 1), and 31 neutral poly
morphisms, including nine novel and 22 previ•
ously reported (fable 4).

Data AnalY11ls

Probable Disease-Causing Mutathms

Sequences were analyzed using Sequence
Navigator 1.0.r (Applied Biosystems} and
Sequencher 3.0 (Gene Codes C.Orporation, Ann
Arbor, MI). Missense mutations were analyzed
further for the conservation of the amino acid
residue in the mquse and pufferfish protein se
quences, using Pfam (www.sanger.ac.uk/Soft
ware/Pfam/). PHDsec [Rost and Sander, 1994]
was used to predict the effect of the mutation
on secondary protein sttucture.
Confinnation of putative pathogenic se
quence variants was achieved through repeated
analysis of the index patient and a segregation
study including affected and unaffected family
members. Segregation analysis was not possible
in one out of 12 families, where linkage analysis
had been performed on DNA extracted from
blood spots collected on Guthrie cards.
Mutations are .named following the recom
mendations of Cotton and Scriver (1998],
whereas nucleotide positions are numbered in
the traditional way, where the first coding nucle
otide ofthe cDNA is at position 212 for genomic
sequence Accession# !33243 and position 3648
for Accession# 139891.

Protein mmcating mutations. Two nonsense
and three frameshift mutations were detected
in the study.
Q563X. The C>T transition at c.1898
(g.22716) in exon 8 is predicted to truncate
polycystin-1 by 3 1 739 amino acids, correspond
ing to the loss of most of the protein.
S2269X. S2269X results from a C>G trans•
version at c.7017 (g.30915) in exon 15. It is pre
dicted to ttuncate polycystin-1 by 2,033 amino
acids, spanning the REJ domain and all of the
transmembrane and cytoplasmic regiOT"..; of the
protein.
c.5105-5I06de1AT. A 2 bp deletion, c.51055106delAT (g.29004-29005deIA1), was found
in exon 15 of the PKD1 gene. The mutation
causes a fram..shift at amino acid position 1632
and a premature termination signal at codon
1656, corresponding to the ioss of most of the
PKD repeats, the REJ domain, the transmem•
brane domains, and the entire cytoplasmic re
gion of the protein.
c.5159delG. A SU".gle hp deletion, c.5159delG
(g.29058delG), was detected in exon 15 of the
gene, !eading to a shift in the reading frame at
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TABLE 2. Primers and Conditions for Nested PCR Ame!lflcation of PKDl
Exons
Ex2
XL-1
Ex3
XL-1
Ex4
XL-1
Ex5(a)
XL-1
Ex5(b)
XL-I
Ex S(c)
XL-1
Ex6
XL-2
Ex7
XL-2
Ex8
XL-2
Ex9
XL-2
Ex 10
x.t..2
Ex11-118
XL-2
Ex11-llb
XL-2
Ex11-llc
XL-2
Ex 12
XL-3
Ex 13
XL-3
Ex14
XL-3
Ex l5
Ex15-15(r.,}

fil,.5

Ex 15- lS{b}
XL-5
Ex 16
XL-5
Ex 17
XL-5
Ex18
XL-5
Ex19
Xf...5
Ex20
XL-5
Elt2I
Xl..5
Ex23-2Sa
Ex23-23b
XL-6

Ex24
xu;
Ex25

XL-6

Ex26

XL-6

Primer !:;guence
Ex2F 5' ggaaggcddggcctncto 3'
Ex2R 5' ggggattcggcaaagdgat 3'
Ex3F 5' dcagctgtgggggattcca 3'
OOR 5' ggcagaagggatmtggggg 3'
Ex4F 5' ggdggcatcgacccttccc S'
Ex4R 5' cctggdgggaaggacagag 3'
Ex5oF 5' gtggagccaggaggagca 3'
Ex5aR 5' gggaagacgtgctggagg 3'
Ex5bF 5' tctccagc:acgtcttccc 3'
ExSbR 5' ccgctta::acdgcacgt 3'
Ex5cF 5' dcagccdgctggggacaga S'
IVS5 R 5' ggtgggaacgagggtgtcaac 3'
4349 5' gtgagtgtctgdgccca 3'
4350 5' cctccttcctcctgagltd 3'
435] 5' ggdctgag«tcagttt 3'
4352 5' tztAa:acagccagcgtct 3'
4353 5' gtclgttcgtcctggtgt 3'
4354 5' ccalcttcactgggcaca 3'
4345 5' gttcgggtagggggagtct 3'
43 46 5' gtgaaagctcagagaggcca 3'
4347 5' ggtggcagtgggcaaatca 3'
4348 5' gcctgAggagmgcagggo 3'
l lAF 5' ggg:ccacgggcaitgaccgt 3'
1lAR 5' cgcagtcaigggttgggcctc 3'
l 1 e:= 5' acggaacagc:tcaccgtgct 3'
IIBR 5' aziggtggccaccagggcaggg 3'
UCF 5' gcegtgtcagcgcccgctttg 3'
l lCR 5' agcaccctgtctgcagg::acc 3'
4355 5' ccaggaggcgacaggctn 3'
5135 5' cdggccdgattggcgtc 3'
5228 5' tcacctg.:cacctgggctcac 3'
5136 5' ccg11ggctcagaaaagca 3'
5002 5' ctgtcccggttcactcactgc 3'
4140 5' gagggctgttggggaggaagg 3'
Amplified as 16 fragments using primers and
conditions described previously by Watnlck
et al. [1999]
Ex15Xl.F 5'gcaactacttggaggcccacg 3'
Ex15aR 5' ctcaatgatgggcaa:aggcg 3'
Ex15bF 5' catccaggca11rtgtga� 3'
Exl5bR 5' cctggtggcaagctggg:gU s·
Exl6F 5' ctggatggggctdcagg 3'
Ex16R 5' cctggtggcaagctgggtgtt 3'
Ex17F 5' gggtcccccagtccttccag 3'
Ex17R 5' cattccccagcccgcccaca 3'
Ex1SF 5' gccccctcaccaccccttd 3'
Ex18R 5' gatcccgctgcacccca:a S'
Exl9F 5' gtg11tgccgtggggaccgtc S'
Exl9R 5' gtgngcaggt!l9('21gtctcg 3'
Ex20F 5' ctgctcaccaccccctc:tg 3'
F.x20R 5' ggtcccaagcacgcatgca 3'
Ex21F 5' cgctgctgacagcttgdgtgccc 3'
IVS21R 5' gcagggtgagtllggtggggccmc S'
23aF 5' dgcactgacclcacgcatgt S'
23aR 5' caccagaaagatgggctgai.c 3'
23bF 5' ggggccctggccaacctcag 3'
23bR 5' cgtgtgccccacccgctgca 3'
24F 5' tgtgacctgcgcgttdg S'
24R 5' ccaggctggcccgcagag 3'
25F .5' dgggctcacgtccgctacc 3'
25R 5' cctcgadctgcagaggctc 3'
26F 5' cggctctatcctg119Mggc 3'
26R 5' cagcacasccagtgagagca 3'

Cycling
cGndlUons

Gcnamtc
22s1t1on

64°C(X35)
(0.5'/0.5'/1')
SS°C(X 35)
(0.5'/1'/1')
64°C(X35)
(0.5'/0,5'/ l')
58°C(X35)
(0.6'/1'/1')
64°C{X35)
(0.5'/0,5'/1')
64°C(X35)
(0.5'/0.5'/ l')
SS°C (XSO)
(1',1'/1')
5S°C (X30)
(1'/1'/ l' J
S8°C(X30)
(I'/1'/1')
60"C(XS5)
(0.8'/0.8'/0.8')
61°c (X30l
(1'/1'/1')
66°C(X25)
(0.5'/1'/11
66°C(X25)
(0.5'/I '/1')
66°C(X25)
(0.5'/1'/ 11
61°C(X30)
(0.8'/0.6'/0.8')
68°C (X35)
2-step {0.5'/21
6S°C(X35)
2"6t2p (0.5'/2')

19845-64
20064--74
20045-64
20211-30
20378-97
20630-50
20770-87
21081-98
21081-98
21335-52
21315-35
21579-89
21491-508
21868-886
22104-121
22476-493
22575-592
22863-880
23090-108
23341-360
23608-627
23929-947
24300-320
24610-630
24581-600
24880-900
24849-869
25150-170
25923-940
26256-74
26279-299
26581-598
26769-789
27023-043

66°C(X35)
(0.5'/0.5'/l')
64°C(X 35)
(0.5'/0.5'/1'}
56°C(X30)
(0.5'/0.5'/11
66°C(X35)
(0.510.5'/11
66°C(X35)
(0,5'/0.5' /1')
66°C(X35)
(0.5'/0.5'/ 1 ')
64°C(X35)
(0.5'/0.5'/1')
66°C(XSOJ
0.5'l0.5'/I')
S8°C(X30)
(0.5'/0.5'1')
6S°C(X35)
2-step {0.5'l2')
68°C(X35)
2-step (0.5'/2')
6S°C(XS5)
2-step (0.5'/2')
68�C(X35)
2-st!:E (0.5'/2')

30606-26
30872-92
30841-61
S1086-106
31197-214

31468-85
32262-81
3241i9-508
3257!-90
32895-914
32946-65
33213-32
33225-43
33445-68
33763-86
33957-80
37674-694
38006-026
37979-998
38336-355
38600-617
38786-803
38927-946
39236-255
39272-291
39567-586

Prodl.ld

size !b2)
230
186
273
329
272
275
396
391
306
271
340
331
320
321

352
320
275

287
266
289
247
344
287

239
218

377
204
329
315

(Continued)
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TAB!£ 2. Continued.
Exons

Ex27

Xl-6

Ex28

X1,.6

Ex29

Xlr6

Ex30

X1,.6

Ex31
X1,.6

Ex32

XL-6

Ex33

XL-6

Primer �uence
27F 5' cctcccacccctccctcttg 3'
21R 5' cagagcttggcagggtccgc 3'
28F 5' cgzigcctgzicctccctcctg 3'
28R 5' cggagtggg11ccatggaacg 3'
29F 5' cgtggcctcctgcagtgcgg 3'
29R 5' ggcaggaagaggctgccccg 3'
3-0F 5' cacctgtgtggcdcctctc 3'
3-0R 5' ggctcarttcccagtadcc 3'
31F 5' gctgaccactgccacgtc 3'
31R 5' agtccaagctgcgc:aagg 3'
32F 5' ttggcgcagcttggactc 3'
32R 5' cagggctcgaggtttdc 3'
33F 5' taccttgctgacccgcgc 3'
33R 5' ggtgzigcttcagagcccc 3'

codon 1650 and a termination signal at position
1721. The mutation is predicted to truncate
polycystin-1 by 2;581 amino acids, including the
domains described in the above paragraph.
c.9847delC. A single bp deletion in exon 28,
c.9847delC (g.41352delC), causes a frameshift
at position 3213 and generates a premature stop
codon at residue 3315. Polycystin-1 is truncated
by 987 amino acids, corresponding to most of its
cytoplasmic region.
Splicing mutations. We have identified two
nucleotide substitutions affecting donor splice
sites and therefore predicted to result in aber,
rant RNA splicing.
IVS14+1G>C. A G>C transversion at
g.26942, 1 hp downstream of exon 14, abolishes
the consensus donor splice signal in IVS 14.

Cycling

condHlons

68°C (X35)
2-step(0.5'/l')
5S°C(X30)
(0.S'/0.S'/1')
68°C(X35)
2-step(0.5'/l')
68°C(X35)
2-step(0.5'/21
68°C(X35)
2-step (0.5'/21

58°C(X30)
(0.5'/0.5'/1')
6S°C(X35)
2-step(0.5'/21

Genomic
IY.ls!tlon
41000-019
41205-224
41254-273
41438-457
41486-505
41751-770

41794-813

4191s.m
43585-603
4377S.791
43775-792
43879.896
44064-081
44296-313

Product

slu (be)

225

204

285
199

207
123
250

IVS16+1G>T. A G>T transversion at
g3I394G>T. lbp downstream of exon 16, af.
feets the consensus sequence of the donor splice
site in IVS 16.
In-frame deletions and missense mutations.
These mutations were classified as probably
pathogenic on the basis of family segregation
analysis, the evolutionary conservation of the
amino acid residues involved and/or the pre•
dieted changes in the secondary structure of
the protein.
c.7472-7474de13. A three base pair deletion in
exon 18,c.7472-7474delACC(g.32650-32652del),
results in the deletion of threonine at ccxlon 2421
in the REJ domain of polycystin• l. This is the sec,
ond· threonine in a group of three that are con•
served in the mouse and Fugu proteins.

TABLE 3. Sulnm!:!J! of Novel, Probable Disease-Causing Mutations In the 5' Duplicated Region of PKDI
Amino add change
Predicted effect
(and protein region
FamUy
Affected
on�ein
ordomnln)
S�uence wrlatfon
LocmJon
fam1ly segregrrtron
c.1898C>T g.22716C>T
Q563X(Extracellular)
Ex6
Truncation(non.sense)
Yes
A4
c.7017C>G g.30915C>G
S2269X(RE.I domain)
Truncation(non.sense)
Ex15
Al5
Yes
c.5105-5106deJ(An
Jl 632EsX1656
Ex 15
Tru ncatlon(frame-shift
Not
A52
g.29004de!AT
(PKO domain)
deletJon)
possible
VI 650fsXI721
c.5159delG g.29058delG
Ex 15
Truncation(fuune-&hlft
Yes
A36
(PKD domain)
deletion)
c.9847delC g.41352deJC
F32lfsX33I5(PLAT
Ex28
Truncation(Emme-shift
AlO
Yes
domain)
deletion)
IVS 14 IVS14+1G>C g.26942G>C lntronlc
Aberrantsplicing
Yes
A22
IVS 16 IV516+1G>T g.31394G>T lntnmlc
AbemmtGplldng
A5
Yes
c.1352G>T g.21430G>T
Ex5
G381C(Extmcellular)
Mlssense(loop and
A9
Yes
hellx shortt:ned)
c.6764T>G g.30662T>G
Exl5
Y2J85D(PKO domain)
Mlssense(loop lo::t)
A6l
Yes
c.8565G>A g.37893G>A
Ex23
G2785D(Extracellular)
Mt=mse (loop slightly
A6
Yu
shortened)
Exl8
c.7472-74del (ACC)
242ldelT(REJ domain) In-frame deletion(hell:
Yen
A46
g.32650-52del
replaced by extended
Ex25

c.9292-9331dcl
g.39090delS9

3027del1S 11a

(Extracellular)

sheet)

ln-frnme deletion
(loop lost)

A42

Yes
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c.9292-933IdeL This 39 base pair deletion in
exon 25 is expected to result in the deletion of
13 highly conserved amino acid residues (�i
tions 3027 to 3039) preceding the first trans·
membrane domain of polycystin- .. An example
of the predicted topology change for this dele
tion is shown in Figure 2.
G381C. A G>T transversion at c.1352
(g.Z 1430) in cxon 5 leads to the replacement of
a conserved glycine by a cysteine residue at po·
sition 381. between the first PKD domain and
the c-type lectin domain.

Y2185D. A T>O transversion at c.6764
(g.30662) in exon 15 results in the substitution
of histidine for tryptophan at the conserved po·
sicion 2185 in the PKO repeat region of
polycystin-1. An example of the evolutionary
conservation and topology prediction for this
missense change is shown in Figure 2.
G2785D. A G>A transition at c.8565
(g.37893) in exon 23 is predicted co result in a
histidine for glycine substitution at conserved
position 2785, immediately downstream of the
REJ domain.
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TABLE 4. Polymo!J!hlsms In the 5' Dufllcated R!:1!lon of PKOl
Nu mber
of patients

Loc.atlon

with

chan!:!!:

Exon2
Exon5
Exon5
IVS6
IVS9

1
1
. )·
6 (A15 t
1
3

Exon 11
Exon 11
Exon11
Exon11
Exoa 13
Exon13
Exon13
Exon14
Exon15
Exon 15
Exon 15
Exon15
Exon15
Exon15
Exon15
Exon15
Exon 16
IVS 16
Exon17
&on18

1
1
3
3
3
1
4
3
2
2
2
5
2

Exon21

Exon21
Exon23
Exoo 25
Exon 26
IVS 31

1

5
3
1
1
4
4
1
2
2
5
5

l

Amino
S!:9uence variation
c.487G>A g.19963G>A
c.1234C>T g.21312C>T
c.1330T>C g.21408T>C
g.22160G>A
g.23307del7
(VNlR)
c.2427A g.24474G>A
c.2905A>C g.24952A>C
c.2911G>A g.24958G>A
c.2941C>T g.2'1988C>T
c.3274T>C g.26395T>C
c.3319G>T g.26440G>T
c.3322A>G g.26443A>G
c.3486T>C g.26921T>C
c. 3583C>T g.27483C>T
c.3586C>T g.27486C>T
c.4406T>C g.28306T>C
c.4876A>C g.28775A>C
c.4885G>A g.28784G>A
c.5157C>T g.29056C>T
c.S383C>T g.29280C>T
c.5974G>A g.29872G>A
c.713SC>T g.31255C>T
g.31414G>A
c.7376T>C g.32427T>C
c.7652C>T g.32830C>T
c.8098G>A g.33824G>A
c.8124A>G g.33849A>G
c.8504C>T g.37854C>T
c.9406GT>CC
g.39207GT>CC
c.9541T>C g.39466T>C

g.43740T>C

add

E•!Uon

T�'J?! of change

A92A
A341A
L373L

Sllent exoolc
Silent exon!c
Silent exon1c
lntronlc
lntronlc

Q739R
AB98A

M!ssense
Silen! exoclc
Silent e:xon1c
Silent�nlc
Silent e:xonk
SllMt exonlc
SUent exontc
M1saense
Silent exonlc
Silent exonlc
Mlssense
Silentexonlc
Silent cxoruc
Mlrlseme
Silent exonlc
Silent exonlc
Sl!ent exonlc
lntronlc
SIient exonlc
SIient e:xonlc
Silent exonlc
Mmense

P900P

D910D
Gl021G
TI036T
L1037L

Ml092T

Al124A
S1125S
W1399R
Al555A
TI558T
TI649M
TI724T
L1921L

G2309G

L2389L
L2481L
A2629A
H2638R
R2765C
F3066L
P3110P

Previous reference
Rossetti et al. (2001]
ThomM et a1. (1999]
Rossetti et al. {2001]
Novel
Novel

Novel

Thomas et al. (1999]
Thomas et al. (1999)
Thomes et al . [1999)
Tnomns et al. (1999)

Novel

Thomas et al. [1999]
Novel
Thomas et al. (1999)
Thomas e:t al. (1999)
Watnk:k et al. (1999)
Watnldl d a1. (1999)
P/;:rtnlck et el. {1999)

NOVCII

Watnk:k et al. (1999)
Thomas et aJ. (1999]
Pen1chot et a1. [2000b]
Novel
Wntnlck et al. (1999)
Pmk:hot et a1. (2000b)

Novel

MlsGenae
Mbsense

Watnlck et a1. [1999)
Rouettl et al. (2001]
Peml et a1. (J997]

SUent exonlc
lntroolc

Novd

Penil et al . [1997]

•AJs.l II homozyoote for c.1330T>C. All other lndMdual.t ere hetero.iygotes for polymorpt,{sms llmd.

Probable Neutral PolymoJJJhlsms

The 31 polymorphic variants detected dur•
ing our analysis of the duplicated region of PI<Dl
are shown in Table 4. Here we present in more
detail the novel missense variants.
Q739R. A G to A transition (c.2427,
g.24474) in exon 11 was predicted to result in
an amino acid substitution at codon 739. Hu
man sequence Accession # L33242 and mouse
Pkdl Accession # 008852 suggest a conserved
glutamine at that position. However; another pub·
lished human sequence, Accession #P98161, lists
the same residue as arginine, suggesting a poly•
morphic variant. Computer prediction models
show a marked difference in protein secondary
structure (Fig. 2). In this study, the glutamine
to arginine change was detected in a single af.
fected subject (A42.l). The same substitution
has been found subsequently in an ADPKD
family from Bulgaria, where it did not scgre-

gate with the disease (N. Bogdanova, unpuh•
lished results).
Ml092T. AT co C substitution (c. 3486,
g.26921) in exon 14 was found to occur in duce
unrelated affected subjects. Published human sc•
quences have a methionine residue, while the
mouse protein contains threonine. Again, a dif.
fercnce in secondary protein structure,albeit less
pronounced, is predicted by computer analysis.
TI649M. A C to T substitution (c.S157,
g.29056) in exon 15 results in the replacement
of the conserved threonine at position 1649
by methionine. Computer models predict a
slight change in secondary structure. This
variant was detected in patient A52.l, where
family segregation analysis was not possible.
However, the cloning experiment performed
to characterize the fram eshift dele tion
(c.5105delAT) of the same subject demon•
strated that the mwense variant was carried
on the other chromosome.
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�
Mouse
Human

Fugu

QRNYLEAHVDLRNCVSYQTE!RViEIYRTASCQRPGRMAQMVLPGVD
QRNYlEAHVOLROCVTYQTeyRWEVYRTASCQR?GRPARVALPGVD
LVEASVDLKGCLRYGAOXLWOiLSAPSCDNOPHFASGRVNGAT

AA
PHO sec
wtr..at: SUB sec
P 3acc
tstihcet: SUB ace

IORNYlEAHVOLROCVTYO'f'EXRWEVYRTASCORPGRPARVALPGVDJ
EE
EE I
I EE
ILLLE...•.LL .....LLLL. ....LLLLLLLLLLLL.LLLJ
Jo ebbob:X>ebbebbeooacoebee oeec e ee ebSbllbebbel
ie...b.b.b.b...b...e. ..e............b.b.....ej

p21es (Mutlrtl<>nl
AA
PHO sec
subset SUB MC
P_3aa:
�t:SUSacc

fQRNYLEA.'iVDLRDCVTYOTEQRWEVYRTASCQRPGRPARVALPGVOf
f EEEE EEE EE HHHHEEEEEE E
EEEE I
ILL .............................LLLLL.E••Lll.LI
fGee beb bebeebbb oe bebb abebe ee ebebbbeeffl
10...b.b...b•.b .........b...b....a.. .b.bb....of

e,9292.S331del
Human
Mouse

GLYTSLCOYFSEED�OAVCLTRHLTA
GLYTSLCQYFSEEMMMWRTEGIVpLEETSPSOAVCLTRHLTA

Wild-typo c,92112
AA
PHO IIOC
subset SUB sec
P 311cc
�SUB:icc

fGLYTSL �QYFSEEDMVVVR-TEGlLPLEETSf'B-<lAVCLTRHLTA/
I EE
HHHH
EEEEE I
fLEE ....•.LL LLH ...LLLWJ.U.lllLL .....4
iet,bebbbbbboe�I
fo.b.bbb..bb........o......a ..aa.........ef

nm
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c,929:Jd!\39 (r,lu tp1i2f))
AA
(GlYTSLCOYFSEEOMVWR-OAVCLTRHLTA!
I EEEHHHH HHHHHHHHHHHHHHH I
PHO ace
cubaot: SUS sec
ll.EE.HH .••••HHHHHHHHHHHHHHHL t I
lebbtltbbe bb9G bbb llbbbbbeabeel
P_3 ace
subs.at SUB ace
/o ...bbb ............bbbbb ....ej
QillB
Human (L33243)
Hum.m(P98161)
Mou.so (00i!852)

.Qlli

AA
PHO sec
IUbsot· SUS we
P_3acc
subset SUB ace

AGPGALLHCSPAPGHPGpgAPYLSANASSW
AGPGALLHCSPAPGHPGP.BAPYLSANASSVV
LLQCPLASSC PG gAI.YlSTNASOW
!AGflGALLHCSPAPGHPGPQAPYI.SANASSWJ
I
I EEEE
lllLEEEE.LLLllllilllL ..LlLLLLl
I� oeeobo bbbebellel
fo...bcb.b.... e................J

BI3¥ 1ec1vmomhJc vanaon
IAGPGAl.ll-lCSPAPGHPGPBAJlYl.SANASSWJ
I
HHH
I

AA

PHO l8C
subset: SUB sec:
P_3ecc
Gvt>sot: SUB ace

ILLL.LLLLLLLl.lllll......l.lllll/
111 bcabbeo eoceee s�J
,-....b.......a .....b....co.. .. f

FIGtmE 2. Evolutionary conservation and topology predldlon for mutations \'21850, and.c.9292-93Sldel; and for
polymorphism MIT 1092. Variable amino aclrls are shown In bold and underlined. The human and mouse (and where
possible the Fugu) protein setiuences are aligned. Predicted protein topologies for the wlld-type and variant alleles are
shown for each eiaunple. The abbreviations of E (extended sheet), H (helix), and L (loop) me In accordance with
PHDsec [Rcwl: and Sander, 1994).

DiSCUSSJON

Mutation detection in the duplicated region
of the PKO1 gene has been hindered by the high
(>95%) sequence identity with the homologous
genes, raising concerns about PCR primer speci
ficity and hence the reliability of the analysis.
Most studies have therefore focused on a lim
ited area of the gene. Only a few have screened
most or the entire coding region of PKO I

[Watnick et al., 1999; Thomas et al., 1999;
Rossetti et al., 2001; Phalcdeelcitcharoen et al.,
2001]. ln this study, we have used infonnation
published previously on the sequence of HGl
and HG2 [Loftus et al., 1999], as well as our
own data on additional homologous genes
[Bogdanova et al., 2001], to design amplifica
tion primers that were specific to the duplicated
region of PKDI. The analytical prorocol in-
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eluded long-range amplification, followed by
nested PCR and direct sequencing.
We have tested 17 affected subjects for mu
tations in exons 2-21 and 23-34, which account
for about 69% of the PI<Dl coding sequence. A
total of 12 possible disease-causing mutations
were identified, spread from exon 5 to exon 28.
The results of this study and others [Krawczak
and Cooper, 1997; Afaal et al., 2000; Aguiarl et
al., 2000; Bogdanova et al., 2000; Kirn et al.,
2000; Koptides et al., 2000; Perrichot et al.,
2000a,b; Phakdeekitcharoen et al., 2000, 2001;
Rossetti et al., 2001) suggest that mutations are
dispersed across the entire PKD1 gene, without
any apparent clustering in mutation "hot spots."
Similar to previous studies [Krawczak and
Cooper, 1997; Afzal et al., 2000; Aguiari et al.,
2000; Phakdeekitcharoen et al., 2000, 2001), all
mutations that we have identified were private,
i.e. confined to individual families.
Our analytical procedure is not problem-free:
it is relatively costly and includes sequential
amplification steP.5 that can introduce sequence
errors and therefore should be avoided in diag
nostic p rotocols. However, in the case of
ADPKD, the choice is limited by the character
istics of the PKDl gene and of the pathogenic
mutations. The a.sic of non-specific PCR ampli
fication, due to the homologous genes, imposes
the need of consecutive amplification steps. The
spread of mutations across the PKD I gene, their
diversity (with truncating defects accounting for
a little over 50% of our patients), and their pri
vate nature, all interfere with designing a hier
archical diagnostic procedure, prioritizing
common defects and mutation hot S{Xlts,
The large number of private ADPKD muta
tions, together with the proposed random sec
ond-hit mechanism [Qian ct al., 19961, rnalce
phenotype-genotype correlatior.s difficult to as
sess. The analysis of such correlations will have
to be limited to comparing the general effects of
the nature of mutations (truncating vs. nrisscnse)
and localization in specific protein domains. In
our small group ofpatients, there was no signifi
cant difference between the age at onset ofESRF
as related to the type of gennline mutation (data
not shown).
In view of the lack of functional assays and
the prohibitively high costs of analyzing the
PKDJ gene in a sufficient number of control
chromosomes, the distinction between disease-

causing missense mutations, and "neutral vari•
ants" resulting in amino acid substitutions, has
to rely on family segregation studies, assessment
of the evolutionary conservation of the amino
acid residue involved, the nature of the substi
tution, and the predicted effect on protein con
formation. The predictive value of segregation
analysis is limited in small families, as co-inher
itance can be due to chance. As for evolution
ary conservation and conformational changes,
all three novel missense mutations, classified as
non-pathogenic in our study due to lack of co•
segregation, were predicted to result in confor
mational changes and one of the three (f/
Ml649) was conserved between mouse and hu
man, emphasizing the problems of interpretation
in PKDl mutation analysis. Moreover, while in
dependent segregation of missense mutations
and the ADPKD phenotype indicates a lack of
drastic effect on protein function, modifying ef
fects on disease severity remain a possibility and
:nerit further studies. In addition, the accumu
lation of "neutral" polymorphisms may affect
protein function through numerous changes in
topology even in the absence of an obvious
pathogenic mutation. The existence of such "hy
permorphic" alleles has been proposed by
Watnick et al. [1998].
Differences between the PKDl nucleotide
sequence and those of the homologous genes can
provide an indication of the age of single nucle
otide polymorphisms (SNPs) and the order of
duplication events. In the case ofM/Tl092, the
mouse seauence
encodes threonine, while both
°
puhlished human PKDl sequences, as well as
all homologous genes, code for methionine at
that amino acid position. The current data would
suggest a very recent origin, subsequent to the
duplication events, of the back mutation result
ing in the human M/f1092 polymorphism.
At po.,;tion 1649, threonine is conserved be
tween the mouse and human PKO! orthologs
and in HG2t while the other HGs encode me
thionine. The findings may indicate that the
origin ofT/M1649 variant preceded some of the
dupllcation events and that HGs l, 3, 4, and 5
were derived from the Ml649 allele.
The Q/R.739 {Xllymorphism is evident in the
two published human PKDl sequences, with
Q739 encoded by sequence #U3242, and R739
encoded by #P98161. The homologous genes
show differences. Based on the mouse PKO!
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sequence (Accession # 008852), one could ar•
gue that Q739 is the ancestral allele, which gave
rise to HG3 and HG4, whereas HGs 1,2, and 5
appear to be the products of duplication events
involving the derived R739 allele.
Reliable conclusions on PKO1 gene genealogy
and the origins and age of the HGs have to await
the accumulation of SNP frequency data in hu,
mans, i:i.s well as information on other mamma•
lian species. Such data will also allow conclusions
· on the role of the homologues genes as reservoirs
of mutations in gene conversion events.
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